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A Study Of Hypoxia Inducible Factor And Related Genes In Disease In Man 
ABSTRACT 
In this study, the mRNA and protein levels of hypoxia inducible factor 1 (HIF-la), and 
a number of genes regulated by hypoxia (VEGF. GLUT-1, p53), were detennined in four breast 
carcinoma cell lines, peripheral blood mononuclear cells (PBMCs) of patients with breast 
cancer and Type 1 diabetes (TIDM), and in human breast and brain tumour tissue. Breast 
carcinoma cells and PMBCs from both patients and normal controls were exposed to hypoxia 
(~ 1% 0 2) and/or high glucose. Both up-regulated and down-regulated HIF-Ja, GLUT-1 and 
p53 mRNA expression was observed in the breast carcinoma cell lines exposed to hypoxia 
and/or high glucose, and in controls for osmolarity, confirming that hypoxic regulation oflllF-
la, p53 and possibly GLUT-I occurs post-transcriptionally. Conversely, up-regulation of HIF-
1 a and GLUT-1 mRNA was observed in patients with TIDM exposed to high glucose. The 
GLUT-1 mRNA up-regulation observed in patients without complications differed 
significantly from normal controls, where up to a 2 fold increase in expression was observed 
over that of patients with complications. This may indicate that the expression and function of 
glucose transporters differs in these patients, potentially leading to fewer complications. 
Investigation of breast and glial cell tumour tissue demonstrated that both HIF-1 a and GLUT-
1 mRNA expression levels increase with disease progression, indicating that up-regulation of 
lllF-la is partly at the transcriptional level (Soodergaard et al, 2002). Follow-up survival 
studies in all patients with glial cell tumours showed that HIF-la protein expression is a 
significant prognostic factor in cumulative overall survival. An additional investigation of p53 
or p73 polymorphisms in the development of carcinoma of the breast did not find that they 
were significant risk factors in the development of the disease in the British Caucasoid 
population. Further studies are required using larger sample populations investigating HIF -1 a 
protein to determine the precise role of HIF-1 in the response to hypoxia and angiogenesis in 
disease in man. 
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Chapter 1. Introduction 
1.0 Introduction 
There are many ancient, medieval and modern day researchers who have offered 
theories about the group of diseases known as cancer. The oldest recorded description of 
cancer dates back to 1600 B.C. Egypt, where tumours of the breast were written in 
papyrus. Hippocrates (460-370 B.C.) originated the word cancer having used the word 
'carcinoma' to describe different types of tumours. He believed that an excess of black bile 
produced by the stomach and spleen caused cancer (Coagner, 1991). Modern research has 
concluded that cancer is a combination of uncontrolled cellular proliferation and/or lack of 
apoptosis. Rigorous scientific research during the past twenty to thirty years has resulted in 
an enormous accumulation of knowledge underlying the molecular and cellular basis of 
cancer. A major area of investigation has been the analysis of genes that determine tumour 
cell proliferation and viability. 
1.01 Knudson Hypothesis 
One of the most significant theories in modern biology, Knudson's 'two-hit' 
hypothesis (Knudson. 1971) was proposed from the evidence in familial retinoblastoma 
cases to elucidate the mechanism by which common cancers, such as breast cancer, 
become more prevalent with age. The hypothesis explains the relationship between the 
hereditary and nonhereditary, or sporadic, forms of cancer. The simplified model suggests 
that two separate genetic events are required for the development of a cancer. The first 
event is inherited in the familial form and the time required for the second hit to occur is 
shorter than two hits to occur in a normal person. This hypothesis explains why the familial 
form of retinoblastoma occurs at an earlier age and is usually bilateral. Thus, inherited 
cancer occurs earlier whereas sporadic cancer has later onset. 
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1.02 Multistage Model 
It is largely acknowledged that cancer is a genetic disease that arises from acquired 
mutagenetic changes. The resulting damage to a cells' genetic material is both a multi-hit 
(genetic and factorial) and multi-step (transformation, promotion, overt) process which 
occurs over a prolonged period of time affecting either or both proto-oncogenes and 
tumour suppressor genes (Cohen and Ell we in, 1991 ). 
Initial studies into the development of cancer, or carcinogenesis, believed it to be a 
two-stage process (Berenblum and Shubik, 1949). Later investigations proposed that 
carcinogenesis was a six to seven stage process (Armitage and Doll, 1954). It is now 
understood that multistage carcinogenesis is analogous to a 'two-hit' model of tumour 
development and is often characterised by four sequential stages: initiation, promotion 
(which leads to the appearance of benign tumours), progression and malignant conversion 
(Harris et a/, 1992). Genetic changes which cause initiation or promotion could involve 
mutations that activate a cellular oncogene, inactivate a tumour suppressor gene, or 
inactivate an anti-metastasis gene. The overall process can occupy a major fraction of the 
life span of the individual. Evidence also suggests that failure to activate apoptosis after 
DNA injury may be an additional route to carcinogenesis (section 1.2.3) (Griffiths et al, 
1997). 
Tumour formation usually arises as a consequence of alterations in the control of 
cell proliferation and disorders in the interactions between cells and their surroundings that 
result in invasion and metastasis. Although a particular genetic alteration may be necessary 
for turnourigenesis, in most cases a single event, such as oncogene inactivation, is not 
sufficient. Early research demonstrated that tumour progression occurs in a stepwise 
fashion with each step determined by the activation, mutation or loss of specific genes 
(Foulds, 1957). The control of cell proliferation is highly complex as a cell driven through 
its proliferation cycle by a series of co-ordinated stepwise genetic events which determine 
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entry into S-phase and mitosis. Proto-oncogenes and tumour suppressor genes may modifY 
these steps. The rate of cell proliferation is probably a balance of the growth promoting 
effects of the proto-oncogenes and the constraints imposed by the action of tumour 
suppressor genes (Cooke & Stanton 1994, Marshal) 1991). Thus, the cumulative effects of 
genetic abnormalities are required to convert a normal cell into a cancer cell. 
Although the majority of tumours are angiogenic and able to induce the formation 
of new vasculature, the normal cells from which these tumours arise are commonly anti-
angiogenic. They frequently secrete low levels of inducers that are masked by high levels 
of inhibitors of angiogenesis (Kerbel, 2000). As these normal cells progress to malignancy 
they become potently angiogenic (Rastinejad & Bouck, 1997). Cells in a developing 
tumour acquire their hyper-angiogenic phenotype as a result of the sequential activation of 
oncogenes and inactivation of tumour suppressor genes. These mutations have been shown 
to increase the proliferation and/or viability of cultured tumour cells (Hanahan and 
Weinberg, 2000; Semenza, 2000). Both oncogenes and tumour suppressor genes also 
control the production of a variety of secreted molecules that regulate angiogenesis. 
1.1 Proto-Oncogenes and Oncogenes 
Proto-oncogenes encode elements of intracellular signal transduction pathways 
leading from growth stimuli outside a cell to DNA within the cell nucleus. They are 
expressed in normal cells and may code for growth-factor receptors, intracellular signal-
carrying molecules and transcription factors. The expression of proto-oncogenes is tightly 
controlled by a number of regulatory mechanisms and their expression is usually short 
lived so that the gene product only exists at the required level when a growth response is 
required. This may be achieved by transcriptional up-regulation. enhancement of mRNA 
stability, post-translational modification or a combination of these events (Cooke & 
Stanton. 1994 ). 
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Cancer cells commonly express oncogenes that can arise in cells Vta two 
mechanisms: infection of cells by tumour viruses and conversion of cellular proto-
oncogenes to oncogenes. Oncogenes are generally derived from the genetic material within 
each normal proto-oncogene, thus oncogenes are proto-oncogene conversions generally 
having resulted from proto-oncogene mutation, amplification, chromosomal translocation 
or retroviral activation (Varmes, 1984). Oncogenes contribute to tumourigenesis by 
activation, overexpression or amplification resulting in disordered proliferation or 
differentiation. They exert a positive driving force for cell growth by their inability to 
cease in response to the absence of stimulation. 
A number of oncogenes and proto-oncogenes play a key role in the multi-step 
induction of tumour angiogenesis. Tumour angiogenesis requires that endothelial cells 
receive angiogenic signals from their environment. The expression of oncogenes within 
cells is a critical event in the early stages of tumour formation and it is believed that 
tumours originate from the oncogenic transformation of a single cell. Oncogenes enable 
tumours to provide these signals by enhancing the secretion of angiogenic factors, by 
limiting the production of inhibitors and by stimulating the degradation of the extracellular 
matrix. These stimuli activate proto-oncogenes within endothelial cells as they respond to 
new blood vessels. 
The involvement of oncogenes and cellular proto-oncogenes in mediating 
angiogenesis and tumour growth is depicted in Figure 1.1. Angiogenic factors belonging 
to the growth factor class of oncogenes can simultaneously support tumour cell growth and 
sustain angiogenesis (reviewed in section 1.3) (Rastinejad & Boucle, 1997). 
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Figure 1.1. Schematic representation of the cellular components and specific steps in the 
process of tumour angiogenesis regulated by proto-oncogenes and oncogenes. The cellular 
position of some cell cycle regulators is demonstrated. Nuclear onco-proteins, 
transcriptional modifiers, are expressed in most cells however, when a mutation occurs 
their expression becomes abnormal triggering a series of processes resulting in tumour 
formation. 
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1.2 Tumour Suppressor Genes 
Tumour suppressor genes (anti-oncogenes) can be defined as genes in which their 
deletion, reduced expression or inactivation contributes to carcinogenesis. Tumour 
suppressor genes are foremost among the protective mechanisms that have developed to 
reduce the chances of developing cancer. They prevent tissue overgrowth, nullify cells 
with damaged genomes and metastases. Their products act downstream from growth-signal 
pathways and as long as they are fully active, these genes serve as guardians against 
tumour progression. It is only when one or more of them become defunct that uncontrolled 
cell multiplication can occur leading to cancer. The loss of a tumour-suppressor gene is 
generally characterised by a mutation in one copy of the gene and loss of the homologous 
copy (Levine, 1995). 
Tumour suppressor genes can exert an influence on angiogenesis by stimulating the 
cells in which they are expressed to secrete high levels of inhibitors of angiogenesis. A 
variety of cells expressing tumour suppressor genes switch their phenotypes from anti-
angiogenic to angiogenic when a tumour suppressor gene is inactivated. This switch may 
be a result of decreased synthesis and secretion of an inhibitor of angiogenesis, such as 
thrombospondin-1 (Dameron et a/, 1994 ). 
1.2.1 Genomic Imprinting 
Genomic imprinting, a recently discovered mechanism, involves tumour suppressor 
gene inactivation through mutation or parent-specific inactivation of a non-mutated gene 
by imprinting. The activity of genes may be altered epigenetically in a manner dependent 
on the parent of origin of each of the two alle1es (Figure 1.2). The effects of genomic 
imprinting can be seen by differences in the expression of an inherited disease depending 
on the sex of the transmitting parent. Evidence also exists that genomic imprinting may 
play a role in the pathogenesis of some embryonal tumours (Ferguson-Smith et a/, 1990). 
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The model suggests that preferential retention of paternal alleles occurs in the tumour 
tissue. (Adapted from Ferguson-Smith et a/, 1990). 
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1.2.2 p53 
Perhaps the best known of all tumour suppressor genes is p53. Alterations of the 
p53 gene complex are one of the most frequently encountered genetic events in human 
malignancy where half of all tumours have an altered form of the gene (Hollstein et a/, 
1994). Genetic alterations in the p53 tumour suppressor gene occur in the majority of 
human cancers, are complex and are a significant factor in the development of malignant 
progression, including carcinoma of the breast, where half of all tumours have an altered 
form of the gene (Hollstein et a/, 1991, Nigro et a/, 1989). The wild-type p53 tumour 
suppressor gene is fully active when the p53 protein is expressed at normal ambient levels 
in the cell and does not depend on overexpression of the tumour suppressor protein. 
p53 functions biochemically as a transcription factor and transcription activation is 
lost in mutant proteins. The p53 gene is located on chromosome 17q13.1 (Benchimole et 
a/, 1985; Umesh et a/, 1988) and corresponds to approximately 20 kb of genomic DNA 
consisting of 11 exons, of which the first exon is non-coding, followed by a large 10 kb 
intron (Lamb and Crawford, 1986). Gene transcription is controlled by two regulatory 
sites; a 400 bp element 5' upstream of exon 1 (P1) and a second promoter element P2 
located in intron 1 approximately 1 kb downstream ofP1 (Harlow et a/, 1985, Reisman et 
a/, 1988). The entire p53 transcript is 2.8 kb long and produces a 53 kDa phosphoprotein 
containing 393 amino acids. 
p53 is thought to monitor the integrity of the cellular genome by acting as a cell 
regulator as it is often described as a Gl Check Point. p53 is activated in response to DNA 
damage and elicits apoptosis, cell-cycle arrest or senescence thereby maintaining healthy 
cells and preventing formation of tumours. Depending on the extent of DNA damage, p53 
will respond by inducing either G 1 arrest, which allows for DNA repair to take place 
before S phase entry (survival), or apoptosis. Cells that cannot be repaired will enter the 
apoptotic pathway. Cells deficient inp53 or expressing mutantp53 have a block in the GI 
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phase of the cell (Levine et a/, 1991 ), thus a mutated form of p53 looses its regulating and 
arresting activity. 
The p53 phosphoprotein is a nuclear protein that is expressed in very low levels in 
normal cells and tissues and it has a short half-life. The C-terminal region of the protein 
contains signals for nuclear localisation (Dang and Lee 1989, Addison et a/, 1990, 
Shaulsky et a/, 1990) whereas mutant proteins with deletions in the C-terminal region 
show cytoplasmic localisation (Sturzbecher et a/, 1988). Thus the protein displays nuclear 
and/or cytoplasmic localisation. 
The p53 protein has the ability to regulate transcription by binding to DNA. There 
are 5 highly conserved regions in the p53 protein (I-V) corresponding to codons 12 to 290 
(Nigro et a/, 1989; Levine et a/, 1991, 1994; Vogelstein and Kinzler, 1992), which 
function as a specific DNA-binding domain. Missense mutations occur predominately 
between codons 120 and 290, which contains 86 % of p53 mutations, whereas non-sense 
mutations tend to occur outside this region (Levine et al, 1993). Missense mutations of 
abnormal p53 will result in a defective protein product that cannot bind to a target gene 
with a p53 responsive element. Hence, these conserved regions serve as important 
functional domains. 
1.2.2.1 The p53 Gene Family 
Recently it has been suggested that p53 may not control cancer alone but may be 
part of a larger family (Oren, 1998). The discovery of new p53 family members has raised 
the possibility that p53 is assisted in preventing tumour formation and has dispelled the 
opinion that p53 was unique in form and function. In addition to the newly discovered p53 
homologue p73, p53CP (p53 competing protein), p40, NBP (non-p53 p53RE-binding 
protein), p51 and p63 have been proposed as new additional members of the family (Bain 
and Sun, 1997; Trink et a/, 1998; Zeng et al, 1998; Osada et al, 1998; Yang et al, 1998) 
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Table 1.1. The p53 tumour suppressor gene family. 
p53 Family Member lsoforms References 
(X. Yang et a/, 1998~ 
p Schmale and Bamberger, 1997 
y Yang et a/, 1998~ Schmale & Bamberger, 1997 
p63 
~p63 Yang et a/, 1998 
p40 Trinket a/, 1998 
p51 Osada et a/, 1998 
p53CP Bain and Sun, 1997~ Tan et al, 2001 
NBP Zeng et a/, 1998~ Zeng et a/, 2001 
p73L Senoo et a/, 1998 
(X. Kaghad et a/, 1997~ Ichimiya et a/, 1999 
p Kaghad et a/, 1997~ Zaika et a/, 1999 
y De Laurenzi et a/, 1998 
p73 0 De Laurenzi et al, 1998 
E De Laurenzi et a/, 1999 
~ De Laurenzi et a/, 1999 
11 Ishimoto et a/, 2002 
~p73 Ishimoto et a/, 2002 
p53 CP = p53 competing protein 
NBP = non-p53 p53 responsive DNA element (RE) binding protein 
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(Table 1.1). Both p73 and p63 have an additional C-tenninal extension found in p53 that 
undergoes alternative splicing resulting in multiple isofonns with different biological 
activities. While it is well established that p53 is a tumour suppressor gene, experiments 
with knock-out mice have determined that p63 plays a major role in ectodermal 
differentiation (Yang et a/, 1999) and that p73 is involved in neurogenesis (Yang et a/, 
2000), (reviewed in Yang et a/, 2002). 
1.2.2.2 p73 
p73 was the first p53 homologue described and is mapped to chromosome 1p36.33 
(K.aghad et a/, 1997), a region frequently deleted in several cancers, including breast 
(Caron et a/, 1993, Nagai et a/, 1995, Schwab et a/, 1996, Thompson et a/, 1997, White et 
a/, 1995). p73 is both structurally and functionally similar to p53 where over-expression 
can activate transcription of p21 Wafi/Cipl(wild-type p53 activated fragment/cdk-interacting 
protein I), a cyclin-dependent kinase inhibitor gene, and induce apoptosis in a p53 
independent manner (Kaghad et a/, 1997, Jost et a/, 1997), as well as activating the 
transcription ofp53-responsive genes involved in cell-cycle control (Jost et a/, 1997). 
The structural homology between p53 and p73 is most extensive within the 
conserved activation (29%), sequence specific DNA binding (63%) and oligomerisation 
domains (42%), (Figure 1.3). p73 encodes 8 distinct polypeptides (a., 13, y, 1>, E, l;, TJ, and 
t\N), whose profiles vary between tumours and normal tissues and have different 
biological activities (lchimiya et a/, 1999; Zaika et a/, 1999; DeLaurenzi et a/, 1998; 
DeLaurenzi et a/, 1999; Ishimoto et a/, 2002). These different p73 variants exist in cells, 
resulting in a family of proteins that further complicates the understanding of p73 
signalling in cancer cells. The p73a. and p7313 isofonns were the first originally described. 
p73a. encodes 14 exons and consists of 636 amino acids whereas p7313 consists of 499 
amino acids, derived from an alternative splicing of exon 13 and lacks a 
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Figure 1.3. Structural homology and structure of the p53, p73a and p63a proteins. 
636AA 
641 AA 
The percent identity at the amino acid level relative to p53 is indicated for each domain. The highest homology between the three proteins is within the 
central sequence-specific DNA binding domain with significant similarity in theN-terminal transactivation and C-terminal oligomerisation domains. Only 
p73 and p63 contain SAM-like domains. AA= amino acids, SAM =sterile alpha motif 
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C-terrninal tail (Kaghad et al, 1997). p73 is monoallelically expressed in neuroblastoma 
cell lines (Kaghad et al, 1997) and it is found to have marked peculiarity as variations in its 
expression have been found from tissue to tissue and from person to person (Nomoto et al, 
1998; Tsao et a/, 1999). The humanp73 promoter has recently been characterised (Ding et 
a/, 1999) and is found to contain a TAT A-like box which has low homology to the p53 
promoter (Levrero et a/, 2000). 
The role of the p73 gene was originally thought to be that of a classical tumour 
suppressor gene (Kaghad et a/, 1997). This however has not been supported by recent 
studies in malignant tumours where it has been frequently found to be expressed and not 
mutated (Nomoto et a/, 1998, Sunahara et a/, 1998, Takahashi et a/, 1998). Consistent loss 
of heterozygosity in tumours can be used as an indication of the presence of a tumour 
suppressor gene. Loss of heterozygosity studies have also been used to indicate the 
location of inherited genes predisposing to familial forms of tumours (Ponder, 1988). p73 
is expressed at low levels in all normal tissues and it is not expressed in neuroblastomas 
that contain deletions in chromosome 1 p. As the maternal chromosome is preferentially 
lost in some neuroblastomas, this suggests that at least one tumour suppressor on 1p is an 
imprinted gene. Experiments with normal peripheral blood specimens showed that 
expression of p73 was exclusively from the maternally derived chromosome (Kaghad et a/, 
1997). Additionally, monoallelic expression of p73 was found to occur in a number of 
cancer cell lines and in normal tissue (Kaghad et a/, 1997) and activation of the silent allele 
was found in renal cell carcinoma and lung cancer that is similar to loss of imprinting (Mai 
et al, 1998; Mai et a/, 1998b). However, biallelic expression ofp73 was observed in some 
normal tissue and lymphocytes as well as in bladder cancer and normal bladder suggesting 
that p73 expression could be tissue independent and that it is not monoallelically expressed 
in all human tissues (Kaghad et a/, 1997; Yokomizo et a/, 1999). A recent study has shown 
that the p73 gene is not an imprinted gene in ovarian cancer but could be involved in 
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advanced ovarian cancer through overexpression (Chen et al, 2000). 
Within the 5' untranslated region of the p73 gene there is a double nucleotide 
substitution at position 4 and 14 of exon 2 (Kaghad et al, 1997, DeLaurenzi et a/, 1998), 
(Figure 1.4). The frequency of these polymorphisms has been studied in a number of 
patients with different tumours including bladder, colorectal, oesphageal, liver, lung, 
neural, prostrate and renal cell carcinoma, and most recently breast cancer (Soulitzis et a/, 
2002; Yokomizo et a/, 1999, Sunahara et a/, 1998, Nimura et a/, 1998, Mihara et a/, 1999, 
Nomoto et al, 1998, Kovalev et a/, 1998, Takahashi et a/, 1998, Mai et a/, 1998, 
Ahomadegbe et a/, 2000). Although p73 has frequent heterozygous deletions, mutations in 
the remaining allele are extremely rare. To date no frarneshift mutations inp73 have been 
found in human primary tumours. In breast cancer, only one somatic missense mutation 
has been discovered (Han et a/, 1999). Overexpression of wild type p73 mRNA has also 
been observed in carcinoma of the breast (Zaika et a/, 1999), however the exact 
mechanism of this modification is not understood. The studies would suggest the p73 may 
augment rather than inhibit tumour development suggesting a contradictory role for p73 in 
malignancy (reviewed in Stiewe and Putzer, 2002). 
1.2.2.3 p63 
Various reported homologs ofp53 are now known to be isoforms ofthe same gene, 
p63 (Hibi et a/, 2000). p53CP shows similar binding specificity and also binds both double 
and single-stranded DNA oligonucleotides. p53CP may have p53-like functions by binding 
and transactivating p53 downstream target genes. A recent study has proposed that p53CP 
is p63, the official third member of the p53 gene family (Tan et a/, 2001). Both p51 and 
p40 map to human chromosome 3q, a region where deletions are commonly associated 
with bladder and other types of cancer. p40 has recently been reported to be 
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Figure 1.4. p73 allelic polymorphism. 
The 5' untranslated region of the gene consists of a double nucleotide substitution at 
position 4 and 14 (Kaghad et a/, 1997, DeLaurenzi et al, 1998). 
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oncogenic (Hibi et a/, 2000). pSI, is found to be highly expressed in skeletal muscle and 
placenta. and appears to bear more similarity to p73 than to pS3. It has been concluded that 
pSI and p63 are actually the same molecule and it is sometimes referred to as pSI/p63 
(Osada et a/, I998). Another study has also concluded that NBP is not p73 but is actually 
the pS3 homologue p63 (Zeng et a/, I998; Zeng et a/, 200 I). Thus, NBP and pS3CP appear 
to be the same family encoded by the p53 analogue p63. 
Unlike pS3, but like p73, p63 encodes 3 polypeptides (a, 13, y) that are translated 
from RNA molecules that share a common S' end and differ at their 3' end due to 
alternative splicing (Yang et a/, 1998; Schmale and Bamberger, I997). p53 encodes one 
major transcript however bothp63 andp73 each contain two separate promoters that direct 
expression of two different classes of proteins; TAp63/p73 which contains an acidic N 
terminus with homology to the transactivation domain of pS3, and £\Np63/73 which 
contain N-terrninally truncated products that lack the TA domain (Yang et a/1998; Yang 
et a/, 2000).The transactivation competent (TA} variants ofp63 and p73 can activate many 
pS3 target genes and can in some circumstances double for pS3 in its anti-proliferative 
action (Jost et a/, 1997; Yang et a/, I998). In contrast, variants lacking the transactivation 
domain (£\N) actually antagonise TA family members, including pS3 (Pozniak et a/, 2000; 
Liefer et a/, 2000). Thus, different variants exert opposing effects on cell fate and cell 
behaviour (reviewed in Michael and Oren, 2002; Little and Jochemsen, 2002). 
Both p73 and p63 contain a SAM (sterile alpha motit)-like domain at the C-
terrninus that is involved in protein-protein interactions (Chi et a/, 1999). The SAM 
domain is a compact globular domain composed of five helices (Levrero et a/, 1999). 
When both p63 and p73 are overexpressed they carry out many of the same function as 
pS3, such as transactivating some of the same target genes and inducing apoptosis or cell 
cycle arrest (Jost et a/, I997; Yang et a/, 1998). lsoforms encoded by splice variants or 
generated by transcription at alternative initiation sites are known to antagonise the effects 
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(Lohrum and Vousden, 2000; Yang et a/, 2000). It has also been demonstrated that mice 
lacking p53 give rise to spontaneous tumours, whereas those lacking p73 or p63 are not 
tumour prone (Yang et al, 2000). In contrast to p53, no known viral oncoproteins bind to 
or inactivates p73 or p63 (Marin et a/, 1998; Dobblestein et a/, 1998; Steegenga et a/, 
1999). However,p73 deficient mice exhibit inflammation of many organs suggesting a role 
for p73 in the inflammation response (Yang et al, 2000). 
Although these proteins belong to the same gene family, there are substantial 
differences in their normal physiological functions. Biologically, p73 appears to be more 
involved in neurogenesis and p63 in embryogenesis rather then in cancer (Yang et al, 
1999; Yang et al, 2000; Mills et a/, 1999). A mutational study showed very low frequency 
in cancers (Han et al, 1999; reviewed in K.aelin, 1999). However, it is now established that 
both of these p53 homologues have distinct and separate roles and may regulate a 
multitude of cellular and homeostatic processes (reviewed in Yang et al, 2002). 
1.2.2.4 p53 and Human Papilloma Virus (HPV) 
Since p53 was originally discovered as a protein that coprecipitates with the large T 
antigen of Simian Virus-40 (SV -40) (Lane and Crawford, 1979; Linzer and Levine, 1979), 
other viral oncoproteins have been reported to bind to and inactivate p53, including E6 of 
human papilloma virus (HPV) (Samow et a/, 1984). Studies have shown that p53 may be 
inactivated by the E6 protein of cervical associated HPV, which belongs to the papovavirus 
family of oncogenic DNA viruses (Lechner et a/, 1992). Once infected into a host cell, 
these viruses produce proteins that interact with host-derived proteins to bring about 
transformation. HPVs, especially HPV 16 and 18, are associated with high-grade cervical 
intraepithelial neoplasia (CIN) and invasive squamous carcinomas. The integration of these 
viruses in the genome results in increased expression ofE6 and E7 proteins which have the 
ability to transform cells into a neoplastic state. It is known that the E6 protein binds to p53 
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(Wemess et al, 1990) using the E6-associated protein (E6-AP) after which a rapid 
degradation of the p53 protein occurs which is mediated by ubiquitin-dependent 
proteolysis (Huibregtse et al, 1993). The introduction of a single HPV16-E6 gene causes 
the immortalisation of cells and dramatically reduces p53 protein levels (Band et al., 
1991). Tumour development is thought to arise through p53 mutations or by neutralisation 
of wild-type p53 by interaction with HPV proteins. Hence, formation of a p53-E6 complex 
sequesters the p53 protein thereby preventing it from performing its normal suppressor 
function. There are currently no known viral proteins that binds to or inactivates p73 or 
p63 (Marin et al, 1998; Dobblestein and Roth, 1998). 
1.2.2.5 p53 and p73 
The gene coding for p53 contains a single nucleotide polymorphism that results in 
either a proline or arginine at codon 72 (Figure 1.5). It has recently been shown that the 
arginine form of p53 is more susceptible to degradation by the human papillomavirus 
(HPV) E6 protein (Matlashewski et a/, 1987), whilst individuals homozygous for p53 Arg 
are 7 times more likely to develop HPV-associated cancer (Storey et a/, 1998). However, 
this has not been confirmed by studies in other populations (Hayes et a/, 1998, Rosenthal 
et a/, 1998, Helland et a/, 1998, Josefsson et a/, 1998, Hildestein et a/, 1998). p73 has also 
recently been reported to be resistant to E6-ubiquitin mediated proteolysis with both the 
p73p variant and mutant p73 being potent inhibitors of the growth of HPV E6 expressing 
human cancer cells (Prabhu et a/, 1998). It is important to determine whether members are 
involved in the same pathway, or whether they act as back-up genes for one another. 
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Figure 1.5. Nucleotide substitution resulting in p53 Pro/ Arg allelic expression. 
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1.2.2.6 p53 and MDM-2 
The MDM-2 (mouse double minute 2) oncoprotein (HDM-2 in humans) is a well-
known regulator ofp53 and p73. MDM-2 binds directly to theN-terminus ofp53, where it 
is then neutralised and degraded through ubiquitin-dependent proteolysis (Kubbutat et a/, 
1997; Haupt et al, 1997). p53 induces the expression ofMDM-2 that will then control p53 
activity and stability resulting in an autoregulatory feedback loop (Strano et a/, 2001; 
Michael and Oren, 2002). HDM-2 can bind to p73 where it promotes its stability and 
reduces its transcriptional activity but it does not degrade it (Zeng et a/, 1999; Ongkeko et 
a/, 1999). 
Additional studies have suggested that the p14 ARF (alternative reading frame) 
protein is critical for p53 to respond to certain oncogenic stimuli, perhaps by modulating 
the interaction ofHDM-2 with p53 (Zhang et a/, 1998; Kamijo et a/, 1998). It is thought 
that the destruction of p53 is mediated by binding to complexes containing HDM-2 and 
p300 (Grossman et a/, 1998). The p300/CBP complex also binds to theN-terminus ofp73 
promoting its transcriptional activity (Steegenga et a/, 1999). It is known that pl4ARF can 
physically interact with both HDM-2 and p53 thereby antagonising the effects of HDM-2 
on p53 (Zhang et a/, 1998; Kamijo et a/, 1998). However, p73 is not ubiquitinated by 
HDM-2 (Zeng et a/, 1999) and HDM-2 is known to enhance p63-dependant transcription 
(Zeng et a/, 2001). 
1.2.3 Apoptosis 
Two types of cell death have been characterised: necrosis and apoptosis. Necrosis 
is a pathological form of cell death that is not implicated in normal cell kinetics. It is 
associated with exogenous cell damage due to severe departures from ideal physiological 
conditions such as hypoxia and ischemia (Arends & Wyllie, 1991). Apoptosis is however 
involved in tissue kinetics and is typically triggered by a variety of stimuli including 
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growth factor withdrawal (Williams et a/, 1990), ionising radiation (Gobe et a/, 1988), heat 
and cytotoxic drugs (Lowe et a/, 1993). Apoptotic cell death is characterised by distinctive 
morphological changes which include membrane blebbing, cytoplasmic and nuclear 
condensation, chromatin fragmentation and formation of apoptotic bodies (Wyllie, 1980). 
It is an active process in which apoptotic cells are recognised by phagocytes and removed 
before they disintegrate. Apoptosis plays important roles in a variety of developmental 
events and in the control of tissue homeostasis (Oppenheim, 1991; Raff, 1992) and in 
disease processes, including cancer (Thompson, 1995). 
Both proto-oncogenes and oncogenes have been shown to be involved in the 
control of apoptosis, or programmed cell death. Genes such as c-Myc (Koskinen and 
Alitalo, 1993) and p53 (van Slooten et a/, 1998) play a role in the induction of apoptosis, 
whereas Bcl-2 acts specifically to block apoptosis (van Slooten et a/, 1998). It is known 
that Bcl-2 family proteins are key regulators of the apoptotic pathway and play an 
important role in tumourigenesis (reviewed in Schmitt and Lowe, 1999; ZOrnig et a/, 
2001). 
There are three main theories as to how cell might decide between apoptosis and 
growth arrest in response to p53: the dose-response model proposes that low levels of p53 
induce growth arrest and that high levels trigger apoptosis, the cell-background model 
proposes that a response to p53 is determined by the cell milieu, and that the promoters of 
different p53-responsive genes are recognised by differently modified forms of p53 (Lane, 
2001). However, it is also known that a p53-independent pathway of apoptosis also exists 
(Strasser et a/, 1994; Naik et a/, 1996). Many cell types are capable of executing apoptosis 
during embryogenesis through a route independent ofp53 (Donehower et a/, 1992). DNA 
repair systems are intricately involved in apoptotic signalling and the loss of mismatch 
repair or base excision and double-strand-break repair systems weakens that signalling 
(Hickman, 2002). 
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Normal tissue homeostasis is maintained through the regulation of cell proliferation 
and apoptosis. Thus, inhibition of cell death by suppression of genes that induce cell death 
or activation of genes that are responsible for cell survival, contribute to the development 
of tumours. Angiogenesis also plays a critical role in the inhibition of apoptosis by 
increasing the levels of growth factor thereby contributing to tumour progression (Naik et 
a/, 1996). The formation of tumours is a complex process that also involves the 
accumulation of lesions in genes that normally regulate the pathways of cell proliferation, 
differentiation and death required for tissue development. 
Some cells engage apoptosis more readily than others at the same levels of damage 
or when survival signals are withdrawn suggesting that certain types of cells can survive 
carcinogenic damage better than others. Some tissues have a higher incidence of cancer 
then others. The high prevalence of epithelial tumours would indicate that epithelial cells 
have a higher survival threshold than other cell types (Hickman, 2002). 
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1.3 Tumour Angiogenesis 
Angiogenesis, the process by which new blood vessels are fonned, is an important 
event in physiological or pathological conditions as it is fundamental to healing, 
reproduction, and embryonic development. Accumulating evidence indicates that 
progressive tumour growth is dependent on angiogenesis (Harris, 1997). Tumours induce 
blood vessels from the host tissue to sprout capillary tips that migrate towards and 
ultimately penetrate the tumour, providing it with a circulating blood supply and, therefore, 
an almost limitless source of nutrients. Thus, cancer is driven by persistent unregulated 
angiogenesis. 
It has been thirty years since it was first demonstrated that tumour growth is 
dependent upon adequate vascularisation (Folkman et a/, 1971, Folkman 1972). 
Subsequently, two distinct phases of tumour growth were identified: the avascular and 
vascular phases (Folkman, 1975). The avascular phase oftumour growth consists of a self-
limiting growth phase due to constraints on the diffusion of nutrients and catabolic 
products imposed by the tumour surface area in relation to its volume. In contrast, the 
vascular phase of tumour growth comprises a phase of rapid exponential expansion. 
Within humans, most tumours persist in situ for a long period of time in an 
avascular, quiescent state, from months to years. In this phase the tumour may contain only 
a few million cells as the cancerous tumour remains limited and will not grow beyond 2 
mm in size unless vascularisation has occurred (Weidner et a/, 1991, Folkman, 1995). The 
process of neovascularisation of the tumour is a critical step in the progression of the 
disease. Without neovascularisation, even cells that are perfectly capable of growing 
without constraint cannot fonn tumours of clinically relevant size as the limited diffusion 
of 02 from nearby host vessels limits their growth. Additionally, cell division is balanced 
by cell death. When a subgroup of cells within the tumour switches to an angiogenic 
phenotype by changing the local equilibrium between positive and negative regulators of 
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angiogenesis, tumours will start to grow rapidly and become clinically detectable. The 
different properties of endothelial cells can also influence their response to angiogenic and 
antiangiogenic molecules as the microvascular and capillary endothelial cells in distinct 
tissues display different biological properties depending on microenvironmental or genetic 
backgrounds. 
Angiogenesis is the only mechanism by which new vessels develop in adults. In an 
adult, the proliferation rate of endothelial cells is very low compared to many other cell 
types in the body. More than 1013 endothelial cells line the inside of blood vessels and 
cover an area of approximately I 000 square meters in a 70 Kg adult. The turnover time of 
these cells can exceed 1000 days. Tumour endothelial cells divide much more rapidly than 
normal endothelial cells, up to 50 times as fast as in breast cancer (Harris, 1997). Excessive 
angiogenesis also contributes to the pathology of a number of diseases including; cancer 
(Weidner et a/, 1991), atherosclerosis (Shweiki et a/, 1992), arthritis (Peacock et a/, 1992), 
psoriasis (Nickoloff et a/, 1994), diabetic retinopathy (Adamis et a/, 1994), endometriosis 
(Shifren et a/, 1996), and menorrhagia (Shifren et a/, 1996). In the disease process, 
angiogenesis can be the key contributor to the pathologic process or a beneficial 
compensatory response. 
1.3.1 Angiogenic Process 
The angiogenic process is complex involving not only endothelial cell proliferation 
but also the digestion of the extracellular matrix surrounding the capillaries by 
collagenases and proteases. Consequently, endothelial cells migrate and new capillaries 
differentiate. New capillaries arise mainly from the small venules in response to the 
angiogenic stimulus imparted by the tumour. The multi-step process requires the 
interaction of numerous factors able to stimulate the growth and development of new blood 
vessels. This may occur either directly, by activating the endothelial cells or promoting 
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enzyme synthesis for the release of angiogenic factors, or indirectly, by stimulating the 
stromal cells to produce enzymes (collagenases) that cause the degradation of the 
extracellular matrix and induce angiogenesis, thus facilitating the release of endothelial 
cells (Hannahan and Folkman, 1996). Local dissolution of the basement membrane, due to 
proteases, allows endothelial cells to migrate towards the source of the angiogenic factor 
and align themselves end to end to form a sprout, which subsequently develops a lumen 
(Ausprunk and Folkman, 1971). A confluence of sprouts permits blood flow resulting in 
the formation of a new basement membrane around the immature vessel (Jain et a/, 1997). 
The angiogenic process is demonstrated in Figure 1.6. 
1.3.2 Regulators of Angiogenesis 
Multiple angiogenic-mitogenic molecules, released by both tumour cells and host 
cells, mediate the induction of angiogenesis. The increase in vasculature allows for the 
rapid growth of a tumour and increases the probability of tumour cells entering the 
circulation and, hence, subsequent dissemination (Ellis and Fidler, 1995). To assure 
efficient exchange of oxygen and nutrients, every cell of the body needs to be sufficiently 
close to a blood capillary. Neovascularisation is critical for sustained tumour growth as it 
allows oxygenation and nutrient perfusion of the tumour as well as removal of waste 
products (Skobe et a/, 1997). The vascular and lymphatic systems are the major vehicles of 
transport of cancer cells released from the primary tumour. However, the extent of 
neovascularisation varies in different regions of the same tumour. 
Several positive and negative regulators of angiogenesis have been identified which 
are produced by tumour cells as well as by inflammatory cells {Table 1.2). These cells are 
stored in the extracellular matrix in a bioactive form. The endothelial cell surface also 
contains receptors for angiogenesis factors. Most of these factors act as paracrine factors 
produced by local cells or by recruited monocytes. 
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Figure 1.6. Schematic representation of the initial stages of angiogenesis. 
A capillary sprout emerging from a functional microvessel lined with endothelial cells in 
the interstitium is shown. During the process the basement membrane is degraded by 
proteases, endothelial cells migrate towards the stimulus, endothelial cells trailing behind 
the leading cell(s) proliferate, the lumen forms (canalisation) in the endothelial sprout, 
branches and loops form by confluence of sprouts to permit blood flow, the vessel is 
invested with pericytes and a basement membrane forms around the immature vessel (Jain 
et a/, 1997). 
A = Activation 
B = Proteolysis of extracellular matrix 
C = Disruption of cellular adhesion 
D = Proliferation of endothelial cells 
(Adapted from Sage, 1996). 
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F = Migration and chemotaxis 
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H = Angiogenic factors/stimulus 
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Table 1.2. Endogenous positive and negative regulators of angiogenesis. 
Positive Regulators Function Reference 
Angiogenin Stabilise vessels and inhibit Fett et a/, 1985 
permeability 
Fibroblast growth factors Stimulates angio/arteriogenesis Shing et al, 1984; 
(Basic and Acidic) Maciag et a/, 1984 
Granulocyte colony-stimulating factor Endothelial mitogen Bussolino et a/, 1991 
Hepatocyte growth factor Stimulates angio/arteriogenesis Rosen et a/, 1993; 
Endothelial mitogen Bussolino et a/, 1993 
Interleukin-8 Endothelial mitogen and motogen Koch et a/, 1992 
Placental growth factor Weak endothelial mitogen Maglione et a/, 1991 
Platelet-derived endothelial cell Recruits smooth muscle cells, causes Ishikawa et a/, 1989 
growth fuctor DNA synthesis 
Proliferin Endothelial motogen Jackson et a/, 1994 
Transforming growth factors a and ~ Angiogenic in vivo Schreiber et a/, 1986; 
Roberts et a/, 1986 
Tumour Necrosis Factor a Stimulates formation of tubular Friter-Schroder et a/, 1987; 
structure of endothelial cells in vitro Leibovich et a/, 1987 
Vascular endothelial growth fuctor Stimulates angio/vasculogenesis, Senger et a/, 1983; 
permeability, leukocyte adhesion Ferrara et a/, 1989 
Negative Regulators Function Reference 
Angiostatin (38 kDa fragment of Inlullits proliferation, chemotaxis O'Reilly et a/, 1995 
plasminogen) 
bFGF soluble receptor Mitogen and chemotactic to Schweigerer et a/, 1987 
endothelial cells 
Interferon alpha Inhibition of endothelial cell motility Sidky et al, 1987 
and growth 
Metallo-proteinase inhibitors Suppresses pathological Moses et al, 1990 
angiogenesis 
Placental proliferin-related protein Inhibition of endothelial cell motility Jackson et a/, 1994 
Platelet factor 4 Inhibits proliferation and VEGF-A Sharpe et al, 1990; 
activity, chemotaxis Taylor and Folk:man, 1982 
Prolactin (16 kDa fragment) Inhibition of endothelial cell motility Clapp et a/, 1993 
and growth 
Thrombospondin-1 Inhibits proliferation, chemotaxis Rastinejad et al, 1989; 
Iruela-Arispe et a/, 1991 
Transforming growth factor ~ Inlullits proliferation of endothelial Roberts et a/, 1986 
cells in vitro 
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1.3.3 Promoters of Angiogenesis 
Some of the positive regulators of angiogenesis include; acidic and basic fibroblast 
growth factor (aFGF and bFGF), transforming growth factors a and p (TGF-a!P). tumour 
necrosis factor (TNF-a.), angiogenin, and vascular endothelial growth factor (VEGF). The 
FGFs were among the first angiogenic factors to be well characterised. FGF is not a 
specific endothelial cell growth factor and has many cell targets including smooth muscle 
cells and neurons (Klagsburn and Moses, 1999). These inducers of angiogenesis can be 
exported from tumour cells, mobilised from extracellular matrix or released by 
macrophages attracted to the tumour (Folkman, 1995). bFGF is distributed widely in 
normal and neoplastic tissues and its expression has been reported in a variety of human 
tumours, including brain (Folkman, 1995). 
1.3.3.1 Vascular Endothelial Growth Factor 
Vascular endothelial growth factor (VEGF) is the most potent and specific growth 
factor for endothelial cells. It plays a major role in regulating normal embryonic 
vasculogenesis and angiogenesis as well as tumour angiogenesis (reviewed in Dvorak: et al, 
1999; Ferrara, 1999). It was originally isolated as the vascular permeability factor (Senger 
et a/, 1983) and subsequently as a growth factor which induced proliferation of endothelial 
cells a few years later (Ferrara and Henzel, 1989). VEGF is a 46 kD dimeric glycoprotein 
and is a specific endothelial cell mitogen that has a high affinity for heparin binding 
(Neufield et a/, 1999). The human gene has been assigned to chromosome 6p21.3 
(Vincenti et al, 1996) and is organised in eight exons, separated by 7 introns, and by its 
coding regions which spans approximately 14 kb (Tischer et a/, 1991) (Figure 1. 7). 
There are currently four family members which are dimeric glycoproteins; VEGF-
A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PIGF) (Senger et a/, 1983; 
Olofsson et a/, 1996; Joukov et a/, 1996; Achen et a/, 1998; Maglione et a/, 1991). VEGF-
-29-
Chapter 1. Introduction 
A is found in at least six splice variant isofonns that have been designated VEGF121, 
VEGF14s, VEGF16s, VEGF183, VEGF189 and VEGF206, which refers to the number of 
amino acid residues in the mature protein (Leung et a/, 1989; Poltorak et a/, 1997; Keck et 
a/, 1989; Houck et a/, 1991; Jingjing et a/, 1999; Tischer et a/, 1991). The isoforms arise 
from alternative splicing of mRNA transcripts and each exhibit different heparin-binding 
affinity (Houck et a/, 1992). The independent roles of each isoform are poorly understood. 
All five peptides are biologically active but differ in their physiochemical 
properties. The N-terminal region of VEGF contains eight cysteine residues that enable the 
isofonns to dimerise. All ofthe known exons of the VEGF gene are expressed in VEGF206, 
whereas the other isofonns are characterised by partial or complete deletion of exon 6 
(Jingjing et a/, 1999) (Figure 1.7). The major subtype VEGF 121, consists of exons 1-5 
encoding 141 amino acids of the N-tenninal region and six C-terminal amino acids 
encoded by exon 8 (Tischer et a/, 1991). Complete deletion ofexon 6 is found in VEGF 121 
and VEGF16s, whereas only a part of exon 6 is missing in VEGF145, VEGF183, and 
VEGF 189· Exon 6 encodes a stretch of highly basic amino acids and the exon 7 encoded 
region ofVEGF displays a mild heparin-binding ability (Ferrara et a/, 1991). VEGF121 is a 
soluble form of VEGF and possess no heparin binding ability whereas VEGF 189 and VEGF 
165 do bind heparin but VEGF 189 binds more strongly than does VEGF 165 (Houck et a/, 
1992). VEGFI65 is the most abundant of the five isoforms in vivo and is commonly used in 
studies investigating the biological effects ofVEGF (Ferrara, 1993). The different isofonns 
have distinct biological activity where the differences in their ability to regulate vascular 
permeability or their mitogenic activity may involve splicing out these important domains 
(Keyt et a/, 1996). 
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Structural characterisation of the human VEGF gene shows that it comprises eight exons. VEGF isoforms arise from alternative splicing, where 
VEGF121 lacks exons 6 (composed of exons 6A, 6B and 6C) and 7, VEGF16s lacks exon 6, whilst only part of exon 6 is missing is VEGF124, 
VEGF183 and VEGF189. All known exons are expressed in VEGF206· (Adapted from Tischer et al, 1991; Jingjing et al, 1999). 
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1.3.3.1.1 VEGF Receptor Family 
VEGF is specific for vascular endothelium as it binds to membrane receptors that 
belong to the tyrosine kinase family of growth factor receptors, which are found only on 
vascular endothelial cells and may be up-regulated in many tumours (Guillemin & 
Krasnow, 1997). VEGF binds the receptor tyrosine kinases and stimulates the local 
proliferation of blood capillaries to increase oxygen delivery. A 3-D molecular model of 
the VEGF receptor binding domain is shown in Figure 1.8 (MUller et a/, 1997). 
The VEGF receptor family includes flt-1 (fms-like-tyrosine kinase) (Shibuya et a/, 
1990; Finnerty et a/, 1993), flt-4 (Pajusola et a/, 1992; Finnerty et a/, 1993; Pajusola et a/, 
1994), flk-1 (also known as KDR) (Matthews et a/, 1991, Sarzani et a/, 1992) and 
neuropilin receptors 1 and 2 (Neufeld et a/, 1999). The receptors are transmembrane 
proteins that contain an extracellular, a transmembrane and an intracellular tyrosine kinase 
domain. The flt-1 gene encodes the VEGF receptor 1 (VEGFR-1), flk-1 genes encode the 
VEGFR-2 and the flt-4 gene encodes VEGFR-3, all of which can be upregulated by 
exposure to VEGF. The VEGFR-1 is generated by mRNA splicing and both VEGFR-1 and 
VEGFR-2 bind VEGF-A. The flt-1 and flk-1 genes were the first discovered and therefore 
the best characterised. The flt-1 gene contains a HIF-1a binding site and responds to 
hypoxic induction. Although the flk-1 gene also responds to hypoxic induction with 
increased expression, it does not contain a HIF-1a binding site and this response is 
believed to occur via a posttranscriptional mechanism (Giordano, 1999). The flt-4 receptor 
preferentially binds to VEGF-C and -D. As both VEGF and its receptors are required for 
angiogenesis, they are considered to be one of the most crucial regulatory pathways in 
angiogenesis. 
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Figure 1.8. A 3-D molecular model of the VEGF receptor binding domain (Milller et a/, 
1997) 
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1.3.3.1.2 VEGF Induction and Expression 
VEGF is known to be a major factor in the neovascularisation of tumours as it is a 
potent angiogenic factor. VEGF functions as a survival factor for newly formed blood 
vessels during developmental neovascularisation but it is not required for the maintenance 
of mature vessels (Benjamin and Kishat, 1997). VEGF is essential for angiogenesis and is 
produced by many normal and tumour cells, including glioma and carcinomas (Thomas, 
1996). VEGF gene expression is induced by environmental stresses such as hypoxia 
(Shweiki et a/, 1992), hypoglycaemia (Schweiki et a/, 1995), in the presence of growth 
factors (Horiuchi et a/, 1997), oncogenes (Mukhopadhyay et a/, 1995) and tumour 
suppressor mutations (Fontanini et a/, 1997). 
The major control point for the hypoxic induction of the VEGF gene is the 
regulation of the steady state levels of mRNA (lkeda et a/, 1995; Levy et a/, 1996). 
Hypoxia is a potent inducer of VEGF mRNA expression in vitro and VEGF up-regulation 
is achieved by increased RNA stability (Levy et a/, 1996). Hypoxia up-regulates VEGF 
expression by activating a hypoxia-inducible factor-1 (HIF-1) binding sequence in the 5'-
flanking region of the VEGF promoter, which results in increased VEGF mRNA 
transcription and stability (Liu et a/, 1995). This region functions as a cis-element 
regulating the hypoxic induction ofVEGF. It has been suggested that an adjacent sequence 
located immediately downstream within the hypoxia response elements is also essential for 
the hypoxic induction of the promoter (Lui et a/, 1995). A discrepancy between the 
transcriptional rate and the steady-state mRNA level may be induced by hypoxia (Levy et 
a/, 1996). It has been demonstrated that hypoxic induction ofVEGF in C6 glioma cells is 
due to both transcriptional activation and increased stability of mRNA mediated by the 
presence of hypoxia responsive elements in the VEGF gene (Ikeda et a/, 1995). 
VEGF is the most widely studied angiogenic factor. However, little is known about 
the molecular mechanism of hypoxic induction and activation of expression of VEGF in 
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tumours. VEGF is thought to act as a paracrine angiogenic factor, that is, it is produced and 
secreted by the tissue to which new capillaries grow (Klagsburn and Moses, 1999). Thus, 
its expression results in the delivery of oxygen and nutrients required for tumour growth. 
To date there is no evidence for translational or post-translational control of VEGF 
expression. p53 protein depresses VEGF production and supports the secretion of 
thrombospondin-1, a multifunctional angiogenesis inhibitor that modulates endothelial cell 
adhesiveness (Bussolino et a/, 1997). Thus, p53 mutations induce angiogenesis. 
1.3.3.1.3 VEGF and Angiogenesis 
It has long been recognised that increased expression of VEGF is essential for the 
establishment of angiogenesis in most solid tumours. A model for this induction has 
recently been put forth suggesting that increased levels of VEGF result from the 
synergistic effects of tumour hypoxia and tumour-specific genetic alterations (mutations) 
involving oncogenes and tumour suppressor genes. The increased expression of VEGF 
results in the formation of dysfunctional vasculature that cannot adequately perfuse the 
complete tumour. Tumour progression is then dependent upon the cellular adaptation of 
hypoxia that is independent of angiogenesis. Consequently, most solid tumours share the 
similar characteristic that poor clinical outcome is significantly correlated with vascular 
density and tumour hypoxia (Semenza, 2000). 
It is known that VEGF plays an important role in embryogenesis and it functions as 
a major angiogenic factor in both normal and in pathological conditions. It has been 
proposed that VEGF participates in the development of diabetic retinopathy. In simple 
diabetic retinopathy, VEGF may also be responsible for retinal microvascular 
hyperpermeability, an early functional disorder which occurs in this phase of diabetic 
retinopathy (Murata et a/, 1996). It has also been suggested that the overexpression of 
VEGF plays an important role in the development of blood-retinal barrier (BRB) 
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breakdown in simple diabetic retinopathy (Matthews et a/, 1997). 
Recently, a study has shown that the potential tumour suppressor gene p73 can 
function as a transcriptional repressor of the VEGF gene promoter suggesting a role for 
p73 in angiogenesis by repressing VEGF expression (Salimath et a/, 2000). p73 behaves 
similarly to p53 in its inhibitory effect on VEGF expression. Tumour suppressor genes 
such as p53 and p73 play a role in tumour cell proliferation and are also able to modulate 
cell survival functions by inhibiting VEGF expression. 
1.3.4 Inhibitors of Angiogenesis 
Several angiogenesis inhibitors have recently been described (Table 1.2). Some of 
these inhibitors are natural molecules that act directly on endothelial cells to block their 
migration, proliferation and/or their ability to form capillary-like tubes, and include 
proteins such as angiostatin, endostatin, platelet factor-4, and thrombospondin-1 (reviewed 
in Hanahan and Folkman, 1996). 
Thrombospondin-1 (TSP-1) was one of the first natural angiogenesis inhibitors to 
be described, where its expression is inversely correlated with angiogenic activity 
(Rastinejad et a/, 1989). It is a secreted heparin binding glycoprotein found in the 
circulation and is associated with the extracellular matrix. It is also constitutively secreted 
by certain types of normal cells (Folkman, 1995). It is known that TSP-1 is regulated by 
p53, where loss of p53 results in suppression of TSP-1 and a concomitant increase in 
angiogenic activity (Dameron et a/, 1994). 
Angiostatin is an angiogenesis inhibitor that forms as a proteolytic fragment of 
plasminogen by the action of elastase or matrix metalloproteinase-2 (O'Reilly et a/, 1994; 
Giordano, 1999). Endostatin is a proteolytic fragment ofthe carboxyl terminus of collagen 
XVIII and is a potent inhibitor of the growth of primary and metastatic tumours (O'Reilly 
et a/, 1997) and induces apoptosis in endothelial cells (Dhanabal et a/, 1999). 
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Additionally, VEGF can be neutralised by specific anti-VEGF antibodies and 
sequestered by soluble receptors (Presta et a/, 1997; Goldman et a/, 1998). Moreover, 
specific inhibitors of VEGF receptor kinases can inhibit VEGF-mediated signal 
transduction (Fong et a/, 2002). 
1.4 Tumour Hypoxia 
Angiogenesis can be initiated by a variety of physical signals, including tissue 
hypoxia. As tumours grow and divide rapidly they exhaust local supplies and central 
regions of tumour become hypoxic. Resistant tumour cells tend to develop in oxygen 
deprived areas of the tumour (Harris, 1997). The blood vessels supplying tumours are 
relatively poorly organised and disordered compared with those of normal tissues, leading 
to inefficient delivery of oxygen and other nutrients to many of the cells in tumours. As 
oxygen diffuses from blood capillaries through the mass surrounding cells it is depleted by 
normal cell metabolism. 
The degree of hypoxia experienced by a cell in vivo is determined by its proximity 
to the arterial blood supply and rates of oxygen consumption by the cell and its neighbours. 
The human body maintains sufficient oxygen to meet the metabolic demands of each cell 
thus, hypoxia is a cellular phenomenon characterised by oxygen levels that are inadequate 
to meet metabolic demands (Jiang et al, 1996). Cells, which are hypoxic because of their 
distance from blood vessels, are likely to also be deprived of their nutrients and exposed to 
acidic metabolites such as lactic acid. Transient changes in the perfusion of individual 
blood vessels may further reduce oxygen transport and change the oxygenation status of 
some cells near to blood vessels over relatively short time periods (Webster, 1998). 
Hypoxia occurs in many common pathological conditions and moderate levels of 
hypoxia are also known to exist under normal conditions in some normal tissues, for 
example, skin, oesophagus and liver (Webster, 1998). When oxygen becomes rate limiting 
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the cell responds by undergoing the 'Pasteur effect'; as ATP generation by oxidative 
phosphorylation begins to fall off due to lack of oxygen, the cell shuts down nonessential 
cell functions and the resulting energetic deficit is made up by activation of anaerobic ATP 
supply pathways (Hochachka et al, 1996). Hence, the cell abandons oxidative 
phosphorylation and relies solely on glycolysis for energy production. As a consequence, 
the expression of glucose transporters and glycolytic enzymes is increased and 
transcriptionally upregulated to compensate for the decrease in the oxidative capacity to 
generate A TP. Expression of genes encoding components of the electron transport chain is 
repressed, whereas transcription of genes encoding enzymes of the glycolytic pathway is 
activated (Semenza et a/, 1994). Factors that promote angiogenesis are then released 
Hypoxia is also able to stimulate p53 levels and activate the p53 protein which may trigger 
apoptosis (Graeber et al, 1996). Under conditions of severe hypoxic stress, cell 
proliferation is inhibited by the tumour suppressor p53 and cell death follows through the 
transactivation of genes such as p21Wafl/Cipl and the pro-apoptotic gene bax. Tumours that 
do not adapt to severe oxygen and nutrient deprivation undergo apoptosis or necrosis. 
Many biological processes are concerned with adaptation to the availability of 
oxygen and oxygen tension is an important regulator of gene expression. Hypoxia 
influences the proliferation tumour cells (Carmeliet et a/, 1998), the rate of apoptotic death 
(Graeber et a/, 1996) and metastasis (Brizel et a/, 1996). Multiple hypoxic responses 
including adaptation to anaerobic metabolism (glycolysis), erythropoiesis, angiogenesis, 
vasodilation and genetic alterations are all under the control of a single transcription factor, 
hypoxia inducible factor-1 (HlF-1). As tissue hypoxia is a common and prognostically 
important feature of rapidly growing tumours (Hockel et a/, 1996), IDF-1 plays a potential 
role in cancer as well as a number of other diseases. 
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1.4.1 Hypoxia Inducible Factor-1 (HIF-1) 
The discovery that HIF-1 is a key regulator of 02 homeostasis initially resulted 
from analysis of the molecular mechanisms by which erythropoietin gene transcription was 
activated in response to hypoxia (Semenza et a/, 1991; Semenza, 1999). The identification 
of a critical DNA control-sequence termed the EPO 3' enhancer, and its corresponding 
transcription factor (Madan and Curtin, 1993; Beck et a/, 1993), led to the characterisation 
of a short sequence that functions as a hypoxia response element (HRE). Transfection 
studies of this enhancer sequence found that is was involved in the regulation of genes 
encoding different gene products, such as glycolytic enzymes (Maxwell et a/, 1993). 
Further analysis of the erythropoietin 3' enhancer defined HIF-1 as a DNA binding 
complex that is critical for the function of this sequence (Wang et a/, 1995). 
HIF-1 is a transcription factor that is a central component of the hypoxic response 
pathway as it regulates the transcriptional response of a number of genes, including 
erythropoietin (EPO), vascular endothelial growth factor (VEGF), inducible nitric oxide 
synthase (iNOS), glucose transporter I (GLUT-1)and glycolytic enzymes under conditions 
of hypoxia (Semenza and Wang, 1992; Levy et a/, 1995; Melillo et a/, 1995; Firth et a/, 
1994; Firth et a/, 1995; Semenza et a/, 1994; Guillernin and Krasnow 1997). More recently 
a novel HIF-1 responsive gene, RTP801 has been identified and is known to be involved in 
apoptosis (Shoshani et a/, 2002). 
1.4.1.1 Structure ofHIF-1 
HIF-1 is a heterodimer consisting of an alpha (a.) and beta (13) subunit with 
molecular weights of 120 kDa and 91-94 kDa respectively. Both subunits are members of 
the basic helix-loop-helix (bHLH)-per-arnt-sim (PAS) family of transcription factors 
(Wang et a/, 1995, Guillemin and Krasnow, 1997) and contain bHLH domains responsible 
for heterodimerisation through the two helices and DNA binding through their basic 
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domain (Figure 1.9). Both heterodimers also contain a PAS motif that is found in a 
number of transcription factors including the Drosophila proteins Period, Single-minded, 
Trachealess and mammalian proteins such as Aryl Hydrocarbon Receptor (AHR). PAS 
domains are also required for dimerisation and target gene specifity (Jiang et a/, 1996; 
Zelzer et a/, 1997). The C-terminal half ofHIF-1a contains domains required for hypoxia-
induced nuclear translocalisation, protein stabilisation and transactivation (Huang et al, 
1998; Jiang et a/, 1996; Kallio et a/, I 998). The HIF-1a subunit is composed of 826 amino 
acids whereas the HIF-1 J} subunit is composed of789 amino acids (Wang et a/, 1995). 
HIF-la is encoded by the human HIF1A gene (Iyer et a/, 1998). Recent sequencing 
of the HIF1A gene promoter found that it belongs to the TAT A-less promoter gene family 
(Iyer et a/, 1998). The HIF1A promoter is composed of a GC rich sequence containing 
several Sp1 putative binding sites, which are located downstream from the transcription 
initiation site. The promoter also contains several putative HREs which are HIF-1 cis 
acting elements (Iyer et a/, 1998). Constitutive transcription of the TAT A-less promoters is 
dependent on Spl, NF-1 binding sites or Initiator sequences located upstream or 
downstream from the + 1 transcription start site (Minet et a/, I 999). 
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Under hypoxia, IDF-1a accumulates, translocates to the nucleus, dimerises with IDF-1r_3, and binds to the target DNA sequence within the hypoxia-
responsive element found in the promoter region of different oxygen-regulated genes. The N-terminal half of the molecule containing the bHLH-PAS 
domain is required for dimerisation and DNA binding (Jiang et a/, 1996). The C-terminal contains domains required for hypoxia-induced nuclear 
localisation, protein stabilization and transactivation (Huang et a!, 1998; Jiang et a/, 1996; Kallio et a/, 1998). 
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1.4.1.2 HIF-1 Transcriptional Activity 
It has been demonstrated that elements in the C-terminal transactivating domain 
(775-826 AA) oflllF-1a are responsive to low oxygen concentrations (Huang et a/, 1998; 
Pugh et a/, 1997). Under hypoxia, a rapid accumulation oflllF-1a occurs in the nucleus 
where it then dimerises with IDF-113 (Wang et a/, 1995). Both dimerisation and DNA 
binding are essential for the function of IDF-1 (Jiang et a/, 1996); the transactivation 
domains in the carboxy-terminal portion are then able to participate in gene transcription. 
The amount oflllF-1a protein in the nucleus is rate limiting and determines the functional 
activity of the IDF-1 complex (Semenza, 1999). A molecular model for the dimerised 
subunits through the bHLH domain was recently determined and is shown in Figure 1.10A 
(Michel et a/, 2000). 
The IDF-13 factor is also known as the aryl hydrocarbon receptor nuclear 
translocator (ARNT). IDF-113 can form heterodimers with other proteins, such as the aryl 
hydrocarbon receptor, and it is abundantly present (Reyes et a/, 1992). Although both 
heterodimers contain C-terminal transactivation domains, the IDF-113 transactivation 
domain is not implicated in the hypoxic response (Wood et a/, 1996). A conflict regarding 
the transcriptional regulation oflllF-1a exists in the literature. The expression of the IDF-
1a gene has been demonstrated to be rapidly up-regulated in response to low cellular 
oxygen tension (Huang et a/, 1996; Bergeron et a/, 1999), however other studies have 
reported that at the mRNA level IDF-1a and IDF-113 are both constitutively expressed and 
do not seem to be significantly modified by hypoxia (Morel and Barouki, 1999). 
Conversely, while the IDF-113 protein is found in normoxic cells, nearly no IDF-1a protein 
can be detected under these conditions. 
Transcriptional activation is mediated by the binding of IDF-1 to the 5' flanking 
sequence of the VEGF gene, a cis-acting hypoxia response element (HRE) located 1 kb 5' 
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to the transcriptional start site (Forsythe et a/, 1996; Canneliet et a/, 1998; Ryan et a/, 
1998), or to the target sequence within the HRE found in the promoter region of a number 
of different· oxygen-related genes. The HRE is a specific 8 bp motif (5' (G/C!f)-
ACGTGC-(G!f) 3') target sequence and was first identified in the erythropoietin gene 
promoter (Semenza and Wang, 1992), a glycoprotein hormone that regulates mammalian 
erythrocyte production and oxygen delivery to tissues. A 3D molecular model for the 
binding ofHIF-1 to its DNA consensus sequence HRE has been proposed and is shown in 
Figure l.lOB (Michel et a/, 2000). 
1.4.1.3 Mediators of HIF-1 Transcriptional Activity 
In addition to hypoxia, the HIF-1 complex is inducible by particular transition 
-' 
elements such as cobalt ions and iron chelating agents such as desferrioxamine (DFO) but 
not by inhibitors of mitochondrial respiration such as cyanide or azide (Pugh et a/, 1997). 
This suggests that at least one key component in the pathway is a heme protein (Kallio et 
a/, 1997). The underlying mechanisms of action are not known however, it has been 
suggested that they increase (Chandel et a/, 1998) or decrease (Bunn and Poyton, 1996) the 
level or production of reactive oxygen species, which may serve as signaling molecules or 
mediators of hypoxia-induced gene transcription (Semenza, 1999). It has recently been 
suggested that the oxygen signal is converted to a redox signal that then may trigger a 
kinase cascade and/or regulate HIF-1 directly (C~J!Ildel et a/, 2000; Haddad et a/, 2000; 
Chandel and Schumacker 2000). 
It is known that HIF-la binds directly to and stabilises p53 (An et a/, 1998) and 
HIF-la mediated transcriptional activity is also inhibited by p53 through interaction with 
p300 (Biagosklonny et a/, 1998). The transactivational activator/histone acetyltransferase 
proteins CBP (CREB binding protein) and p300 have been shown to be directly associated 
with HIF-la and increase transactivational activity through their cysteine-histidine rich 
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A) 
B) 
Figure 1.10. Proposed 3D molecular models ofHIF-1 . A) 3D molecular model of the HIF-
la!HIF-1J3 (ARNT) heterodimer through the bHLH domain. B) 3D molecular model for 
the binding ofHIF-1 to its DNA consensus sequence HRE (Michel et a/, 2000). 
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domain CHI (Ebert et a/, 1998; Kallio et a/, 1998). The interaction of the transactivational 
domains in HIF- la with coactivators such as CBP, p300, SRC-1 and TIF2, is regulated by 
the cellular oxygen concentration and redox state (Kallio et a/, 1998; Ema et a/, 1999; 
Carrero et al, 2000). 
An additional study suggests that p53 accumulation during hypoxia requires an 
increase in a mitochondrial dependent ROS signal in human breast carcinoma MCF-7 cells 
(Chandel et a/, 2000). Thus, it is thought that mitochondria regulate p53 protein levels 
during hypoxia through a redox-dependent mechanism involving ROS that create an 
oxidising signal in the cytosol. The cell presumably senses its oxygen concentration 
through reactive oxygen species so that the stabilisation of the HIF-la protein is redox 
induced (Salceda and Caro, 1997). 
A recent report has found that advanced glycation end products (AGEs) induce 
HIF-la accumulation through an ERK dependent pathway (Treins et a/, 2001). AGEs and 
their intermediates have been implicated in the pathophysiological dysfunction associated 
with the vascular complications of diabetes mellitus (Brownlee, 1995; 2001). ERK 
activates HIF-1 transcriptional activity by promoting the phosphorylation of HIF-la 
subunit (Richard et a/, 1999; Minet et a/, 2000). The PI3K dependent pathway is also 
involved in HIF-1 activation (Jiang et a/, 2000; Zundel et a/, 2000; Zhong et a/, 2000). 
Overexpression of an activated form of phosphatidylinositol 3-kinase (PI3K) or PKB, or 
expression of dominant-negative phosphatase and tensin homologue stimulates HIF-la 
expression in response to hypoxia and induces angiogenesis. PI3K catalyses the conversion 
of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-biphosphate to 
phosphatidylinositol 3,4 phosphate and phosphatidylinositol 3,4,5-triphosphate. All of 
these products are allosteric activators ofphosphatidylinositol-dependent kinase 1 (Sandau 
et a/, 2000). Additionally, epidermal growth factor regulates HIF-la expression through 
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the signalling cascade PI3KIPKBIFRAP (FKBP-rapamycin-associated protein) (Zhong et 
al, 2000). 
1.4.1.4 HIF-1a Degradation 
The HIF-1a half-life has been demonstrated to be less than 5 minutes in normal 
oxygen concentrations (Huang et a/, 1998; Wang et al, 1995), making it one of the most 
quickly degraded proteins found in mammals. The formation of HIF-1 is dependent on the 
stability of the HIF-1a subunit, which is protected from ubiquitination and proteasomal 
degradation in hypoxic conditions (Huang et a/, 1996; Huang et a/, 1998). In oxygenated 
cells HIF-1a is rapidly ubiquitinated and degraded by the ubiquitin-proteasome system, 
thus keeping its protein level extremely low (Salceda and Caro, 1997; Huang et al, 1998; 
Kallio et al, 1999). HIF-la is stabilised by blockage of the ubiquitin-proteasome pathway 
with specific proteasome inhibitors thereby stabilising the HIF-1 complex under normoxic 
conditions (Figure 1.11). Ubiquitin-mediated proteolysis functions by covalently linking 
the protein for destruction to a small, highly conserved ubiquitin protein. This covalent 
attachment signals their destruction by the 26S proteasome, a large complex with multiple 
proteolytic activities (DeMartino and Slaughter, 1999). 
An area in HIF-la, located in the central region of the protein (401-603 AA), has 
been found to be responsible for oxygen dependent degradation and had been labelled as 
the oxygen dependent degradation domain (ODD) (Huang et al, 1998). The whole ODD 
domain may be required for the ubiquitin/proteasome-dependent degradation ofHIF-1a as 
it remains stable even under nonnoxic conditions when part of the ODD is deleted (Huang 
et al, 1998). The region also contains two PEST motifs (proline, glutamic acid, serine, 
threonine) which have been demonstrated to be a trademark of rapid intracellular 
degradation (Rogers et a/, 1986). An additional highly conserved sequence has been found 
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Figure 1.11. Activation ofiDF-1 by hypoxia and subsequent degradation in normoxia via ubiquitination. 
During hypoxia, ubiquitination is prevented and IDF-1a. is stabilised. It then forms a stable heterodimer with IDF-113 (ARNT) and the IDF-1a.j3 heterodimer 
translocates to the nucleus where it binds to hypoxia-response elements (HRE) in the 5' intronic and 3' sequences of genes that are regulated by hypoxia, 
promoting gene transcription. CBP and p300 are transcriptional coactivators, + 1 indicates the transcriptional start site. Under normoxic conditions, an 
unknown oxygen sensor targets IDF- la. for proteolytic degradation. IDF-1a. is rapidly ubiquitinated (Ub) by a characterised complex containing pVHL, Cu12 
(cullin 2), E2 (unknown ubiquitin-conjugating enzyme), Rbx1 (a RING-H2 finger protein), and then destroyed by the proteasome. 
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between residues 557-571 of the HIF-la protein that was shown to be involved in hypoxic 
regulation (Srinivas et a/, 1999). These areas found within the HIF-la protein help to 
understand why the protein degrades so rapidly however they have yet to explain the 
mechanism or mechanisms involved in its degradation. It has been suggested that 
phosphorylation or association with interacting proteins may play a role (Pugh et a/, 1999; 
Srinivas et a/, 1999), however further studies are required to confinn or eliminate these 
theories. 
The product of the V on Hippel Lindau (pVHL) tumour suppressor gene has also 
been suggested to be involved in HIF-la degradation. Inactivation of the VHL gene is 
associated with several types of cancer, most notably central nervous system 
haemangioblastomas and renal carcinoma. pVHL is also associated with ubiquitin-protein 
ligase activity (Lisztwan et a/, 1999). The association ofHIF-1a with pVHL is dependent 
on the HIF-la ODD domain (Maxwell et a/, 1999), within which is a highly conserved 
region that contains a binding site for pVHL. pVHL, along with elongin Band elongin C, 
will bind directly to HIF-la subunits in the presence of oxygen and targets them directly 
for polyubiquitination and destruction (Cockman et a/, 2000; Kamura et a/, 2000). The 
HIF-1 complex has been demonstrated to be active, in addition to HIF-la being 
constitutively expressed, in cells defective in VHL (Maxwell et a/, 1999). In cells that 
constitutively lack the VHL protein (pVHL), HIF-la subunits are stable and HIF-1 is 
active, overproducing mRNAs encoded by HIF target genes. The cells have a high 
expression of HIF-1 induced genes and glucose transporter 1 (GLUT-I) under both 
nonnoxia and hypoxia. 
A recent study has found that HIF-la targeted for ubiquitination destruction is 
regulated through hydroxylation of a proline residue (HIF-1 a P564) by an enzyme tenned 
HIF-a prolyl-hydroxylase (HIF-PH), which functions as an oxygen sensor as it requires 
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both molecular oxygen and iron as a cofactor (Jaakk:ola et a/, 2001; Ivan et a/, 2001; 
Masson et al, 2001). HIF-PH is thought to regulate the HIF transcriptional cascade as it 
mediates the binding of the HIF-1a subunit to pVHL and the subsequent assembly of a 
complex that activates ubiquitination. However, under hypoxic conditions, the proline 
hydroxylation is inhibited and HIF-la is stabilised. This discovery is a further step towards 
deciphering how HIF controls gene expression in response to changes in oxygen tension. 
In addition to stabilising HIF-la, hypoxia also induces the nuclear translocation of 
the protein, providing a potential means by which it escapes from proteasomal degradation 
(K.allio et a/, 1999). HIF-1a nuclear localisation has been proposed as a regulatory step 
involved in its stabilisation (Tanimoto et a/, 2000). A recent report contradicts this finding 
by suggesting that nuclear translocation is not necessary for HIF-la stabilisation and that 
both nuclear and cytoplasmic proteasomes are fully competent for HIF-1a degradation in 
an 02 dependent manner (Berra et a/, 2001). This also contrasts with the mechanism that 
controls p53 degradation via MDM2 {Freedman and Levine, 1998) in that HIF-la protein 
is degraded in both subcellular locations providing a possible explanation for the extremely 
short half-life ofHIF-1a protein. 
1.4.1.5 HIF Splice Variants and Related Proteins 
Several alternatively spliced variants of human HIF-la mRNA have been recently 
identified (Gothie et a/, 2000; Yang-Sook et a/, 2002). Alternative splicing between exons 
1 and 2 produces an additional 3 bp at their junctions without a frame shift, and alternative 
splicing between 13 and 14 results in the loss of exon 14, producing a frame shift and an 
immediate termination codon (Gothie et a/, 2000). The latter variant displays oxygen-
tension-dependent regulation, as it retains the whole of the ODD domain, and 
transactivation by the VEGF promoter. A more recent alternative variant lacks exons 11 
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and 12, resulting in a frame shift and a shorter form of IDF-1a. which lacks part of the 
ODD domain, both TADs and the C-terminal nuclear localisation signals (Yang-Sook et a/, 
2002). 
Several proteins that are structurally related to IDF-la. and IDF-113 have also been 
identified. These include IDF-2a. (Ema et a/, 1997; Flarnme et a/, 1997, Tian el a/, 1997) 
and HIF-3a. (Gu et a/, 1998), as well as ARNT2 (Hirose et a/, 1996) and ARNT3, which is 
also known as MOP 3 (lkeda and Nomura, 1997; Takahata et a/, 1999). HIF-2a. was 
initially described as endothelial and foetal specific and named endothelial PAS protein-I 
(EPAS-1)/HIF-related factor (HRF)IHIF-Iike factor (HLF) and MOP 2 (Tian et a/, 1998, 
Flamme et a/, 1997; Ema et a/, 1997). HIF-2a. exhibits similar characteristics to lllF-1a. 
and its mRNA is abundantly expressed in a variety of organs in a normoxic state in 
patterns similar to those of VEGF mRNA, whereas lllF-1a. mRNA is ubiquitous at much 
lower levels (Wenger et a/, 1997). Their biological functions have yet to be determined 
apart from the finding that mice lacking lllF-2a. die at midgestation due to catecholamine 
deficiency and heart failure (Tian et a/, 1998). 
Recently, a novel ARNT-interacting cytosolic protein (AINT) has been described 
in mice that is reported to interfere with the formation of lllF-1 by sequestering ARNT in 
the cytoplasm (Sadek et a/, 2000). The finding of these new family members suggests that 
they may play a role in mediating the response to hypoxia and demonstrates the complexity 
involved in determining the precise function and involvement oflllF-1 in human disease. 
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1.5 HIF-1 and Human Disease 
There have been several recent publications that have demonstrated the 
involvement of HIF-1 in human disease (Zagzag et a/, 2000; Treins et al, 2001). HIF-1 is 
thought to play an important role in the pathogenesis of a number of conditions including 
myocardial ischemia, cerebral ischemia, lung disease and tumour vascularisation (Martin et 
a/, 1998; Yu et a/, 1999; Forsythe et a/, 1996). Over 40 different target genes have been 
shown to be activated by HIF-1 including VEGF, erythropoietin, insulin-like growth factor 
2, glycolytic enzymes and glucose transporter 1 (Semenza, 2002; Semenza et a/, 1996, 
Forsythe et al, 1996, Firth et a/, 1994, Ebert et a/, 1995). The overexpression of HIF-1a. 
may promote key aspects of tumour progression through the activation of these target 
genes including metabolic adaptation to hypoxia, the promotion of angiogenesis, cell 
survival and proliferation (Table 1.3). Activation ofHIF-1 is known to occur as a primary 
genetic event and as a result of local hypoxia in the tumour microenvironment. 
1.5.1 Cancer 
HIF-la. is overexpressed in the majority of common human cancers including 
breast and brain (Zhong et a/, 1999), and significant correlations have been found between 
HIF-la. protein expression, tumour grade and tumour vascularisation (Zagzag et a/, 2000). 
Thus, HIF-1 plays an important role in promoting tumour progression in these and other 
cancers (Semenza, 2000). 
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Table 1.3. Functional categorisation of target genes transactivated by HIF-1. 
Gene Product Reference 
CeU Proliferation and Viability 
(Increased O, delivery) 
p2I Canneliet et a/, 1998 
Insulin-like growth factor 2 QGF-2) Feldser et a/, 1999 
IGF binding protein I Tazuke et a/, I998 
IGF binding protein 3 Feldser et a/, 1998 
Transfonning Growth Factor P3 Caniggia et a/, 2000 
Energy Metabolism 
(Decreased o, consumotionl 
Adenylate kinase 3 Wood et a/, I998 
Aldolase A Iyer et a/, I998 
AldolaseC Iyer et a/, I998 
Enolase I Iyer et a/, I998 
Glucose transporter I Iyer et a/, I998 
Glucose transporter 3 Iyer et a/, I998 
Glyceraldehyde phosphate dehydrogenase Iyer et a/, I998 
Hexokinase I Iyer et a/, I998 
Hexokinase 2 I yer et a/, I998 
Lactate dehydrogenase A Iyer et a/, I998 
Phosphofiuctokinase L I yer et a/, I998 
Phosphoglycerate kinase I Canneliet et a/, 1998 
Pyruvate kinase M Iyer et a/, 1998 
Erythropoiesis 
(Increased o, delivery) 
Ceruloplasmin Mukhopadhyayeta~2000 
Erythropoietin Jiang et a/, 1996 
Transferrin Rolfs et a/, 1997 
Transferrin Receptor Tacchini et a/, I999 
Vasodilation and Vascularisation 
(Increased o. delivervl 
Heme oxygenase-! Wood et al, 1998 
Vascular endothelial growth factor (VEGF) Canneliet et a/, 1998 
VEGF receptor FL T -1 Gerber et a/, 1997 
Vasomotor Regulation 
(Increased 0. delivervl 
Endothelin-1 Hueta/, 1998 
Nitric oxide synthase 2 Palmer et a/, 1998 
Each of the genes contains a HRE sequence of> 100 bp that includes one or more HIF-1 
binding sites containing the core sequence 5'-TACGTG-3'. HIF-1 mediates increased 
oxygen delivery as well as adaptation to decreased oxygen availability. (Adapted from 
Semenza, 200 1 ). 
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1.5.1.1 Breast Cancer 
Breast cancer is one of the first cancers to be described with the earliest description 
being recorded in 1600 BC in ancient Egypt. Despite recent advances in molecular science 
that have led to a better understanding of the molecular events important in the 
pathogenesis of breast cancer, it remains one of the most common malignancies in women, 
comprising 18% of all female cancers, with nearly 600 000 new cases diagnosed in the 
world each year (McPherson et a/, 2000). Breast cancer is the second leading cause of 
cancer death for all women and the leading cause of cancer death in all women between the 
ages of 35 and 54. It affects approximately 1 in 10 women and is responsible for 23.7% of 
all cancer deaths (Breast Cancer Statistics, 2000). The United Kingdom has the highest age 
standardised incidence and mortality in the world with more than 15 000 deaths each year 
(McPherson et a/, 2000). It is currently believed that breast cancer presents as a spectrum 
of disease from local disease to systemic disease when first detected, requiring both local 
and systemic therapy (Coagner, 1991). 
1.5.1.1.1 Risk Factors 
There are several established and probable risk factors associated with the 
development of breast cancer (Table 1.4). Age is a major aspect related with the 
development of breast cancer, as it is known that the incidence of breast cancer increases 
with age, doubling every ten years until the menopause, where the rate then slows 
dramatically (Breslow and Kessler, 1995). Additionally, the age of menarche and 
menopause is important as women who begin menstruating early in life or who reach the 
menopause after the age of 55 have been shown to be twice as likely to develop breast 
cancer as women who reach the menopause prior to the age of 45. Women aged over 70 
years account for 40% of all breast cancers (McPherson et a/, 2000). 
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Table 1.4. Established and probable risk factors for breast cancer. 
Factor Relative Risk High Risk Group 
Age >10 Elderly 
Age at Menarche 3 Menarche before age 11 
Age at Menopause 2 Menopause after age 54 
Age at First Full Pregnancy 3 First child in early 40's 
Geographical Location 5 Developed country 
Socio-economic Group 2 Groups I and IT 
Family History ~2 Breast cancer in first degree relative 
when young 
Previous Benign Disease 4-5 Atypical hyperplasia 
Cancer in other Breast >4 
Diet 1.5 High intake of saturated fat 
Body Weight Premenopausal 0.7 Body mass index >35 
Body Weight Postmenopausal 2 Body mass index > 35 
Alcohol Conswnption 1.3 Excessive intake 
Exposure to Ionising Radiation 3 Abnormal exposure in young females 
after age 10 
Oral Contraceptives 2 Use for ~ 4 years when young 
1.24 Current use 
Hormone Replacement Therapy 1.35 Use for~ 10 years 
Diethylstilbestrol 2 Use during pregnancy 
(Adapted from McPherson et a/, 2000) 
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Other factors such as age of first pregnancy (Kerlikowske et a/, 1997), geographical 
location and genetic disposition also play a significant role in the lifetime risk of 
developing breast cancer. The difference in the incidence of breast cancer between 
Western and Far Eastern countries is approximately five fold and up to 10% of patients 
with breast cancer in Western countries have a genetic abnormality that predisposes them 
to develop the disease (McPherson et a/, 2000). 
1.5.1.1.2 Genetic Factors 
The susceptibility to nearly any disease has some element of genetic predisposition. 
To date, two genes have been associated with susceptibility to breast cancer, BRCA l 
(Miki et a/, 1994), located on the long arm of chromosome 17, and BRCA 2 (Wooster et 
a/, 1994) mapped to the long arm of chromosome 13, with the possibility that more may 
exist. A recent study reported evidence for a novel breast cancer susceptibility locus on 
chromosome 13q21 (Kainu et a/, 2000). This candidate BRCA3 locus was further studied 
in genetic linkage analysis of breast cancer families of European origin with the fmding 
that its contribution to familial breast cancer was very small (Thompson et a/, 2002). 
Germ1ine mutations in either the BRCAI or the BRCA2 genes are responsible for the 
majority of hereditary breast cancers, each of then accounting roughly for half of the cases 
(Feunteun and Lenoir, 1996). Approximately one third of familial cases are believed to be 
due to mutations in the BRCA I gene and studies have shown that tumours with BRCAl or 
BRCA2 mutations have a higher frequency of specific somatic genetic alterations 
{Tirkkonen et a/, 1997). It is also known that mutations in the p53 tumour suppressor gene 
on the short arm of chromosome 17 is involved in the development of the disease, 
providing strong evidence for the involvement of a tumour suppressor gene in breast 
cancer (Mallein et a/, 1990; Kleihues et a/, 1997). 
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Allele loss studies (loss of heterozygosity) indicate chromosomal regions that may 
contain tumour suppressor genes that exhibit an important two-hit mechanism involving 
both loss of heterozygosity and mutation that is commonly involved in breast cancer. In 
addition. studies of loss of heterozygosity have suggested that chromosome I may house 
genes involved in breast cancer (Devilee et a/, I99I). Chromosome arms including Ip, lq, 
3p, 6p, 7q, lip, 13q, I7p, I7q, 18q show moderate (20-40%) to high (>50%) frequency of 
loss of heterozygosity in invasive ductal breast cancer (Gendler et a/, 1990, Bieche et a/, 
1994). The growing family of p53 tumour suppressor genes, including p73, have been 
mapped to these chromosomes. Many breast tumours show changes in ploidy indicative of 
severe nuclear disarrangement. 
There is genetic evidence that the angiogenic pathway plays a major role in 
carcinogenesis of the breast and may involve different mechanisms at later stages of 
tumour progression (Hellelginger et a/, I999). A small hypoxic tumour, which is 
genetically unstable, will be exposed to a hostile environment and mutations (notably p53) 
producing a phenotype able to resist cell death (apoptosis) will have a survival advantage. 
Mutations enable cells to survive under hypoxic conditions and also switch on the 
angiogenic phenotype by enhancing VEGF production. A strong correlation has been 
found between the expression of VEGF and increased metastasis and prognosis (Saaristo et 
a/, 2000). 
1.5.1.1.3 Classification 
As tumours show characteristic patterns of growth and cellular morphology, 
definite types of breast cancer can be identified and classified (Figure 1.12). Breast 
cancers are derived from the epithelial cells that line the terminal duct lobular unit. 
Tumours that contain specific features are described as invasive carcinomas of special 
type, whereas all others are described as of no special type (Sainsbury et a!, 2000). As long 
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as the tumour remains within the confines of the ductal basement membrane, it constitutes 
a noninfiltrating intraductal carcinoma. It begins as an atypical proliferation of ductal 
epithelium that eventually completely fills the ducts with neoplastic cells (Cotran et a/, 
1999). An invasive breast cancer is one in which there is dissemination of cancer cells 
outside the basement membrane of the ducts and lobules into the surrounding adjacent 
normal tissue. Invasive breast cancers are most commonly classified as either ductal or 
lobular types (Sainsbury et a/, 2000), however there are a wide range of other histological 
types (World Health Organisation, 1981). Cancer cells that remain within the basement 
membranes of the elements of the terminal duct lobular unit and the draining duct are 
classified as in situ or non-invasive. Ductal carcinoma in situ is the most common form of 
non-invasive carcinoma (Page et a/, 1995). Lobular carcinoma in situ is manifested by 
proliferation of cells, in one or more of the terminal ducts, which are large, loosely 
cohesive and have rare mitoses (Cotran et a/, 1999). 
Tumours of no special type are graded by the degree of differentiation and are 
assessed semi-quantitatively by three characteristics: the degrees of glandular formation, 
nuclear pleomorphism and mitotic frequency. These values are combined and the tumour is 
then assigned one of three histological grades: Grade I (score 3-5), Grade ll (scores 6-7) 
and Grade m (scores 8-9), which correlate directly with survival. This histological grading 
system, known as the Scraff, Bloom and Richardson grade after the creators of the system, 
has become an important predictor of both disease free and overall survival (Bloom and 
Richardson, 1957; Sainsbury et a/, 2000). 
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Figure 1.12. Histologic classification of breast tumours. 
(Adapted from the World Health Organisation, 1981). 
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1.5.1.1.4 Staging 
Prognosis and survival in breast cancer is directly related to the stage of disease at 
presentation. When an invasive breast cancer is diagnosed the extent of the disease is then 
assessed and the tumour staged. There are currently two staging classifications in use, both 
of which are inappropriate for breast cancer due to its complexity. The frrst system, the 
tumour node metastases system (TMN), is dependent upon the inaccurate methods of 
clinical assessment and measurement of lymph node status (Table 1.5) (Sobin and . 
Wittekind, 1997; American Joint Committee on Cancer, 1997). The second system, the 
International Union against Cancer (UICC) system incorpomtes the TMN classification 
system (Table 1.6) (International Union Against Cancer, 1997). A separate pathological 
classification, where tumour size and node status are assessed by a pathologist, has been 
added to the TMN system in an attempt to improve the accuracy of classification (Fleming, 
1997). 
Both systems of breast tumour classification consider the size of a tumour (T), 
lymph node involvement (N) and metastatic disease (M) (Rosen and Obennan, 1993). As 
the pathological size of a tumour correlates directly with survival, patients with. smaller 
tumours have a better survival mte than those with large tumours. Stage I cancer defines a 
tumour of a small size that has not progressed outside of its original site whereas a stage IV 
growth is large and has spread widely. The number of axillary nodes involved is also 
directly correlated with survival. The presence of cancer cells in lymphatic vessels 
indicates a more aggressive disease. Patients whose cancer has spread beyond the axillary 
or internal mammary nodes (M1 or stage IV disease) are known to have a much worse 
survival rate than patients whose disease is localised (Miller et a/, 1995). 
A low-grade tumour histologically resembles the tissue of origin, whereas a high-
grade tumour undergoes several changes that it marginally resembles the tissue of origin. 
Both the stage and gmde of a tumour are important as they measure different parameters of 
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Table 1.5. Tumour Node Metastases (TNM) Classification of Breast Tumours 
Classification Description 
Primary Tunwur 
Tis Cancer in situ 
T1 !:> 2 cm, (T1a !:> 0.5 cm,> 0.5 cm- I cm, T1c >I cm- 2 cm) 
T2 >2cm-5 cm 
Tl >5cm 
T4a Involvement of chest wall 
T4b Involvement of skin (includes ulceration, direct infiltration, 
peau d'orange and satellite nodules 
T4c T 4a and T 4b together 
T4d Inflammatory cancer 
Lymph Nodes 
No No regional node metastases 
NI Palpable mobile involved ipsilateral axillary nodes 
N2 Fixed involved ipsilateral axillary nodes 
Nl Ipsilateral internal mammary node involvement (rarely 
clinically detectable) 
Metastases 
Mo No evidence of metastasis 
M1 Distant metastasis (includes ipsilateral supraclavicular nodes) 
(Adapted from Sainsbury et a/, 2000) 
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Table 1.6. Correlation of the International Union Against Cancer (illCC) (1997) and 
TNM classifications of breast tumours with survival rates. 
UICC Stage TNM Grouping Clinical Description SYear Survival 
I T~,No, Mo Tumours ~ cm, no nodal 87% 
involvement, no metastases 
T1, N~, Mo Tumours s;5 cm, with involved II but movable axillary nodes, no 75% 
T2, Na-1. Mo metastases, or tumour >5 cm, no 
nodal involvement, no metastases 
Any T, N2.3, Mo Breast cancers of any size with 
m T3, any N, Mo; possible skin involvement, 46% pectoral and chest wall fixation, 
T4, any N, Mo nodal involvement, no metastases 
Breast cancers with/without nodal 
IV Any T, any N, M1 involvement, pectoral or chest wall 13% 
fixation. skin ulceration, 
disseminated metastases 
For TNM Grouping definitions refer to Table 1.5. 
(Adapted from Sainsbury et a/, 2000) 
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the cancer and are used to predict the direction of the cancer (Sainsbury et a/, 2000). 
Figure 1.13 illustrates histologically low, moderate and high-grade tumours of the breast. 
1.5.1.1.5 Angiogenic Factors 
Breast cancer angiogenesis has been studied extensively and now serves as a 
paradigm for understanding the biology of angiogenesis and its effects on tumour outcome 
and patient prognosis (Leek, 2001). Studies have shown that primary breast cancers 
express multiple angiogenic factors belonging to different growth factor families (Relf et 
a/, 1997; De Jong et a/, 1998). Other studies have shown that quantitation of angiogenesis 
can be used as an independent prognostic factor ( Obermair et a/, 1997; Gasparini et a/, 
1999; 2001). 
Among the angiogenic factors tested at the tumourallevel in breast cancer, VEGF 
is the only factor that provides the most relevant prognostic information (Veikkola et a/, 
2000). Several studies have determined VEGF expression to be of prognostic significance 
in operable breast cancer (Gasparini et a/, 1999; Linderholrn et a/, 2000; reviewed in 
Gasparini, 2001). Additionally, soluble vascular endothelial growth factor receptor-1 
(sVEGFR1), a naturally occurring soluble form of VEGFRI and inhibitor of VEGF, is 
frequently eo-expressed with VEGF in primary breast cancer tissues and it is thought that 
the intratumoral balance between sVEGFR1 and VEGF levels might be crucial for the 
progression of breast cancer (Toi et a/, 2002). Other studies have shown that the expression 
of VEGF correlates with mutant p53 and poor prognosis in human breast cancer 
(Linderholm et a/, 2001 ). 
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A) 
B) 
C) 
Figure 1.13. A) Low-grade carcinoma of the breast. The photo shows well differentiated 
carcinoma cells forming tubular structures infiltrating breast tissue (magnification X500). 
B) Moderate grade carcinoma of the breast. Groups of moderately differentiated carcinoma 
cells infiltrating fibroadipose breast tissue (magnification X500). C) High-grade carcinoma 
of the breast. Poorly differentiated adenocarcinoma composed of pleomorphic tumour cells 
with prominent nucleoli and numerous mitotic figures (magnification X500) (haematoxylin 
counterstain). (Photographs courtesy of Dr. David Hilton, Derriford Hospital, Plymouth, 
UK) 
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1.5.1.1.6 Tumour Hypoxia 
It has been shown that intratumoral hypoxia is associated not only with genetic 
instability but also with resistance to chemotherapy and radiation allowing for a possible 
recurrence of the tumour (Yuan and Glazer, 1998). It is known that independent of 
treatment, solid tumours have a poor prognosis. Thus, hypoxic conditions select for 
chemotherapy-resistant cells, which might subsequently clonally metastasise. 
As radiotherapy relies upon the formation of reactive oxygen species to promote 
radiation-induced cell death, decreased oxygen concentrations in the tumour would 
decrease their formation. It has also been suggested that hypoxic tumour cells express 
survival factors that mediate protection against any apoptosis-inducing stimulus (Semenza, 
2000). Cultured glioma cells exposed to hypoxia have demonstrated increased survival 
after exposure to chemotherapeutic agents (Liang, 1996). The expression of insulin-like 
growth factor 2 (IGF-2) under hypoxic conditions is considered to be a survival factor 
which is regulated by HIF-1 (Feldser et a/, 1999; Semenza, 2000). 
A recent study has suggested that a hypoxic tumour microenvironment may down-
regulate both oestrogen receptor expression and function in hormone responsive breast 
cancer cells and reduces their responsiveness to hormonal agents (Kurebayashi et a/, 
2001). This would indicate that hypoxia may play a key role in the development of 
acquired resistance to hormonal agents. 
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1.5.1.1.7 Treatment of Breast Cancer 
The aim of current treatments for cancer is to maximise the effect on the cancer and 
to minimise any adverse side effects on normal tissues. It is known that the earlier that a 
cancer is detected, the fewer changes it will have undergone, resulting in a better response 
to treatment. 
1.5.1.1.7.1 Surgery 
Established cancers indicate increased cellular changes and increased 
aggressiveness. For any cancer that has already established, surgical removal remains the 
best approach but has limitations as cancers can metastasise to inaccessible sites, resulting 
in a relapse at local or distant sites, and undetectable micrometastases may also be present 
at the time of diagnosis (Saphner et al, 1996). However, surgery is now less aggressive 
then 10 years ago. Treatment of primary, operable breast cancer involves the use of surgery 
with or without adjuvant systemic therapy. Conservative breast surgery combined with 
radiotherapy is the standard procedure for all unifocal cancers less than 3-4 cm in size 
(Early Breast Cancer Treatment Collaborative Group, 1995). 
1.5.1.1.7.2 Radiotherapy 
Radiotherapy is used for about half of all patients who develop cancer in the United 
Kingdom each year (Green lee et a/, 2001) and relies on the generation of reactive oxygen 
species from molecular oxygen to damage DNA and inevitability cause cell death via 
apoptosis (Yamada et a/, 1988; Allan., 1992). Reactive oxygen species, or free radicals, are 
extremely unstable and interact with neighbouring molecules to produce chemically stable 
lesions (Ward, 1990). As all tumours contain regions of hypoxia related to poor blood 
supply, cells found in these regions are usually radioresistant (Weichselbaum et a/, 1993). 
Thus, poor blood perfusion of the tumour or poorly developed microvasculature in the 
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tumour, results in reduced oxygenation, leading to decreased effectiveness of radiotherapy. 
Radiotherapy is therefore confined to the treatment of localised disease in tumours that are 
mdiosensitive, or as an adjunct to surgery or chemotherapy. 
1.5.1.1.7.3 Chemotherapy 
Chemotherapy refers to treatment based on the delivery of drugs that affect cell 
processes such as DNA synthesis (mitosis) and cell proliferation. Chemotherapy is very 
effective against rapidly dividing cells and its efficacy is dependent upon dosage and 
duration. Primary or neoadjuvant chemotherapy is used as a ftrst line of treatment for local 
disease, whereas adjuvant chemotherapy is used in conjunction with another treatment, 
such as surgery. Adjuvant chemotherapy is also used to treat advanced disease in an 
attempt to improve the quality of life when surgery is not an alternative. A tumour larger 
than 5 cm or a smaller tumour with signs of locally advanced disease (TyT4, N2, N3) are 
currently treated with neo-adjuvant chemotherapy (Early Breast Cancer Treatment 
Collaborative Group, 1995). 
Treatment that results in DNA damage will activate the apoptotic pathway. Taxanes 
are plant alkaloids that promote tubulin assembly and induce apoptosis of tumour cells by a 
p53-independent Gv'M cell cycle checkpoint (Lanni et a/, 1997). The development of new 
cytotoxic agents and radiation therapy techniques, administered as adjuvant therapy after 
surgery, has led to a reduction in the risk of relapse of only 20-40 %, depending on the 
chemotherapeutic agents used (Bange et a/, 2001; Hortobagyi, 2000). Moreover, it has 
been demonstrated that simultaneous combination of two or more agents provide more 
effective treatment (Fossati et a/, 1998). 
-66-
Chapter 1. Introduction 
t.S.1.1.7.4 Anti-Oestrogen Receptors 
As steroid hormones are required for the growth of breast cancer, hormone 
treatment is often given as it generates fewer side effects. Treatment is based on the 
principle of depriving the cancer cells of mitogenic hormone by either preventing steroid 
synthesis or by blocking their effects at the target level via the receptor machinery. As 
relatively few cell types contain hormone receptors, drugs aimed at disrupting them remain 
highly specific. Response to treatment is dependent upon cellular localisation. Cells 
situated at a distance from a blood vessel will not receive a sufficient dose of drugs to 
destroy it. Areas of a tumour that are well vascularised tend to respond better to treatment 
then those areas that are not. 
Tamoxifen. an antagonist of the oestrogen receptor in breast tissues, reduces the 
incidence of cancer relapse in hormone receptor positive tumours and can delay or prevent 
the development of breast cancer in women at high risk (Peto and Mack, 2000). A large 5 
year study of women with an increased risk ofbreast cancer treated daily with Tarnoxifen 
has shown a statistically significant 49 % reduction in the incidence of breast cancer 
(Fisher et a/, 1998). However, long term usage of the drug has produced a number of side 
effects which are dependent upon age and race (Gait et a/, 1999}. New oestrogen receptor 
drugs, such as raloxifen. which produce fewer side-effects are now being studied 
(Rosenbaum and Osbome, 2000). 
l.S.l.1.7.S Molecular Targets 
The development of cDNA array analysis has allowed for the pathological 
characterisation of tumours using gene expression profiling, through which gene clusters 
can be identified and localised. A recent study found different gene profile phenotypes 
among 65 tumour samples using cDNA array analysis (Perou et a/, 2000). Several new 
drugs have recently emerged including; trastuzumab (Herceptin) (Baselga, 2001; Slamon 
-67-
Chapter 1. Introduction 
et a/, 2001), the monoclonal antibody against human epidermal growth factor receptor 2 
((HER-2), also known as ERBB2), and the cyclooxygenase inhibitor celecoxib (Harris et 
a/, 2000). ERBB2 is known to be an essential breast cancer oncogene as mitogenic 
signalling has been associated with increased activation of cyclin Dl, an essential factor of 
G liS phase transition of the cell cycle (Lee et a/, 2000). A recent study has shown that 
Herceptin induces normalisation and regression of the vasculature in an experimental 
human breast tumour that overexpresses ERBB2 in mice by modulating the effects of 
different pro- and anti-angiogenic factors (Izumi et a/, 2002). 
Inhibition or the prevention of angiogenesis has been a main focus of cancer 
treatment. There are more than 20 anti-angiogenetic drugs which prevent endothelial cell 
prolifemtion, block activators of angiogenesis, such as VEGF, or inhibit extracellular 
matrix breakdown by proteases, undergoing evaluation in phase I, II or m clinical trials 
(Bange et a/, 2001). In the absence of new blood vessel formation, oxygen and essential 
nutrients become limited, cell functions are not maintained and necrotic death follows. The 
continued identification and characterisation of signalling mechanisms the govern cell 
growth, differentiation, motility and apoptosis will continue to result in the development of 
new molecular therapeutic approaches in the treatment of breast cancer. 
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1.5.1.2 Glioblastoma 
Primary malignant bmin tumours are amongst those human neoplasms that exhibit 
the greatest angiogenic activity thus they are very suitable for angiogenesis studies. 
Glioblastoma multiforme (GBM) is the most common malignant bmin tumour in humans 
and is chamcterised histologically by necrosis and microvascular proliferation (Shweiki et 
al, 1992). GBM is highly invasive and has a median survival of less than one year 
following diagnosis, irrespective of treatment (Burger and Scheithauer, 1993). 
To metastasise to the brain, malignant tumour cells must attach to microvessel 
endothelial cells, respond to brain-derived invasive factors, invade the blood-bmin barrier 
and respond to survival and growth factors (Mentor et al, 1995). Malignant glioma cells 
may be able to induce neovascularisation, however vascular supply may not be sufficient 
for tumour areas with high cell proliferation and the resultant oxygen and nutritional 
deprivation induces extensive necrosis (Russet and Rubinstein, 1989). 
1.5.1.2.1 Genetic Factors 
Alterations (loss or mutation) of the p53 gene are one of the most common 
abnormalities in gliomas and may be an early event in malignant transformation of glioma 
cells. Germline mutations of the p53 gene are associated with increased susceptibility to 
glioma. Also, chromosome 17p deletions and p53 gene mutations are found frequently in 
sporadic gliomas of all malignancy stages (Van Meyel et al, 1994). It is known that under 
hypoxic conditions, IDF-1a accumulates and binds to p53 thereby inhibiting its 
degradation (An et al, 1998). The role of p53 in hypoxic or ischaemic bmin tissue from 
patients with GBM is not known nor is the relation of severity and dumtion of hypoxia to 
the expression ofp53. 
Recent studies suggest that PTEN, a tumour suppressor originally isolated from a 
homozygous deletion on chromosome l0q23 in GBM (Li et al, 1998, Steck et a/, 1997), 
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attenuates hypoxia-mediated HIF-la. stabilisation (Zundel et a/, 2000). PTEN 
downregulates HIF-la expression and HIF-la mediated transcription in human prostate 
and glioma cells (Zhong et a/, 2000; Zundel et a/, 2000). Thus, PTEN loss-of-function 
increases HIF-la expression. 
It has been shown that there is a significant correlation between tumour grade and 
HIF-la expression in GBM, which is unlikely to be due to more extensive pecrosis within 
higher-grade tumours (Zagzag et al, 2000). It is probable that several types of somatic 
mutations common to gliomas contribute to increased IDF-la expression resulting in 
increased HIF-1 mediated transactivation of downstream target genes. An investigation of 
the expression ofHIF-1a, as well as VEGF and p53 in glioblastoma multiforme may help 
elucidate their roles in this disease. 
1.5.1.2.2 Grading 
Astrocytic tumours are classified according to the recommendations of the World 
Health Organisation (WHO) (Kleihues et a/, 2001), where they are divided into four 
grades: pilocytic astrocytoma (Grade 1), astrocytoma (Grade IT), anaplastic astrocytoma 
(Grade Ill), and glioblastoma (Grade IV), (Table 1.7). The histological characteristic of 
nuclear atypia is usually required for tumours of grades ll to IV, which includes coarse 
nuclear chromatin, nuclear pleomorphism, multinucleation and pseudoinclusions. Also, for 
the higher grades of tumour the additional criteria of mitotic activity (Grades m and IV), 
cellularity, vascular proliferation (Grade IV) and necrosis (Grade IV) are also required. 
Grading in usually based on areas showing the highest degree of anaplasia, on the 
assumption that the tumour cell population eventually determines the course of the disease 
(Kleihues and Cavenee, 1997). Figures 1.14 and 1.15 illustrate a low-grade astrocytoma, 
an anaplastic astrocytoma and a high-grade glioblastoma. 
-70-
Chapter 1. Introduction 
Table 1.7. Recommendations of the World Health Organisation (WHO) for the grading 
of gliomas (Kliehues et a/, 2001). 
WHO Grade WHO Designation Histological Criteria 
I Pilocytic astrocytoma 
IT Astrocytoma Nuclear atypia 
(low-grade diffuse) 
m Anaplastic astrocytoma Nuclear atypia, mitotic activity 
N Glioblastoma Nuclear atypia, mitoses, endothelial 
prolifemtion and/or necrosis 
(Adapted from Kleihues and Cavenee, 1997) 
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Figure 1.14. A) A low-grade astrocytoma showing small uniform astrocytic nuclei which 
are forming microcystic spaces with no mitotic activity. B) A highly cellular astrocytic 
tumour showing mitotic activity and nuclear pleomorphism (haematoxylin counterstain). 
(Photographs courtesy of Dr. David Hilton, Derriford Hospital, Plymouth, UK) 
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A) 
B) 
Figure 1.15. A) Glioblastoma showing marked nuclear pleomorphic large atypical 
astrocytic cells. B) Glioblastoma showing 2 features: vascular proliferation to the left of 
the photo and necrosis to the right of the photo (haematoxylin counterstain). (Photographs 
courtesy of Dr. David Hilto~ Derriford Hospital, Plymouth, UK). 
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1.5.1.2.3 Glioma-Induced Angiogenesis 
One event that accompanies glioma progressiOn JS the up-regulation of 
angiogenesis. Low-grade gliomas are moderately vascularised tumours whereas high-
grade gliomas show predominately microvascular proliferation and areas of high vascular 
density (Plate et a/, 1992). Hypoxia seems to play a critical role in the induction ofVEGF 
expression during glioma progression as VEGF is highly expressed in high-grade gliomas 
and has been shown to be hypoxia inducible in glioma cells in vitro (Stratmann et a/, 
1997). 
Transcription of VEGF is greatly enhanced in GBM and it is an important 
regulator of vascular functions in glioma-induced angiogenesis. A characteristic feature of 
GBM is the presence of necrotic regions surrounded by palisading cells, viable cells .which 
are furthest removed from a blood vessel, that express high levels of VEGF mRNA (Plate 
et a/, 1992). The regulation of expression of VEGF in GBM is poorly understood but is 
probably modulated by binding of HIF-la. to the HRE site in the flanking region of the 
gene (Dachs et a/, 1997). There are few published data on the expression ofHIF-la. in 
GBM Recent immunohistochemical analysis ofGBMs found that HIF-la. is expressed in 
the palisading cells and localised in areas adjacent to necrotic zones and within infiltrating 
tumour cells (Zagzag et a/, 2000), suggesting a role for HIF-Ia in GBM These results, 
together with previous findings imply that hypoxia induces HIF-la and VEGF expression, 
as well as tumour vascularisation. 
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1.5.1.2.4 Survival 
The survival of a patient with glioblastoma is dependent upon a variety of clinical 
parameters that include patient age, tumour location and treatment. Treatments available 
include surgical resection, radiotherapy and chemotherapy. The average range of survival 
for patients with low-grade diffuse astrocytomas is more than 5 years, for patients with 
anaplastic astrocytomas is from 2 to 5 years, and for patients with glioblastoma it is less 
than one year (Kieihues and Cavenee, 1997). 
-75-
Chapter I. Introduction 
1.5.2. Diabetes Mellitus 
Diabetes mellitus (DM) is a disorder characterised by abnormally high levels of 
glucose in the blood due to either a deficiency of insulin secretion or to resistance of the 
body's cells to the action of insulin, or to a combination of the above (Kuzuya, 2000). Two 
differentiated forms of the disease were first documented in 600 B.C. by two Indian 
physicians, Chakrata and Susrata, however it wasn't until the mid 1930's that two clinical 
types of diabetes mellitus were proposed to exist, an insulin sensitive and insulin 
insensitive form, the former being due to insulin deficiency (Himsworth, 1936). The 
development of a bioassay for insulin in 1951 confirmed these clinical observations 
(Bornstein and Lawrence, 1951) and continued research in the later half of the 20th century 
that has led to the recognition that DM is a syndrome that is comprised of a genetically 
heterogeneous collection of disorders characterised by high blood glucose levels 
(American Diabetes Association Expert Committee, 2001). 
In 1979 an international workgroup sponsored by the National Diabetes Data 
Group (NDDG) of the National Institutes of Health developed a classification for DM 
based on scientific research conducted during the previous decades (National Diabetes 
Data Group, 1979). DM was officially recognised as a syndrome that included a collection 
of disorders having hyperglycaemia and glucose intolerance as their feature characteristic. 
The World Health Organisation (WHO) Expert Committee on Diabetes approved and 
supported the recommendations of the NDDG in 1980 and both groups went on the further 
distinguish two major forms ofDM in the Western hemisphere which were termed insulin-
dependent diabetes (TIDM) and non-insulin-dependent diabetes (T2DM) (World Health 
Organisation, 1980; 1999). An expert committee of the American Diabetes Association 
proposed further changes to the NDDG/WHO classification having considered the research 
findings of the last 25 years (American Diabetes Association Expert Committee, 1997; 
2001). These proposals include changes to diagnostic criteria as well as the elimination of 
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the terms insulin-dependent DM and non-insulin-dependent DM and their acronyms, 
IDDM and NIDDM, however the terms TlDM and T2DM were proposed to be retained. 
Additionally, it was proposed that forms ofDM involving pancreatic J3-cell destruction be 
included under TlDM (American Diabetes Association Expert Committee, 1997; 2001). 
Different genetic, metabolic, environmental and lifestyle factors can result in 
similar diabetic phenotypes (hyperglycaemia and microvascular complications) implying. 
strong heterogeneity within the syndrome of DM (Kuzuya. 2000). However, chronic 
hyperglycaemia has been identified as the primary risk factor in the development of 
diabetic complications (Nathan, 1996; The Diabetes Control and Complications Trial 
Research Group, 1993; The United Kingdom Prospective Diabetes Study Group, 1998). 
Despite decades of intensive research, the exact causes of TlDM and T2DM remain 
unknown although both can be accompanied by ketoacidosis, blindness, kidney failure, 
premature cardiac disease, stroke, amputations and other diabetic complications (section 
1.5.2.3). 
1.5.2.1 Type 1 Diabetes Mellitus (T1DM) 
Type l diabetes mellitus (T ID M) comprises approximately 5 to 10 % of cases in 
the DM syndrome, of which 15 to 30 %of all cases are diagnosed after 30 years of age 
(Laakso and Pyorala, 1985; Kuzuya, 2000). Incidence rates are increasing in a number of 
countries around the world (Rewers and Norris, 1996) where currently about 0.5% of the 
population in developed countries is affected (Mathis et al, 2001). 
TlDM results from the autoimmune-mediated destruction of pancreatic J3-cells 
islets that leads to nearly total loss of insulin secretion and absolute insulin deficiency 
(WHO, 1999). Early systematic and quantitative studies of the pancreas resulted in the 
description of a specific loss of insulin-producing J3-cells in association with the clinical 
onset ofTlDM (Gepts, 1965). TlDM has since been differentiated into two subclasses, an 
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autoimmune class and an idiopathic class. The autoimmune fonn of TIDM is a chronic 
disease characterised by cellular-mediated (T lymphocytes) autoimmune destruction of the 
insulin producing 13-cells in the pancreatic islets of Langerhans (Atkinson and Eisenbarth, 
2001). Autoimmunity results from the failure to regulate or eliminate autoreactive T cells. 
When most of the 13-cells have been killed off, there is no longer sufficient insulin 
production to regulate blood glucose levels, resulting in hyperglycaemia (Mathis et a/, 
2001). This destructive process may occur over a prolonged period of time prior to the 
development of clinical symptoms from hyperglycaemia. During this time antibodies to 
pancreatic antigens and abnonnalities in pancreatic 13-cell may be detected (Hansen et a/, 
1997). The presence of anti-islet autoantibodies is a distinguishing feature of TlDM, 
which has since become a classic pre-diabetes marker used to follow relatives of TlDM 
probands (Bottazzo et a/, 1974). 
1.5.2.2. Pathogenesis of TlDM 
The development of TlDM has been divided into a series of stages in which an 
individual may progress through some or all of these stages in the advancement of the 
disease. Stage I involves genetic predisposition, stage 2 is environmental triggering of 
autoimmunity, stage 3 is the development of a series of autoantibodies, stage 4 is loss of 13-
cell function through metabolic defects, stage 5 is overt DM and stage 6 is total or near 
total 13-cell destruction (Eisenbarth. 1986). The autoimmune response to islet 13-cells is 
believed to occur in persons who possess certain susceptibility alleles and also lack other 
protective alleles of the HLA or major histocompatibility complex (MHC) genes, which 
regulate immune responses. It is thought that a genetic susceptibility to altered immune 
regulation predisposes certain individuals to the development of autoimmunity of islet beta 
cells (Atkinson and Macl..aren, 1994). The autoimmunity may develop spontaneously or 
may be triggered by environmental agents such as a virus, chemical or unknown toxin, 
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resulting in acute insulitis (Myers et a/, 2001). Non-MHC genes may also contribute to the 
autoimmune response, however it is clear that genetics alone are not sufficient to explain 
the development ofTlDM. 
1.5.2.2.1. Insulin Metabolism 
The human insulin gene was one of the first human genes cloned. It is encoded on 
the short ann of chromosome llpl5.5 and is expressed in the beta cells ofthe pancreatic 
islets, where mature insulin mRNA is transcribed (Owerbach et a/, 1980). The most 
important stimulant of insulin release is glucose, which also initiates insulin synthesis. 
Pancreatic 13-cells release insulin into the circulation in response to rising blood glucose 
levels, where it binds to specific receptors present on cell surfaces. This binding signals 
uptake of nutrients, storage of energy and growth (Gustafson et a/, 1999; Virkamaki et al, 
1999). 
Insulin is a major anabolic hormone (Kahn, 1988) and is necessary for; 
transmembrane transport of glucose and amino acids, glycogen formation in the liver and 
skeletal muscles, glucose conversion to triglycerides, nucleic acid synthesis and protein 
synthesis. Its prime metabolic function is to increase the rate of glucose transport into 
striated muscle cells, myocardial cells, fibroblasts and fat cells in the body. Insulin 
interacts with target cells by first binding to the insulin receptor, which is composed of two 
a and two 13 glycoprotein subunits (Patti and Kahn, 1998). Insulin binds to the extracellular 
portion of the a-subunit and this in turn activates the tyrosine-specific protein kinase 
activity of the cytoplasmic portion of the 13-subunit (Patti and Kahn, 1998). The 13-subunit 
tyrosine kinase then catalyses phosphorylation of the 13-subunit itself as well as other 
intracellular proteins. This is followed by a number of cellular responses, including 
activation or inhibition of insulin-sensitive enzymes in mitochondria, protein synthesis and 
DNA synthesis. 
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1.5.2.3 Diabetic Complications 
The pathogenesis of chronic diabetic complications is thought to be complex and 
multifactorial, although all forms of diabetes are characterised by chronic hyperglycaemia 
and the development of diabetes-specific microvascular pathology (Brownlee, 2001). 
Considerable amounts of epidemiologic and animal data support the link between chronic 
hyperglycaemia and long-term microvascular complications of TIDM, including 
retinopathy, neuropathy and nephropathy (Raskin et a/, 1983; Krolewski et a/, 1988; The 
Diabetes Control and Complications Trial Research Group, 1993) as well as in T2DM (The 
United Kingdom Prospective Diabetes Study Group, 1998). In addition to microvascular 
complications, hyperglycaemia also contributes to macrovascular disease, affecting arteries 
that supply the heart, brain and lower extremities, as well as impaired cellular immunity in 
TIDM (Rich, 1997). 
It is known that intracellular hyperglycaemia causes abnormalities in blood flow 
and increased vascular permeability (Brownlee, 2001). Consequently, there is decreased 
activity of vasodilators such as nitric oxide (section 1.5.2.3.7), increased activity of 
vasoconstrictors such as angiotension ll and increases in permeability factors such as 
VEGF (sections 1.3.3.1 and 1.5.2.3.9) (Brownlee, 2001). The combined effect of these 
changes can lead to ischaemia and hypoxia-induced neovascularisation in the retina, 
proteinuria, mesangial matrix expansion and glomerulosclerosos in the kidney, and 
multifocal axonal degeneration in peripheral nerves. 
Diabetic complications are believed to result from hyperglycaemia through four 
hypotheses involving signal transduction pathways (Table 1.8): increased flux through the 
polyol pathway (section 1.5.2.3.1); increased advanced glycation end-product (AGE) 
formation (section 1.5.2.3.2); activation of protein kinase C (PKC) isoforms (section 
1.5.2.3.3); and increased hexosamine pathway flux (section 1.5.2.3.4). The common 
element linking these four hypothesis is the hyperglycaemia-induced overproduction of 
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superoxide by the mitochondrial electron-transport chain (Du et a/, 2000; Nishikawa et a/, 
2000) (section 1.5.2.3.5). 
1.5.2.3.1 The Polyol Pathway 
Activation of the polyol pathway by hyperglycaemia occurs in numerous cells and 
tissues expressing aldose reductase and sorbitol dehydrogenase (Dvomik, 1987). Under 
conditions of hyperglycaemia, excess glucose is metabolised to sorbitol and fructose by 
nicotinamide adenine dinucleotide (NAD) linked oxidoreductases that further influence 
cellular metabolism, redox potential and signal transduction. Excessive polyol pathway 
activity, induced through a high cellular glucose flux, results in a change in the 
homeostasis of oxidised and reduced nicotinamide adenine dinucleotides (NADP) redox 
couples. Increased oxidation of NADPH to NADP+ occurs that is coupled to the reduction 
of glucose to sorbitol by aldose reductase. An increased reduction ofNAD+ to NADH then 
follows which is coupled to the oxidation of sorbitol to fructose by sorbitol dehydrogenase 
(reviewed in Oates and Mylari, 1999) (Figure 1.16). 
Glucose and its metabolites mediate their adverse affects by altering various signal 
transduction pathways, which are used by vascular and mesangial cells to maintain cellular 
integrity. These effects can vary from cell to cell in complex heterogeneous tissues and can 
result in the development of diabetic complications in target tissues. Conversely, it has 
been shown that cultured human endothelial cells chronically exposed to high glucose 
concentrations exhibit important abnormalities in cell function that could not be attributed 
to alteration of the polyol pathway (Lorenzi, 1992). 
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Table 1.8. Pathogenic pathways of glucose toxicity. 
Non-enzymatic Pathway 
Increased formation of AGEs 
Oxidative stress via AGE/RAGE intemction 
Metabolic Pathways 
Polyol Pathway 
Activation ofPKC 
Hexosamine Pathway 
Increase in oxidative stress 
(Adapted from Lehmann and Schleicher, 2000) 
AGE = advanced glycation end product 
RAGE = receptor for AGE 
PKC = protein kinase C 
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Schleicher and Nerlich, 1996 
Ayo et a/, 1991 
Kolm-Litty et a/, 1998 
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Figure 1.16. Regulation of the polyol pathway in response to hyperglycaemia 
During hyperglycaemia glucose enters the cell via glucose transporters. A high glucose flux through aldose reductase and sorbitol dehydrogenase 
oxidises the NADPHINADP+ co-factor, (which is shared by aldose reductase, glutathione reductase and nitric oxide synthase) and reduces the 
NADH/NAD+ redox couples thereby increasing intracellular stress. Oxidation of the NADPHINADP+ co-factor results in depletion of reduced 
glutathione and increased production of superoxide radicals. Hyperglycaemia induced variations in nicotinamide adenine dinucleotide (NAD) 
homeostasis is thought to increase susceptibility to oxidative tissue damage. (Adapted from Stevens et al, 2000). 
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Hyperglycaemia contributes to the development of diabetic complications by 
directly affecting glycolysis and polyol pathway activity. Several mechanisms have been 
proposed explaining the detrimental effects of increased flux through the polyol pathway 
including; sorbitol-induced osmotic stress, decreased (Na+ + K) ATPase activity, increase 
in cytosolic NADHINAD+ and a decrease in cytosolic NADPH (Brownlee, 2001). These 
proposals have been further investigated clarifying the effects of these potential 
mechanisms. 
Accumulation of intracellular sorbitol, in excess of that required to buffer 
extracellular tonicity, produces intracellular osmotic stress and is believed to result in the 
depletion of myo-inositol, a precursor for phosphoinositide synthesis, and other 
intracellular osmolytes and taurine, a J3-amino acid (Greene et al, 1992; Stevens et a/, 
1993; Burger-Kentischer et a/, 1999). It was believed that sorbitol does not easily diffuse 
across cell membranes resulting in osmotic damage to microvascular cells. However, 
measurement of sorbitol concentrations in diabetic vessels and nerves show that they are 
too low to cause osmotic damage (Brownlee, 2001). Additionally, decreased (Na+ + Kl 
A TPase activity has recently been shown to result from activation of PKC, increasing 
cytosolic phospholipase activity which increases the production of two (Na+ + Kl ATPase 
inhibitors (Xia et a/, 1995). Moreover, although hyperglycaemia increases the cytosolic 
NADHINAD+ ratio in endothelial cells, through oxidation of sorbitol by NAD+, and 
inhibits the activity of glyceraldehydes-3-phosphate (GADPH), a marked decrease in the 
concentration of NAD+ occurs due to its consumption by activated poly (ADP-ribose) 
polymerase (PARP), as opposed to a reduction in NAD+ to NADH (Garcia-Soriano et al, 
2001). 
Finally, the proposal that decreases in cytosolic NADPH, due to the consumption 
of NADPH by the reduction of glucose to sorbitol, is a likely mechanism by which 
increased flux through the polyol pathway causes detrimental effects has been supported 
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by recent studies using transgenic and knockout mice (Lee and Chung, 1999; Brownlee, 
2001). NADPH is required for regenerating reduced glutathione (GSH), thus a decrease in 
concentration would induce intracellular mcidative stress due to aldose reductase 
competing with glutathione reductase for NADPH (DeMattia et a/, 1994 ). Decreased levels 
of GSH were found in transgenic mice overexpressing aldose reductase (Lee and Chung, 
1999) and studies with knockout mice deficient in aldose reductase showed that diabetes 
did not decrease the GSH content nor reduce motor nerve conduction (Brownlee, 2001}. 
Both aldose reductase mediated NADPH oxidation and sorbitol dehydrogenase mediated 
NAD reduction were found to increase free cytosolic NADP+/NADPH and decrease free 
cytosolic NAD+/NADH ratios (Lee and Chung, 1999). 
1.5.2.3.2 Advanced Glycation End-Products (AGEs) 
Glucose may react with proteins without enzymatic action by the chemical 
reactivity of its carbonyl group. This nonenzymatic glycation of proteins and DNA occurs 
during hyperglycaemia and results in the production of advanced glycosylation end-
products (AGEs), potentially altering enzymatic activity and DNA integrity (Brownlee, 
1995; 2001). AGEs attach to collagen in blood vessel walls and irreversibly cross-link to 
plasma proteins, which become resistant to enzymatic degradation. They form both 
intracellularly and extracellularly as a function of glucose concentration (Brownlee, 1995). 
High concentrations of AGEs have been found in diabetic retina vessels (Stitt et a/, 
1997) and renal glomeruli (Horie et a/, 1997). The receptor for AGE (RAGE) (Vlassara et 
a/, 1986) is known to be expressed on vascular cells including macrophages, vascular 
endothelial and smooth muscle cells and mesangial cells (Bierhaus et a/, 1998). 
Stimulation of RAGE by AGE-modified proteins results in increased oxidative stress to 
cells (Yan et a/, 1994). 
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AGEs were originally thought to arise from non-enzymatic reactions between 
extracellular proteins and glucose; from autooxidation of glucose, cleavage of Amadori 
product 1-amino-1-deoxyketose and fragmentation of glycolysis-derived triose phosphates 
(Shinohara et al, 1998). However, it is now thought that intracellular hyperglycaemia is the 
primary initiating event in the formation of both intracellular and extracellular AGEs 
(Degenhardt et a/, 1998). 
There are three general mechanisms by which AGE formation may cause 
pathologic tissue changes: rapid intracellular AGE formation by glucose or fructose can 
alter intracellular protein function in tissues; modification of the extracellular matrix by 
AGE precursors can interfere with normal matrix function; and modification of plasma 
proteins by AGE precursors can induce receptor-mediated cytokine and hormone 
production (Matsumura et al, 2000). 
1.5.2.3.3 Activation of Protein Kinase C (PKC) 
Intracellular hyperglycaemia has been shown to increase PKC activity in cultured 
vascular cells (Xi a et a/, 1994) and in the retina and the renal glomeruli of diabetic animals 
(Koya and King, 1998). It is believed that this is achieved in part through an increase in the 
de novo synthesis of the PKC regulator, diacylglycerol (DAG) from the glycolytic 
intermediate dihydroacetone phosphate (DHAP), where it is then reduced to glycerol-3-
phosphate and subsequently acylated (Koya and King, 1998). Hyperglycaemia may also 
activate PKC indirectly through ligation of AGE receptors (Portilla et a/, 2000) and 
increased polyol pathway activity (Keogh et a/, 1997). 
1.5.2.3.4 The Hexosamine Pathway 
It is thought that hyperglycaemia induced activation of the hexosamine pathway 
may result in changes in both gene expression and protein function which together may 
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contribute to the pathogenesis of diabetic complications (Brownlee, 200 I). The 
hexosamine pathway plays an important role in hyperglycaemia induced and fat-induced 
insulin resistance (Marshall et a/, 1991; Hawkins et a/, 1997). Hyperglycaemia increases 
hexosamine pathway flux by increasing fructose-6-phosphate levels and providing more 
glutamine:fructose-6-phosphate amidotransferase (GFAT), the rate-limiting enzyme of the 
pathway, due to the inhibition of GAPDH by reactive oxygen species (Du et a/, 2000). 
Fructose-6-phosphate is diverted from glycolysis to provide substrates for reactions that 
require UDP-N-acetylglucosamine (Brownlee, 2001). Inhibition of GFAT in the 
conversion of glucose to glutamine, blocks hyperglycaemia induced transcription of TGF-
a. and TGF-131 (Kolm-Litty, 1998). Other transcription factors, such as SP-1 and 
plasminogen activator inhibitor-! (PAI-l), have also been found to be regulated by 
increased flux through the hexosamine pathway (Chen et a/, 1998; Goldberg et a/, 2000). 
Sp-1 is known to be modified by N-acetylglucosamine (GicNAc) (Chen et a/, 1998), which 
may in turn activate other glucose-responsive genes. 
1.5.2.3.5 Mitochondrial Electron Transport Chain 
Hyperglycaemia has been shown to induce the overproduction of superoxides 
through the mitochondrial electron transport chain (Du et a/, 2000; Nishikawa et a/, 2000), 
which is believed to be the common element linking the four-mechanisms of 
hyperglycaemia-induced damage (Brownlee, 200 I). This overproduction of superoxides 
increases the flux through both the polyol and hexosamine pathways, AGE formation and 
PKC activity (Figure 1.17). Mitochondrial superoxides have been shown to induce a 66% 
decrease in GAPDH activity (Du et a/, 2000). This inhibition of GADPH activity may 
activate PARP and deplete NAD+ (Garcia-Soriano et a/, 2001), increase triose phosphates 
levels (Shinohhara et a/, 1998), increase dihydroxyacetone phosphate levels (Du et al, 
2000), and increase fructose-6-phosphate levels (Du et a/, 2000). 
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Figure 1.17. The four hypothetical pathways by which hyperglycaemia is thought to induce mitochondrial superoxide overproduction. 
The glycolytic enzyme GADPH is partially inhibited by excess superoxide, which then diverts upstream metabolites from glycolysis into pathways 
of glucose overutilisation., resulting in increased flux through the various pathways. (Adapted from Brownlee, 2001). GFAT = glutamine::fructose-
6-phosphate amidotransferase, UDP-GlcNAc = UDP-N-acetylglucosamine, DHAP = dihydroxyacetone phosphate, DAG = diacylglycerol, PKC = 
protein kinase C, AGE = advanced glycation end-product. 
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Reductive stress can also trigger production of reactive oxygen species through 
overload of mitochondrial matrix and coenzyme shuttles with NADH and by reaction of 
NADH with NADH oxidase (Oates and Mylari, 1999). It is also believed that mutations in 
mitochondrial DNA may be induced by the overproduction of superoxides resulting in the 
production of defective subunits of the electron-transport complexes. This would 
eventually result in further increases in superoxide production at physiological 
concentrations of glucose, eventually activating all four pathways in the absence of 
hyperglycaemia (Brownlee, 2001 ). 
1.5.2.3.6 Oxidative Stress 
Free radicals are highly reactive molecules as they have unpaired electrons in their 
outer orbits and they become damaging to cellular structures and enzymes when they are 
produced excessively or when there are inadequate antioxidant defence mechanisms 
(Halliwell and Gutteridge, 1999). Oxygen free radicals include the hydroxyl radical (OH), 
superoxide anion (0.2"), hydrogen peroxide and singlet oxygen and their generation can 
oxidise membrane lipids or proteins and inactive enzymes which can then impair cellular 
transport and function eventually leading to cell death (Halliwell, 2001). Oxidative stress 
thus results from an imbalance between the generation of reactive oxygen species and the 
ability of the organism to dispose of them. A forced regulation of osmolytes occurs where 
intracellular concentrations are either increased or decreased through the induction or 
suppression of enzymes. 
It is believed that reactive oxygen species generated as a result of hyperglycaemia 
play a role in the development of diabetic complications such as nephropathy, retinopathy 
and neuropathy. The oxidative stress hypothesis suggests that fiber and microvessel 
damage is promoted by defective antioxidant resistance in diabetes (Nagamatsu et a/, 
1995; Low et a/, 1997). Many studies have shown that diabetes and hyperglycaemia 
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increase mcidative stress (Guigliano et a/, 1996). Hyperglycaemia can increase the 
formation of free radicals and lipid peroxides through several mechanisms including direct 
auto-oxidation of glucose (glycoxidation), where glucose initiates free radical production 
and alters the ratio of reduced NADH to NAD+, induction and activation of various 
lipoxygenase enzymes, activation of glycation pathways, interaction of nitric oxide with 
superoxide anions, and reduction of the activity of the antioxidant defence mechanisms 
(Ido et a/, 1997; Giuglioano et a/, 1996; Baynes and Thorpe, 1999). 
1.5.2.3. 7 Nitric Oxide (NO) 
Nitric oxide (NO) is produced from the oxidation of L-arginine by nitric oxide 
synthase (NOS) (Moncada et a/, 1991). It serves as an intracellular or intercellular 
mediator and is released from the endothelium and a variety of other tissues. It is a free 
radical that can act in a paracrine or autocrine manner to produce both beneficial and 
detrimental cellular responses. It has been demonstrated in the physiology of every organ 
system featuring prominently in the control of blood vascular, immune and nervous 
activities and the regulation of gene expression (Ignarro et a/, 1996; 1999). 
NO was originally identified as a potent endothelial-derived relaxing factor for 
vascular smooth muscle. The human body contains three known forms of NOS defmed in 
terms of their original cellular source; endothelial NOS (ecNOS or type m NOS), 
macrophage/cytokine inducible NOS (iNOS or type ll NOS) and neuronal NOS (ncNOS or 
type I NOS) (Moncada et a/, 1991). Both the ecNOS and ncNOS forms are constitutive, 
calcium/calmodium-dependent enzymes that synthesise small basal quantities of NO 
(Knowles and Moncada, 1994). The activity and expression of the iNOS form is low or 
absent in resting cells but can be rapidly induced by the action of certain cytokines and 
lipopolysaccharide and is independent of intracellular calcium concentrations. iNOS can be 
expressed in many cells including pancreatic J3-cells, macrophages, fibroblasts, vascular 
-90-
Chapter 1. Introduction 
endothelial cells, masangial cells and cardiac myocytes (Knowles and Moncada, 1994; Xie 
and Nathan, 1994). 
1.5.2.3.8 Mitogen-Activated Protein Kinases (MAPKs) 
The four major hypothesis believed to contribute towards the development of 
diabetic complications also share the capacity to activate mitogen-activated protein kinases 
(MAP.Ks) which in turn can trigger cellular events necessary for the development of 
diabetic retinopathy, nephropathy and neuropathy (Tomlinson, 1999). Three main groups 
of MAP.Ks are known; the extracellular signal regulated kinases (ERK), the c-Jun N-
tenninal kinases (JNK), and the p38 kinases, all of which have subtypes. JN.Ks respond to 
several forms of cellular stress (Ip and Davis, 1998) and ERKs are primarily regarded as 
growth factor signalling kinases (Davis, 1995). p38 is an osmotic response element that 
can be activated by glucose or diabetes (Igarashi et a/, 1999). Cellular oxidative stress is 
known to activate MAP.Ks (Wang et a/, 1998) and it has been shown that hydrogen 
peroxide can activate all three MAP.Ks (Guyton et a/, 1996; Clerk et a/, 1998). Ligand 
binding to RAGE (Lander et a/, 1997) and PKC (Clerk et a/, 1998) can also activate 
MAP.Ks. 
1.5.2.3.9 Vascular Endothelial Growth Factor (VEGF) 
VEGF (described and characterised in section 1.3.3.1) induces vascular endothelial 
cell proliferation, migration and vasopenneability in many cells and tissues (Aiello and 
Wong, 2000). In vivo, VEGF has been identified as a primary initiator of proliferative 
diabetic retinopathy and as a potential mediator of non-proliferative retinopathy (Aiello et 
a/, 1994). It has been known that intraocular VEGF levels are increased in diabetic patients 
and that a correlation exists between the levels of glycated proteins and the development of 
retinopathy (Singh et a/, 2001). VEGF has also been implicated in the development of 
-91 -
Chapter 1. Introduction 
neuropathy and nephropathy in patients with diabetes (Aiello and Wong, 2000). 
AGEs stimulate VEGF expression in epithelial cells and in vascular smooth muscle 
cells (Lu et a/, 1998; Yamagishi et al, 1997). A recent study has found that AGEs stimulate 
VEGF expression in mice retina through an increase in HIF-la accumulation and 
activation ofHIF-1 through an ERK dependent pathway (Treins et a/, 2001). 
It has also been reported that PKC is involved in the generation of VEGF (Doanes 
et a/, 1999). PKC activation enhances angiogenesis by participating in the intracellular 
signalling of VEGF in endothelial cells (Takahashi et a/, 1999; Wu et a/, 2000). A study 
has shown that elevated glucose concentrations increase the expression ofVEGF in human 
aortic smooth muscle cells which was inhibited by PKC inhibitors (Williams et a/, 1997). 
Additionally, it is known that VEGF can activate several PKC isoforms (Xia et a/, 1997; 
Aiello et al, 1997). Thus, it is possible that the production of VEGF is stimulated 
synergistically by activated PKC and hypoxia derived from oxidative stress and increased 
flux through the polyol pathway (Tomlinson, 1999). 
1.5.2.3.10 Retinopathy 
Patients with T1 DM are at higher risk for development of severe retinal 
complications and visual loss. Damage is caused by both microvascular leakage due to 
breakdown of the inner blood-retinal barrier and microvascular occlusion (Watkins, 1998). 
Diabetic retinopathy involves 5 basic pathological processes that occur at the level 
of the retinal capillary: formation of microaneurysm, excessive vascular permeability, 
vascular occlusion, proliferation of new blood vessels and fibrous tissue on the retina, and 
contraction of the fibrovascular proliferation and the vitreous. The classification of diabetic 
retinopathy is based on the severity of intraretinal microvascular changes and the presence 
or absence of retinal neovascularisation. Nonproliferative diabetic retinopathy occurs when 
only intraretinal microvascular changes occur whereas proliferative diabetic retinopathy 
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involves the formation of new vessels or fibrous tissue on the retina (Chew, 2000). 
Proliferative retinopathy occurs in response to severe ischemia and hypoxia of the retina. 
Hyperglycaemia is known to be important in the development of tissue in the lens 
and optic nerve (Greene et a/, 1988; Kinoshita, 1986). Tissue injury can result from 
excessive intracellular production of sorbitol from glucose caused by an increase flux 
through the polyol pathway (Brownlee, 2001). Transport of glucose into the retina across 
the blood-retinal barrier occurs via the GLUT-1 transporter (Pessin and Bell, 1992). There 
have been few reports on the in vivo expression of GLUT -1 in retina and its microvessels 
(K.umagai et a/, 1996, Badr et a/, 2000). However, a recent study has shown that diabetes 
results in the downregulation of GLUT -1 expression in retinal microvessels, but not in the 
retinal pigment epithelium of rats, suggesting that glucose entering the retina in diabetes is 
likely to be greater across the retinal pigment epithelium than across the retinal vasculature 
{Badr et a/, 2000). 
Diabetic retinopathy is also mediated by the hypoxic regulation of angiogenic 
growth factors including VEGF (Singh et a/, 2001). Retinal epithelial cells produce VEGF 
and the synthesis and release of VEGF is increased when the cells are grown under 
reduced oxygen tension (Aiello et a/, 1995). Thus, VEGF overexpression can have a 
detrimental effect in the retina. It is also known that retinal endothelial cells possess many 
VEGF receptors (Thieme et a/, 1995). The correlation between elevated VEGF levels and 
the development of a disordered vascular network has been extensively studied in both 
animal models (Murohara et a/, 1998; Rivard et a/, 1999; Rivard et a/, 1999b) and human 
subjects (Losordo et a/, 1998; lsner et a/, 1999; Kalka et a/, 2000; Lathi et a/, 2001; Bashir 
et a/, 2002). It is believed that multiple signals converge and augment the angiogenic 
signal through a VEGF signalling cascade. It is clear that the interaction of several signals 
result in neovascularisation. 
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A recent study has reported that the stimulation of VEGF by AGEs, through the 
activation of lllF-1, could play an important role in the development of diabetic 
retinopathy (Treins et a/, 2001). It is known that lllF-la expression is induced during 
normal retinal development however, it is downregulated by hyperoxia, and upregulated 
upon returning to normoxic conditions (Ozaki et a/, 1999). Retinal hypoxia in the diabetic 
state due to reduction of blood flow stimulates the expression of VEGF and results in 
retinal neovascularisation and increased retinal vascular permeability (Veves and King, 
2001). 
1.5.2.3.11 Nephropathy 
Thirty to forty percent of patients with TIDM develop nephropathy within 10 years 
of diagnosis (lbrahim and V ora, 1999). Increased excretion of albumin and other proteins 
in the urine is an early and progressive marker or renal dysfunction in diabetes (Mogensen 
et a/, 1995). Diabetic nephropathy is clinically defmed as the presence of persistent 
proteinuria (total urinary protein excretion > 0.5g/24 hours) in sterile urine of diabetic 
patients with concomitant retinopathy, but without other renal disease or other heart failure 
(American Diabetes Association, 1998). Overt diabetic nephropathy is characterised by a 
progressive decline in renal function, resulting in end-stage renal disease. 
Diabetic nephropathy occurs in several distinct and interconnected phases; an early 
phase of physiologic abnormalities of renal function, a microalburninuria phase and a 
clinical phase with persistent clinical proteinuria progressing to end-stage renal failure 
(Mogensen, 1995; 1997). Microalburninuria is defined as an increase in the albumin 
excretion rate to a range of 20 to 200 ~g/minute. Albumin excretion rates in healthy 
individuals range from 1.5 to 20 ~glminute (median 6.5 ~glminute). As the disease 
progresses albuminuria increases until end stage nephropathy, when it may decrease 
(Ibrahim and Vora, 1999). Large studies have shown that high albumin excretion rates are 
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the most important risk factor for the later development of incipient and overt nephropathy 
in TIDM (Microalbuminuria Collaborative Study Group, 1993; Mathiesen et a/, 1995). 
The development of diabetic nephropathy is characterised by progressive 
thickening of the glomerular and tubular basement membranes, expansion of the mesangial 
matrix, and increased synthesis of collagens due to increased proliferation of mesangial 
cells, accumulation of the extracellular matrix and obliteration of glomerular capillaries 
(Lehmann and Scheicher, 2000). These characteristics can influence the glomerular 
filtration capacity and hemodynamics as well as being responsible for the increased 
secretion of albumin and decreased filtration that occurs in patients with diabetic 
nephropathy (Khasigov et a/, 2000). 
It is known that chronic hyperglycaemia can lead to sorbitol accumulation in a 
variety of tissues, including renal tubuli and glomeruli, which then leads to tissue damage 
through a disruption of cellular osmoregulation in addition to depletion of myoinositol 
(Greene, 1988). However, it is believed that renal damage in the diabetic kidney is unlikely 
to occur through a mechanism involving the polyol pathway (Schleicher and Nerlich, 
1996). It is known that glucose transporter- I (GLUT-I) is the main transporter of glucose 
in the glomeruli (Heilig et a/, 1995; Heilig et a/, 1997) (section 1.5.2.4.1). Experiments 
involving the administration of an aldose reductase inhibitor to streptozotocin-induced 
diabetic rats have shown that histologic lesion of glomerular disease remained unaffected 
(Rasch and Osterby, 1990). 
The role of VEGF in the development of diabetic nephropathy has recently been 
explored. VEGF expression is found to be upregulated in glomerular endothelial, tubular 
and mesangial cells by hypoxia, hyperglycaemia induced PKC activation or transforming 
growth factor-~ (TFG-~) mediated pathways (Del Prete et a/, 1998; Cooper et al, 1999). 
Increased expression ofVEGFR-2 receptors have also been observed in diabetic rat models 
(Cooper et al, 1999). Studies have also demonstrated that VEGF isoforms mediate repair in 
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glomerular cells (Ostendorf et a/, 1999) suggesting that increased VEGF expression may 
be a repair response and/or a cause of pathological changes in diabetic nephropathy. 
1.5.2.3.12 Neuropathy 
Diabetic neuropathy is associated with risk factors for macrovascular disease and 
with other microvascular complications such as poor metabolic control, dyslipidaemia, 
body mass index, smoking, microalbuminuria and retinopathy (Cameron et a/, 2001). The 
most common form of diabetic neuropathy, a heterogeneous condition, is distal symmetric 
polyneuropathy which damages distal peripheral nerves together with the autonomic 
nervous system. Neuropathies may be sensory, motor or mixed and may involve primarily 
small or large nerve fibers (Brown and Asbury, 1984; Tomlinson et a/, 1997). Diffuse 
peripheral neuropathy also causes diffuse damage to the autonomic nerves, both 
parasympathetic and sympathetic. Studies in human and animal models have shown 
reduced nerve perfusion and endoneuria) hypoxia . 
Investigations on biopsy material from patients with mild to severe neuropathy 
show graded structural changes in nerve microvasculature including basement membrane 
thickening, pericyte degeneration and endothelial cell hyperplasia (Cameron et a/, 2001). 
Increased polyol pathway activity by hyperglycaemia results in the accumulation of 
sorbitol and fructose in nerves, which in turn cause damage by an unknown mechanism. 
Decreased myoinositol uptake, inhibition of Na+/K+ ATPase and changes in the specific 
activity of PKC then occur, resulting in Na + retention, edema, myelin swelling, axoglial 
disjunction and nerve degeneration (Vinik et a/, 2000). This complex interaction of 
metabolic factors accounts for endothelial dysfunction, reduced nerve perfusion and 
function. Thus, vascular dysfunction, driven by metabolic change, is a main factor in the 
development of diabetic neuropathy. 
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1.5.2.4 Glucose Transporter Gene Family 
Glucose transport has been highly investigated in diabetes research and has led to 
the discovery of a family of glucose transporters. The glucose transport (GLUT) family of 
integral membrane glycoproteins mediates the facilitative transport of glucose across 
mammalian cell plasma membranes. There were originally 7 members which have been 
designated GLUT-I through 5 in order of their identification by cDNA cloning and share 
39 % to 65 % identity with each other and 50-76 % similarity between amino acid 
sequences (Mueckler, 1994; Baldwin, 1993, Pessin and Bell, 1992). Two additional 
members were included in the family however GLUT-6 was found to encode a pseudogene 
(Kayano et a/, 1990) and the existence of GLUT -7 is disputed (Burchell, 1998). 
Recently, homology searches of the EST databases have identified several glucose-
like sequence fragments from which full-length cDNAs were isolated and characterised 
using PCR and RACE technologies (Doege et a/, 2000a; 2000b; 200Ia; lbberson et a/, 
2000; Phay et a/, 2000; McVie-Wylie et a/, 2001). These searches have resulted in the 
identification of a total of 7 new members of the GLUT family that exhibit significant 
similarity (>28% identical amino acids) with GLUT-I were identified; GLUT-6, 8, 9, 10, 
11, 12 and HMITI (reviewed in Joost and Thorens, 2001) (Table 1.9). One of the original 
GLUT proteins that was designated GLUT-9 (Doege et a/, 2000a) was recently renamed 
GLUT-6 (Joost et a/, 2001). Additional homology searches have identified 4 presumed 
pseudogenes that exhibit significant similarity with the GLUT family. The extended GLUT 
family has been subsequently divided into three sub-classes; Class I comprises the totally 
characterised glucose transporters GLUT-I to 4, Class IT comprises the fructose-specific 
transporter GLUT-5 and related proteins GLUT-7, 9, and 11, and Class m comprises five 
isotypes GLUT-6, 8, 10, 12 and HMITI (Doege et a/, 2001; Joost and Thorens, 2001). The 
GLUT proteins are expressed in a cell specific manner in different tissues and display 
unique regulatory functions, which indicates that each transporter plays a precise role in 
glucose metabolism. 
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Glucose transporters are widely distributed and are found on the surface of all. 
mammalian cells in either inward or outward facing conformations. All family members 
have a similar membrane topology that includes I2 membrane-spanning a-helical 
segments consisting of a large exofacial (outward facing) loop between membrane 
spanning segment I (Ml) and M2 and a large hydrophilic segment connecting M6 and M7 
(Bell et al, 1990; Mueckler, 1994). This region of the molecule is believed to form the 
hexose pore (Leinhard et al, 1992). The amino and carboxy termini are exposed to the 
cytoplasmic face. A sugar moiety of variable length is attached to the exofacial domain 
that is involved in determining the cellular location of the proteins (Kurnagai et a/, 1994). 
A single cell can express more than one transporter isoform and most tissues express 
several. The glucose transporter genes are not located at one specific site; rather they are 
dispersed on different chromosomes or on different regions of a specific chromosome. 
1.5.2.4.1 Glucose Transporter 1 (GLUT-I) 
The human GLUT-I gene was the first to be characterised, it is located on 
chromosome 1p35-p31.3 and found to consist of 10 exons of 2544 nucleotides in length 
(Mueckler et a/, 1985; Fukumoto et a/, 1988). The introns of the GLUT-I gene interrupt 
the protein-coding region, as in all the family members. GLUT -1 is the most widely 
distributed isoform and is expressed in foetal and adult tissues (Birnbaum et a/, 1986; 
Mueckler et a/, 1985). It is abundant in human erythrocytes, placenta and endothelia and 
mediates basal glucose uptake and transport across blood-brain barrier and other barrier 
tissues. GLUT-I is associated with cells undergoing proliferation and is induced in growth-
factor stimulated cells. In addition, the level of expression of GLUT -1 correlates with the 
glycolytic activity of the cells in which it is expressed. It is known that GLUT-1 and 
GLUT -4 continuously recycle in living cells even in the absence of insulin (Czech and 
Buxton, 1993; Davies et a/, 1990). A three-dimensional model of the human facilitative 
-98-
Chapter 1. Introduction 
Table 1.9. Characteristics of the extended facilitated glucose transporter family. 
lsoform 
Size 
Function Tissue Location Reference (Amino 
Acids) (Sites of Expression) 
GLUT-I 492 Basal transport Erythrocytes, brain, Mueckler et al, 1985 placenta, kidney, colon 
Glucose sensor, low- Liver, pancreatic P-cells, GLUT-2 524 
affinity transporter kidney, small intestine Fukumoto et al, 1988 
GLUT-3 496 Basal transport, high- Brain, placenta, testes, Kayano et al, 1988 
affinity transporter kidney, neurons 
GLUT-4 509 Insulin-regulated Fat, muscle, heart, Fukumoto et al, 1989 glucose transport skeletal muscle 
GLUT-S 501 High-affinity fructose Small intestine, testes, Kayano et al, 1990 transporter skeletal muscle, fat 
GLUT-6 507 Low-affinity Brain, spleen, leukocytes Doege et al, 2000a; (fonnerly GLUT -9) transporter Joost et al, 2001b 
GLUT-7 528 Mediated glucose Liver Burchell, 1998 
release from the ER 
GLUT-8 477 High-affinity glucose Testes, brain, blastocyst, Doege et al, 2000b; 
(fonnerly GLUTX I) transporter heart, skeletal muscle Carayannopoulos et al, 2000; lbberson et a/, 2000 
GLUT-9 540 No data published Liver, kidney, lung Phay et a/, 2000 
GLUT-10 541 Glucose transporter Liver, pancreas, heart, McVie-Wylie et al, 2001; kidney, skeletal muscle Dawson eta/, 2001 
GLUT-11 496 Fructose transporter Heart, skeletal muscle Doege et al, 2001a; 2001b 
(formerly GLUTlO) Sasaki et a/, 2001 
GLUT-12 617 . Possible glucose Heart, prostate, skeletal Rogers et al, 1998; (formerly GLUT -8) transporter muscle, small intestine, Rogers et a/, 2002 
fat 
HMlT 629 High-affinity myo- Brain Uldry et a/, 2001 inositol transporter 
Note: GLUT-9 was re-named GLUT-6 which was previously used for a pseudogene 
(Kayano et a/, 1990). (Adapted from Joost and Thorens, 2001). 
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glucose transporter GLUT-I has been recently proposed and is shown in Figure 1.18 
(Zuniga et al, 2001). 
GLUT -1 is often the predominant isoform expressed in cultured cells. The level of 
glucose transporter activity, GLUT -1 protein and mRNA in cultured cells can be altered by 
a number of different stimuli including stress. However, the effect of additional stimuli on 
glucose transporter expression is often specific for a given cell line or cell type. 
1.5.2.4.1.2 Glucose Metabolism 
Glucose is the main source of energy for most cells and transport across plasma 
membranes is rate-limiting for glucose metabolism in the majority of mammalian cells 
(Klip et al, 1994; Baldwin 1993). After glucose is transported into cells or tissue, it is 
either converted into glycogen or it undergo glycolysis where it is released as lactate or 
oxidised in the Krebs cycle. The enzyme glycogen synthase regulates the incorporation of 
glucose into glycogen and the pyruvate dehydrogenase multienzyme complex regulates the 
entry of glucose carbon into the Krebs cycle for oxidation. Glucose is eventually 
completely oxidised to C02 and H20 in the mitochondria. Increased glycolysis is 
associated with upregulation of glycolytic enzymes and abnormal expression of glucose 
transporters (Hennipman et al, 1987). In the majority of cells and tissues intracellular 
glucose is low and glucose transport is rate-limiting for glucose utilisation. Thus, glucose 
homeostasis requires a controlled regulation of glucose flux into and out of cells or organs. 
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Figure 1.18. Proposed ribbon model of the human facilitative glucose transporter GLUT-
1. Helices 1-5, 8 and 10-12 (coloured) are arranged in a 9-member barrel-like manner. 
Loops are white. (Zuniga et a/, 2001 ). 
- 101 -
Chapter 1. Introduction 
1.5.2.4.1.3 Glucose Transport 
Glucose transport in most tissues IS a passive process as it occurs down a 
concentration gradient by facilitative diffusion. As the plasma membrane is impermeable 
to large polar molecules, the cellular uptake of glucose occurs using membrane-associated 
carrier proteins that bind glucose and carry it across the lipid bilayer (Bell et a/, 1990). 
The glucose molecules bind to the outward facing fonn of the transporter, which then 
undergoes a conformational change and transports the sugar into the cell. Glucose 
transporters can be regulated acutely, chronically or both. Acute stimulation of glucose 
transporters occurs through either translocation of the transporter to the plasma membrane 
or activation of glucose transporters that pre-exist at the cell surface (Behrooz and Ismail-
Beigi, 1999). Insulin increases the rate of glucose transport across the cell membrane in 
both muscle and adipose tissue by increasing the number of glucose transporters in the 
plasma membrane, which in turn increases the net rate of translocation of the transporter 
from an intracellular store to the cell membrane (Kahn, 1996). Under high glucose 
transporter activity the rate of glucose transport is not susceptible to insulin and glucose 
transport occurs with near equilibrium in both directions across the cell membrane. 
1.5.2.4.1.4 Glucose Transport and Cancer 
It has been long known that there is increased glycolysis in cancer cells compared 
to normal cells (Warburg, 1956). Tumour cells exhibit high glycolytic activity and 
accumulate high levels of lactate compared to normal cells, which can be attributed to an 
increased expression of glucose transporters. The expression of glucose transporters has 
been studied in a wide variety of human tumour types. Increased GLUT -1 expression has 
been observed under hypoxic conditions in cancer cells (Clavo et a/, 1995) and in cells 
transfonned by oncogenes (Flier et a/, 1987, Godwin and Lieberman, 1991). 
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Glucose uptake has been shown to be up-regulated in breast cancer cell lines where 
increased GLUT-1, GLUT-2, GLUT-4 and GLUT-5 expression was demonstrated 
(Zamora et a/, 1996). In breast cancers with higher tumour grade and proliferative activity, 
increased expression ofGLUT-1 was found (Wang et a/, 1996). 
1.5.2.4.1.5 Glucose Transport and Hypoxia 
Several stimuli, such as hypoxia, inhibition of oxidative phosphorylation and 
exposure to alkaline pH, have been shown to increase the rate of glucose transport in a 
variety of experimental models (Wheeler, 1998; Shetty et a/, 1992; Hakimian and Ismail-
Beigi, 1991 ). It is thought that hypoxia mediates the enhancement of GLUT -1 mediated 
glucose transport by at least two independent cell-signalling pathways, which involve 
multiple mechanisms. One pathway involves the inhibition of oxidative phosphorlyation 
after hypoxia, which leads to acute stimulation of glucose transport and a delayed 
induction of GLUT -1 expression. A second pathway involves the induction of an oxygen 
sensor mechanism that also stimulates GLUT-1 gene transcription (Behrooz and Ismail-
Beigi, 1999) (Figure 1.19). 
During aerobic metabolism, molecular oxygen becomes an electron acceptor, 
which results in the production of ATP or cellular energy, and oxidative phosphorylation 
occurs. Inhibition of this process through production of hypoxic conditions or exposure to 
pharmacological inhibitors results in an increase in the cellular demand for glucose 
metabolism through the glycolytic pathway to generate lactate (Behrooz and Ismail-Beigi, 
1999). Thus, decreased mitochondrial respiration and ATP synthesis activates the 
stimulation of glucose transport. It has been demonstrated that decreased levels of 
intracellular ATP increase cytosolic calcium concentrations and enhance GLUT-1 function 
and expression. However, not all cells exposed to hypoxia exhibit decreases in intracellular 
ATP levels suggesting that localised changes in intracellular ATP levels may modulate 
glucose transport (Mitani et a/, 1996). 
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Figure 1.19. Hypoxia induced GLUT-1 mediated glucose transport. 
At least two independent pathways are involved in hypoxia enhanced GLUT -1 mediated 
glucose transport, an oxygen-sensing and signalling pathway involving hypoxia inducible 
factor 1 (HIF-1 ), and inhibition of oxidative phosphorylation which results in increased 
GLUT -1 mRNA stability and activation and translocation of pre-existing GLUT -1 
molecules. (Adapted from Behrooz and Ismail-Beigi, 1999). 
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As many cellular processes are oxygen dependent, several oxygen consuming 
reactions could serve as second messangers that trigger a hypoxic response. It is believed 
that these reactions work independently or in conjunction to modulate specific changes in 
gene expression and gene product function. Oxygen sensing involves the oxygen molecule 
binding reversibly to intracellular receptors under hypoxic conditions, which then transmit 
a hypoxic signal. It is believed that heme-containing molecules act as oxygen sensors 
which are able to bind to oxygen as well as certain divalent cations such as Co2+, Nr, and 
Mn2+ (Goldberg et a/, I988). These metal ions can substitute for iron in the sensors' heme 
moiety and maintain the molecule in an active state. This oxygen-sensing system and 
signalling pathway is ubiquitous and in addition to controlling GLUT-I gene expression 
through transcription. it also regulates a number of hypoxia-inducible· genes in a variety of 
cell types. The oxygen sensing signalling pathway can be activated without inhibition of 
oxidative phosphorylation or decreases in intracellular A TP content (Behrooz and Ismail-
Beigi, 1997). 
1.5.2.4.1.6 Neurons 
Neurons are dependent upon glucose and oxygen for energy. The majority of 
adenosine triphosphate (A TP) generated in neurons for normal functions is dependent upon 
the aerobic oxidation of glucose and the integrity of the oxidative phosphorylation 
pathway. The facilitative uptake of glucose into mammalian brain cells occurs via GLUT-I 
and GLUT 3. GLUT-I is most abundant in brain microvessels (Maher et a/, 1994) and its 
mRNA is distributed in a diffuse pattern throughout the brain (Bondy et a/, 1992). A recent 
study found that hypoxia stimulates a reversible increase in GLUT-I steady-state mRNA 
levels in primary cultures of rat neurons and glia, due to enhanced RNA stability and not 
increased transcription, and is temporally associated with increased GLUT-I protein and 
transporter activity (Bruckner et a/, I999). Thus, hypoxia and glucose deprivation 
synergise to increase GLUT gene expression. 
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1.6 HIF -1 Interactions 
HIF-la activates transcription of a large number of different glucose transporters 
and glycolytic enzymes, and a number of stress response and oxygen regulated genes 
including p53, VEGF and iNOS, all of which are implicated in vasodilation, neo-
vascularisation and tumour metastasis (lyer et al, 1998; Ryan et a/, 1998; Carmeliet et al, 
1998; Zhong et al, 1999). In response to hypoxia, or stress, oncoproteins provide hypoxic 
tumour cells with a growth advantage, angiogenic factors attract new vasculature to 
increase oxygenation and glucose transporters and glycolytic enzymes allow to switch to 
energy saving glycolysis (Dachs and Tizer, 2000). 
1.6.1 Tumour Suppressor: p53 
There have been many recent advances in understanding the functional role of p53 
in tumourigenesis, however the mechanisms underlying the stabilisation of p53 in hypoxia 
have yet to be detennined. It is known that increased HIF-1 expression is associated with 
multiple genetic alterations that promote tumour angiogenesis, such as loss-of-functions 
mutations in tumour suppressor genes and by oncogene activation. As HIF-1 is a key 
transcriptional activator of genes encoding glucose transporters and glycolytic enzymes 
(Iyer et al, 1998), genetic alterations may also contribute to the metabolic adaptation and 
increased survival of tumour cells in hypoxic environments (Ravi et a/, 2000). 
A recent study proposed that the HIF-la subunit binds to p53 and stabilises p53 by 
protecting it from proteasomal degradation (An et al, 1998), however another study has 
proposed that mechanisms other than HIF-la activation contribute to oxygen-regulated 
p53 induction (Wenger et a/, 1998). As HIF-la and p53 both bind to distinct regions of the 
transcriptional coactivator p300 (Blagosklonny et a/, 1998), which is required for full 
activity of both transactivators, it has been proposed that the interaction ofHIF-la and p53 
may be indirect and insufficient for hypoxic stabilisation ofp53. High levels ofp53 inhibit 
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lllF-inducible transcription via p300 (Blagosklonny et a/, 1998), however up-regulation of 
lllF-la is not sufficient for p53 induction (Wenger et a/, 1998).1t is possible that both p53 
and lllF-1a can bind simultaneously to p300 as the lllF binding site has been localised to 
amino acids 346 to 400 (Arany et a/, 1996) and that for p53 to a p300 fragment containing 
amino acids 1514 to 1922 (Gu et a/, 1997). 
Another recent study has shown that loss of p53 function increases lllF-1 activity 
resulting in the overexpression of VEGF that is commonly observed in a wide variety of 
cancers (Ravi et a/, 2000). It was found that p53 interacts with lllF-1a in vivo and inhibits 
the hypoxia-induced expression of HIF-1a by assisting its ubiquitination, through the 
binding of the ubiquitin-protein ligase MDM2 to p53, and consequential degradation. 
Thus, p53 decreases the stability of HIF-1a in an MDM2-dependent manner, indicating 
that lllF-1a is the preferential target of MDM2 (Ravi et a/, 2000). This mechanism of 
tumour suppressor action is similar to that proposed for the von Hippei-Lindau (YID.) 
tumour suppressor which affects lllF-1a degradation through ubiquitination. Thus p53 
mediated inhibition of VEGF expression, in conjunction with its ability to up-regulate 
inhibitors of angiogenesis, such as thrombospondin-1 (Dameron et a/, 1994 ), indicate that 
p53 regulates angiogenesis using dual functions. 
1.6.2 Angiogenic Factor: VEGF 
HIF-1 is the best-characterised regulator of VEGF gene transcription. It plays a 
central role in the hypoxic induction of the VEGF gene by binding to its target DNA 
sequence. A hypoxic response element is located approximately 1 kb 5' to the transcription 
start site of the human VEGF gene (Forsythe et a/, 1996; Lui et a/, 1995). Studies have 
shown a strong correlation between the level of hypoxia-induced HIF-1 DNA-binding 
activity and VEGF mRNA expression (Forsythe et a/, 1996; Wood et a/, 1996). 
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VEGF expresston is induced in both transformed and nontransfonned cells 
exposed to various cytokines and growth factors (Jackson et a/, 1997; Ryuto et a/, I996) 
all of which have also been shown to induce IDF-Ia protein expression and/or HIF-1 DNA 
binding activity (Zhong et a/, 2000). Further immunohistochemical studies have also 
shown that VEGF and IDF are both highly expressed in pseudopalisading cells 
surrounding areas of necrosis in GBM (Plate et a/, 1992; Zagzag et a/, 2000) suggesting 
that IDF-1 mediates hypoxia-induced VEGF expression in GBM. Moreover, a recent study 
has shown that AGEs stimulate VEGF mRNA expression in mice retina through and 
increase in IDF-Ia accumulation and activation ofiDF-1 (Treins et a/, 200I). Thus, AGE 
induced VEGF expression, through the activation ofiDF-I, could play an important role in 
the development of diabetic complications. 
1.6.3 Metabolite: GLUT-1 
The key regulator of the oxygen sensing and signalling pathway is IDF-1 
(Semen.za, 2002). There are no less than two independent pathways involved in hypoxia 
enhanced GLUT-1 mediated glucose transport, an oxygen-sensing and signalling pathway 
involving hypoxia inducible factor I (IDF-I ), and inhibition of oxidative phosphorylation 
which results in increased GLUT-I mRNA stability and activation and translocation of 
pre-existing GLUT-I molecules (Behrooz and Jsmail-Beigi, 1999). As in other oxygen-
regulated genes, both the mouse and rat GLUT -I gene contains a cis-acting element 
located in the 5' flanking region of the gene that is necessary for transcriptional response to 
hypoxia (Ebert et a/, I995; Behrooz and Ismail-Beigi, I997). Exposure to hypoxia for 
prolonged periods of time results in the induction ofmRNA and GLUT-I protein (Bashan 
et a/, 1992), however the half-life ofGLUT-1 mRNA is decreased (Stein et a/, I995). The 
response is mediated by transcriptional and post-transcriptional regulatory mechanisms 
that lead to an overall increase in cell and plasma membrane GLUT content. Enhanced 
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transcription occurs to increase the availability of glucose so that the cell can survive 
metabolic alterations. Increases in glucose uptake and glycolysis are thought to help the 
cell preserve high-energy phosphates and sustain the cells from lethal injury during 
hypoxia. 
1.6.4 Vasoactive Agent: Nitric Oxide 
IDF-1 is essential for iNOS induction under hypoxia conditions (Jung et a/, 2000), 
and NO is known to modulate the expression oflllF-1 in hypoxia (Liu et a/, 1998; Huang 
et a/, 1999; Kimura et a/, 2000). This interaction has not been thoroughly defmed. It is 
thought that the thiol groups in IDF-1 or the proteins that are involved in the regulation of 
IDF-1 are potential targets for nitric oxide (Palmer et a/, 2000). Additionally, it has 
recently been demonstrated that NO generated by iNOS expression inhibits IDF-1 activity 
in hypoxic C6 cells suggesting a negative feedback loop in the lllF-1/iNOS cascade (Yin 
et a/, 2000). The molecular mechanism of this NO-mediated inhibition oflllF-1 binding is 
not known, however several theories have been suggested. One theory suggests that NO 
may bind to ferric heme oxygen and superoxide which may affect the signal pathway for 
lllF activation (Stamler, 1994). Enhanced oxidative stress enhances the cellular redox state 
and thereby determines IDF-1a binding activity (Haddad and Land, 2000). 
It is also known that VEGF expression is regulated by NO, where NO has been 
shown to stimulate VEGF expression by stabilising IDF-1 expression (Klagsbrun and 
D' Amore, 1996). Additionally, it has been shown that NO down-regulates the expression 
of VEGF (Liu et a/, 1998; Huang et a/, 1999). The exact role that NO plays in this 
regulation remains unclear. Studies have shown that NO induces VEGF expression in 
glioblastoma and hepatoma cells (Chin et a/, 1997; Kimura et a/, 2000). A recent study in 
breast carcinoma cell found that VEGF contributes to tumour growth through inhibition of 
apoptosis and increased NOS activity (Harris et a/, 2002). It has recently been 
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demonstrated that the additional IDF-1 binding site located downstream within the HRE, 
now deemed the IDF-1 ancillary sequence (HAS), is a novel cis-element for VEGF gene 
induction by NO and hypoxia (Kimura et a/, 2001 ). 
Figure 1.20 summarises the response mechanisms of IDF-1 to hypoxia and cellular 
stresses. 
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The diagram summarises HIF-1 response mechanisms when induced by hypoxia and/or 
cellular stresses. 
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1. 7 Aims of the Project 
The aims of this study were to determine the role of HIF-1 in disease including 
carcinoma of the breast, brain tumours and diabetes mellitus through: 
• An investigation of the effect of the cellular stresses of hypoxia and hyperglycaemia on 
HIF-la, p53, VEGF, and GLUT-/ gene and protein expression and regulation in 
established breast carcinoma eel/lines and in isolated PBMCs from patients with TJDM 
and normal healthy controls. 
The primary cellular response to either excess or depletion of local glucose or 
oxygen concentrations is a shift in metabolic pathways usually via glycolysis. Exactly how 
conditions of stress, such as hypoxia, hypoglycaemia or hyperglycaemia act at the 
molecular level to initiate disease progression is not clearly understood. Changes in gene 
pattern expression prompted by cellular stress and specific transcription factor involvement 
have only recently begun to be investigated. 
Since the discovery of HIF-1 (Wang and Semenza, 1992), the characteristics of 
HIF-1 and other stress regulated genes have been explored in studies using cultured cell 
lines. Gene expression in response to hypoxia is complex, differs between models and may 
be significantly different in in-vitro cell culture compared to the in-vivo environment 
(Sander et a/, 1997). This project used established breast carcinoma cell lines as a model 
system for breast tumour tissue as well as cultured PBMCs in exploring the characteristics 
ofHIF-1. 
- 112-
Chapter I. Introduction 
• An investigation of the levels of H/F-1 a; VEGF, p53 and GLUT-1 expression and 
localisation in breast and brain tumour tissue and determining whether levels of some of 
these genes are associated with disease progression and survival. 
The ability of cancer cells to respond to and survive under hypoxia through the 
induction of oxygen related genes relates to their capacity to sense hypoxia and to activate 
the HIF pathway. It is possible that constitutive up-regulation or increased inducibility of 
HIF-la may be associated with increased induction of oxygen related genes, tumour 
growth and disease progression. 
• An investigation of the p53 and putative p73 gene tumour suppressor involvement in 
breast carcinoma by investigating its genomic and expression status in isolated PBMCs of 
patients with breast cancer and normal healthy control populations, as well as determine 
whether p53 and p73 gene status is related to susceptibility, aggressiveness of the disease 
and patient survival. 
The candidate tumour suppressor gene p73, which is implicated in the pathogenesis 
of several different types of cancer, may also be involved in the development of carcinoma 
of the breast. To elucidate the role of p73 in the development of breast cancer and the 
allelic-specific expression as a potential imprinted tumour suppressor, the allelic 
expression ofthep73 gene was investigated in the PBMCs of patients with breast cancer. 
p53 has been implicated in the regulation of angiogenic balance through control of 
the expression of VEGF. p73 has been found to down-regulate endogenous expression of 
VEGF gene expression at mRNA and protein levels (Salimath et a/, 2000). 
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2.1 Subjects 
2.1.1 Patients with Breast Cancer 
Ninety-eight patients with breast cancer attending the Breast Cancer Clinic (Dr. S. Kelly) 
at Derriford Hospital, Plymouth, U.K., were used in DNA genotyping studies. Local 
ethical committee approval had been obtained. At presentation the ages ranged from 27 to 
80 years (mean± SD =52 ± 12.3 years). The clinical characteristics of the patients are 
presented in Table 2.1. 
2.1.2 Patients with Type-1 Diabetes Mellitus (T1DM) 
Thirty-eight British Caucasoid patients with TlDM, as defined by the National Diabetes 
Group 1979, attending the Diabetic Clinic (Dr. BA Millward) at Derriford Hospital, 
Plymouth, UK, were used in RNA studies. Local ethical committee approval had been 
obtained. At presentation the ages ranged from 17 to 70 years (mean ± SD = 42.4 ± 12.8 
years). The patients consisted of individuals without complications (diabetic controls (DC) 
section 2.1.3.2) and with complications, patients who have had TlDM for more than 10 
years with nephropathy, neuropathy and/or retinopathy. The clinical characteristics of all 
patients are presented in Table 2.2. 
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Table 2.1. Clinical characteristics of patients with breast cancer (section 2.1.1). 
Variable Frequency (n) 
Patients 97 (100) 
Age (median 52 years) 
<52 49.5 (48) 
~52 50.5 (49) 
Tstage 
1 51.5 (50) 
2 35.1 (34) 
3 11.3 (11) 
4 2.1 (2) 
N stage 
0 53.6 (52) 
1 26.8 (26) 
2 10.3 (10) 
3 9.3 (9) 
Grade 
1 9.3 (9) 
2 30.9 (30) 
3 59.8 (58) 
Smoking habits 
Non-smoker 82.5 (80) 
Smoker 17.5 (17) 
Chemotherapy 
Yes 63.9 (62) 
No 36.1 (35) 
Radiotherapy 
Yes 84.5 (82) 
No 15.5 (15) 
Mean age at diagnosis was 52.0 ± 12.3 years (27- 80 years), mean survival time was 5.5 ± 3.9 
years (0.70 - 24.2 years). (± standard deviation). n = actual number of patients (in 
parenthesis). 
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Table 2.2. Clinical characteristics of patients with TlDM and normal controls (section 2.1.2) 
Characteristics Normal Patients with TlDM 
Controls 
Without Complications With Complications All Patients 
Number of subjects 6 9 29 38 
Sex(m:t) 4:2 2:7 12:17 14:24 
Age (years) 35 ± 6.4 44.9 ± 15.0 41.6 ± 12.3 42.4 ± 12.8 
(Range) (27-44) (27-70) (17-69) (17-70) 
Age at onset (years) 
- 19.0 ± 14.0 14.2 ± 9.7 15.4 ± 10.9 
(Range) (2-42) (1-37) (1-42) 
Duration (years) 
- 28.4 ± 11.7 27.4 ± 9.0 27.7±9.6 
(Range) (13-51) (8-43) (8-51) 
HbA1c 
- 7.92 ± 0.7 8.73 ± 1.5 8.54 ± 1.4 
(Range) (7.2-9.2) (6.1-12.4) (6.1-12.4) 
Insulin Dose (Units) 
- 49.8 ± 29.9 40.7± 18.6 42.8 ± 21.7 
(Range) (20-118) (10-94) (10-118) 
All patients had TlDM as defmed by the National Diabetes Data Group, 1979. The data 
are expressed as mean values(± standard deviation). 
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2.1.3 Controls Subjects 
2.1.3.1 Normal Controls (NC) 
a) Controls used for DNA genotyping consisted of 142 sequential cord blood samples, 
obtained after normal obstetric delivery at the Maternity Unit, Derriford Hospital, 
Plymouth. No individual or family history of TlDM or any other autoimrnune disease was 
associated with the subjects. The characteristics of the normal controls are listed in Table 
2.2. 
b) Eighty-five individuals of Cornish Celtic ancestry (at least three generations of both 
maternal and paternal relatives have resided in Cornwall) were used as an additional 
control population in the DNA genotyping studies. 
c) Controls used in RNA studies consisted of 10 Caucasoid healthy individuals with no 
personal history of diabetes or any other autoimmune disease. 
2.1.3.2 Diabetic Controls (DC) 
Patients with TlDM, as defined by the National Data Group 1979, who have no history of, 
nor documented long term diabetic complications after 20 or more years of the disease 
were used as normal controls in the RNA studies. These patients have had TlDM for at 
least 20 years but remain free of retinopathy (fewer than 5 dots or blots per fundus), 
proteinuria (negative on urine Albustix on at least three consecutive occasions over then 
previous 12 months) and no overt neuropathy. The clinical characteristics of the patients 
are listed in Table 2.2 (patients with TIDM without complications). 
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2.2 Tumour Samples 
2.2.1 Breast Cancer 
Approximately a I cm2 sample of fresh breast tumour from 22 individuals with breast 
cancer was collected immediately following operative removal, snap-frozen and stored in 
liquid nitrogen prior to RNA extraction. Tumours were classified according to WHO 
guidelines (Kleihues et a/, 1993). No normal tissue was obtained for study. At presentation 
the ages ranged from 42 to 91 years (mean ± SD = 66.7 ± 15.8 years). Local ethical 
committee approval had been obtained. The clinical characteristics of the patients are 
presented in Table 2.3. 
2.2.2 Glioblastoma Multiforme 
Forty-one samples of formalin fixed and paraffm embedded sections of brain tumours were 
studied. Tissue from 34 of these tumour samples was snap-frozen and stored in liquid 
nitrogen prior to RNA extraction. Tumours were classified according to current World 
Health Organisation (WHO) guidelines (Kleihues et a/, 1993): 27 glioblastomas, 4 
anaplastic astrocytomas, 5 diffuse astrocytomas (only 3 with frozen tissue), 5 pilocytic 
astrocytomas (none with frozen tissue). Two frozen samples of normal brain tissue 
obtained at autopsy were also used. Local ethical committee approval had been obtained. 
At presentation the ages ranged from 25 to 80 years (mean± SD =55± 15.3 years). The 
clinical characteristics of the patients are presented in Table 2.4. 
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Table 2.3. Frequencies of the clinicopathological characteristics of patients with breast 
cancer and their tumours (section 2.2.1). 
Variable Frequency (n) 
Patients 100 (22) 
Age (median 66 years) 
<66 45.5 (10) 
~66 54.5 (12) 
Tstage 
1 68.2 (15) 
2 31.8 (7) 
3 0 (0) 
4 0 (0) 
N stage 
0 45.5 (10) 
1 36.4 (8) 
2 9.1 (2) 
3 9.1 (2) 
Grade 
1 4.5 (1) 
2 36.4 (8) 
3 59.1 (13) 
The mean age at diagnosis was 66.7 ± 15.8 years (42-91 years), mean survival time was 3.4 
± 1.4 years (1.2-8.0 years) (± standard deviation). n = actual number of patients (in 
parenthesis). 
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Table 2.4. Clinical characteristics of normal controls and patients with glial cell tumours 
(section 2.2.2). 
Characteristics Normal Diffuse Anaplastic Glioblastomas All Patients 
Controls Astrocytomas Astrocytomas 
Number of 2 3 4 27 34 
subjects 
Sex (m:t) 2:0 0:3 1:3 18:9 19:15 
Age at Diagnosis 
(years) 74.5 ± 19.1 30.7 ± 5.13 43.5 ± 11.3 59.4 ± 13.1 55.0 ± 15.3 
(Range) (61-88) (25-35) (32-59) (35-80) (25-80) 
Survival (years) 
-
4.46± 0.23 2.36 ± 0.71 0.58 ± 0.51 1.13 ± 1.4 
(Range) (4.01-4.73) (1.08-4.05) (0.01-2.11) (0.01-4.73) 
Survival (weeks) 232.0 ± 11.72 122.9 ±·37.0 30.1 ± 26.3 58.8 ± 70.5 
-(Range) (208.74-245.97) (56.14-21 0.67) (0.74-109.47) (0.74-245.97) 
The data are expressed as mean values(± standard deviation). 
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2.3.1 Water 
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All general purpose, specialised and stock solutions were prepared using either sterile 
bottled water (Baxter Healthcare, Thetford, UK) or double distilled tap water obtained 
from an Elix S Millipore water filtration system {Millipore Ltd, Watford, UK). All PCR 
based applications were prepared solely with sterile bottled water. 
2.3.2 Reagents 
Reagents used in all experiments were of molecular biology grade, analytical grade or 
equivalent. All general-purpose reagents were acquired from four main suppliers: 
a) BDH Laboratory Supplies, Merck Limited (Lutterworth, UK) 
Acetic acid, ethylene diamine tetra-acetic acid, hydrochloric acid, magnesium chloride, 
maleic acid, orthoboric acid, sodium chloride, sodium citrate, sodium hydroxide, Tween-
20 (poly-oxethylenesorbitanmonolaurate) 
b) Sigma Chemicals (Poole, UK). 
Ammonium persulfate, Aprotonin, Brilliant Blue, Ethidium bromide (2,7-diamino-10-
ethyl-9-phenly-pheanthridinium), Dimethyl sulphoxide (DMSO), Dithiothreitol (DTT), 
Formamide, Glycine, Glycerol, HEPES, MOPS, N-Laurosarcosine, Phytohaemaglutinin 
(PHA, Lectin), Leupeptin, Pepstatin. Phenylmethylsulphonylfluoride (PMFS), Potassium 
Chloride, Sodium Dodecyl Sulphate, Sodium Floride, Sodium Orthovanadate, Sodium 
Sulfide, Sucrose, Temed, Tris (hydroxymethyl) aminomethane, Triton X-100, Trypan blue, 
Xylene cyanol 
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c) Fischer Scientific (Loughborough, UK). 
Orange G, Cryovials. 
d) Rathburn Limited (Walkerburn, UK). 
Chloroform, Ethanol, Industrial Methylated Spirit and Methanol. 
2.3.2.1 Specialised Reagents and Materials 
• Agarose, Expand™ high fidelity PCR system, 100 bp and 123 molecular weight 
markers, Random primer labelling kit, Restriction enzymes and buffers were obtained from 
Roche Diagnostics (Lewes, UK). 
• Deoxynucleoside 5'-triphosphates (dNTPs), Ficoll Type 400, mdioactive isotopes (a32P 
dUTP, -(2P dATP), Rainbow Protein marker, Rapid Hybridisation buffer, T4 
Polynucleotide kinase (T4 PNK), were supplied by Amersham Pharmacia Biotech (Little 
Chalfont, UK). 
• Super Taq polymerase and I OX Super Taq buffer were obtained from HT Biotechnology 
(Cambridge, UK). 
• Custom oligonucleotide amplimers were produced by MWG Biotechnology (Germany) 
and lnvitrogen Life Technologies (Paisley, UK). SuperscriptTM preamplification system for 
first strand cDNA system was also obtained from Invitrogen Life Technologies (Paisley, 
UK). 
• Nucleon® DNA extraction kit was purchased from Scotlab (Coatbridge, UK). 
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• RNA Stat-601M was supplied by Biogenesis (Poole, UK). MAXIScript1M and RPA 11 
kits were obtained from AMS Biotechnology Limited (Oxfordshire, UK). 
• All tissue culture reagents were attained from Invitrogem Life Technologies (Paisley, 
UK) and included; Lymphoprep1M, Fetal calf serum (FCS), Dulbecco's Modified Eagles 
Medium (DMEM), 20% glucose solution, Hank's balanced salt solution (HBSS), L-
glutamine, non-essential amino acids (NEAA), Penicillin/streptomycin, Phosphate buffered 
saline (PBS), RPMI 1640, Trypsin-EDTA, Neomycin (G418). 
• All tissue culture plastics were supplied by Fahrenheit (Milton Keyes, UK). 
• E. Coli strain MC1061/P3 (carrying the P3 plasmid) was obtained from Invitrogen Life 
Technologies (Paisley, UK). The pCHllO Eukaryotic Assay Vector and JM109 
Competent cells were purchased from Promega (Southampton, UK). 
• Ampicillin, Dialysis tubing, 25% Gluteraldehyde, IPTG, Kanamycin, Potassium 
Ferricyanide, Potassium Ferrocyanide, Sodium Sulfide, Sulfuric Acid, Tetracycline, X-gal 
were supplied by Sigma Chemicals Ltd. (Poole, UK). 
• Tryptone, Yeast Extract and Agar were obtained from Difco, USA. 
• 2% Bisacrylamide, 30% and 40% (19:1) Acrylamide were attained from Bio-Rad 
Laboratories (Hemel Hempstead, UK). 
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• Antibodies were obtained from several suppliers; Anti-mouse IgG peroxidase conjugate 
and Horseradish Peroxidase Rabbit Anti-mouse IgG from Sigma (Poole, UK), HIF-1 ex 
from AbCam (Cambridge, UK), Glucose transporter 1 (GLUT-1) from Biogenesis Ltd. 
(Poole, UK), p53 from Novacastra (Newcastle upon Tyne, UK), Vascular endothelial 
growth Factor (VEGF) from CN Biosciences (Nottingham, UK). Catalysed signal 
amplification system from DAKO (Cambridgeshire, UK). 
• Coomassie Plus Protein Assay Reagent Kit and SuperSignalR Chemiluminescent 
Substrate were provided by Perbio Science UK Ltd. (Chester, UK). 
2.4 Autoclaving 
All glassware, solutions, instruments and plastics used in experiments involving DNA, 
RNA and protein analysis or tissue culture were autoclaved at a temperature of 121 °C 
under a pressure of 15 psi for a duration of 30 minutes in a top loading autoclave 
(PriorClave Ltd, Woolwich, UK). 
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2.5 Cell Culture 
All cell culture work and cell maintenance was performed in a Microflow class II 
biological safety cabinet (Microflow Ltd., Hampshire, UK) using sterile techniques. The 
cabinet was swabbed with alcohol both before and after work was performed in it. All 
plastics were obtained from Fahrenheit (Milton Keynes, UK) and consisted of: 1 ml, 5 ml, 
and 10 ml individually wrapped sterile pipettes, sterile vented 25 cm2 and 75 cm2 flasks, 
sterile individually wrapped cell scrappers, sterile 15 ml and 50 ml tubes. Cell cultures 
were maintained at a constant temperature of 37 °C in an atmosphere of 5 % C02 (BOC, 
Bristol, UK) in dry Leec incubator (Jencons-PLS, Leighton Buzzard, UK). Cells cultures 
used in hypoxia experiments were incubated at 37 °C in an atmosphere of 1% 02, 5% C02, 
95% N2 (BOC, Bristol, UK) in a dry C02/02 incubator (NuAire™, Minnesota, USA). Cell 
cultures were viewed on an inverted Leica DMIL microscope (Jencons-PLS, Leighton 
Buzzard, UK). 
2.5.1 Established Cell Lines 
Established breast carcinoma cell lines were generously provided by Dr. Corine L 'Hote 
from the Ovarian Cancer Group at the Imperial Cancer Research Fund, Oxford, UK, 
having originated from the European Collection of Animal Cell Cultures (ECACC, Porton 
Down, UK) or the American Type Culture Collection (ATCC, Manassas, Virginia, USA). 
Saos-2 cells were kindly made available by Dr. Alan Storey from the Imperial Cancer 
Research Fund Skin Tumour Laboratory, London, UK. Cells were monitored daily, 
passaged at a dilution of 1/10 weekly, or more frequently when required, and stocks of 
each cell line were stored in liquid nitrogen. A summary of the culture conditions for the 
established cell lines is listed in Table 2.5. 
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Table 2.5. Culture conditions of established cell lines. 
Cell Line Origin Media Passage 
ECACC (# 86012803) DMEM 
MCF7 Pleural effusion from breast tissue 10% FCS, At confluence 
of a female Caucasian (69 years) 1 mM glutamine, 1:6 weekly 
100 U/ml pen-strep 
ECACC (#89050205) DMEM 
Saos-2 Primary osteogenic sarcoma from 10%FCS, Prior to confluence 
bone tissue of a female Caucasian 100 U/ml pen-strep 1:4 weekly 
(11 years) 
ATCC (# HTB-30) RPMI 1640 
SKBR3 Pleural effusion adenocarcinoma of 10% FCS, At confluence 
the breast from a female Caucasian 50 U/ml pen-strep 1:4 weekly 
(43 years) 
ECACC (# 85102201) DMEM 
T47D Pleural effusion infiltrating ductal 10%FCS, At confluence 
carcinoma of the breast from a 100 U/ml pen-strep l:IO weekly 
female Caucasian (54 years) 
ECACC (# 87012601) RPMI 1640 
ZR75 Ascitic effusion infiltrating ductal 10%FCS, At confluence 
carcinoma of the breast from a 50 U/ml pen-strep 1:10 weekly 
female Caucasian (63 years) 
ATCC = American Type Culture Collection 
ECACC =European Collection of Animal Cell Cultures 
Pen-strep = penicillin-streptomycin 
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T47D (ECACC ## 85102201) 
Adherent human breast epithelial cells established from the pleural effusion of an 
infiltrating ductal carcinoma of the breast of a 54 year-old postmenopausal female. The 
cells carry receptors for a variety of steroids and tend to form monolayers. Cells were 
grown in Dublecco's Modified Eagles Medium (DMEM) supplemented with 10% FCS 
and toO units (U)/ml of penicillin-streptomycin (lOOOOU/ml, Life Technologies Ltd., 
Paisley, UK). Cells were passaged at confluence 1:10 weekly. 
MCF7 (ECACC ## 86012803) 
Adherent cells were derived from a pleural effusion obtained from a 69 year-old female 
Caucasian. The cells express the wildtype and variant oestrogen receptors, as well as the 
progesterone receptor. Cells exhibit some features of differentiated mammary epithelium 
including oestradiol synthesis and formation of domes and may carry a B or C type 
retrovirus. Cells were cultured in DMEM medium supplemented with 10 % FCS, 1 mM 
glutamine (Invitrogen Life Technologies, Paisley, UK) and 100 U/ml of penicillin-
streptomycin. Cells were passaged at confluence 1:6 weekly. 
Saos-2 (ECACC ## 89050205) 
Adherent human epithelial cells derived from a primary osteogenic sarcoma from the bone 
tissue of an 11 year-old female Caucasian. These cells are p53 null as p53 expression over 
a longer period of time than a transient transfection leads to apoptosis. Cells were cultured 
in DMEM supplemented with 10 % FCS and 100 U/ml of penicillin-streptomycin. Cells 
were passaged prior to confluence 1:4 weekly. 
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SKBR3 (ATCC ## HTB-30) 
Adherent human breast epithelial cells derived from a malignant pleural effusion 
adenocarcinoma of the breast of a 43 year-old female Caucasian. Cells were cultured in 
RPMI 1640 media supplemented with 10 % FCS and 50 U/ml of penicillin-streptomycin. 
Cells were passaged at confluence 1 :4 weekly. 
ZR7S (ECACC ## 87012601) 
These colony forming adherent human breast epithelial cells were originally derived from 
a malignant ascitic effusion in a 63 year-old female Caucasian with infiltrating ductal 
carcinoma. The cells have receptors for both wild-type and variant oestrogen receptors, 
progesterone receptor and other steroid hormones. Cells were cultured in RPMI 1640 
media supplemented with 10 % FCS and 50 U/ml of penicillin-streptomycin. Cells were 
passaged at confluence 1:10 weekly. The cells grow very slowly, do not form a confluent 
monolayer and attach only lightly to the substrate. 
2.5.2 Characteristics of Human Breast Carcinoma Cell Lines 
The characteristics of the human breast carcinoma cell lines used in this study are listed in 
Table 2.6. These cell lines were chosen to reflect the heterogeneity of the human breast 
cancer progression pathway. The cell lines represent different stages and phenotypes of 
breast carcinoma. 
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Table 2.6. Characteristics of human breast carcinoma cell lines. 
Cell ER Tumorigenic 
Line Status Potential 
MCF7 + + 
SKBR3 
-
++ 
T47D + + (with oestrogen) 
ZR75 + ++ 
( +) = positive 
(-) = negative/ not known 
ER = oestrogen receptor 
pS3 Status 
Wild-type 
Mutant 
Single allele 
mutant 
Wild-type 
TNFa = tumour necrosis factor alpha 
Other 
Growth inhibited 
byTNFa 
Secrets IGFBP's 
HER2/c-erbB2+ 
-
Interferon+ 
IGFBP = insulin-like growth factor binding protein 
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Pratt and Pollack, 1993 
Fogh et a/, 1977; 
Hynes et al, 1989 
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2.5.3 Peripheral Blood Mononuclear Blood CeUs (PBMCs) 
Isolated PBMCs (section 2.6.9) were cultured for 5 days in 20 ml of RPMI I604 media 
supplemented with 10 % FCS, 50 U/ml of penicillin-streptomycin and 5 J.l.g (0.25 J.l.g/ml) of 
PHA in a 75 cm2 flask, under both normal and experimental conditions (section 2.5.8) 
prior to RNA extraction (section 2.10.2.2). 
2.5.4 Cell Passage 
Adherent cell lines grown in 75 cm2 flasks (Fahrenheit, Milton Keynes, UK) where 
passaged when each cell monolayer was confluent. The cell monolayer was first washed 
twice in IO m1 of Hank's Balanced Salt Solution (HBSS) medium (lnvitrogen Life 
Technologies, Paisley, UK) then 2 ml of IX Trypsin/EDTA solution (lnvitrogen Life 
Technologies, Paisley, UK) was added to each flask and incubated at room temperature for 
I0-40 minutes until total cell detachment was achieved. An equal volume (2 ml) of Foetal 
Calf Serum (FCS) was then added to the flask to stop the trypsinisation reaction; the cell 
suspension was transferred to a sterile I5 ml tube (Fahrenheit, Milton Keynes, UK) and 
centrifuged at I400 rpm for 4 minutes in a MSE Mistral centrifuge (MSE Scientific 
Instruments, Leicester, UK). The supematant was then carefully decanted and the cell 
pellet was resuspended and washed in 5 ml of HBSS medium with gentle pipetting or 
vortexing. The tube was again centrifuged at 1400 rpm for 4 minutes, the supematant 
decanted and the pellet washed a second time in 5 ml of HBSS. Following a fmal 
centrifugation at I400 rpm for 4 minutes, the supematant was decanted and the cells were 
resuspended in 5-I 0 ml of appropriate culture medium. The cells were then counted using 
a Neubauer haemocytometer (Fischer Scientific, Loughborough, UK). For cell passage, the 
cell densities were adjusted to I 05-106 cells/ml and I ml of the cell suspension was then 
transferred to a sterile 75 cm2 flask containing I9 ml of appropriate culture medium. For 
cell experiments, the remaining cell suspensions were split as required into separate 75 cm2 
flasks. 
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2.5.5 CeU Counting 
Culture and experimental cell conditions were standardised by detennining cell densities. 
The concentration of cell suspensions was determined by individual cell counting using a 
Neubauer haemocytometer under an inverted Leica DMIL microscope (Jencons-PLS, 
Leighton Buzzard, UK). The cell number within a defined area of known depth within the 
chamber was counted and the cell concentration derived from the count. Cell suspensions 
were mixed with gentle pipetting, then a 50 J.d aliquot was transferred to the edge of the 
haemocytometer where the suspension was drawn into the chamber by capillary action. 
Cells lying within a 1 mm2 bounded area were counted in each of the separate chambers 
and averaged. The total cell number was determined using the following fonnula; 
c=(nx 104) 
where c is the cell concentration (cells/ml), and n is the number of cell counted. The 104 
multiplication factor is derived from the volume counted and is based on the assumption 
that the depth of the Neubauer chamber is 0.1 mm and that only the central 0.1 mm2 area is 
used, hence 0.1 mm3 or 104 ml. 
2.5.6 Cryopreservation 
Adherent cell lines were grown to near confluence, detached, washed and counted as 
above. Cell densities were adjusted to 5 X 106 cellslml in the appropriate culture medium. 
Cells were prepared for freezing by slowly mixing 1 ml of cell suspension with 0.6 ml of 
FCS (Life Technologies, Paisley, UK) and 0.2 ml ofDMSO (Sigma Chemicals Ltd, Poole, 
UK) in a sterile 15 ml tube. A 1 ml volume of the cell mixture (10% DMSO, 30% FCS, 50 
% cell suspension) was then aliquoted into 2 separate 2 ml cryovials (Nalgene, Fischer 
Scientific, Loughborough, UK) and tightly closed. The cells were allowed to freeze slowly 
by fust storing the cryovials at -20 °C for 6 hours, then transferring to -80 oc for 12-16 
hours prior to final transfer to liquid nitrogen for indefinite storage. 
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2.5.7 Cell Resuscitation 
A frozen ampoule containing cells was carefully removed from storage in a liquid nitrogen 
canister (Jencons-PLS, Leighton Buzzard, UK) and left to thaw at room temperature for 
approximately 1 minute. The ampoule was then transferred to a 37 °C waterbath (Grant, 
Cambridge, UK) for 1-2 minutes until fully thawed and then wiped with a tissue soaked in 
70% alcohol prior to opening. Once opened, the contents of the vial were transferred to a 
25 cm2 vented flask, which contained 9 ml of pre-warrned media. An additional 1 ml of 
media was added to the ampoule to wash and collect any remaining cells. This was then 
added to the flask, which was then closed and placed in a 37 °C, 5% COz Leec incubator 
(Jencons-PLS, Leighton Buzzard, UK) overnight. The next day the media was carefully 
removed by aspiration, replaced with the appropriate growth media and the flask returned 
to the incubator. 
2.5.8 Experimental Culture Conditions 
2.5.8.1 High Glucose 
Established breast carcinoma cell lines and PBMCs were cultured at normal glucose levels 
(no supplement), moderate glucose levels with a supplement of 10 mM glucose, or at high 
glucose levels with a supplement of 20 mM glucose. The basal level of glucose was 
determined for each media used, RPMI 1640 medium contained 2000 mgllitre of D-
glucose, equivalent to 11 mM, DMEM medium contained 4500 mgllitre of D-glucose, 
equivalent to 25 mM. A supplement of 10 mM D-glucose (moderate glucose) 
corresponded to an addition of 184 IJ.I of a 20 % solution of D-glucose to a 75 cm2 flask 
containing 20 ml of culture medium, equating to 21 mM total D-glucose for cells cultured 
in RPMI 1640 medium and 35 mM total D-glucose for cells cultured in DMEM medium. 
A supplement of 20 mM D-glucose (high glucose) corresponded to an addition of 360 fJ.I of 
a 20 % solution of D-glucose to a 75 cm2 flask containing 20 ml of culture medium, 
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equating to 31 mM total D-glucose for cells cultured in RPMI 1640 medium and 45 mM 
total D-glucose for cells cultured in DMEM medium. 
2.5.8.2 Osmolarity 
2.5.8.2.1 Mannitol 
Mannitol is a non-metabolisable analogue of D-glucose. PBMCs and established breast 
carcinoma cell lines were cultured in mannitol to control for osmolarity. Mannitol was 
added to the cultures in an amount equal to the amount of excess D-glucose over the basal 
glucose level in the media. For cells cultured in high glucose conditions (a supplement of 
20 mM D-glucose), a parallel culture was established where 20 mM mannitol was used as 
a supplement. This corresponded to the addition of 7.3 J.d of a 500 mg/ml mannitol stock 
solution to a 75 cm2 flask containing 20 ml of culture medium. 
2.5.8.2.2 l.rGiucose 
L-glucose is a non-metabolisable analogue of D-glucose as it does not contain a reactive 
aldehydic group at the Cl carbon, thus it can be used as a control for glycation reactions 
that are non-enzymatic that D-glucose can undergo. PBMCs and established breast 
carcinoma cell lines were cultured in an equivalent concentration of L-glucose to control 
for high glucose. For cells cultured in high glucose conditions (a supplement of20 mM D-
glucose), a parallel culture was established where 20 mM L-glucose was used as a 
supplement. This corresponded to the addition of 7.2 J.d of a 500 mg/ml L-glucose stock 
solution to a 75 cm2 flask containing 20 rnl of culture medium. 
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2.5.8.3 Hypoxic Exposure 
2.5.8.3.1 Cobalt Chloride 
Cobalt chloride (CoC}z) is an agent known to mimic hypoxia through chemical induction. 
Cells were cultured in 60-500 J.1M CoC}z (Sigma Chemicals Ltd., Poole, UK) for 6, 24 and 
48 hours prior to harvesting. 
2.5.8.3.2 C0z/02 1neubator 
A hypoxic environment was created in a 37 °C COz/Oz incubator (NuAire™, Minnesota, 
USA), which was able to produce an internal hypoxic atmosphere of 1% Oz, 5% C02 and 
95% Nz. The incubator required approximately 16 hours to reach the set internal 
atmospheric conditions. Both 0 2 and C02 percentages inside the incubator chamber were 
measured using a Fyrite™ gas analyser (Jencons-PLS, Buzzard Leighton, UK), (section 
2.5.8.4.3). 
Established cell lines were passaged and transferred to new 75 cm2 flasks 2 days prior to 
exposing to the hypoxic environment and the media was replenished with 20 ml the 
appropriate media. For hypoxic conditions, cells were exposed to 1% 0 2 (5% C02, 95% 
Nz) in a 37 °C COz/Oz incubator (NuAire™, Minnesota, USA) for 2,4,6,8,24 and 48 hours. 
As a control, an aliquot of cells of the respective cell line exposed to hypoxic conditions 
was exposed to normoxic conditions (21% 0 2, 5% C02, 74% N2) for the same period of 
time. At each established time point, 2 m1 of supernatant was collected from the flask and 
stored in cryovials at -70 °C. 
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2.5.8.3.3 Fyrite® Gas Analyser 
The Fyrite® Gas analyser allows for the determination of the percentage of carbon dioxide 
or oxygen in an atmospheric sample. The technique employs the 'Orsat' method of 
volumetric analysis involving chemical absorption of a sample gas and it allows accurate 
readings to within +/- 0.5 % compared to actual value. The sampling assembly, consisting 
of a centre tube connected to two reservoirs, contains an absorbing fluid that will absorb 
either 02 or C02. The reagent used to absorb Oz is chromous chloride, and COz is 
potassium hydroxide. Each sampling assembly containing the appropriate absorbing fluid 
was first vented of air by depressing the plunger valve at the top of the assembly. The 
assembly was inverted and vented, then held vertical whilst the volume scale was set at the 
top level of the fluid column to zero. The air sample inside the incubator was pumped into 
the sampling assembly by attaching one end of a sampling rubber connecter tube to an air-
sampler valve on the exterior surface of the incubator and placing the other end over the 
plunger valve. The plunger valve was depressed and the sample pumped into the sampling 
assembly by squeezing and releasing an aspirator bulb 18 times. The sample gas was 
absorbed into the fluid by inverting the assembly then allowing all fluid drops to drain to 
the bottom of the assembly prior to reading the volume scale. The % reading on the 
volume scale corresponded to the actual % gas inside the incubator. 
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2.6 Deoxyribonucleic Acid (DNA) Methodologies 
2.6.1 Extraction of Total DNA 
High molecular weight DNA was extracted from whole blood using a Nucleon® BACC 
(blood and cell culture) genomic DNA extraction kit (Scotlab, Coatbridge, UK). Up to 25 
ml of peripheral venous blood was collected in 5% ethylenediaminetetracetic acid {EDTA) 
vacutainer tubes (Becton Dickinson, Oxford, UK). The blood was transferred to 50 ml 
sterile Falcon tubes (Fahrenheit, Milton Keynes, UK) and a 4 X volume of Nucleon® A 
(lOmM Tris-HCL, 320 mM sucrose, SmM MgCh, 1% Triton X-100, pH 8.0) was added 
and the solution was gently shaken for 4 minutes at room temperature. The samples were 
then centrifuged in a MSE Mistral 1000 centrifuge (MSE Scientific Instruments, Leicester, 
UK) at 1300 X g for 4 minutes, the supematant containing lysed red cells was discarded 
and 2 m1 of Nucleons B (400 mM Tris-HCL, pH 8.0, 60 mM EDTA, 150 mM NaCl, 1% 
SDS) was added to the tubes. The pellets were resuspended by vortexing and the solutions 
were incubated in a 37 °C waterbath (Grant, Cambridge, UK) for 10-15 minutes to 
facilitate nuclear membrane disruption and protein denaturation. The solutions were then 
transferred to 15 m1 sterile polypropylene tubes where 500!11 of SM sodium perchlorate 
was added and the tubes were inverted 10-15 times to emulsify the phases. The samples 
were then centrifuged at 1300 X g for 3 minutes and 200 111 of Nucleon silica resin was 
added to each tube without disrupting the phases and then centrifuged at 1,300 X g for 3 
minutes. The upper aqueous phase containing the DNA was carefully removed from each 
tube and transferred to clean 15 ml sterile tubes ensuring that no resin had been carried 
over. The tubes were then centrifuged for 1 minute at 1300 X g and the supernatants were 
again transferred to clean 15 ml sterile tubes where the DNA was precipitated out by the 
addition of a 2X volume of ice-cold 100% (v/v) ethanol (Rathbum Ltd., Walkerbum, UK). 
The tubes were inverted several times and the DNA was hooked out using sterilised glass 
pipettes with sealed tips. The DNA was then washed in 70% (v/v) ethanol, placed in 1.5 ml 
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sterile micro-centrifuge tubes and resuspended in 500 J.ll of sterile water. DNA samples 
were kept at 4 °C for 24 hours to ensure complete dissolution, after which DNA samples 
were stored at -20 °C. 
2.6.2 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) is used to enzymatically amplify in vitro specific 
DNA sequences using oligonucleotide primers that flank the region of interest in the target 
DNA PCR was frrst described by Kleppe and colleagues in 1971 (Kleppe et al, 1971), but 
was devised and named by Mullis and colleagues at Cetus Corporation in California, USA, 
in 1986. (Mullis et al, 1986; Mullis & Faloona 1987). The technique is based on repeated 
cycles of high temperature template denaturation, oligonucleotide primer (amplimer) 
annealing and polymerase mediated primer extension. The extension product of one cycle 
of the PCR reaction serves as template in the next cycle, causing an approximate doubling 
of the amount of the particular nucleic acid with each cycle and an exponential 
accumulation of it overall. Assuming 100% efficiency and a doubling of the desired target 
in each cycle, 30 cycles could in theory produce 1 X 109 copies from one target copy. The 
simplicity of the reaction, as well as its speed and sensitivity, makes it ideally suited for a 
wide variety of applications, including the diagnosis and characterisation of genetic 
diseases, as well as cancer. 
2.6.3 Optimisation of PCR 
PCR reaction conditions were optimised for each set of amplimers. Optimising reaction 
conditions included varying essential components in each assay. Key parameters for PCR 
optimisation include: 
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a) Cycle conditions 
b) Magnesium concentration 
c) Deoxynucleotide ( dNTP) concentration 
d) Amplimer concentration 
e) Enzyme concentration 
Optimisation techniques included using an initial Hot Start, where all reaction components 
were heated to above 80 °C prior to the addition of the last component, which preceded 
programme cycling in an attempt to avoid amplification of non-target sequences in the 
DNA background (mispriming) and primer dimerisation. Optimisation of cycling 
conditions involved varying the temperatures in the amplification reaction, denaturation 
(92-96 °C), amplimer annealing (50-75 °C) and DNA extension (68-72 °C}. Initial 
annealing temperatures were determined using either Touchdown PCR, where cycling is 
started with a relatively high annealing temperature, or by using a temperature 2-5 °C 
below the true melting temperature (T m) of the amplimers. Balanced dNTP concentrations 
ofbetween 20 and 200 J.1M of each nucleotide and amplimer concentrations ofbetween 0.2 
and 1.0 J.1M of each amplimer were optimal. Magnesium concentrations (1.0 to 3.0 mM) 
and Taq DNA polymerase (0.5 to 5.0 units per 50 J.tl reaction) were determined empirically 
for each reaction. In some assays, an additional final incubation of either 68 °C or 72 °C 
for 10 minutes immediately after cycling was added to optimise the yield ofPCR products. 
2.6.4 Custom Oligonucleotides (Amplimers) 
For either DNA or RNA studies, gene sequences of interest were obtained from a public 
databank (Genebank, www.ncbi.nlm.nih.gov). Sense (5' to 3') amplimers were designed to 
be complimentary to the DNA template sequence of interest and anti-sense (3' to 5') 
amplimers were designed reverse complimented. Amplimers ranged in length from 18-35 
bases and contained a GC content of 50% or greater. Custom oligonucleotide amplimers 
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were produced by MWG Biotechnology (Gennany) or lnvitrogen Life Technologies 
{Paisley, UK). All amplimers were supplied lyophilised and were resuspended in 1 ml of 
sterile water (Baxter Healthcare, Thetford, UK) prior to dilution to a working concentration 
of 1 pmoVml. Table 2.7 lists custom oligonucleotides and their respective PCR reaction 
conditions used for all DNA or RNA studies. 
2.6.5 PCR Reactions 
All standard PCR reactions were perfonned in 0.2 ml thin walled micro-centrifuge tubes 
(Advanced Biotechnology, Epsom, UK) in a final reaction volume of 50 ~1. Generally, 
100-500 ng of genomic DNA or cDNA, 7.5 pmol of each amplimer pair, 1.0-2.0 mM of 
MgCh, 0.125 mM of each dNTP, 1 X Super Taq Buffer (50 mM Tris-HCl, pH 9.0, 1.5 mM 
MgCh, 250 mM KC!, 1% Triton X-100, 0.1% (w/v) gelatine), and 0.8 units ofSuperTaq 
DNA polymerase were used in each reaction mixture. All PCR reactions were perfonned 
on a 48/48 well DNA Engine Thennocycler (Genetic Research Instrumentation, USA) and 
stored at 4 °C pending analysis by gel electrophoresis. 
2.6.6 Nested PCR 
Nested PCR involves using two sets of amplimers. The first amplimer set is targeted within 
the amplification product of the second set; hence two rounds of amplification are required 
to amplify the specific target DNA. The amplicon of the second reaction is shorter than 
that of the first (Figure 2.1 ). The procedure is designed to increase the sensitivity of PCR 
by directly reamplifying the product from a primary PCR reaction with a second PCR. The 
advantage of nested PCR is increased sensitivity and specificity of the reaction, since the 
internal primers anneal only if the amplicon has the corresponding expected sequence. 
Nested PCR was used to identify p73 alleles in the high molecular weight DNA extracted 
from PBMC's of patients with breast cancer. In the first round ofPCR, intronic amplimers 
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were employed in a 50J.1l reaction volume. In the second round of amplification, a l J.ll 
aliquot of the first round product was transferred to a new 0.2 ml thin-walled tube and 
amplified using a second set of internal amplirners (see Table 2.7 for amplimers and cycle 
conditions). The amplified DNA products were visualised by running 10 1-11 of each sample 
mixed with 2 1-11 of loading buffer on a 1% agarose gel containing 0.01% ethidium 
bromide. The PCR products were subsequently digested with the restriction endonuclease 
Sty 1 (Roche Diagnostics, Lewes, UK). 
2.6.6.1 Restriction Enzyme Digestion of PCR Products 
Identification of p73 alleles from patients with breast cancer required digesting the 
amplified PCR products with Sty 1 restriction endonuclease (Roche Diagnostics, Lewes, 
UK). Amplimers and PCR cycle conditions used in the assay are listed in Table 2.7. The 
DNA was digested by mixing 5-10 J.lg of amplified product with 10 units of Sty I 
restriction endonuclease, 1/l Oth volume of endonuclease buffer (Roche Diagnostics, 
Lewes, UK), 0.1 J.ll of acetylated bovine serum albumin (BSA) (10 J.lg/J.ll) and distilled 
water to a final reaction volume of 20 1-11 in a 0.5 ml micro-centrifuge tube. The reaction 
was incubated for 1 hour at 37 oc in a waterbath (Grant, Cambridge, UK). Digested 
products were visualised by running 10 1-11 of each sample mixed with 2 J.ll of loading 
buffer on a 1.5% agarose gel containing 0.01% ethidium bromide for 1 hour at 200 volts. 
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Table 2. 7. Custom Oligonucleotide Amplimer sequences and PCR reaction conditions used in assays for DNA and RNA studies. 
Amplimer Sequences Length Gene Cycles Cycle Conditions Product Genebank Reference (mer) (base pairs) Accession # 
Initial 
60 °C for 5 minutes, 
5' TGACGGGGTCACCCACACTGTGCCCATCTA 3' (sense) 30 13-actin 35 72 °C for 1.5 minutes 661 bp MI0277 Nakajima-Iijima 
5' CTAGAAGCATTTGCGGTGGACGATGGAGGG 3' (antisense) 30 94 oc for 45 seconds 
60 °C for 45 seconds et a/, 1985 
Additional 
72 °C for 10 minutes 
5' CCACTTCCACATAATGTGAGTTCGG 3' (sense) 25 94 °C for 1 minute Wangetal, 
5' GGTTCACAAATCAGCACCAAGCAGG3' (antisense) 25 HIF-1a 30 55 oc for 2 minutes 520bp U22431 1995 
72 °C for 3 minutes 
95 oc for 30 seconds • 487bp 
5' GTCGGACAGCCTCACCAAACAGAGC 3' (sense) 25 HIF-1a 35 55 oc for 1 minute (with exon 14) Gothie et a/, 
splice 72 °C for 2.5 minutes U22431 2000 
5' GTT AACTTGATCCAAAGCTCTGAG 3' (antisense) 24 variant 350bp 
Additional (without exon 14) 
72 °C for 10 minutes 
5' ATGCCTCCACAGAGGCTATGCC 3' (sense) 22 95 °C for 1 minute Tiscber et a/, 
5' GCACTAAGGAACGTCTGTAGGC 3' (antisense) 22 VEGF 30 61 °C for 1.5 minutes 441 bp M63971 1991 
72 °C for 1. 5 minutes 
5' GGCTATGGCCACCCGTTCTGCTGGC 3' (sense) 25 95 oc for 1 minute Mueclder et a/, 
GLUT I 30 54 oc for 1.5 minutes 525 bp K03195 1985 5' GCCGTTGCAGTGGTTGCAACCC 3' (antisense) 22 72 °C for I. 5 minutes 
Note: All PCR cycle conditions included one Hot Start cycle of94°C for 4 minutes and all reactions had a total reaction volume of 50 jJ] using 1.5 mM MgCl2. 
(HMW) =High Molecular Weight DNA, *=Expand High Fidelity PCR System (Roche Diagnostics, Lewes, UK) was used in this assay. 
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Table 2.7. (continued) Custom Oligonucleotide Amplimer sequences and PCR reaction conditions used in assays for DNA and RNA studies. 
Amplimer Sequences Length Gene Cycles Cycle Conditions Product Genebank Reference (mer) (base pairs) Accession# 
1 .. Round NestedPCR 
18 GC allele 5' CACCTGCTCCAGGGATGC 3' (sense) 95 oc for 30 seconds 482 & 284 bp 
5' AAAATAGAAGCGTCAGTC 3' (antisense) 18 30 58 °C for 1 minute (undigested) 
p73 68 °C for 2.5 minutes Yll416 Kaghad et a/, 
2nd Round Additional AT allele 1997 68 °C for 10 minutes 376& 106 bp 5' CAGGCCCACTTGCCTGCC 3' (sense) 18 
5' CTGTCCCCAAGCTGATGA 3' (antisense) 18 30 Followed by Sty 1 234& 50 bp 
restriction enzyme (digested) 
digestion 
5' GCCAGAGGCTGCTCCCCC 3' (sense) 18 95 °C for 30 seconds p53 Pro 30 61 oc for 1 minute Storey et a/, 5' CGTGCAAGTCACAGACTT 3' (antisense) 18 68 oc for 2.5 minutes 177 bp M22887 1998 
Additional 
68 °C for 10 minutes 
5' TCCCCCTTGCCGTCCCAA 3' (sense) 18 95 °C for 30 seconds p53 Arg 30 61 °C for 1 minute Storey et a/, 
5' CTGGTGCAGGGGCCACGC 3' (antisense) 18 68 °C for 2.5 minutes 141 bp M22887 1998 
Additional 
68 °C for 10 minutes 
5' TTCCTCTTCCTGCAGTACTCC 3' (sense) 21 95 °C for 1 minute M22887 Buchman et a/, 
5' AGTTGCAAACCAGACCTCAGGC 3' (antisense) 22 p53 30 56 °C for 1.5 minutes 144 bp 1988 
72 °C for 1. 5 minutes 
Note: All PCR cycle conditions included a Hot Start of94°C for 4 minutes and all reactions had a total reaction volume of 50 ,.U using 1.5 mM 
MgCh. (HMW) =High Molecular Weight DNA , 
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Figure 2.1. Schematic representation of Nested Polymerase Chain Reaction . 
First Set of 
Amplimers 
Second Set of 
Amplimers 
Target DNA 
Genomic DNA 
l 
First Amplicon 
l 
Specific Amplification of the target DNA 
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2.6.7 Agarose Gel Electrophoresis 
Agarose gels (1.5%) were prepared by dissolving 1.5 grams of multi-purpose agarose in 
100 m1 of 1 X TBE (89JJM Tris base, 89JJM boric acid, 200JJM EDT A, pH 8.0) in a 500 ml 
Duran glass bottle by boiling. The agarose solution was then cooled to 60-65 °C prior to 
adding 10 J.d of a 10 mglml solution of ethidium bromide (0.01% v/v). The solution was 
gently mixed and then poured into a 14 X 11 cm perspex gel mould tray (Life 
Technologies, Paisley, UK) that was sealed at both ends with masking tape. Two plastic 14 
well tooth-combs were positioned 1 mm above the tray and the gel was then allowed to set 
at room temperature for 30 minutes. Once set, the combs and masking tape were carefully 
removed and the gel and tray were placed into a horizontal gel electrophoresis tank (Life 
Technologies, Paisley, UK) containing 0.5 X TBE buffer sufficient to cover the gel. 
Samples were prepared for loading by mixing 10 J ..Ll of DNA product with 2 J.d of either 6 
X gel loading buffer (0.25% w/v bromophenol blue, 0.25 % w/v xylene cyanol, 15% v/v 
Ficoll Type 400) or Orange G loading buffer (0.25% w/v xylene cyanol, 10% v/v glycerol 
in I 0 X TBE) and loaded into the gel. The gel was run at 200 volts for 30 minutes to I hour 
or until the dye fronts migrated an appropriate distance through the gel. DNA molecular 
weight markers of either 100 base pairs (bp) or 123 bp were run concurrently to facilitate 
fragment sizing. The gels were visualised via irradiation with UV light on a 
transilluminator (UVP International, Cambridge, UK) at A.302 nm and photographed using 
a gel imager software package (Vision Works 3.0, UVP International, Cambridge, UK) and 
video linked to a Sony graphic printer using type N UPP-11-HA thermo film (Sony 
Corporation, Tokyo, Japan). 
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2.6.8 Purification of PCR Fragments 
Following agarose gel electrophoresis, PCR fragments were recovered and purified using 
one of the below methods. 
2.6.8.1 Glass Wool 
PCR fragments were purified after gel electrophoresis by spinning through glass wool. 
DNA bands were excised from 1% agarose gels (1 gram of agarose in 100 ml of 0.5 X 
TBE) containing 0.01% v/v ethidium bromide, using a clean, sharp scalpel blade while 
visualised with UV light on a transilluminator. Excised bands were placed into a 0.5 ml 
micro-centrifuge tube containing a loosely packed piece of glass wool and of which the 
bottom had been pierced with a needle. The 0.5 m1 tube was then placed in a 1.5 m1 micro-
centrifuge tube and centrifuged at 13,000 rpm for 10 minutes. The DNA in the collected 
eluant was then precipitated out by the addition of a 1/lOth volume of 3M sodium acetate, 
pH 5.2 and 2 -3 volumes of 100% ethanol. The solution was mixed and placed at -20 ac 
for at least one hour. The DNA was then collected by centrifugation at 13,000 rpm for 15 
minutes, the supernatant decanted and the pellet washed with 3 volumes of 70% ethanol. 
The DNA was then centrifuged at 7,500 for 5 minutes, the supernatant removed and the 
sample air-dried for 5 -10 minutes and subsequently resuspended in 25-50 J.Ll of water. 
2.6.8.2 Quick PreciplV (Advanced Biotech Corp., USA) 
Following purification by spinning through glass wool, the DNA was precipitated by 
adding 2 J.LI of Quick Precip™ (Advanced Biotech Corp., USA), 1/lOth volume of 5 M 
sodium chloride and 2-3 volumes of ice-cold 100 % ethanol to the tube, which was then 
mixed by vortexing. The solution was then centrifuged at 13,000 rpm for 3 minutes, the 
supernatant decanted and the pellet washed with 1 volume of 70 % ethanol. The solution 
was again centrifuged at 13,000 rpm for 30 seconds, the supernatant decanted, the sample 
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air-dried for 5 minutes and the DNA pellet was then resuspended in 50 J.d of sterile water. 
The DNA was then stored at- 20 °C. 
2.6.8.3 Wizard™ PCR Preps DNA Purification System (Promega, Southampton, UK) 
PCR fragments were separated by electrophoresis through a I% low-melting point agarose 
gel run in I X Tris-Acetate (TAE) buffer as described above (section 2.6.7). DNA bands 
were excised from the gel using a clean, sharp scalpel blade while visualised with UV light 
on a transillwninator. Excised bands were placed into a I.5 ml sterile micro-centrifuge tube 
and incubated in a waterbath at 70 °C until the agarose gel had completely melted. Next, I 
ml of resin was added to the tube, the sample mixed gently by pipetting up and down, then 
it was transferred a 2 ml disposable syringe barrel attached to the column extension of a 
Wizard™ minicolumn. The syringe plunger was inserted into the barrel and the resin/DNA 
solution was gently pushed into the minicolumn. The coluinn was washed in the same 
manner by pushing 2 ml of 80 % isopropanol through the column The syringe was 
removed and the minicolumn was transferred to a sterile 1.5 ml micro-centrifuge tube and 
centrifuged at 13000 rpm for 2 minutes to dry the resin. The minicolumn was again 
transferred to a new 1.5 ml micro-centrifuge tube where 50 ~I of sterile water was applied 
to the colwnn, incubated at room temperature for I minute prior to centrifugation at 13000 
rpm for 30 seconds. The rninicolumn was removed and the eluted DNA was stored at- 20 
oc. 
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2.6.9 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) From Whole Blood 
Peripheral blood mononuclear cells (PBMCs) were isolated from 20-50 ml of peripheral 
venous blood collected from both patients and healthy controls into 5% 
ethylenediaminetetracetic acid (EDTA) vacutainer tubes (Becton Dickinson, Oxford, UK). 
using Lymphoprep™ (Invitrogen Life Technologies, Paisley, UK). The blood was 
transferred to 50 ml sterile Falcon tubes (Fahrenheit, Milton Keynes, UK) where it was 
diluted with an equal volume of PBS (Invitrogen Life Technologies, Paisley, UK) and 
mixed by inverting. Next, 7 ml of the diluted blood was carefully laid on top of an equal 
volume (7 ml) ofLympoprep™ in sterile 15 ml tubes which were then centrifuges at 2000 
rpm at room temperature for 30 minutes in a MSE Mistral centrifuge (MSE Scientific 
Instruments, Leicester, UK) resulting in 4 layers separated out by density gradient. The 
white mononuclear cells layer was collected using a Pasteur pipette (Richardsons of 
Leicester, Leicester, UK), transferred to a clean 15 ml tube and washed by adding a 4 times 
volume of PBS and gently inverting. The solution was then centrifuged at 1400 rpm at 
room temperature for 15 minutes, the supernatant discarded and the cells washed with 
another 4 times volume of PBS. After a final centrifugation at 1200 rpm at room 
temperature for 10 minutes, the supernatant was again discarded and the resulting cell 
pellet resuspended in 1 ml ofRPM11640 medium supplemented with 10% FCS, 50 U/ml 
of penicillin-streptomycin and 5 J.lg (0.25 J.lg/ml) of phytohaemaglutinin (PHA) (Sigma 
Chemicals Ltd, Poole, UK) with gentle pipetting and counted using a haemocytometer. 
The cell density was adjusted to 1 X 106 cellslml and the cells suspension was then divided 
into the appropriate number of flasks required for culture experiments. 
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2. 7 Plasmid DNA Methodologies 
Expression vectors express cloned DNA sequences if they are fused to appropriate 
transcription and translation start signals. Both vector and target DNA can be cleaved at 
appropriate sites, covalently joined together and used to amplify the amount of material or 
express a particular sequence by replicating autonomously in an appropriate host (E. coli). 
Four individual expression plasmids were used in this work; pcDNA3, pCHllO, pUC18 
and pG~Z. A summary of their characteristics is found in Table 2.8. 
2.7.1 pcDNA3 Plasmid (Invitrogen Life Technologies, Paisley, UK) 
pcDNA3 is a P3 low-copy 60 Kb episomal plasmid which encodes a kanamycin resistance 
gene as well as amber mutants of the tetracycline and ampicillin resistance genes. E. coli 
harbouring the plasmid P3 permit selection and maintenance of plasmids that encode the 
tRNA suppressor F gene (supF). When E.coli carrying the P3 plasmids are transformed 
with supF plasmids, such as pcDNA3, they are rendered resistant to both tetracycline and 
ampicillin by suppression of the amber mutants. As spontaneous reversion of the amber 
point mutations on the P3 episome is high, colonies were selected for both tetracycline and 
ampicillin resistance. 
Two pcDNA3 plasmids (5.4 Kb, Invitrogen Life Technologies, Paisley, UK) containing 
p53 DNA encoding the arginine (Arg) and proline (Pro) alleles (approximately 1.8 Kb 
each) cloned at the Barn HI site, were made available by Dr. AI an Storey from the Imperial 
Cancer Research Fund Skin Tumour Laboratory, London, UK (Storey et a/, 1998). Total 
plasmid sizes were approximately 7.2 Kb each. A map of the pcDNA3 plasmid is shown in 
Figure 2.2. 
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Table 2.8. Characteristics of expression plasmids. 
Plasmid Supplier Size Resistance E.Coli Host 
Invitrogen Life ampicillin, 
pcDNA3 Technologies, 5400 bp kanamycin, MC1061/P3 
Paisley, UK tetracycline 
Amersham 
pCH110 Pharmacia Biotech, 7128 bp ampicillin JM109 
Little Chalfont, UK 
Amersham 
pUC18 Pharmacia Biotech, 2686 bp ampicillin JM109 
Little Chalfont, UK 
Promega, 
pGE~Z Southampton, UK 3197 bp ampicillin JM109 
bp = base pairs 
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Pvul 
pcDNA3 
5.4 kb 
• There Is an ATG upstream 
oftheXballlle. Bsml 
Figure 2.2. Map of the pcDNA3 plasmid. 
Tth1111 
The pcDNA3 plasmid is a low copy number plasmid that carries drug resistance markers 
for kanamycin, tetracycline and ampicillin. The kanamycin gene is fully active and is used 
to select for cells carrying the pcDNA3 plasmid. (lnvitrogen Life Technologies, Paisley, 
UK). 
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2.7.2 Preparation of Competent Cells 
The plasmid DNA was transformed into competent cells of the appropriate host strain, 
JM109 cells for pUCl8 plasmid with insert, pG~Z plasmid with insert and pCH110 
eucaryotic control plasmid, and MC1061/P3 cells for pcDNA3 plasmids. 
2.7.2.1 JM109 
The bacterial host strain was streaked onto Luria-Bertani (LB) agar plates (LB medium 
with 1.5 % w/v agar) with 100 j.lg/ml ampicillin and without ampicillin using a flame 
sterilised loop and left to grow overnight in a 37 °C incubator (Leec, Jencons-PLS, 
Leighton Buzzard, UK). A 25 ml aliquot of LB medium (1% Tryptone, 0.5 % Yeast 
Extract, 1% NaCl) was then inoculated with a single colony and incubated overnight in a 
waterbath (Grant, Cambridge, UK) at 37 °C with vigorous shaking at 200 rpm. Two sterile 
500 ml flasks of LB medium were then inoculated with 5 ml of cells from the overnight 
cultures and shaken at 200 rpm at 37 °C in a waterbath until the OD600 reached 0.45-0.55. 
Each solution was then chilled on ice for two hours and subsequently collected by 
centrifugation at 2500 X g for 15 minutes at 4 °C. The pellet was resuspended in 10-20 ml 
of ice-cold trituration buffer and diluted to 500 ml with the same solution, then incubated 
on ice for 45 minutes and centrifuged at 1800 X g for 10 minutes. The supematant was 
decanted and 50 ml of ice-cold trituration buffer was added to the cells that were gently 
resuspended by pipetting up and down. Next, 80% glycerol was added drop-wise with 
gentle swirling to a fmal concentration of 15% v/v. The competent cells were then 
aliquoted in 1 ml volumes into sterile 1.5 ml micro-centrifuge tubes, snap frozen in liquid 
nitrogen and stored at -70 °C. 
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2.7.2.1 MC1061/P3 
Competent cells were prepared for MC1061/P3 cells containing P3 for transformation with 
a SupF plasmid from a non-revertant colony sensitive to ampicillin (Amps) and 
tetracycline (Tef), triple antibody selection. Using a flame-sterilised loop, MC1061/P3 
cells were streaked onto LB plates containing 50 ~g of kanamycin for selection of E. coli 
containing P3 and left to grow overnight in a 37 °C incubator (Leec, Jencons-PLS, 
Leighton Buzzard, UK). Approximately 20-30 single isolated kanamycin resistant (KanR) 
colonies were then patched onto separate LB plates containing 100 ~g/ml of ampicillin 
only, 15 ~g/ml of tetracycline only and 50 ~g/ml of kanamycin only and left to grow 
overnight in a 37 °C incubator (Leec, Jencons-PLS, Leighton Buzzard, UK). Single 
isolated colonies exhibiting sensitivity to both tetracycline and ampicillin (KanR Tet8 
Amps) were selected to prepare competent cells. A 25 ml aliquot of LB medium was then 
inoculated with a single colony and incubated overnight in a 37 oc waterbath (Grant, 
Cambridge, UK) with vigorous shaking at 200 rpm. Next, 1 ml of the overnight culture 
was added to two 500 ml sterile flasks containing 100 ml of LB medium. The cultures 
were shaken at 200 rpm at 37 °C until the OD600 reached 0.45-0.55. Each solution was then 
aliquoted into pre-chilled sterile 50 ml tubes, left on ice 10-15 minutes, and centrifuged at 
4000 rpm at 4 oc for 15 minutes. The supematant was decanted and the resulting cell 
pellets resuspended in 33 ml ofFSB transformation (10 mM potassium acetate, pH 7.5, 45 
mM MnCh, 10 mM CaCh, 100 mM KCI, 3 mM Hexaaminecobalt (lli) chloride, 10% 
glycerol) buffer by gentle vortexing, then incubated on ice a further 10-15 minutes. The 
supematant was again decanted and the cell pellets were resuspended in 8 ml of FSB 
transformation buffer and resuspended with gentle vortexing. A 280 ~1 aliquot ofDMSO 
(v/v 3.5 %) was then added to the suspension, mixed immediately by swirling and 
incubated on ice for 5 minutes. A second 280 ~l aliquot of DMSO was added (final 
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concentration 7 %), the tube mixed by swirling and then incubated on ice for 10-20 
minutes. The competent cells were then aliquoted in 210 J.1l volumes into sterile 1.5 ml 
micro-centrifuge tubes, snap frozen in liquid nitrogen and stored at -70 °C. 
2.7.3 Transformation of Competent Cells 
A pUC18 plasmid with insert and a pG~Z plasmid with insert were used as positive 
controls in the transformation assays. JM109 competent cells were also used for 
amplification ofPCR products. 
2.7.3.1 JM109 
A 600 J.!l aliquot of competent cells was thawed on ice and 18 ng of plasmid DNA was 
added to 3 separate aliquots of 200 J..ll and incubated on ice for 30 minutes. After 
incubation, cells were heat shocked in a waterbath at 42 °C for 5 minutes and immediately 
cooled on ice for one minute. Cells were then allowed to recover by adding 2 ml of LB 
medium to each tube and incubating in a waterbath (Grant, Cambridge, UK) at 37 °C with 
shaking at 200 rpm for 1 hour. Cells were then plated directly in 50-200 J..ll aliquots onto 
LB plates containing 50 J..lg/ml of ampicillin with a top gel containing 40 J..ll of 2% 5-
bromo-4-chloro-3-indolyl ~-D-galactopyranoside (X-gal) (Sigma Chemicals Ltd., Poole, 
UK) and 40 J..ll of 100 mM Isopropyl ~-D-thiogalactopyranoside (IPTG). The plates were 
left to incubate at room temperature for 30 minutes, then inverted and incubated in a 37 °C 
incubator (Leec, Jencons-PLS, Leighton Buzzard, UK) for 12-16 hours. Blue/white 
screening of colonies for recombinants was used, where white colonies were selected. 
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2.7.3.2 MC1061/P3 
Four 210 ).11 aliquots of competent cells were thawed at room temperature until barely 
liquid and then placed on ice for 10 minutes prior to the addition of DNA. A 0.5 )ll (750 
ng) and I)ll (I500 ng) aliquot of each plasmid DNA was added to the thawed tubes, mixed 
by swirling and then incubated on ice for 30 minutes. Cells were heat shocked in a 
waterbath at 42 °C for exactly 90 seconds and immediately cooled on ice for I-2 minutes. 
Cells were allowed to recover by adding 400 ).11 of SOC medium (2 % Tryptone, 0.5 % 
Yeast Extract, 0.05% NaCl, 2.5 mM KCl, IO mM MgCh, 20 mM glucose) to each tube 
and incubating in a waterbath (Grant, Cambridge, UK.) at 37 °C with shaking at 200 rpm 
for I hour. Transformed cells were then plated directly in 50-200 J!l aliquots onto LB 
selective agar plates containing IOO J.tg/ml of ampicillin and IS J!g/ml of tetracycline and 
incubated in a 37 °C incubator (Leec, Jencons-PLS, Leighton Buzzard, UK.) for I2-I6 
hours. 
2.7.4 Isolation of Plasmid DNA 
To each of four sterile 50 ml tubes, IO ml of autoclaved LB medium or SOB medium (2 % 
Tryptone, 0.5 % Yeast Extract, 0.05 % NaCl, 2.5 mM KCl, 10 mM MgCh) and IO )ll of 
ampicillin were added. Each medium was then inoculated with a single transformed 
competent bacterial colony and grown at 37 °C, with shaking (250 cycles per minute), to 
late log phase. Four sterile 500 ml flasks of pre-warmed LB medium containing 500 ).11 of 
ampicillin each were then inoculated with I ml of the late log phase cultures and incubated 
overnight in a waterbath (Grant, Cambridge, UK.) at 37 °C with vigorous shaking at 250 
cycles per minute. The cultures were then transferred to 250 ml Oak Ridge centrifuge tubes 
(Nalgene, USA) and centrifuged at 6000 rpm for 20 minutes at 4 °C. The supernatant was 
then discarded and the plasmid DNA was extracted from the resulting pellet via either 
small or large-scale methods. 
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2.7.5 Extraction of Plasmid DNA 
Plasmid DNA was extracted from bacterial cell cultures following the method ofBimboim 
and Doly, 1979, using either small or large-scale methods. 
2.7.5.1 SmaU-Scale Preparation 
Bacterial cells were harvested by placing 1.5 ml aliquots into sterile 1.5 ml micro-
centrifuge tubes and centrifuging at 13000 rpm for 1 minute at room tempemture. The 
supematant was decanted and the pellet was resuspended in 100 J.d of Solution I (50mM 
glucose, 25 mM Tris-HCI, 10 mM EDTA) by gentle vortexing. Next, 200 J.d of Solution 11 
(1% SDS, 0.2N NaOH) was added, mixed by gently inverting the tube and then incubated 
on ice for 5 minutes. Following the incubation, 150 J.ll of Solution m (3M sodium acetate, 
pH 4.8) was added, mixed by gently inverting the tube, incubated on ice for 5 minutes, and 
centrifuged at 13000 rpm for 5 minutes at room tempemture. A 400 J.ll aliquot of the 
supematant was carefully tmnsferred to a new sterile 1.5 ml micro-centrifuge tube, 1 ml of 
ice-cold 100 % ethanol added, mixed by vortexing and then incubated on ice for 10 
minutes. The tube was then centrifuged at 13000 rpm for 3 minutes at room tempemture to 
collect the precipitated plasmid DNA. The supematant was then discarded and the DNA 
pellet was resuspended in 100 J.l] of Solution IV (50 mM Tris-HCI, pH 8.0, 100 mM 
sodium acetate) by gentle vortexing. The DNA was then reprecipitated by adding 250 J.ll of 
ice-cold 100 % ethanol, mixing by vortexing and incubating on ice for 10 minutes. The 
DNA was again collected by centrifugation at 13000 rpm for 3 minutes at room 
temperature, the supematant discarded and the pellet washed with 1 volume of 70 % 
ethanol. After a final centrifugation at 13000 rpm for 1 minute, the supematant was 
discarded and the pellet was resuspended in 15 J.ll ofTE buffer, pH 8.0. 
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2.7.5.2 Large-Scale Preparation 
Bacterial cells were harvested by aliquoting into sterile 50 ml tubes and centrifuging at 
6000 rpm in a MSE Europa 24M centrifuge (MSE Scientific Instruments, Leicester, UK) at 
4 °C for 20 minutes. The supernatant was discarded and the pellet was resuspended in 10 
ml of Solution I (50mM glucose, 25 mM Tris-HCI, 10 mM EDTA). Next, 20 ml of 
Solution n (1% SDS, 0.2N NaOH) was added, mixed and kept on ice for 5 minutes to 
precipitate out chromosomal DNA, high molecular weight RNA and protein/membrane 
complexes. Following incubation on ice, 15 ml of Solution m (3M sodium acetate, pH 4.8) 
was added, mixed and again incubated on ice for 1 0 minutes, followed by centrifugation at 
7,000 rpm at 4 °C for 20 minutes. The supernatant was carefully decanted and allowed to 
warm to room temperature after which a 0.6 volume of isopropanol was added. The 
solution was mixed and then left at room temperature for 15-30 minutes. The solution was 
then centrifuged at 9000 rpm at 15 °C for 15 minutes, the supernatant decanted and the 
pellet washed with 1 ml of 70 % ethanol. The ethanol was decanted and the solution was 
allowed to air dry for 10 minutes before it was dissolved in 2.5 ml ofTE buffer, pH 8.0. 
2.7.6 Purification of Plasmid DNA 
Plasmid DNA was purified by equilibrium centrifugation in cesium chloride (CsCl) 
ethidium bromide continuous gradients (Sambrook et a/, 1989). The DNA present in the 
centrifuged CsCI solution will move to a position of equilibrium in the gradient equivalent 
to its buoyant density. In CsCI solutions of appropriate density, the DNA will form bands 
near the centre of the tube, RNA will pellet at the bottom and proteins float near the top. 
The exact volume of the DNA solution was determined and one gram of CsCI was added 
for every ml of solution. For a 2.5 ml sample volume, 2.5 g of CsCI was added to the DNA 
solution followed by 0.25 ml of ethidium bromide solution (10 mgfml). The solution was 
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mixed thoroughly then centrifuged at 13,000 rpm for 3 minutes. The supematant was 
transferred to a 13 x 23 mm Quick-Seal centrifuge tube (Beckman, USA) which was then 
sealed by heating and centrifuged at 80,000 rpm in a fixed angle rotor ultracentrifuge at 20 
ac for 24 hours (Beckman TL-100, USA). The superhelical plasmid DNA formed from the 
CsCl gradient was collected from the tube observed under UV light by inserting a needle 
with a syringe just below the band of plasmid DNA. A second needle was inserted into the 
top if the tube to form a vent. The collected DNA was then transferred to a sterile I5 ml 
tube where the ethidiurn bromide was removed by adding an equal volume of water 
saturated isopropanol and mixed. When the two phases settled and separated, the upper 
phase containing the ethidium bromide was removed and discarded and an equal volume of 
water-saturated isopropanol was 
Again added and mixed. The extraction procedure was repeated until both the aqueous and 
organic phases were clear in colour. The DNA was then transferred to a sterile 1.5 ml 
micro-<:entrifuge tube and then precipitated by adding a 1/lOth volume of 3M sodium 
acetate and 3 volumes of ice-cold IOO % ethanol. The sample was stored at -20 oc for at 
least I hour then centrifuged at 13,000 rpm for IO minutes. The supematant was decanted 
and the pellet washed with 700/o ethanol. The DNA pellet was air-dried for 5-IO minutes 
and resuspended in IOO J.d of distilled water. The quality of the DNA was determined 
spectrophotometrically and its quality was assessed by electrophoresis through a I % 
agarose gel in 0.5 X TBE buffer. The DNA was stored at -20 °C until required. 
2.7.7 Restriction Endonuclease Mapping of Inserts 
The concentrations of the purified plasmid recombinants containing DNA inserts were 
determined spectrophotometrically at OD260, where up to I70 J..lg of purified plasmid was 
obtained. Approximately 1 J..lg of each purified plasmid was digested using restriction 
enzymes BamH I, EcoR I and Hind ill (I unit/J..lg DNA, Roche Diagnositics, Lewes, UK). 
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A 5 J.d aliquot of purified plasmid was added to a sterile 1.5 ml micro-centrifuge tube 
containing 1 unit of the appropriate restriction enzyme, 1.5 J.li of 10 X restriction buffer 
and sufficient water to a 15 J.d total reaction volume. The samples were then incubated in a 
waterbath at 37 °C for 1.5 hours. Following digestion, 10 J.d of the sample was run on a 2 
% horizontal agarose gel inc 0.5 X TBE buffer along with 5 J.1l of the undigested sample 
and a 23 Kb molecular weight marker (Roche Diagnostics, Lewes, UK). The gel was 
visualised via irradiation with UV light on a transilluminator (UVP International, 
Cambridge, UK) at A-302 nm and photographed using a gel imager software package 
(Vision Works 3.0, UVP International, Cambridge, UK) and video linked to a Sony 
graphic printer using type IV UPP-11-HA thermo film (Sony Corporation, Tokyo, Japan). 
2.7.8 Transfection ofSaos-2 Cells 
Saos-2 cells were transfected with purified recombinant plasmid containing DNA inserts 
using highly efficient calcium phosphate precipitation where the transfected DNA enters 
the cytoplasm of the cell by endocytosis and is then transferred to the nucleus. 
2.7.8.1 pcDNAJ (containing p53 Pro and pSJ Arg DNA Inserts) 
Approximately 24 hours prior to transfection, exponentially growing Saos-2 cells were 
harvested by trypsinisation and replated at a density of 2 X 105 cells/cm2 in 60 mm tissue 
culture dishes in 4 ml of appropriate medium and incubated for 24 hours at 37 °C in an 
atmosphere of 5 % C02 in a dry C02/02 incubator (Leec, Jencons-PLS, Leighton Buzzard, 
UK). Next, 10-40 J.Lg of each DNA sample to be transfected was added to a sterile 1.5 ml 
micro-centrifuge tube, sufficient water added to 180 J.Ll, the sample mixed by pipetting up 
and down and then 20 Jll of2.5 M CaCh was added and again mixed. A 200 Jll aliquot of2 
X HBS (2 X HEPES buffered saline, 280 mM NaCI, 50 mM HEPES, 1.5 mM sodium 
phosphate, pH 7.15) was added to a separate sterile 15 ml conical tube and using a 
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mechanical pipettor attached to a sterile 1 ml pipette, the solution was bubbled. The diluted 
calcium phosphate-DNA suspension was then added dropwise with a Pasteur pipette into 
the bubbling solution and allowed to precipitate for 20-30 minutes at room temperature. 
The medium in the 60 mm tissue culture dishes was aspirated off and 3.6 ml of appropriate 
fresh medium added. The DNA precipitate was then added dropwise with a Pasteur pipette 
into the medium above the cell monolayer, the plate was gently swirled and incubated 6-14 
hours at 37 °C in an atmosphere of 5 % C02 in a dry COJ!02 incubator (Leec, Jencons-
PLS, Leighton Buzzard, UK). The DNA precipitate was aspirated off and the cells were 
then washed with 4 ml of 1 X versene (0.2 gllitre in PBS; 8g of NaCI, 0.2 g of KCI, 1.2 g 
of sodium phosphate, 0.2 g of potassium phosphate, 0.2 g ofEDTA, 1.5 ml of phenol red) 
followed by 4 ml of PBS which was aspirated off. The cells were glycerol shocked by 
incubation in 0.5 m1 of 20 % glycerol in PBS for I minute then 3 ml of complete medium 
was added to the dish and mixed by gentle swirling. The solution was aspirated off and the 
cells were washed in 3 m1 of complete medium. The medium was aspirated off, 4 m1 of 
complete medium was added to the dish and the cells were incubated at 37 °C in an 
atmosphere of 5 % C02 in a dry COJ}02 incubator (Leec, Jencons-PLS, Leighton Buzzard, 
UK) for 48 hours. 
2.7.8.2 pCHllO Eukaryotic Assay Vector (Amenbam Pbarmacla Biotecb, Little Cbalfont, UK) 
The pCHllO plasmid contains a functional lacZ gene that is expressed from the SV40 
early promoter in eukaryotes (Hall et a/, 1983). P-galactosidase , the product of the lacZ 
gene, can be easily assayed as it is transiently expressed thereby providing an internal 
marker for monitoring expression. Cells transfected with the vector can be fixed and 
stained using a colourmetric assay to detennine transfection efficiency. A map of the 
pCHllO eukaryotic assay vector is shown in Figure 2.3. 
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The pCH110 plasmid was transfonned into competent JM109, amplified and isolated as 
described above (sections 2.7.3.1 and 2.7.4). Soas-2 cells were trypsinised, plated at 2-3 X 
105 cells in a sterile 60 mm tissue culture dish and transfected with 10 Jlg of pCHllO 
vector as described above. After 48 hours incubation at 37 °C in an atmosphere of 5 % C02 
in a dry COJI02 incubator, the cells were washed twice with a 4 ml volume of PBS which 
was then removed by aspiration. The cells were then fixed in 4 ml of 0.1 % gluteraldehyde 
(Sigma Chemicals Ltd., Poole, UK.) in PBS for 10 minutes and washed twice with 4 ml of 
PBS and removed with aspiration. The washed cells were then stained in 4 oil of freshly 
made 13-galactosidase stain (3 mM potassium ferricyanide, 3 mM potassium ferrocyanide, 
0.08% X-gal, 2 mM MgCh) for 24 hours. Cells were verified for blue staining indicating 
the presence of the transfected vector. 
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Hind. (1} ATG Kpn1{204) 
pCH110 
7128bp 
I I 
Figure 2.3. Map of the pCHll 0 eukaryotic assay vector. 
The pCHllO plasmid contains a functionallacZ gene which is expressed from the SV40 
early promoter in eukaryotics (Hall et a/, 1983). f3-galactosidase , the product of the lacZ 
gene, can be easily assayed as it is transiently expressed thereby providing an internal 
marker for monitoring expression. (Amersham-Pharmacia Biotech, Little Chalfont, UK) 
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2.7.9 Selection ofTransfected Saos-2 Cells 
Geneticin (G418) was used to select for transfected cells. G418 blocks protein synthesis in 
mammalian cells by interfering with ribosomal function. It is an aminoglycoside that is 
similar in structure to neomycin, gentamycin and kanamycin. Selection conditions were 
determined by adding varying concentrations of Geneticin (G418) (50 mg/ml, Invitrogen 
Life Technologies, Paisley, UK), ranging from 100-800 )lg/ml, to tissue culture dishes 
containing Soas-2 cells and cultured for up to 10 days to determine the optimal potency. 
The dishes were examined for viable cells and the optimal concentration of antibiotic 
determined. Approximately 48 hours after transfection, cells were trypsinised, split 1: 10 
into an appropriate number of sterile 60 mm tissue culture dishes and incubated 12-16 
hours at 37 °C in an atmosphere of 5 % C(h in a dry C02/02 incubator (Leec, Jencons-
PLS, Leighton Buzzard, UK). Selection for stable transformants was performed by adding 
500 )lg/ml of Geneticin (G418) to the medium. The medium was changed every 2-4 days 
for 2-3 weeks to remove the debris of dead cells and to allow colonies of resistant cells to 
grow. Stable transformants were then trypsinised and replated in new tissue culture dishes. 
2.7.10 Storage of Plasmid Cultures 
2.7.10.1 Short Term Storage of Bacteria 
Colonies containing recombinant plasmid were picked from the original agar plates and 
streaked onto fresh LB agar plates containing antibiotics and incubated at 37 °C for 12-16 
hours. After incubation, well-isolated single colonies were picked with a sterile inoculating 
loop and streaked onto fresh LB agar plates containing the appropriate antibiotics and 
again incubated at 37 °C for 12-16 hours. The plates were then sealed with Nescofilm™ 
and stored at 4 °C for 2-3 months. 
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2.7.10.2 Long Term Storage of Bacteria 
Colonies containing recombinant plasmid were picked from the original agar plates and 
streaked onto fresh LB agar plates containing antibiotics and incubated at 37 °C for 12-16 
hours. After incubation, well-isolated single colonies were picked with a sterile inoculating 
loop and grown in 10 ml ofLB culture medium in sterile 50 ml tubes at 37 °C with shaking 
(250 cycles per minute) in a waterbath (Grant, Cambridge, UK) for 12 -16 hours. The 
cultures were prepared for storage by mixing each thoroughly with 15% glycerol (0.15 ml 
of glycerol to 0.85 ml bacterial culture). Aliquots of I ml were then transferred into 1.8 ml 
sterile cryogenetic vials (Coming, New York, USA), snap frozen in liquid nitrogen and 
stored at -70 °C indefinitely. 
2.7.11 Recovery of Bacteria From Long Term Storage 
A cryovial of frozen bacterial culture was removed from storage at -70 °C. While still 
frozen, a sample of culture was scraped from the surface using a sterile inoculating loop 
and streaked onto the surface of a fresh LB agar plate containing antibiotics. The 
remaining frozen culture was returned to storage at -70 oc and the LB agar plate was 
incubated at 37 °C in a Leec incubator (Jencons-PLS, Buzzard Leighton, UK) for 12-16 
hours. 
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2.8 Labelling of DNA 
2.8.1 Radiolabelling 
2.8.1.1 Random Primed Labelling of DNA 
DNA probes used in hybridisation reactions were radiolabelled with a 32P dCTP using a 
Random Primed DNA Labelling Kit (Roche Diagnostics, Lewes, UK). The method is 
based on the hybridisation of a mixture of all possible hexanucleotides to the DNA to be 
labelled. The complimentary strand is synthesised from the 3'0H terminal of the random 
hexanucleotide primer using Klenow enzyme, labelling grade. Approximately 25 ng of 
DNA to be labelled was added to a sterile 0.2 m1 micro-centrifuge tube and denatured by 
heating in a waterbath at I 00 °C for I 0 minutes followed by immediately cooling on ice for 
at least I minute. To the same tube, I J.ll each of dATP, dGTP, and d1TP (0.5 mM) were 
added, 2 Ill of reaction mixture (hexanucleotide mixture in I 0 X reaction buffer), 5 Ill of 
a 32P dCTP (3000 Ci/mmol), sufficient water to make up to I9 J.ll reaction volume and 1 Ill 
ofK.Ienow enzyme (2 units/Ill). The solution was mixed by pipetting up and down and then 
incubated in a waterbath at 37 °C for 30 minutes. The reaction was stopped by the addition 
of21ll of0.2 M EDTA, pH 8.0. 
2.8.1.2 5' End Labelling of DNA 
DNA molecular weight markers were radiolabelled using a 5' -End labelling system, 
Ready-To-Go™ T4 Polynucleotide Kinase (PNK) (Amersham Pharmacia Biotech, Little 
Chalfont, UK). A tube containing 8-10 units ofFPLCpure™ T4 polynucleotide Kinase (50 
mM Tris-HCl, pH 7.6, 10 mM MgCh, 5 mM DTT, 0.1 mM spermidine, 0.1 mM EDTA, 
pH 8.0, 0.2 J.1M ATP and stabilisers) was reconstituted in 25 J!l of sterile water, incubated 
at room temperature for 5-10 minutes, then mixed by gentle pipetting up and down. Next, 
5-10 pmol of DNA was added to a sterile 0.2 ml micro-centrifuge tube and denatured by 
- I65-
Chapter 2. Materials and Methods 
heating at 65 °C in a waterbath for 5 minutes, then cooled for 5 minutes at room 
temperature. The heat denatured DNA was then added to the tube along with sufficient 
water to make a final reaction volume of 49 f.d and I j.tl of y 32P dA TP (3000 Cilmmol, I 0 
J.1CiiJ.LI). The solution was gently mixed by pipetting up and down, centrifuged at 13000 
rpm for 30 seconds and incubated at 37 oc in a waterbath for 30 minutes. The reaction was 
then stopped by the addition of 5 j.li of 250 mM EDTA. The sample was precipitated to 
remove unincorporated nucieotides by adding 2 j.tl of Quick PrecipTM (Advanced Biotech 
Corp., USA), l/IOth volume of 5 M sodium chloride and 2-3 volumes of ice-cold IOO% 
ethanol to the tube, which was then mixed by vortexing. The solution was then centrifuged 
at 13000 rpm for 3 minutes, the supernatant decanted and the pellet washed with I volume 
of 70 % ethanol. The solution was again centrifuged at 13000 rpm for 30 seconds, the 
supernatant decanted, the sample air-dried for 5 minutes and the labelled DNA was then 
resuspended in 50 Jll of sterile water. The labelled DNA was then stored at - 20 °C for up 
to 1 week. 
2.8.1.2.1 Removal of Unincorporated Radiolabelled Nucleotides 
Labelled DNA was separated from unincorporated deoxyribonucleoside triphosphates by 
column chromatography through a Sephadex G-50 column (Sambrook et a/, I989). A 
slurry of Sephadex G-50 (Sigma Chemicals Ltd., Poole, UK) was prepared by adding 30 
grams of Sephadex G-50 to 250 ml of TE buffer, pH 7.6, in a 500 rnl Duran bottle an 
incubating at room temperature for I2 -I6 hours. The solution was then heated in a 
waterbath at 65 °C for 2 hours and then left to cool to room temperature for 3 hours. The 
supematant was then decanted and an equal volume of TE buffer, pH 7.6, was added to 
equilibrate the resin. A Sephadex G-50 chromatography column was prepared by pushing a 
small amount of sterile glass wool to the bottom of a disposable glass Pasteur pipette using 
a sterile bio-Ioop. The equilibrated Sephadex G-50 resin was mixed well and gently added 
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to the plugged pipette using a sterile plastic Pasteur pipette, avoiding the fonnation of air 
bubbles, until about 1 cm below the top of the column. The column was clamped to a 
holding stand and continually irrigated with TE buffer, pH 7.6, to avoid it drying out or 
cracking. Immediately following column packing and irrigation the labelled DNA sample, 
mixed with 180 J.d ofTE buffer, pH 7.6, was added to the top of the column. As soon as 
the labelled DNA sample has entered the resin another 180 J.d ofTE Buffer, pH 7.6, was 
added to the column to wash the DNA sample through. Elution fractions were collected 
into separate sterile 0.2 ml micro-centrifuge tubes. The sample was washed through the 
column using an additional 11 aliquots of 180 J.d of TE buffer, pH 7.6, with eluted 
fractions collected for each. 
2.8.1.2.2 Labelling Efficiency 
The degree of labelling was detennined by comparison of incorporated with total input 
radioactivity in the collected reaction aliquots. The specific activity was detennined using 
liquid scintillation counting of each collected sample in a scintillation counter (Beckman 
Instruments, USA). Unincorporated nucleotides will elute more slowly through the resin 
than labelled DNA therefore an elution profile consists of a leading peak of radioactivity 
consisting of nucleotides incorporated into DNA followed by a trailing peak of 
radioactivity consisting of unincorporated deoxyribonucleoside triphosphates. 
Incorporation was routinely > 70 %, with specific activities of 109 cpm/ ~g of DNA 
Collected fractions containing the incorporated nucleotides from the leading peak were 
pooled and stored in a labelled sterile 1.5 ml micro-centrifuge tube at- 20 °C for up to 1 
week. 
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2.8.2 Digoxigenin (DIG) Labelling 
A random primed labelling reaction using Digoxigenin-11-2'-deoxy-uridine-5'-
triphosphate (DIG-11-dUTP) (Roche Diagnostics, Lewes, UK) was used to label two 
separate amplified IllF-la DNA probes (Table 2.9). Approximately 3.5 J,tg of DNA was 
first denatured by heating in a waterbath (Grant, Cambridge, UK) at 95 °C for 10 minutes 
then chilled on ice for at least 1 minute. Next, the freshly denatured DNA was added to a 
sterile 0.2 ml micro-centrifuge tube along with 2J,tl of lOX hexanucleotide mixture, 2J,tl of 
10 X DIG DNA labelling mixture, I J.ll of labelling grade Klenow enzyme and sufficient 
sterile water to a final reaction volume of 19 J.ll. The tube was mixed, briefly centrifuged 
and incubated in a 37 °C waterbath for 1 hour, after which 2 J.ll of0.2 M EDTA, pH 8.0 
was added to stop the reaction. The DIG-labelled DNA was then precipitated with 2.5 J.ll of 
3M sodium acetate, pH 5.2 and 75 J,tl of pre-chilled 100% (v/v) ethanol for 2 hours at -20 
°C. The tube was then centrifuged at room temperature at 13000 rpm for 10 minutes, the 
supernatant decanted and the pellet washed with 50 J.ll of70% (v/v) ethanol. The tube was 
again centrifuged at 13000 rpm for 5 minutes, the supematant decanted and the pellet air-
dried for 10 minutes prior to being resuspended in 50J.l} of TE buffer. The DIG-labelled 
DNA was then stored at -70 °C. 
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Table 2.9. Amplimer sequences and reaction conditions for HIF-la probe synthesis used 
in Digoxigenin (DIG) labelling. 
Amplimer Sequence Length Gene Cycle Cycles Product (mer) Conditions (base pairs) 
94 •c for 1 minute 
5' GCCACTTCGAAGTAGTGCTGACC 3' (sense) 23 IDF-1a. 55 OC for I minute 30 135 bp 
68 OC for 1.5 minutes 
5' GCTTCCATCGGAAGGACTAGG 3' (antisense) 21 Additional 
68 OC for 10 minutes 
5' CACCTATGACCTGCTTGGTGC 3' (sense) 21 94 •c for I minute 
IDF-1a. 55 •c for 1 minute 30 283 bp 
5' GGCAAGCATCCTGTACTGTCC 3' (antisense) 21 68 •c for 1.5 minutes 
Additional 
68 •c for I o minutes 
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2.9 Sequencing of PCR products 
PCR products were sequenced using two separate methods based on the chain-termination 
DNA sequencing methods (Sanger et a/, 1977). 
2.9.1 Sequenase PCR Product Sequencing Kit (Amersham Pharmacia Biotech, 
Little Chalfont, UK) 
This method requires no purification of the PCR product and all gel purifications, 
sedimentations and filtrations are eliminated by the use of two enzymes which effectively 
remove excess dNTPs and primers from the DNA produced in the PCR amplification. 
2.9.1.1 Enzymatic Pre-Treatment of PCR product 
The PCR product was treated with a combination of Exonuclease I and Shrimp Alkaline 
Phosphatase. Exonuclease I removes residual single-stranded primers and any extraneous 
single-stranded DNA produced by the PCR. The Shrimp Alkaline Phosphatase removes the 
remaining dNTPs from the PCR mixture which would interfere with the labelling step of 
the sequencing process. A 5J.d aliquot ofPCR amplified product was added to a sterile 0.5 
ml micro-centrifuge tube containing 1 ).11 of Exonuclease (10.0 units/).11) and 1 ).11 of Shrimp 
Alkaline Phosphatase (2.0 units/).11) and mixed by pipetting up and down. The solution was 
then incubated in a waterbath at 37 °C for 15 minutes, and the enzymes inactivated by 
heating to 80 °C in a waterbath for 15 minutes. 
2.9.1.2 Annealing 
Next, a 3.5 J.d aliquot of the treated PCR product was transferred to a new sterile 0.5 ml 
micro-centrifuge tube and 6.5).11 of primer (1 pmoV).I.l) was added to the tube to make a 10 
J.ll total reaction volume. The DNA was then denatured by heating for 2-3 minutes at 100 
°C in a thermal cycler (Techne Ltd., Cambridge, UK) and quickly cooled by placing the 
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vial directly in ice for 5 minutes. The solution was centrifuged at 13000 rpm for 30 
seconds then 2 J.d of 5 X reaction buffer (200 mM Tris-HCI, pH 7.5, 100 mm MgCh, 250 
mM NaCl), 1J.d of0.1M DTT, 2 J.l.l of 1:5 diluted labelling mixture (7.5 J.1M dCTP, 7.5 f,1M 
dGTP, 7.5 f,1M dTTP), 0.5 J!l of a 32P dATP (10J.1Ci/J.1l) and 2 J!l of Sequenase version 2.0 
T7 DNA Polymerase (1.6 units/J.l.l) with 2 units/r.d of inorganic pyrophosphatase in 20 mM 
Tris-HCl, pH 7.5, 2 mM DIT, 0.1 mM EDTA, 50 % glycerol) were added to the tube to 
make a total reaction volume of 17.5 J!l. The solution was mixed by pi petting up and down 
and incubated at room temperature for 5 minutes. 
2.9.1.3 Termination Reaction 
Sterile 0.5 ml micro-centrifuge tubes were labelled G, A, C, T and 2.5 J.l.l of appropriate 
termination mixture was added to each and pre-warmed in a waterbath at 37 oc for 1 
minute (ddG termination mixture: 80J!M dGTP, 80J!M dATP, 80 J.1M dCTP, 80 f,1M dTTP, 
8 f,1M dGTP, 50 mM NaCl; ddA termination mixture; 80J!M dGTP, 80J!M dATP, 80 f,1M 
dCTP, 80 f,1M dTTP, 8 f,1M dATP, 50 mM NaCl; ddT termination mixture: 80f,1M dGTP, 
80f,1M dATP, 80 f,1M dCTP, 80 f,1M dTTP, 8 f,1M dTTP, 50 mM NaCl; ddC termination 
mixture: 80J!M dGTP, 80J!M dATP, 80 ~ dCTP, 80 ~ dTTP, 8 f,1M dCTP, 50 mM 
NaCI). A 3.5 J.l.l aliquot of the labelling reaction was added to each termination tube, the 
solution mixed by pipetting up and down and then incubated in a waterbath at 37 oc for 5-
10 minutes. The reactions were stopped by the addition of 4 J!l of stop solution (95 % 
formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF) and then 
heated in a waterbath at 75 °C for 2 minutes immediately prior to loading into the 
sequencing gel. 
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2.9.1.4 Denaturing Gel electrophoresis For Manual Sequencing 
A Bio-Rad Sequence Gen IJTM electrophoresis system (Bio-Rad Laboratories, Hemel 
Hempstead, UK) was used which consisted of two 21 X 40 cm glass plates with 0.25 cm 
spacers, 2 clamps and a 24 well vinyl sharktooth comb. The glass plates were washed and 
then dried with 70% industrial methylated spirit (IMS). The inner surface of the back plate 
was then covered in a thin layer of Repelcote (2% solution of dimethydichlorosilane in 
octamethylcyclotetra-siloxane, Merck Ltd., Lutterworth, UK) to prevent the gel from 
tearing as the plates are pried apart after electrophoresis. A small amount of petroleum 
jelly was applied to the edges of the back plate and the two spacers were placed at the sides 
of the plate. The front plate was laid on top of the back plate and spacers and clamped 
together. The sandwiched plates were then placed in a casting tray at a 45° angle. A 6 % 
denaturing polyacrylamide gel was prepared by mixing 7.5 ml of20 X glycerol tolerant gel 
buffer (prepared by mixing 216 grams of Iris-base with 72 grams of taurine and 4 g of 
EDTA in sterile water to a final volume of 1 litre), with 7.5 ml of water, 99 ml of Ultra 
Pure™ Sequagel concentrate solution, and 36 ml of Ultra Pure™ Sequagel diluent (Sigma 
Chemicals Ltd, Poole, UK). Half of the gel mix was transferred to a 100 ml conical flask 
and 0.8 ml of ammonium persulfate and 40 J.d ofTEMED was added to the flask, mixed by 
gentle swirling, poured immediately into the casting tray and allowed to polymerise for 30 
minutes to seal the bottom of the plates. Following polymerisation, 0.8 ml of ammonium 
persulfate and 40 J.li of TEMED was added to the remaining gel mix, the solution was 
drawn into a syringe and carefully injected into the gel plate sandwich until it reached the 
edge of the plates. Air bubbles were removed by gently tapping the glass. The flat edge of 
the comb was then inserted halfway into the space between the plates and the gel was 
allowed to polymerise for 1 hour at room temperature. When the gel was set the casting 
tray was removed and the gel sandwich was placed vertically into the lower buffer tank 
that contained l X glycerol tolerant buffer. The upper buffer chamber was also filled with 
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1 X glycerol tolerant buffer, the system was connected to a constant power supply 
(PC3000 Powerpac, Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) and the gel was 
pre-run at 1600 volts for approximately 30 minutes until the temperature of the gel reached 
50-55 °C. The gel system was disconnected, the vinyl comb was removed and carefully 
reinserted with the sharkteeth downwards to create weUs. The sequencing samples were 
then loaded into the wells in the order of G, A, T and C using a l 0 J.ll Drummond 
sequencing pipette (Drummond Laboratories, USA) and run at 2000 volts for 2-4 hours. 
After electrophoresis, the gel apparatus was disassembled and the gel plates gently pried 
apart leaving the gel attached to one of the gel plates which was then soaked in a 5 % 
acetic acid, 15% methanol solution for 5 -15 minutes to remove the urea and detach the 
gel form the plate. A piece of 3 MM filter paper (Amersham Pharmacia Biotech, Little 
Chalfont, UK) was laid on top of the gel and the gel and filter paper were covered in Saran 
WrapTM and dried at 75 oc for 2 hours on a Sue 300 gel dryer (Heto Laboratory equipment, 
Surrey, UK). The dried gel was then placed in an Cronex autoradiography cassette (K.odak, 
UK) containing lighting and intensifying screens. In a dark room, a piece of Kodak X-
OMATTM LS X-ray film (Scientific Imaging Systems Ltd., Cambridge, UK) was placed on 
top of the gel and the cassette was firmly closed. The cassette was placed at -80 °C where 
the film was exposed for at least 24 hours. The film was then developed in Kodak X-ray 
developer (Anachem, Luton, UK) for 3 minutes, placed in an indicator stop-bath solution 
(3 % sulphuric acid) for 30 seconds, and fixed in a liquid fixer solution for at least 1 
minute (Anachem, Luton, UK). The film was then rinsed for 1 minute under tap water and 
air-dried. 
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2.9.2 Automated (ABI Prism 377 Automated Sequencer, Perkin Elmer, Cbesire, UK) 
Automated sequencing on purified PCR fragments was performed on 4.25 % gels with 
urea on an ABI 377 Prism automated sequencer (Perkin Elmer, Chesire, UK) using 
BigDye terminator cycle sequencing kits (Perkin Elmer, Chesire, UK) at the Molecular 
Genetics Laboratory, Exeter, UK. Sequencing results were analysed using Factura software 
and Sequence Navigator, which aligns sequences using Clustal software (Perkin Elmer, 
Chesire, UK). 
2.10 Ribonucleic Acid (RNA) Methodology 
2.10.1 Ribonuclease Free Environment 
The successful isolation of intact RNA by any procedure requires tbat four important steps 
be performed (Sambrook et a/, 1989): 
1) effective disruption of cells or tissues 
2) denaturation of nucleoprotein complexes 
3) inactivation of endogenous ribonuclease (RNase) activity, and 
4) purification of RNA away from contaminating DNA and proteins. 
The most important of these steps is the immediate inactivation of endogenous RNase 
activity, which is released from membrane bound organelles upon cell disruption. RNases 
are active and stable enzymes that are difficult to inactivate. Thus, all glassware, plastics 
and instruments used in RNA work was soaked overnight at room temperature in a solution 
ofO.I% diethylpyrocarbonate (DEPC) to remove RNase and then autoclaved at 121°C, 15 
psi for 30 minutes to remove residual traces of DEPC which may cause 
carboxymethylation of RNA. Tubes used in the preparation of first strand cDNA synthesis 
were dipped in a silicone solution (Repelcote, BDH Laboratory Supplies, Merck Ltd., 
Lutterworth, UK) after DEPC treatment and prior to autoclaving. All solutions were made 
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using 0.1% DEPC treated water and subsequently autoclaved. Latex gloves were worn 
throughout all procedures and were changed frequently. When required, all reagents and 
solutions were kept on ice to avoid degradation of RNA by endogenous or residual 
RNases. 
2.10.2 Isolation of RNA 
Two separate methods were used in isolating RNA from peripheral blood mononuclear 
cells (PBMCs), established cell lines, and breast and brain tumour tissue. 
2.10.2.1 RNeasy™ Total RNA Purification Kit (QIAGEN Ltd., Crawley, UK) 
RNA from near confluent adherent cell lines was obtained by direct lysis with the addition 
of 600 IJ.l of Lysis Buffer RTL (containing guanidinium isothiocyanate (GTC) and P-
mercaptoethanol (P-ME)) to 75 cm2 tissue cultures flasks after complete aspiration of the 
cell culture medium. The resulting lysate was transferred to a RNase free 1.5 ml micro-
centrifuge tube and homogenised by rapid shearing through a needle and syringe for 30 
seconds. The lysate was then centrifuged at 13,000 rpm for 3 minutes in a Biofuge 13 
rnicrocentrifuge (Heraeus Sepatech, Germany). A 600 J.d volume of 70% ethanol was 
added to the homogenised lysate and mixed by pipetting. The mixture was then applied to 
an RNeasy spin column that was held in a 1.5 ml micro-centrifuge tube and centrifuged at 
10,000 rpm for 15 seconds. The flow-through was then discarded and the column was 
washed by the addition of 700 J.d of Wash Buffer RW1 by an additional centrifugation at 
10,000 rpm for 15 seconds. The flow-through was again discarded and the column was 
washed twice with 5001J.l of Wash Buffer RPE (containing 80% ethanol) and centrifuged as 
above. After discarding the flow-through, the column membrane was then dried by 
centrifugation at 13,000 rpm for 2 minutes, ensuring the evaporation of any residual 
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ethanol. The RNA was then eluted into a new 1.5 ml collection tube by the addition of 50 
fll ofDEPC treated water and centrifugation at 10,000 rpm for I minute. 
2.10.2.2 RNA STAT-60™ Total RNA Isolation Reagent (Biogenesis, Poole, UK) 
RNA STAT- 601M, a mono-phase solution containing guanidinium thiocyanate and phenol, 
is a single-step method for the isolation of total RNA. As above, RNA from near confluent 
adherent cell lines was obtained by direct lysis with the addition of I ml of RNA STAT-
60TM per 5-10 X 106 cells, to 75 cm2 tissue cultures flasks after complete aspiration of the 
cell culture medium. The cell lysate was collected to a corner of the flask using a cell 
scmpper where the homogenate was then sheared through was a 1 ml pipette several times 
prior to being transferred to an RNase free 1.5 ml micro-centrifuge tube. Whole tissue 
samples (up to lOO mg) were first homogenised in a borosilicate glass 7 ml Dounce tissue 
grinder (Wheaton Science Products, Millville, N.J., USA) using 10 strokes and 1 ml of 
RNA STAT-60TMper 50-100 mg oftissue. The homogenised lysate was then tmnsferred to 
a 1.5 micro-centrifuge tube. The homogenates were stored for 5 minutes at room 
temperature to allow for complete dissociation of nucleoprotein complex. Next, 200fll of 
chloroform per I ml of RNA STAT-60TM was added, the sample was shaken vigorously 
for 15 seconds and left at room temperature for 2-3 minutes. Following centrifugation at 
13,000 rpm for 15 minutes at 4°C, the upper aqueous layer was transferred to a new 1.5 ml 
micro-centrifuge tube and precipitated with 0.5 ml of isopropanol, per I ml ofRNA STAT-
601M used in homogenisation. The sample was mixed and stored at room tempemture for 
5-10 minutes then centrifuged at 13,000 rpm for 10 minutes at 4°C. The pelleted RNA was 
then washed by vortexing with I ml of75% ethanol per I ml of RNA STAT-601M used in 
the initial homogenisation. The sample was then centrifuged at 7,500 rpm for 5 minutes at 
4°C, the supematant removed and the sample air-dried for 5 -10 minutes and subsequently 
resuspended in 50 Ill ofDEPC treated water. 
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2.10.3 Quantitation of DNA and RNA 
The concentration and purity of the isolated DNA or total RNA was determined 
spectrophotometrically using a scanning wavelength (A240 nm to A280 run) Cecil 5000 
spectrophotometer (Cecil Instruments, Cambridge, UK) blanked with water. In 
determining the nucleic acid concentrations it is implicit that an absorbance reading of 1.0 
at 260 nm is equivalent to a 40 J.lg/ml RNA solution, a 40 J.lg/ml single stranded DNA 
solution or a 50 J.lg/ml double stranded DNA solution (Sambrook et a/, 1989). 
Concentrations of either DNA or RNA samples were determined by multiplying the 
absorbance reading at A260 nm by the dilution factor and the relevant nucleic acid 
concentration. The purity of samples was determined by calculating the absorbance ratio of 
the optical density (OD)240 to OD280• Samples with a ratio greater than 1.80 were 
considered pure and free from protein contamination. 
2.10.4 Reverse Transcription of Total RNA 
First strand cDNA was prepared using a SUPERSCRIP'fTM Preamplification System 
(Invitrogen Life Technologies, Paisley, UK). Four J.lg of total RNA was mixed with I J.ll of 
Oligo dTt2-t8 (0.5 J.lg/J.ll), which hybridises to the 3' poly (A) tails, and DEPC-treated water 
to a fmal reaction volume of 12 J.ll. in a sterile 0.5 ml siliconised micro-centrifuge tube. 
The sample was then incubated at 70 °C in a waterbath (Grant, Cambridge, UK) for 10 
minutes and cooled on ice for at least 1 minute. Next, 2 J.ll of IOX PCR buffer (Invitrogen 
Life Technologies, Paisley, UK), 2J.ll of 25 mM MgCh, 1 J.ll of 10 mM dNTP mix and 2 J.d 
of 0.1 M dithiothreitol {DTT) were added to the sample, gently mixed, briefly centrifuged, 
then incubated at 42 oc for 5 minutes. After incubation, 1 J.ll (200 units) of SUPERSCRIPT 
II RNase H- reverse transcriptase (RTase) was added to catalyse the cDNA synthesis, the 
sample was mixed and again incubated at 42 oc for 50 minutes. The reaction was then 
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tenninated by incubating the sample at 70 °C for 15 minutes, followed by chilling on ice 
for at least 1 minute. The sample was collected by brief centrifugation, then 1).11 of RNase 
H was added and the sample incubated at 37 oc for 20 minutes. The resulting cDNA was 
then either used immediately in subsequent PCR amplification reactions (reverse 
transcription polymerase chain reaction (RT-PCR)) or stored at-20 °C. 
2.10.5 Northern Blotting 
2.10.5.1 Separation of Total RNA by Agarose Formaldehyde Gel Electrophoresis 
Total RNA was separated by electrophoresis in a 1.5 % horizontal slab agarose 
fonnaldehyde gel prepared by dissolving 1.5 grams of multi-purpose agarose in 10 ml of 
10 X MOPS (0.2 M 3-[N-Morpholino]propane-sulphonic acid, 0.5M sodium acetate, pH 
7.0, 0.01 M EDTA) and 73 ml of water in a 500 ml Duran glass bottle by boiling. The 
agarose solution was then cooled to 50-55 °C prior to adding I 0 J.l.l of a I 0 mgfml solution 
of ethidium bromide (0.01% v/v) and 17 ml offonnaldehyde (37 % v/v, Sigma Chemicals 
Ltd., Poole, UK). The solution was gently mixed and then poured into a 11 X 14 cm 
perspex gel mould tray (Life Technologies, Paisley, UK) that was sealed at both ends with 
masking tape in a fume hood. A plastic 14 well tooth-comb was positioned I mm above 
the tray and the gel was then allowed to set at room temperature for 30 minutes. Once set, 
the comb and masking tape were carefully removed and the gel and tray were placed into a 
horizontal gel electrophoresis tank (Life Technologies, Paisley, UK) containing 1 X MOPS 
buffer sufficient to cover the gel. Up to 100 J.l.g of total RNA in a 6 J.l.l volume was added to 
a sterile 1.5 ml micro-centrifuge tube containing 12.5 J.l.l of fonnamide, 2.5 J.l.] of 10 X 
MOPS buffer and 4 J.l.] of 37 % (w/v) fonnaldehyde. The solution was mixed by pipetting 
up and down, incubated in a waterbath at 65 °C for 5 minutes and then chilled on ice for at 
least I minute prior to adding 2.5 J.l.l of loading buffer (50% (v/v) glycerol containing 0.1 
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mglml bromophenol blue). The samples were loaded onto the gel and a RNA molecular 
weight marker ll (5 f.d of a 1 mglml stock solution, 1.6-7.4 Kb, Roche Diagnostics, Lewes, 
UK), prepared as described above, was run concurrently. The gel was run at 100 volts for 
3-4 hours or until the dye front had migrated approximately 8 cm through the gel. 
Following electrophoresis, the gel was visualised via irradiation with UV light on a 
transilluminator (UVP International, Cambridge, UK) at A.302 nm, a ruler was placed 
alongside the gel and photographed using a gel imager software package (Vision Works 
3.0, UVP International, Cambridge, UK) and video linked to a Sony graphic printer using 
type IV UPP-11-HA thermo film (Sony Corporation, Tokyo, Japan). 
2.10.5.2 Transfer 
Immediately following electrophoresis, the molecular weight marker and any unused areas 
of the gel were trimmed away with a scalpel blade and the bottom left hand corner of the 
gel was cut to serve as an orientation point. Two sheets of 3MM Whatman 
chromatography paper were placed over a 30 cm X 20 cm plastic support so that the ends 
of the paper fell into a large plastic container. The container was filled with 20 X SSC 
blotting buffer until the level of the liquid almost reached the top of the support. Capillary 
action wet the 3MM paper and when it was thoroughly wet any air bubbles were removed 
by smoothing with a glass rod. The gel was inverted and placed on the support. A sheet of 
Hybond™-N+ positively charged nylon membrane (Amersharn Pharmacia Biotech, Little 
Chalfont, UK) was cut to the size of the gel and placed on top of it avoiding trapping any 
air bubbles beneath it. Two sheets of 3MM paper cut to the size of the gel were soaked in 
blotting 20 X SSC were placed on top of the nylon membrane with any air bubbles 
smoothed out. A stack of absorbent paper towels was placed on top of the 3 MM paper 
approximately 5 cm high, followed by a glass plate and a 500 g weight. The RNA was 
allowed to transfer 6-18 hours. After blotting, the towels and Whatman paper were 
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removed from the gel, the membrane was marked with a pencil, removed from the gel and 
washed in 3 X SSC for 10 minutes. The membrane was either UV fixed (254nm, 2 
minutes) or oven baked between 2 sheets of3MM Whatman paper at 80 °C for 2 hours and 
stored at room temperature until probed. 
2.10.5.3 Radiolabelled Probes 
Detailed description and synthesis of probes for HIF-1a, VEGF, p53 and 13-actin are 
described in Table 2.10. Probes used in Northern hybridisations were radiolabelled and 
separated as described in section 2.8.1.1. 
2.10.5.4 Hybridisation 
Hybridisation of radiolabelled probes to immobilised RNA was performed in sealed 
revolving cylindrical siliconised borosilicate glass tubes 20 cm in length X 3 cm in 
diameter or 20 cm in length X 8 cm in diameter, with screw caps in a Techne HB-ID 
hybridisation oven (Techne Ltd., Cambridge, UK), using two separate hybridisation 
buffers. 
2.10.5.4.1 Hybridisation Buffer (Sambrook et al, 1989) 
The membrane carrying immobilised probe was first blocked with non-homologous DNA 
to mask non-specific binding sites. Sonicated salmon sperm DNA (10 mg/ml) was 
denatured by heating at I 00 °C in a waterbath for 5 minutes, cooled on ice for at least I 
minute and then added to pre-hybridisation solution (5 X SSPE (3.6 M NaCl, 0.2 M 
sodium phosphate, 0.02 M EDTA, pH 7.7), 5 X Denhardt's solution (O.I % (w/v) BSA, O.I 
% (w/v) Ficoll™, 0.1 % (w/v) polyvinylpyrrolidone (PVP)), 0.5 % (w/v) SDS). The 
membrane was then pre-hybridised at 65 °C with rotation for I hour in I 0 ml of pre-
hybridisation buffer. The labelled probe, with specific activity > 5 X I06 cpm (section 
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2.8.1.1.2) was denatured by heating at 100 °C in a waterbath for 5 minutes, cooled on ice 
for 10 minutes, added to the tube containing the membrane and pre-hybridisation solution 
and incubated with rotation at 65 °C for 12 -16 hours. Following hybridisation, the pre-
hybridisation solution was discarded and the membrane was washed twice by incubating 
the membrane in 50 rnl of2 X SSPE, 0.1 % (w/v) SDS with rotation for 10 minutes each at 
room temperature. The membrane was then washed in 50 ml of pre-warmed 1 X SSPE, 0.1 
% (w/v) SDS with rotation at 65 °C for 15 minutes, followed by a wash in 50 rnl ofpre-
warmed 0.1 X SSPE, 0.1% (w/v) SDS with rotation at 65 °C for 10 minutes. 
2.10.5.4.2 Rapid-Hyb Buffer (Amersham Pharmacia Biotech, Little Chalfont, UK) 
Hybridisation with commercial Rapid-Hyb buffer eliminates the necessity of adding non-
homologous DNA to mask non-specific binding sites on the membrane, as it contains 
chemical blocking agents. A 10 ml aliquot of the buffer was added to a hybridisation tube 
and pre-warmed to 65 °C in a hybridisation oven. The membrane containing immobilised 
RNA was then immersed completely in the pre-warmed buffer and incubated with rotation 
at 65 °C for 15 minutes. The labelled probe, with specific activity> 5 X 106 cpm was 
denatured by heating at 100 °C in a waterbath for 5 minutes, cooled on ice for 10 minutes, 
added to the tube containing the membrane and pre-hybridisation solution and incubated 
with rotation at 65 oc for 2-4 hours. Following hybridisation, the pre-hybridisation 
solution was discarded and the membrane was washed by incubating the membrane in 50 
ml of 2 X SSC, 0.1 % (w/v) SOS with rotation for 20 minutes at room temperature. The 
membrane was then washed twice in 50 ml ofpre-warmed 1 X SSC, 0.1% (w/v) SOS with 
rotation at 42 oc for 15 minutes each, followed by 2 washes in 50 ml ofO.l X SSC, 0.1% 
(w/v) SOS with rotation at 42 °C for 10 minutes each. 
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2.10.5.5 Autoradiography 
Following washings, the membrane was then drained and placed on a piece of 
SaranWrap™ where it was enclosed in the wrap and air bubbles removed. The wrapped 
membrane was then placed in a Cronex autoradiography cassette containing lighting and 
intensifying screens. In a dark room, a piece of Kodak XLS5 X-ray film (Scientific 
lmaging Systems Ltd., Cambridge, UK.) was placed on top of the wrapped membrane and 
the cassette was frrmly closed. The cassette was placed at -80 °C where the film was 
exposed for 3-7 days. The film was then developed in Kodak X-ray developer (Anachem, 
Luton, UK.) for 3 minutes, placed in an indicator stop-bath solution (3 % sulphuric acid) 
for 30 seconds, and fixed in a liquid fixer solution for at least 1 minute (Anachem, Luton, 
UK.). The film was then rinsed for l minute under tap water and air-dried. Membranes 
were stored wet at 4 °C wrapped in SaranWrap™. 
2.10.5.6 Membrane Stripping 
Wet membranes were stripped of bound probes by boiling a solution of 0.5 % (w/v) SDS, 
pouring it on the membrane and allowing the solution to cool to room temperature. 
Membranes were then rehybridised as described above (section 2.10.6.4) or stored wet at 4 
oc wrapped in SaranWrap™. 
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2.10.6 Ribonuclease Protection Assay (RP A) 
The ribonuclease protection assay (RP A) is a sensitive technique used for the detection and 
quantitation of target RNA sequences and related RN As. A radiolabelled RNA probe is 
allowed to hybridise to target RNA in solution after which remaining single-strand probe is 
removed from the reaction by incubation with ribonuclease (RNase). Reaction products are 
resolved by polyacrylamide gel electrophoresis to quantitate the amount of protected probe 
(Figure 2.4). The technique does not require the transfer of RNA to a solid support and 
multiple mRNA species can be probed in a single reaction. RP As were performed using a 
RPA J1TM kit (AMS Biotechnology Ltd., Oxfordshire, UK). 
2.10.6.1 RPA Probes 
RPA probes were synthesised by RT-PCR (section 2.10.4) from total RNA isolated from 
PBMCs or established breast carcinoma cell lines using a MAXIscript™ In Vitro 
transcription Kit (AMS Biotechnology Ltd., Oxfordshire, UK). A 23 base T7 phage 
promoter sequence was appended to either the sense or antisense PCR amplimers. 
Amplification of the target DNA then yields a PCR product that contains the T7 promoter 
either upstream or downstream of the sequence of interest (Table 2.10). 
• The probe for HIP-la mRNA was synthesised from 5 JJ.g of total RNA from the breast 
carcinoma cell line T47D exposed to hypoxia(< I % 0 2) for 24 hours. The length of the 
HIP-la probe was 543 bp, corresponding to positions 161-681 bp, and produced a 
protected fragment size of 520 bp. 
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Figure 2.4. Schematic Representation of the Ribonuclease Protection Assay 
Total RNA I Antisense Probe 
Combine and eo-precipitate 
1 
Denature and Hybridise (2-24 hrs) 
1 
Digest with RNase 
1 
Precipitate RNA and Inactivate RNase 
1 
Denaturing PAGE Analysis 
1 
Quantitation using Fluor-S™ lmager 
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• The probe for VEGF mRNA was synthesised from 5 IJ.g of total RNA from glioblastoma 
tissue. The length of the VEGF probe was 464 bp, corresponding to positions 779-1220 
bp, and produced a protected fragment size of 441 bp. 
• The probe for p53 mRNA was synthesised from 5 11g of total RNA from PBMCs of a 
normal healthy individual. The length of the p53 probe was 463 bp, corresponding to 
positions 244-684 bp, and produced a protected fragment size of 440 bp. 
• The probe for GLUT-1 mRNA was synthesised from 51J.g of total RNA from PBMCs of 
a normal healthy individual. The length of the GLUT-1 probe was 548 bp, corresponding 
to positions 2106-2631 bp, and produced a protected fragment size of 525 bp. 
A 13-actin antisense probe was synthesised from a pTRI-Actin-Mouse DNA template, 
linearised pTRIPLEscript DNA, supplied with the kit. The 13-actin gene fragment is a 250 
bp Kpni-Xbal fragment of the mouse 13-actin gene subcloned from pAL4 1 (Aionso et a/, 
1986) that produces an expected transcript size of 304 bases. Due to the high abundance of 
the 13-actin transcript, the probe was synthesized at a lower specific activity. 
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Table 2.10. T7 amplimer sequences and reaction conditions for RPA probe synthesis. 
T7 Amplimer Sequence Length Gene Protected fragment Cycles Cycle Conditions 
(mer) (base pain) 
5' TAATACGACTCACTATAGGGAGGCCCTGCTTGGTGCTGATTTGTGAACC 3'(rry 49 542bp 94 °C for I minute 
HIF-1a (520 bp protected) 30 55 °C for 2 minutes 
5' GGTTCACAAATCAGCACCAAGCAGG3' (antisense) 25 position 161-68I 72 oc for 3 minutes 
5' ATGCCTCCACAGAGGCTATGCC 3' (sense) J 22 
1" rmmd 
464bp 5' GCACTAAGGAACGTCTGTAGGC 3' (antisense) 22 95 °C for 1 minute VEGF ( 441 protected) 30 61 °C for 1.5 minutes 
a) 5' TAATACGACTCACTATAGGGAGGGCACTAAGGAACGTCTGTAGGC 3' (rry 45 position 779-1220 72 °C for 1.5 minutes 
b)S' TAATACGACTCACTATAGGGAGGCGGTATGGTGTCCTAAGGC 3'(rry 42 
5' GCTCCACTGAACAAGTTGGCC 3' (sense) J 2I 463 bp 95 oc for I minute 1" roiUld 
5' CCTCTACCTAACCAGCTGCC 3' (antisense) 20 p53 ( 440 bp protected) 30 60°C for 1.5 minutes position 244-684 72 oc for 1.5 minutes 
5' TAATACGACTCACTATAGGGAGGCCTCTACCTAACCAGCTGCC 3'(rry 43 
I" round (amplimers Table X) 
95 °C for 1 minute 
5' TAATACGACTCACTATAGGGAGGGCCGTTGCAGTGGTTGCAACCC 3'(rry 45 56 oc for l.5 minutes 
GLUT-1 548bp 30 72 °C for l. 5 minutes 
5' GCCGTTGCAGTGGITGCAACCC 3' (antisense) 
(525 bp protected) 
2nd round (T7 amplimers) 22 position 2I 06-263I 
95 oc for 1 minute 
61 °C for 1.5 minutes 
72 °C for 1.5 minutes 
Note: All PCR cycle conditions included a Hot Start of 94°C for 4 minutes and all reactions had a total reaction volume of 50 JJ] using 1.5 mM 
MgCh. First round PCR reactions amplimers and cycle conditions are listed in Table 2.7. T7 amplimers were used with first round sense or 
antisense amplimers and 1 J.d of the first round product. 
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2.10.6.2 Transcription 
Amplified PCR product was added directly to the transcription reaction without 
purification. Either 5 J.d of a 50 J.d PCR reaction volume, or a 5 J.d resuspended volume 
from 10 J.ll of a 50 J.ll ethanol precipitated PCR reaction volume (corresponding to 
approximately 1 J.lg of DNA), was combined with 2 1.d of 10 X Transcription buffer 
(containing DTT and spermidine), 1 Ill each of 10 mM ATP, CTP and GTP solutions, 1J.ll 
of a 1:100 diluted solution of 10 mM UTP, 2.5 Ill of a32P UfP (30 TBq/mmol, 800 
Cilmmol, 10 mCilml, Amersham Pharmacia Biotech, Little Chalfont, UK), 2J.ll ofT7 RNA 
polymerase (5 U/J.ll) and sufficient water to produce a final reaction volume of 20 J.ll in a 
sterile 1.5 ml micro-centrifuge tube. The solution was mixed by pipetting up and down, 
centrifuged at 13000 rpm for 30 seconds and incubated at 37 oc in a waterbath for 1 hour. 
Next, 1 J.ll of RNase free DNase I (2 U/J.ll) was added to the solution, mixed by flicking 
and incubated at 37 oc for a further 15 minutes after which 1 Ill of0.5 M EDTA was added 
to the tube to terminate the reaction. An equal volume (20 J.ll) of Gel Loading Buffer was 
added to the labelled probe, the tube was vortexed briefly, heated at 92 oc for 5 minutes in 
a waterbath (Grant, Cambridge, UK) then loaded onto a 5 % polyacrylamide 8 M urea gel, 
purified and eluted (section 2.10.5.5). 
The ~-actin probe was synthesised as in the above 20 J.ll transcription reaction with the 
exception of having utilising 1 J.ll of 1 mM UfP (50 J.lM) and 1.6 J.ll of a 32P UfP (lJ.lM). A 
Century™ RNA molecular weight marker (100-500 MW, AMS Biotechnology Ltd., 
Oxfordshire, UK) was labelled as described above in a 20 J.ll transcription reaction volume 
with the exception of having used 1 J.ll of 10 mM UfP. 
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2.10.6.3 Hybridisation 
For each sample, 10 J..Lg of total RNA was mixed with approximately 500 pg of 
radiolabelled probe (1-4 J..Ll) in a sterile 1.5 ml micro-centrifuge tube. A 1/10th volume of 
5M ammonium acetate and 2.5 volumes of 100 % ice-cold ethanol were added to each 
tube, briefly vortexed, centrifuged at 13000 rpm for 30 seconds and incubated at -20 °C 
for a minimum of 15 minutes. Precipitated RNA and probe were then centrifuged at 13000 
rpm for 15 minutes at 4 °C, the supematant drawn off using a pipette and the pellet 
resuspended in 20 J..Ll of hybridisation buffer (80% formamide, 100 mM sodium citrate, pH 
6.4, 300 mM sodium acetate, pH 6.4, 1 mM EDTA) by vortexing. The tubes were then 
centrifuged at 13000 rpm for 30 seconds, incubated at 92 °C in a waterbath for 5 minutes, 
vortexed briefly, and centrifuged at 13000 rpm for 30 seconds prior to incubating in a 
waterbath at 42 °C for 12-16 hours. 
2.10.6.3 RNase Digestion 
Following hybridisation, 200 J..Ll of RNase AI RNase Tl mix was added to each sample, 
mixed by vortexing and centrifuged at 13000 rpm for 30 seconds. The samples were then 
incubated at 37 °C for 30 minutes in a waterbath to digest any unprotected single stranded 
RNA. Next, 300J..Ll of RNase inactivation/precipitation solution was added to each sample, 
mixed by vortexing, centrifuged at 13000 rpm for 30 seconds and incubated at -20 °C for 
at least 15 minutes to precipitate out protected fragments. Samples were then centrifuged at 
13000 rpm for 15 minutes at 4 °C, the supematant decanted and resuspended in 8 J..Ll of Gel 
Loading Buffer II with vigorous vortexing for 1 minute. The samples were then heated at 
94 oc for 4 minutes in a waterbath (Grant, Cambridge, UK), vortexed briefly, centrifuged 
at 13000 rpm for 30 seconds, then separated on a 5 % polyacrylamide 8 M urea gel. 
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2.10.6.4 Denaturing Polyacrylamide Gel Electrophoresis 
Samples mixed with gel loading buffer were loaded onto a vertical 0.75 mm 5 % 
polyacrylamide 8 M urea gel run in I X Tris-Boric Acid {TBE) in a Mini-Protean ll 
electrophoresis cell (Bio-Rad Laboratories, Hemel Hempstead, UK), which consisted of a 
electrophoresis unit with clamps which holds a gel sandwich unit, glass plates, casting 
stand and buffer tank. Two glass sandwich plates, both 9 cm X I 0 cm with one containing 
0.75 mm spacers, were washed and dried with 70% industrial methylated spirit (IMS). The 
glass plates were clamped together and secured in a gel-casting tray. A 5 % acrylamide/8 
M urea gel was prepared by mixing 4.8 g of urea, I ml of 10 X TBE, 1.25 rn1 of 40 % 
acrylamide with 7.75 rn1 of sterile water in a 100 m1 conical flask. The solution was mixed 
with gentle heating on a Jenway 1000 stirrer and hotplate (Jencons-PLS, Buzzard 
Leighton, UK) for at least I hour prior to adding 80 J.d of I 0 % ammonium persulfate and 
IO JJ.I ofTEMED. The gel solution was then immediately poured into a gel sandwich unit 
using a 10 ml syringe, a IO well plastic comb was inserted into the top of the gel carefully 
avoiding any air bubbles and the gel was left to polymerise at room temperature for at least 
30 minutes. The set gel was then removed from the casting stand and clamped to the 
electrophoresis cell creating a buffer chamber which was filled with 1 X TBE. The comb 
was gently removed from the gel, the wells rinsed with I X TBE, the buffer tanked was 
filled to approximately 3 cm above the electrophoresis cell and gel assembly with I X 
TBE. Samples mixed with gel loading buffer and heated were then loaded onto the gel and 
electrophoresis was performed at I00-200 volts for 40 minutes to I hour until the dye front 
reached the bottom of the gel. The gel apparatus was then disassembled and the gel plates 
gently pried apart leaving the gel attached to one of the gel plates which was then laid onto 
a piece of 3MM filter paper (Amersham Pharmacia Biotech, Little Chalfont, UK). The gel 
and filter paper where covered in Saran Wrap1"' and placed in a Cronex autoradiography 
cassette containing lighting and intensifying screens. In a dark room, a piece of Kodak X-
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OMA'fTM LS X-ray film (Scientific lmaging Systems Ltd, Cambridge, UK) was placed on 
top of the gel and the cassette was firmly closed. The cassette was placed at -80 °C where 
the film was exposed for at least 24 hours. The film was then developed in Kodak X-ray 
developer (Anachem, Luton, UK) for 3 minutes, placed in an indicator stop-bath solution 
(3 % sulphuric acid) for 30 seconds, and fixed in a liquid fixer solution for at least 1 
minute (Anachem, Luton, UK). The film was then rinsed for 1 minute under tap water and 
air-dried 
2.10.6.5 Gel Purification of Probe 
Following electrophoresis, the gel apparatus was disassembled and the gel plates gently 
pried apart leaving the gel attached to one of the gel plates that was then wrapped in 
Saran Wrap™ and placed in a Cronex autoradiography cassette containing lighting and 
intensifying screens. In a dark room, a piece of Kodak: X-OMAT™ LS X-ray film 
(Scientific Imaging Systems Ltd, Cambridge, UK) was placed on top of the gel, secured 
with masking tape and an outline of the gel was traced onto the film with a felt permanent 
marker pen. The cassette was firmly closed and the film exposed for 10-30 seconds. The 
film was then developed in Kodak X-ray developer (Anachem, Luton, UK) for 3 minutes, 
placed in an indicator stop-bath solution (3 % sulphuric acid) for 30 seconds, and fixed in a 
liquid fixer solution for at least 1 minute (Anachem, Luton, UK). The film was then rinsed 
for 1 minute under tap water and air-dried. The film was used to precisely locate the area 
of the gel containing the full-length transcript, the slowest migrating and most intense 
band, by aligning it with the gel and tracing the area on the gel. The transcript was then 
excised with a scalpel, placed into a sterile 1.5 m! micro-centrifuge tube containing 350 J.d 
of elution buffer (0.5 M ammonium acetate, 1 mM EDTA, 0.1 % SDS) and incubated in a 
waterbath at 37 °C for 12-16 hours allowing approximately 95% recovery of the labelled 
probe from the gel. The eluted probe was then labelled and stored at -70 °C. 
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2.10.6.6 Quantitation of mRNA Gene Expression 
Signal band intensities were quantitated by densiometric scanning of the autoradiographs 
using a Fluor-S™ imager and Multi-Analyst® image analysis software (Bio-Rad 
Laboratories, Hemel Hempstead, UK). Background intensity was subtracted from band 
intensity values. Results are expressed as fold increase from control levels or as the ratio of 
intensity of the expression of the gene of interest compared to the housekeeping gene P-
actio. Statistical significance was as~~ssed on the data groups using analysis of variance 
(ANOVA) followed by F-test and the Student's t-test for comparison of means with values 
ofp<0.5 considered as significant. 
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2.11 Protein Methodologies 
2.11.1 Lactate Assay 
Lactate acid is a by-product of carbohydrate metabolism, where it is oxidised to pyruvate 
to produce energy. Measurement of lactate acid in cell culture supematants can be used to 
indicate changes in cell glycolysis. Lactate acid production in cultures cells was measured 
using a Sigma Diagnostics Lactate kit (Sigma Chemicals, Poole, UK). The assay is based 
on an enzymatic reaction where the addition of excess nicotinamide adenine dinucleotide 
(NAD) and lactate dehydrogenase (LD) to the sample of interest produces a catalytic 
reaction where lactate is then measured spectrophotometrically at 340 nm in terms of the 
increased generation of reduced nicotinamide adenine dinucleotide (NADH). Formed 
pyruvate and hydrazine become trapped which them force the reaction to completion. An 
increased absorbance reading at 340 nm due to the increased formation of NADH becomes 
the measurement of any lactate originally present. 
2.11.1.1 Deproteinisation 
Cell culture supematants were first deproteinised by mixing 0.2 ml of supematant sample 
with 0.4 ml of 10% Trichloroacetic acid (TCA) in a sterile 1.5 m1 micro-centrifuge tube by 
vortexing for 30 seconds. The samples were incubated on ice for 5 minutes, centrifuged at 
1500 X gat 4 °C for 10 minutes. The supematant was then transferred to a sterile 1.5 ml 
micro-centrifuge tube ready for use. 
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2.11.1.2 Measurement of Lactic Acid 
The appropriate number of vials containing purified NAD (I ml of NADILD solution 
required per sample tested) were each resuspended in 2 ml of glycine buffer, 4 ml of sterile 
water and 0.1 ml of LD by inverting several times. Following this, I ml of the NADILD 
solution was added to 50 J.ll of each sample in sterile 1.5 ml micro-centrifuge tubes, mixed 
by vortexing and incubated at 37 °C in a waterbath (Grant, Cambridge, UK) for 15 
minutes. A blank for the spectrophotometer was prepared by mixing with 1 ml ofNADILD 
solution and incubating at 37 °C in a waterbath for 15 minutes. Absorbance readings at 340 
nm were then measured for each sample against a blank of 50 J.ll of I 0 % TCA mixed with 
1 ml of the NAD/LD solution incubated at 37 °C for 15 minutes. 
2.11.1.3 Quantitation of Lactate 
A lactate calibration curve was prepared to access the linearity of the spectrophotometer 
and cuvettes used in the assay. The Lactate Standard Solution (40 mgldL) was diluted 1:10 
by adding 1 ml ofLactate Standard to a 15 ml sterile tube containing 9 ml of sterile water. 
An appropriate number of NAD vials were reconstituted as described above with the 
exception of the addition of 0.23 ml of water to each vial, as opposed to 4 ml. Lactate 
standards ranging from 0-13.32 mmol/L were prepared by serial dilution from the diluted 
Lactate Standard (0.04 mglml) in 10 ml borosciliate glass test tubes (Fischer Scientific, 
Loughborough, UK), (Table 2.11). The tubes were mixed well and incubated at 37 °C in a 
waterbath (Grant, Cambridge, UK) for 15 minutes. Next, I ml of each sample was 
transferred to a disposable cuvette and the absorbance read at 340 nm using standard 1 as a 
reference blank. The absorbance values versus corresponding lactate concentrations were 
then plotted. Quantities of lactate in each sample, in millimoles per litre (mmol/L), were 
determined using the following equation: 
(A340 X RV) I (6.22 X sv X l) 
- 193-
Chapter 2. Materials and Methods 
Table 2.11. Preparation oflactate standards for a lactate calibration curve from a 0.04 
mglml stock standard (Sigma Chemicals Ltd., Poole, UK) by serial dilution. 
Standard Volume of Volume of lactate diluted Volume of Final lactate 
water standard (0.04 mglml) prepared NAD concentration 
(ml) (ml) solution (ml) (mmol/L) 
1 2.0 0 1.0 0 
2 1.9 0.1 1.0 1.33 
3 1.7 0.3 1.0 4.00 
4 1.5 0.5 1.0 6.66 
5 1.2 0.8 1.0 10.66 
6 1.0 1.0 1.0 13.32 
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where A340 is the fmal absorbance at 340 nm, RV is the reaction volume in millilitres, 6.22 
is the millimolar absorptivity ofNADH at 340 nm, SV is the sample volume in the cuvette 
and 1 is the lightpath in centimetres. To determine lactate quantities in milligrams per 
decilitre (mg/dL), the above equation was multiplied by 90, the molar weight oflactic acid, 
and divided by 10, the conversion of results in terms of 1 litre to 100 ml. 
2.11.2 Quantitation of Protein 
Protein concentrations were determined using the Coomassie® Plus Protein Assay reagent 
Kit (Perbio Science Ltd., Chester, UK), a dye-binding colourimetric method based on the 
Bradford method of total protein quantitation (Bradford, 1976). When the Coomassie® 
binds protein in an acidic medium, an immediate absorbance shift occurs from 465 nm to 
595 nm with a simultaneous colour change of the reagent from red/brown to blue. The 
absorbance reading of each sample at 595 nm can then be compared against a BSA protein 
standard curve to determine the total protein concentration. 
Protein standards ranging from 0.025-2.0 mg/rnl were prepared by serial dilution from a 2 
mg/ml bovine serum albumin (BSA) stock standard with sterile water in 10 ml borosciliate 
glass test tubes (Fischer Scientific, Loughborough, UK), (Table 2.12). A 50 J.ll aliquot of 
each standard and 5-50 J.ll of each unknown sample were pipetted into appropriately 
labelled 10 ml borosciliate glass test tubes. Sample volumes of less than 50 J!l were 
completed with sufficient sterile water. A blanking tube was prepared using 50 J.ll of sterile 
water. Next, 1.5 ml of Coomassie®plus dye reagent was added to each tube and mixed by 
vortexing. A 1 m1 aliquot of the mixed sample and dye solution was added to a disposable 
polystyrene cuvette (Sigrna Chemicals Ltd., Poole, UK), which was then placed into a 
fixed wavelength WPA UVllOl Biotech Photometer (Jencons-PLS, Buzzard Leighton, 
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Table 2.12. Preparation of diluted BSA standards for protein curve from a 2 mg/ml stock 
standard (Perbio Science Ltd., Chester, UK) by serial dilution. 
Volume of BSA Volume of water Final BSA concentration Sample ID 
(l.d) (~I) (mglml) 
300 ~1 of stock 0 ~1 2.0 mg/ml -
375 ~I of stock 125 ~I 1.5 mg/ml A 
325 ~I of stock 325 ~1 1.0 mg/ml B 
175 ~I of sample A 175 ~] 0.75 mg/ml c 
325 ~I of sample B 325 ~I 0.50 mg/ml D 
325 ~I of sample D 325 ~] 0.25 mg/ml E 
325 ~I of sample E 325 ~] 0.125 mg/ml F 
100 ~I of sample F 400 ~I 0.025 mg/ml G 
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UK) previously blanked with water, and the absorbance at 595 run was measured for each 
tube. A standard curve was then prepared by plotting the absorbance reading at 595 run for 
each BSA standard versus its concentration. Using the standard curve, the protein 
concentration was then determined for each unknown sample considering any dilution 
factor. 
2.11.3 Electrophoretic Mobility Shift Assay (EMSA) 
The Electrophoretic Mobility Shift Assay (EMSA) is used to detect the interaction of DNA 
binding proteins with their cognate DNA recognition sequences, in both a qualitative and 
quantitative manner. Purified proteins or crude cell extracts are incubated with a 32P 
radiolabelled DNA probe containing a puntative protein-binding site. The reaction 
complexes are then separated from the free probe through a nondenaturing polyacrylamide 
gel. The DNA-protein complexes migrate more slowly than the unbound probe. The 
specificity of the DNA binding protein for the puntative binding site can be determined 
with competition experiments using oligonucleotides containing a binding site for the 
protein of interest (specific competitor) or another unrelated sequence (non-specific 
competitor). Specific interactions can then be identified by the differences in the nature and 
intensity of the complex formed in the presence of either competitor. 
2.11.3.1 Preparation of Nuclear Extract 
Two separate methods were used in the preparation of crude nuclear extract from 
peripheral blood mononuclear cells (PBMCs) (section 2.5.3), and established breast 
carcinoma cell lines (section 2.5.1). 
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2.11.3.1.1 Dignam, Lebovitz and Roeder, 1983 
Nuclear extracts were prepared with Dignam Buffers A and C containing 0.5 mM AEBSF, 
0.184 mglml sodium orthovanadate, 0.42 mglml sodium fluoride and 2.2 J.lg/ml aprotonin. 
After exposure to 1% 02 or 21% 0 2 for predetermined time intervals, adherent cells were 
washed twice by adding 5 ml of PBS directly to the 75 cm2 flask and aspirating off. A 0.5 
ml aliquot ofDignam Buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCh, 10 mM KCl, 0.5 
mM DIT, 0.2 % NP-40) was added to the flask and the cell lysate was collected to a 
corner of the flask using a sterile cell scrapper. Cells grown under normoxic conditions 
(21% 02, 5% C02, 74% N2) were also processed in the same manner as a control. PBMC 
suspensions were collected into 50 ml sterile tubes, centrifuged at 1400 rpm for 4 minutes 
and the supernatant decanted. A 0.5 ml aliquot ofDignam Buffer A was added to the 50 ml 
tube and resuspended by pipetting up and down. Cells were collected with a 1 ml pipette, 
placed into a sterile 1.5 ml micro-centrifuge tube, incubated on ice for 20 minutes and then 
centrifuged at room temperature at 13000 rpm for 15 minutes. The supernatant was 
transferred to a sterile 1.5 ml micro-centrifuge tube, labelled and stored at -70 °C as the 
cytoplasmic protein. The remaining pellet was then resuspended in 50 J.ll ofDignam Buffer 
C (20mM HEPES, pH 7.9, 25% glycerol, 0.42 M NaCI, 1.5 mM MgCh, 0.5 mM DIT, 0.2 
mM EDT A) with pipetting and incubated on ice for 10 minutes with occasional mixing. 
The solution was then centrifuged at room temperature at 13000 rpm for 1 minute. The 
supernatant was then transferred to a sterile 1.5 ml micro-centrifuge tube, labelled and 
stored at -70 °C as the crude nuclear extract. 
2.11.3.1.2 Semenza and Wang, 1992 
Nuclear extracts were prepared with Buffers A and C containing 0.5 mM dithiothreitol 
{DIT), 0.4 mM phenylmethylsulfonyl fluoride (PMSF), 2 J.lg/ml of leupeptin, 2J.lg/ml of 
aprotinin, 2 J.lg/ml of pepstatin and 1 mM sodium vanadate. After exposure to 1% 0 2 or 
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21% 0 2 for predetermined time intervals, adherent cells were washed twice by adding 5 ml 
of PBS directly to the 75 cm2 flask and aspirating off. Cells grown under normoxic 
conditions (21% 02, 5% C02, 74% N2) were also processed in the same manner as a 
control. An additional 5 ml of PBS was then added to the flask and cells were scraped off 
using a sterile cell scrapper. Cells were collected with a l ml pipette, placed into a sterile 
15 ml tube and centrifuged in a Mistral 1000 centrifuge (MSE Scientific Instruments, 
Leicester, UK) at 1500 rpm at room temperature for 5 minutes. The supernatant was 
decanted and the pellet was washed once with 4 packed cell volumes (PCV) of Buffer A 
(10 mM Tris-HCI, pH 7.8, 1.5 mM MgCI2, 10 mM KCI), centrifuged at 1500 rpm for 2 
minutes, the supernatant decanted and the pellet resuspended in 4 PCVs of Buffer A by 
vortexing and then incubated on ice for 10 minutes. Cells grown under normoxic 
conditions (21% 02, 5% C02, 74% N2) were also processed in the same manner as a 
control. PBMC suspensions were collected into 50 ml sterile tubes, centrifuged at 1400 
rpm for 4 minutes and the supernatant decanted. The pellet was washed once with 4 PCV 
of Buffer A, centrifuged at 1500 rpm for 2 minutes, the supernatant decanted and the pellet 
resuspended in 4 PCVs of Buffer A by vortexing and then incubated on ice for 10 minutes. 
The cell suspension was then homogenised with a type B pestle of Dounce homogeniser 
(Wheaton Science Products, Millville, N.J., USA) using 10 strokes. The homogenate was 
then transferred to a 1.5 ml sterile micro-centrifuge tube and centrifuged at 3500 rpm at 4 
°C for 5 minutes. The supernatant was then decanted and the pellet was resuspended in 2 
PCVs of Buffer C (20 mM Tris-HCl, 1.5 mM MgCh, 420 mM KCl, 20 % glycerol), and 
mixed on a Luckham RlOOffW Rotatest shaker on ice for 30 minutes. The nuclear debris 
was then pelleted by centrifugation at 13500 rpm at 4 oc for 30 minutes. The supematant 
was transferred to dialysis tubing (Sigma Chemicals Ltd, Poole, UK) and dialysed against 
500 ml of Buffer D (20 mM Tris-HCl, pH 7.8, 100 mM KCL, 0.2 mM EDTA, 20 % 
glycerol) at 4 °C for 4 hours, changing the dialysis buffer once at mid dialysis. The 
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dialysate was then collected and transferred to a sterile 1.5 ml micro-centrifuge tube and 
centrifuged at 13500 rpm at 4 °C for 10 minutes. The supematant was then transferred to 
another sterile 1.5 ml micro-centrifuge tube and snap-frozen in liquid nitrogen. The nuclear 
extracts were then stored at -70 ° C. 
2.11.3.1.2.1 Preparation of Dialysis Tubing 
Glycerin was removed from the dialysis tubing by washing it in running water for 3-4 
hours. Sulphur compounds were removed by treating the tubing with 0.3% (w/v) sodium 
sulfide at 80 oc for I minute. The tubing was then washed with hot water (60 °C} for 2 
minutes then transferred to a solution of 0.2% (v/v) sulphuric acid. The tubing was then 
rinsed with hot water to remove the acid and stored in a 500 ml Duran bottle in distilled 
water. 
2.11.3.2 Oligonucleotide Probe Labelling 
The EMSA was performed using a 5' end labelled HIF-1a. coding sense strand 
oligonucleotide sequence, 5' AGCITGCCCTACGTGCTGTCTCAG 3' (HIF-1 binding 
site underlined), which corresponded to nucleotides 1-18 of the erythropoiesis (EPO) 
enhancer {highlighted). A 2 J..l.l aliquot ofHIF-1a. sense oligonucleotide (1.75 pmoVJ.1l) was 
added to a 0.2 ml sterile micro-centrifuge tube containing I J.1l ofT4 polynucleotide kinase 
10X buffer (Promega, Southampton,UK), 1 JJI ofy2P ATP (3000 Ci/mmol at 10 mCi/ml), 
5J.1l of sterile water and 1 J.1l of T4 polynucleotide kinase. The labelling reaction was 
incubated at 37 °C for 10 minutes in a waterbath (Grant, Cambridge, UK), the reaction 
stopped with the addition of 1 J.1l of0.5 M EDTA and then diluted with 89 J.1l ofTE buffer, 
pH 8. The radiolabelled oligonucleotide HIF-1 probe was then annealed to a 6 fold molar 
excess of cold unlabelled HIF-1 antisense strand oligonucleotide 5' 
ACGGGATGCACGACAGAGTCITAA 3' and used as a DNA consensus probe in 
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subsequent binding reactions. Probe annealing was performed by mixing a 50 J.l.l aliquot of 
the HIF-1 radiolabelled sense oligonucleotide in a 0.2 ml sterile thin-walled micro-
centrifuge tube with 10 J.l.l of unlabelled HIF-1 antisense oligonucleotide (1.75 pmoVJ.d) 
and incubating the sample at 70 °C for 5 minutes in a Cyclogene thermocycler (Techne 
Ltd., Cambridge, UK). The solution was then left at room temperature to cool overnight. 
The consensus probe was then stored at -80 °C. 
2.11.3.3 Binding Reaction 
A 15 J.l.g sample of nuclear protein extract was added to a 0.2 ml sterile micro-centrifuge 
tube containing 2 J.l.l of binding buffer. Sufficient sterile water was added to make a final 
reaction volume of 10-20 J.l.l and the solution was then pre-incubated at room temperature 
for 10 minutes. Next, 1 Ill of labelled consensus probe was added to the reaction tube and 
the incubation continued for an additional 20 minutes. The samples were then mixed with 
5J.1.l of lOX gel loading buffer (250 mM Tris-HCl, pH 7.5, 0.2 % bromophenol blue, 40 % 
glycerol). 
2.11.3.4 Non-Denaturing Gel Electrophoresis 
Samples mixed with gel loading buffer were loaded onto a vertical 0. 75 mm 4 % non-
denaturing polyacrylamide gel run in 0.5 X Tris-Boric Acid (TBE) in a Protean ll 
electrophoresis cell (Bio-Rad laboratories, Hemel Hempstead, UK), which consisted of a 
electrophoresis unit with clamps which holds a gel sandwich unit, glass plates, casting 
stand and buffer tank. Two glass sandwich plates, 20 cm X 20 cm and 16 X 20 cm, were 
washed and dried with 70% industrial methylated spirit (IMS). The plates were separated 
by 0. 75 mm spacers, clamped together and secured in a gel-casting tray. A 4 % non-
denaturing polyacrylamide gel was prepared by mixing I ml of 10 X TBE, 0.5 ml of2% 
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bisacrylamide, 2 ml of 40 % acrylamide, 0.625 ml of 80% glycerol with 15.9 ml of sterile 
water in a 100 ml conical flask. Next, 150 1-11 of ammonium persulfate and 10 !Jl of 
TEMED were added to the flask to polymerase the gel, the solution was mixed and then 
poured into the gel plate assembly along an edge of one of the spacers using a sterile 10 ml 
plastic pipette. A plastic 0.15 mm 14 well comb was inserted into the top of the gel, 
avoiding the formation of air bubbles, and the gel was left to polymerise for 1 hour at room 
temperature. The set gel was then removed from the casting tray and clamped to the 
electrophoresis cell creating a buffer chamber which was filled with 0.5 X TBE. The comb 
was gently removed from the gel, the wells rinsed with 0.5 X TBE, the buffer tanked was 
filled to approximately 3 cm above the electrophoresis cell and gel assembly with 0.5 X 
TBE and the unit was pre-run at 100 volts for 30 minutes. Samples mixed with gel loading 
buffer were then loaded onto the gel and electrophoresis was performed at 150 volts for 3-
4 hours until the dye front reached the bottom of the gel. The gel apparatus was then 
disassembled and the gel plates gently pried apart leaving the gel attached to one of the gel 
plates which was then laid onto a piece of 3MM filer paper (Amersham Pharmacia 
Biotech, Little Chalfont, UK). The gel and filter paper where covered in Saran Wrap™ and 
placed in a Cronex autoradiography cassette containing lighting and intensifying screens. 
In a dark room, a piece of Kodak XLS5 X-ray film (Scientific Imaging Systems Ltd., 
Cambridge, UK) was placed on top of the gel and the cassette was firmly closed. The 
cassette was placed at -80 °C where the film was exposed for at least 24 hours. The film 
was then developed in Kodak X-ray developer (Anachem, Luton, UK) for 3 minutes, 
placed in an indicator stop-bath solution (3 % sulphuric acid) for 30 seconds, and fixed in a 
liquid fixer solution for at least 1 minute (Anachem, Luton, UK). The film was then rinsed 
for I minute under tap water and air-dried. 
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2.11.3.5 Competition and Supershift Assays 
Competition assays were performed by pre-incubating a 10 fold excess of unlabelled HIF-1 
antisense oligonucleotide with nuclear extract and binding buffer for 30 minutes at room 
temperature prior to the addition of the HIF-1 labelled consensus probe. Supershift assays 
were performed by pre-incubating 1-3 J.d of HIF-la. monoclonal IgG 2b antibody (clone 
Hla.67, 2 separate lots from Balb/c mouse ascites, one lot from cell max culture 
supernatant, Abeam, Cambridge, UK) with the nuclear extract and binding buffer mixture 
at either room temperature or on ice for 30 minutes prior to the addition of the HIF-1 
labelled consensus probe. 
2.11.4 Western Blotting 
2.11.4.1 Preparation of Protein 
Protein samples were prepared as either whole cell lysates or as isolated cytoplasmic 
protein from peripheral blood mononuclear cells (PBMCs) (section 2.5.3), and established 
breast carcinoma cell lines (section 2.5.1). 
2.11.4.1.1 Cytoplasmic Protein 
Cytoplasmic protein was isolated from adherent cells and PBMCs exposed to 1% 02 or 
21% 02 for predetermined time intervals as described above in the preparation of nuclear 
extracts (section ... method of Dignam, Lebovitz and Roeder, 1983). Cells grown under 
normoxic conditions (21% 02, 5% C02, 74% N2) were also processed in the same manner. 
Sample protein concentrations were determined (section 2.11.2) and then stored in labelled 
sterile 1. 5 ml micro-centrifuge tubes at -70 °C. 
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2.11.4.1.2 Whole Cell Lysate 
After exposure to 1% 02 or 21% 0 2 for predetennined time intervals, adherent cells were 
washed twice by adding 5 rnl of PBS directly to the 75 cm2 flask and aspirating off. An 
additional 1.5 m1 of PBS was then added to the flask and cells were scraped off using a 
sterile cell scrapper. Cells were collected with a 1 ml pipette, placed into a sterile 1.5 ml 
micr<H:entrifuge tube and centrifuged at 7500 rpm at room temperature for 1 minute. The 
supematant was decanted and the pellet was resuspended in 500 J.d of Laemmli sample 
buffer. Cells grown under nonnoxic conditions (21% 0 2, 5% C02, 74% N2) were also 
processed in the same manner. PBMC suspensions were collected into 50 rnl sterile tubes, 
centrifuged at 1400 rpm for 4 minutes, the supernatant decanted and the pellet was 
resuspended in 500 J.ll of Laemrnli sample buffer. The solution was then transferred to a 
sterile 1.5 ml micro-centrifuge tube. The resuspended cell suspensions were then sonicated 
for at least 1 minute until the lysate was homogenous. Sample protein concentrations were 
determined (section 2.11.2), the samples were labelled and stored at -70 °C. 
2.11.4.2 SDS-Polyacrylamide Gel Electrophoresis 
One-dimensional gel electrophoresis under denaturing conditions separates proteins based 
on molecular size as they move through a polyacrylamide gel matrix towards an anode. 
Sample proteins are solubilised by boiling in the presence of SDS and P-mercaptoethanol, 
which reduces disulfide bonds. 
A Protean ll electrophoresis cell (Bio-Rad laboratories, Hemel Hempstead, UK) and glass 
plate sandwich was assembled as for non-denaturing gel electrophoresis (section 2.11.3.4). 
SDS-denatured protein samples were electrophorised on a 6 % or 12 % 80S-
polyacrylamide resolving gel topped with a 4 % stacking gel (see Table 2.13 for SDS-
polyacrylamide gel recipes). The desired percentage of acrylamide in the resolving gel is 
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Table 2.13. Recipes for the prepamtion of SDS-polyacrylarnide gels used in Western 
blotting. 
Stacking Gel Resolving Gel 
Reagents 
4% 6% 12% 
0.5 M Tris-HCI. pH 6.8 6.3 ml - -
1.5 M Tris-HCl, pH 8.8 
-
10 ml lOml 
30% Arcylamide/ 3.3 ml 8ml 16ml 
0.8 % Bisacrylamide 
10%SDS 0.25 ml 0.4 ml 0.4 m] 
Water 15.9 ml 21.2 ml 13.2 ml 
10% (w/v) Ammonium 0.125 ml 0.4 ml 0.4m1 
Persulfate 
TEMED 0.025 ml 0.032 m] 0.016 ml 
Total Volume 25 ml 40ml 40ml 
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2.11.4.3 Transfer 
Immediately following electrophoresis, the gel apparatus was disassembled and the gel 
plates gently pried apart leaving the gel attached to one of the gel plates. The stacking gel 
was removed from the resolving gel and any unused areas of the gel were cut away using a 
scalpel blade. One corner of the gel was removed to serve as an orientation point and the 
gel was then quickly rinsed in transfer buffer to achieve equilibration. The electroblotting 
cassette was assembled by first placing a fibre pad pre-soaked in transfer buffer (20 mM 
Tris, pH 8.0, 150 mM glycine, 20% methanol) on the panel of the gel holder, then 3 pieces 
of3M filter paper cut to the dimensions of the gel and saturated in transfer buffer, followed 
by the gel which was carefully placed on top. A sheet of Hybond ECL nitrocellulose 
membrane (Amersham Pharmacia Biotech, Little Chalfont, UK), cut to the dimensions of 
the gel and soaked in transfer buffer for 1 hour prior to transfer, was carefully placed on 
top of the gel avoiding trapping any air bubbles beneath it. A further 3 pieces of sized and 
saturated 3M filter paper were placed on top of the membrane followed by a final pre-
soaked fibre pad. The cassette was closed by securing the latch of gel holder and then 
placed between the electrodes in the Trans-Blot Cell (Bio-Rad Laboratories, Hemel 
Hempstead, UK) with the membrane facing the anode side. A cooling coil was inserted 
into the Trans-Blot Cell, the tank filled with transfer buffer, covered and the protein 
allowed to transfer at room temperature for 12-16 hours at 3 volts. 
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2.11.4.5 Immunodeteetion 
Following transfer, the Trans-Biot cell was disassembled and the membrane removed from 
the blotting cassette. The orientation of the gel was marked on the membrane, which was 
then quickly rinsed in transfer buffer prior to being placed in a solution of 5% (w/v) non-
fat dry milk in TBS-Tween (NFDM), to block non-specific sites on the membrane, and 
incubated at room temperature for 1.5 hours with gentle shaking on a Luckham RIOO/TW 
Rotatest shaker (Jencons-PLS, Buzzard Leighton, UK). After blocking, the membrane was 
incubated in primary antibody (see Table 2.14 for antibodies and working dilutions) 
diluted in NFDM for 1.5 hours at room temperature with gentle shaking or at 4 °C for 12-
16 hours. The membrane was then washed 3 times (1 X 15 minutes, 2 X 10 minutes) in 
TBS-Tween (20 mM Tris-HCl, pH 7.6, 100mM NaCI, 0.1 % Tween-20) at room 
temperature for 35 minutes with gentle shaking. Following this, the membrane was then 
incubated in secondary antibody diluted in NFDM at room temperature for 1 hour with 
gentle shaking and subsequently washed 3 times (1 X 15 minutes, 2 X 10 minutes) in TBS-
Tween (20 mM Tris-Hcl, pH 7.6, lOOmM NaCI, 0.1% Tween-20) at room temperature for 
35 minutes with gentle shaking. The membrane was drained, placed on SaranWrap™, 
covered with SuperSignal® Chemiluminescent Substrate (SuperSignal® Chemiluminescent 
Substrate for Western Blotting, Perbio Science Ltd., Chester, UK) and incubated at room 
temperature for at least 15 minutes. The membrane was then drained and placed on a new 
piece of SaranWrap™ where it was enclosed in the wrap and air bubbles removed. The 
wrapped membrane was then placed in a Cronex autoradiography cassette containing 
lighting and intensifYing screens. In a dark room, a piece of Kodak XLS5 X-ray film 
(Scientific Imaging Systems Ltd., Cambridge, UK) was placed on top of the wrapped 
membrane and the cassette was firmly closed. The film was exposed repeatedly for an 
appropriate length of time, ranging form 1 to 30 minutes. The film was then developed in 
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Table 2.14. Antibodies, working dilutions and SDS-polyacrylamide gel percentages used in Western blotting assays. 
Primary Antibody Host Supplier Working Secondary Supplier Dilution Antibody 
Cell Max Anti-mouse 
Anti-HIF-la System, Abeam, 1:500 IgG, Sigma 
Monoclonal IgG 2b culture (Cambridge, UK) peroxidase Chemicals Ltd. 
supernatant Clone Hla67 conjugate (Poole, UK) 
Anti-mouse 
Anti-HIF-la Balb/c Abeam 1:500 IgG, Sigma 
Monoclonal IgG 2b mouse (Cambridge, UK) peroxidase Chemicals Ltd. 
Clone Hla67 conjugate (Poole, UK) 
Anti-rabbit 
GLUT-I Rabbit Biogenesis 1:100 IgG, Sigma 
polyclonal (Poole, UK) peroxidase Chemicals Ltd. 
conjugate (Poole, UK) 
Note: All antibodies were prepared by dilution in TBS-Tween containing 5 % non-fat dry milk. 
HIF-la =Hypoxia Inducible Factor-la 
GLUT -1 = Glucose Transporter 1 
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Working Resolving 
Dilution Gel 
1:2000 6% 
1:2000 6% 
1:2000 12% 
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Kodak X-ray developer (Anachem, Luton, UK) for 3 minutes, placed in an indicator stop-
bath solution (3 % sulphuric acid) for 30 seconds, and fixed in a liquid fixer solution for at 
least I minute (Anachem. Luton, UK). The film was then rinsed for I minute under tap 
water and air-dried. Membranes were stored wet at 4 °C wrapped in SaranWmpr"'. 
2.11.4.6 Membrane Stripping 
Membmnes can be stripped of bound antibodies and reprobed seveml times. Membranes 
were placed in stripping buffer (100 mM P-mercaptoethanol, 2% SDS, 62.5 mM Tris, pH 
6. 7) and incubated at 56 °C for 30 minutes. The membrane was then washed at room 
tempemture for 15 minutes in seveml changes ofTBS-Tween. 
2.11.4.7 Gel Staining 
SDS-polyacrylamide gels were stained for 1 hour in Coomassie Blue staining solution (10 
% acetic acid, 20 % methanol, 0.05 % (v/v) Coomassie brilliant blue R-250) with gentle 
shaking on a Luckham RlOO/TW Rotatest shaker (Jencons-PLS, Buzzard Leighton, UK) 
and destained in seveml changes of water to verify efficiency of protein tmnsfer. 
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2.11.5 Immunocytochemistry 
Immunocytochemistry was performed with the aid of the Histopathology Department at 
Derriford Hospital, Plymouth. 
2.11.5.1 Hypoxia Inducible Factor-la. (HIF-la.) 
Immunocytochemical detection of HIF-la was performed on Glioblastoma and Breast 
tumour tissue using a DAKO® catalysed signal amplification (CSA) system (DAKO, 
Cambridgeshire, UK), which results in a greater amplification of signal allowing for the 
detection of small quantities of target antigen. First, 5J.1.m sections of paraffin-embedded 
tissue were collected onto 3-aminopropyltriethoxysilane coated glass slides, placed in 
holding trays, dewaxed in 3 X 3 minute washes in xylene and subsequently rehydrated 
with 3 X 3 minute washes in graded alcohol, in Hellendahl jars. The slides were then 
rinsed in de-ionised water for 3 minutes. Antigen retrieval was performed by pre-treating 
the slides in a microwave oven for 25 minutes on full power in 10 mM citrate buffer, pH 
6.0, followed by rinsing in de-ionised water. The slides were then blocked in a 3 % 
solution of hydrogen peroxide at room temperature for 5 minutes to quench endogenous 
peroxidase activity. The solution was then tapped off the slides and the tissue sections were 
covered with a few drops of Avidin D blocking solution and incubated at room temperature 
for 15 minutes. The slides were then rinsed in TBST (0.05 M Tris-HCI, pH 7.6, 0.3 M 
NaCI, 0.1 % Tween 20) and incubated at room temperature in biotin blocking solution for 
15 minutes. The solution was tapped off the slides and HIF-la monoclonal antibody (clone 
OZ12, Neomarkers, Fremont, USA), diluted 1:1000 in TBST, was applied and incubated 
12-16 hours at room temperature. The sections were then washed 3 X 5 minutes in TBST 
and a link antibody (biotinylated rabbit anti-mouse immunoglobulins) was applied and the 
slides incubated at room temperature for 15 minutes. The slides were washed 3 X 5 
minutes in TBST and incubated at room temperature in Streptavidin-Biotin complex for 15 
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minutes. The slides were washed 3 X 5 minutes TBST and then incubated at room 
temperature for 15 minutes in Amplification reagent (Biotinyl tyramide and hydrogen 
peroxide in PBS containing carrier protein). The slides were washed 3 X 5 minutes in 
TBST and then incubated in Streptavidin-peroxidase at room temperature for 15 minutes. 
The slides were again washed 3 X 5 minutes in TBST and then incubated in 3,3 '-
diaminobenzidine (DAB) substrate-chromogen solution for 5 minutes. The slides were 
rinsed for 2 minutes in tap water, incubated in DAB enhancer solution (0.02 M copper 
sulphate, 0.12 M NaCl) for 2 minutes and subsequently rinsed again in tap water for 2 
minutes. The slides were then conterstained in 10% haematoxylin for 20 seconds, rinsed 
thoroughly in tap water, dipped in acid alcohol (10 % HCl, 70 %Industrial Methylated 
Spirits (IMS)) for 3 seconds and washed in Scott's Tap Water substitute (0.16 M 
magnesium sulphate, 0.017 sodium hydrogen carbohydrate). Slides were then dehydrated 
by washing 3 X 1 minute in alcohol followed by 3 X 1 minute in xylene. The slides were 
mounted with cover slips in a Tissue-Tek coverslipping machine. A negative control 
consisted of a slide containing sample tissue incubated in TBST followed through the same 
procedure. A positive control consisted of an additional slide of sample tissue known to 
stain positive in optimisation assays. 
2.11.5.2 Vascular Endothelial Growth Factor (VEGF) 
Immunocytochemistry was performed as for HIF-1a without the use of the catalysed 
signal amplification (CSA) system, using an antibody to Vascular Endothelial growth 
Factor (AB-5, CN Biosciences, Nottingham, UK). Initial slide dewaxing, rehydrating 
blocking were performed as above. Antigen retrieval was performed by pre-treating the 
slides in a microwave oven for 30 minutes on full power in 1 mM EDTA, pH 8.0, followed 
by rinsing in de-ionised water. Slides were incubated with primary antibody diluted 1:350 
in TBST at room temperature for 12-16 hours. Washes consisted of 2 X 5 minutes in 
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TBST. Both secondary and tertiary antibodies were applied at a dilution of 1:50 and 
incubated at room tempemture for 30 minutes. Slides were incubated in DAB substrate-
chromogen solution, enhanced, counterstained, dehydrated and mounted as described 
above. A negative control consisted of a slide containing sample tissue incubated in TBST 
followed through the same procedure. A positive control consisted of an additional slide of 
sample tissue known to stain positive in optimisation assays. 
2.11.5.3 p53 
Immunocytochemistry was performed as for HIF-1a without the use the catalysed signal 
amplification (CSA) system, using primary antibodies to p53 (polyclonal CM1, 
Novacastra, Newcastle Upon Tyne, UK). Slides were blocked in normal goat serum prior 
to incubation with primary antibody diluted 1:64000 in TBST at room temperature for 12-
16 hours. All further procedures were performed as described above. 
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2.12 Statistical Analysis 
2.12.1 Allele and Genotype Frequencies 
Allele frequencies were determined as the percentage of the total number of copies of 
individual alleles present in the populations studied. Genotype frequencies were 
determined as the percentage of the total number of each particular genotype found in the 
populations studied. Comparison of allele and genotype frequencies between patients and 
controls were determined using the ·/ test with contingency tables. The x2 value was 
calculated using the following equation: 
[Observed (n)- Expected (n)]2 I Expected (n) 
where (n) represents the number of observations. Some x2 values were determined using a 
Statcalc program found in the statistical program Epi Info 6 (Epiglue 1.0; World Health 
Organisation, Geneva, Switzerland). The p values were then corrected (pc) for the number 
of variables using the Bonferroni inequality method and were considered significant when 
pc<0.05 (Bonferroni, 1936; Thompson, 1941). 
2.12.2 Hardy-Weinberg Equilibrium 
The Hardy-Weinberg Equilibrium test is used to determine whether a hi-allelic 
polymorphism follows a normal distribution within a population and is represented by the 
following equation: 
p2 + 2(pq) + q2= I 
where p and q represent the frequencies (f) of each allele within the population. The 
Hardy-Weinberg principle (Hardy, 1908) states the allele frequencies remain constant from 
generation to genemtion thus Hardy-Weinberg equilibrium occurs if the frequency is not 
significantly different from the expected frequency using a p value <0.05. 
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2.12.3 Odds Ratio 
The Odds Ratio is used to determine the odds of developing a disease condition based on 
the number of individuals with a particular genotype within a population versus a control 
population. It is represented by the following equation: 
(pqA X cB/(pqB X eA) 
where pqA represents the number of individuals with the genotype of interest in the sample 
population, pqB represents the number of individuals in the same population without the 
genotype of interest, eA represents the number of individuals in a control population with 
the genotype of interest, and cB represents the number of individuals in the same control 
population without the genotype of interest. 
.-' 
2.12.4 Association Analysis 
Statistically significant associations between independent samples were determined using 
the statistical package SPSS (version 9.0.0; SPSS Inc., Chicago, USA) using non-
parametric Mann-Whitney U, Kruskal-Wallis H or Spearman's coefficient of correlation 
tests. Analysis of variance (ANOV A) was also performed followed by the F-test and the 
Student's t-test for comparison of means with values ofp<0.05 considered as significant. 
2.12.5 Survival Analysis 
Statistical analyses were performed using the stati.~tical program SPSS (version 9.0.0; 
,!"' 
SPSS Inc., Chicago, USA). Univariate analysis of overall survival was performed as 
outlined by Kaplan and Meier (Kaplan & Meier, 1985), where the log-rank test was used to 
determine significant differences between these. The cox proportional hazards model was 
used for multivariate analysis, although statistical power was limited due to relatively low 
number of cases in each study. Multivariate analysis was perfof91ed using a backward 
elimination procedure to remove variables with p~0.10. The qualifying criteria for 
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inclusion in the multivariate analysis were p<O.l, or hazard ratios <0.5 or >2 in the 
univariate analysis. Hazard ratios and p values are noted for each variable in multivariate 
analysis. For all tests, a p value of less than or equal to 0.05 was considered as significant. 
All p values given are results of two-sided tests. 
2.12.6 Nottingham Prognostic Index (NPI) 
The NPI is a prognostic index based on multiple factors and is used to predict 
overall survival in patents with breast cancer (Haybittle et a/, 1982). The factors include 
tumour size, histological grade and lymph node stage, all of which are used to create an 
index predicting survival: 
NPI =size (cm) x 0.2 +Grade (1-3) +Node stage (1-3) 
where grades I to 3 define well, moderate or poor differentiation, and node stages I to 3 
define no nodal involvement, involvement of up to 3 nodes, or involvement of 4 or more 
nodes. The higher the value for NPI the worse the prognosis. 
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3.0 HIF-la, GLUT-1 and p53 Expression In Breast Carcinoma Cell 
Lines Exposed To Hypoxia and High Glucose 
Hyperglycaemia is known to cause oxidative and reductive stress and it has been 
proposed that this will ultimately lead to a state of redox imbalance within the cell. It has 
been suggested that hyperglycaemia-induced redox imbalance mimics the effects of 
hypoxia (Williamson et al, 1993). GLUT-I is responsible for basal glucose transport and 
was the first in the family of glucose transporters to be cloned (Meuckler et al, 1985). 
Under hypoxic conditions a cell must undergo metabolic adaptations to survive which 
includes an increase in glucose uptake facilitated by upregulation of GLUT-I mRNA 
expression. Hypoxia is a potent stimulus for GLUT-I mRNA induction in a variety of 
tissue types including various tumour cell lines (Ebert et al, 1995) and in a variety of 
human cancers (Younes et al, 1996). 
Presently little is known about the hyperglycaemia-induced expression of HIF-la 
in breast carcinoma cell lines. The expression profiles of both the HIF-I a and GLUT-I 
genes under hypoxic and hyperglycaemic conditions may offer a possible explanation as to 
how cancer cells behave under conditions of extreme stress. Further information about 
HIF-1 DNA binding activity and HIF-la and GLUT-I protein expression levels will also 
offer additional insight. Thus, one of the aims of this study was to quantitate the expression 
of HIF-I a and GLUT-I mRNA in breast carcinoma cell lines exposed to hypoxia and high 
glucose. 
It is known that HIF-1 a expression is induced by exposure to hypoxia or treatment 
with cobalt chloride (Wang et al, 1995), a hypoxia-mimicking agent. HIF-1 a, VEGF, p53 
and fJ-actin expression were first studied using Northern blotting, in breast carcinoma cells 
treated with varying concentrations of CoCh (60 mM to 500 mM) for up to 24 hours, to 
determine whether HIF-I a expression could be induced in these cells. CoCh has been 
used previously to induce HIF-I in Hep3B cells (Semenza et al, 1994; Wang and Semenza, 
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1993). Probes for each gene were created by PCR amplification of T47D cell genomic 
DNA, were radiolabelled and then hybridised to blots containing 50 to 125 J.lg of mRNA. 
Subsequently, the expression of HJF-1 ~ p53 and GLUT-I mRNA was quantitated 
in cell lines exposed to hypoxia, high glucose, both hypoxia and high glucose, and 
subsequently normoxia, using the RP A. A probe for HIF-1 a was amplified via RT-PCR 
from cDNA synthesised from total RNA isolated from the T47D breast carcinoma cell line 
exposed to hypoxia {<1% 0 2) for 24 hours. Probes for p53 and GLUT-I were amplified as 
above from genomic DNA but without exposure to hypoxia. 
Four individual breast carcinoma epithelial cell lines {T47D, MCF7, SKBR3, 
ZR75) were cultured in their recommended tissue culture media at normal glucose levels 
(no supplement), moderate glucose (supplemented with lO mM D-glucose) or high glucose 
(supplemented with 20 mM glucose). For hypoxic conditions, cells were exposed to 1% ~ 
(5% C02, 95% N2) in a 37° C C0i02 incubator for 2, 4, 6, 8, 24 and 48 hours. An aliquot 
of cells was also exposed to normoxic conditions (21% 0 2, 5% C02, 74% N2) for the same 
period of time. The cell lines were also conditioned to long-term high glucose by culturing 
for more than 30 days in media supplemented with 20 mM D-glucose. For experiments 
where hypoxic cells were returned to normoxic conditions, cell were firstly exposed to 1% 
0 2 (5% C02, 95% N2) in a 37° C C02/02 incubator for 24 hours and subsequently exposed 
to normoxia (21% 02, 5% C02, 74% N2) for 1, 2, 4, 6, 8 and 24 hours. 
A further aim of this study was to investigate the illF-1 DNA binding activity and 
illF-1 and GLUT-I protein expression in cellular and nuclear extracts isolated from breast 
carcinoma cells exposed to hypoxia and long-term high glucose (20 mM D-glucose > 30 
days culture). Several cellular steps are required to activate illF-1: the accumulation of 
illF-la., the nuclear translocation of illF-la. and illF-113. the formation of the illF-1 
complex and the binding to DNA (Chilov et a/, 1999). illF-1 forms DNA-binding 
complexes containing the p300/camp-response-element-binding protein when bound to its 
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target HIF-1 binding site under hypoxic conditions (Arany et a/, 1996).1t is known that the 
cellular redox state determines HIF-1a binding activity (Haddad and Land, 2000; Haung et 
a/, 1996). 
The DNA-binding activity of HIF-1 was analysed by electrophoretic mobility shift 
assays (EMSA), using a double stranded oligonucleotide probe containing the HIF-1 
binding site from the EPO enhancer (Semenza & Wang, 1992) that binds both HIF-1 and 
constitutively expressed factors. Protein expression levels were determined by Western 
blot analysis using a monoclonal antibody to HIF-1a and a polyclonal antibody to GLUT-
I. 
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3.1 Northern Analysis of HIF-la, VEGF, p53 and P-Actio mRNA 
Expression In Breast Carcinoma Cell Lines Exposed To Hypoxia 
Figure 3.1 illustrates Northern blot analysis of T47D breast carcinoma cells 
exposed to 60 and 120 J.lM cobalt chloride for 17.5 hours. Blots were hybridised with 
VEGF, p53 and !}-actin DNA probes and RNA expression was normalised with 28S:18S 
RNA expression. Upregulation of both VEGF and p53 mRNA is seen at exposure to both 
concentrations of cobalt chloride (Table 3.1 ). 
Breast carcinoma cells and peripheral blood mononuclear cells (PBMC) from a 
normal healthy individual were also exposed to hypoxia (~ 1% 0 2) for up to 8 hours. 
Northern blot analysis of 100 J.l.g ofmRNA from MCF7 breast carcinoma cells exposed to 
hypoxia for up to 6 hours of is shown in Figure 3.2 where no up-regulation of HIF-la 
mRNA expression can be seen, only consistent expression, however up-regulation of 
VEGF mRNA is observed after 4 hours exposure to hypoxia (Table 3.2). Figure 3.3 
illustrates Northern blotting ofPBMCs for HJF-la mRNA expression where upregulation 
can be seen at 2 hour exposure to hypoxia (Table 3.3). 
As Northern blotting was found to require large quantities of mRNA for genetic 
expression and proved difficult to optimise, the technique was abandoned in favour of the 
relatively new and more sensitive RP A 
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Figure 3.1. Northern blot analysis of VEGF,p53 and ~actin mRNA expression in T47D 
breast carcinoma cells. Cells were exposed to 60 and 120 mM cobalt chloride (CoCh) for 
17.5 hours, RNA was isolated and up to 70 to 125 j..lg were analysed by Northern blotting 
using a A) VEGF, B) p53 and C) f3-actin DNA probe, following blot stripping. In this 
example 70 j..lg of mRNA was blotted and probed. D) Both 28S and 18S mRNA bands are 
shown. Levels of expression are given in Table 3.1. 
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Table 3.1. Levels of VEGF,p53 and p..actin mRNA in the T47D breast carcinoma cell 
line exposed to 60 and 120 mM cobalt chloride for 17.5 hours analysed by 
Northern blotting. 
Cobalt Fold mRNA expression Ratio of Chloride 28S:18S 
(CoCh) VEGF p53 {J-actin RNA 
60mM 1.51 1.67 1.07 1.87 
120mM 5.02 1.92 0.90 1.40 
Results are expressed as the fold change (increase or decrease) in mRNA against the level 
obtained under nonnoxic conditions (21% 0 2, 5% C02, 74% N2 at 37° C), after 
nonnalisation for 28S:18S RNA expression. Average ratio of 28S:18S RNA is 1.84 
(control ratio = 2.26). 
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Figure 3.2. Northern blot analysis of HIF-1 a mRNA expressiOn in MCF7 breast 
carcinoma cells. Cells were exposed to hypoxia(~ 1 % 0 2) for up to 6 hours, RNA was 
isolated and 100 J.Lg was analysed by Northern blotting using a A) HIF-1u and B) VEGF 
probe. C) Both 28S and 18S mRNA bands are shown. Results show no up-regulation of 
HIF-1 a mRNA however up-regulation of VEGF mRNA is seen after 4 hours of hypoxic 
exposure. Levels of expression are given in Table 3.2. 
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Table 3.2. Levels of HIF-1 a and VEGF mRNA in the MCF7 breast carcinoma cell line 
exposed to hypoxia (~1% 0 2) for up to 6 hours analysed by Northern blotting. 
Hypoxic Fold mRNA expression Ratio of Exposure 288:188 
(~1%02) HIF-la VEGF RNA 
1 hour 0.72 0.78 1.54 
2 hours 0.60 0.89 1.69 
3 hours 0.60 1.01 1.78 
4 hours 0.49 1.24 1.66 
5 hours 0.29 1.16 1.76 
6 hours 0.48 1.21 1.63 
Results are expressed as the fold change (increase or decrease) in mRNA against the level 
obtained under normoxic conditions (21% 0 2, 5% C02, 74% N2 at 37° C), after 
normalisation for 288:188 RNA expression. Average ratio of 288:188 RNA is 1.64 
(control ratio= 1.42). 
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Figure 3.3. Northern analysis of HIF-1 a mRNA expression in PBMCs of a normal healthy 
individual. A) Cells were exposed to hypoxia (~1 % 0 2) for up to 8 hours, RNA was 
isolated and 50 j.lg was analysed by Northern blotting using a IDF-la probe. B) Both 28S 
and 18S mRNA bands are shown. Results show up-regulation of HIF-1 a mRNA at 2 hours 
exposure to hypoxia. Levels of expression are given in Table 3.3. 
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Table 3.3. Levels of HIF-1 a mRNA expression in PBMCs of a normal healthy individual 
exposed to hypoxia(~ I% 0 2) for up to 8 hours analysed by Northern blotting. 
Hypoxic Fold HIF-la Ratio of 
Exposure mRNA expression 288:188 
(~1% 02) RNA 
2 hours 2.94 1.74 
4 hours 1.19 1.78 
8 hours 1.38 1.78 
Results are expressed as the fold change (increase or decrease) in mRNA against the level 
obtained under normoxic conditions (21% 0 2, 5% C02, 74% N2 at 37° C), after 
normalisation for 288:188 RNA expression. Average ratio of 288:188 RNA is 1.82 
(control ratio = 1.97). Up-regulation of H1F-1 a mRNA is seen after 2 hours exposure to 
hypoxia. 
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3.2 HIF-1 a, GLUT-1 and p53 mRNA Expression In Breast Carcinoma 
Cell Lines Exposed To Hypoxia 
The effect of hypoxia on the induction of HIF-I a, GLUT-I and p53 mRNA in 
breast carcinoma established cell lines was analysed by RP A. Probes to all 3 genes were 
prepared as described above and in chapter 2, section 2.10.6.1. The intensity and size of 
the HIF-la, p53, VEGF and the GLUT-I probes used in the RP As is shown in figure 3.4. 
Despite the synthesis of at least 2 separate and intensely strong VEGF probes, limited 
success was obtained when used in RP A. 
The fold changes in mRNA expression from normoxia for each gene in each of the 
breast carcinoma cell lines exposed to hypoxia for up to 48 hours are listed in Table 3.4 
(Figure 3.5). A change of less than 2 fold expression from nonnoxic levels (increase or 
decrease) was considered as non-significant due to background noise or other 
inconsistencies. 
In 3 of the 4 cell lines (SKBR3, T47D, ZR75) that were exposed to hypoxia (<1% 
0 2) for up to 48 hours, little or no change in HIF-I a mRNA expression was observed from 
nonnoxic levels (Table 3.4; Figure 3.6). However, the SKBR3 cell line displayed a 2.7 ± 
0.7 fold increase in HIF-I a mRNA expression from nonnoxic levels. Considering the 
standard error for this time point, the increase in mRNA expression was probably 
negligible. Thus, prolonged exposure to hypoxia failed to increase HIF-I a mRNA 
expression in these breast carcinoma cell lines. 
As with HIF-I a mRNA expression, 3 of the 4 cell lines (MCF7, SKBR3, ZR75) 
displayed minor but non-significant variations in GLUT-I mRNA expression from 
normoxic levels (Table 3.4) These cell lines showed decreased expression for GLUT-I 
mRNA after 2 and 4 hours of hypoxic exposure (mean 0.45 and 0.61 fold expression, 
respectively, equivalent to 2.2 and 1.6 fold decrease from normoxic levels), (Figure 3.7). 
However, the T47D breast cell line showed an increase in GLUT-I mRNA expression with 
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prolonged exposure to hypoxia, up to an 8.8 fold increase at 24 hours exposure. With the 
exception of the T47D cell line, prolonged hypoxic exposure seemed to decrease GLUI'-1 
mRNA expression in the majority of breast carcinoma cell lines. 
Decreased expression of p53 mRNA from normoxic levels was observed in the 
majority of the breast carcinoma cell lines (Table 3.4; Figure 3.8). As with GLUI'-1, 
hypoxia decreased p53 mRNA expression under hypoxia, however this was non-
significant. 
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1 2 3 4 5 
lllF-la lllF-la VEGF VEGF GLUT-I 
542 bp 542 bp 576 bp 464 bp 548 bp 
520 bp 520 bp 553 bp 441 bp 525 bp 
SOObp 
400bp 
300bp 
M 6 
p53 
463 bp Product 
stze 
440 bp Protected 
fragment 
Figure 3.4. RPA probes used in the analysis of samples. Lane 1 and 2 contain the HIF-la 
probe, lane 3 and 4 contain 2 separate VEGF probes, lane 5 contains the GLUT -1 probe 
and lane 6 contains the p53 probe (M= 100 bp ladder). PCR assays consisted of2 separate 
rounds ofPCR using 2 amplimer sets for each probe~ conditions were optimised by varying 
magnesium concentrations and annealing temperatures. 
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HIF- la 
GLUT-I MCF7 
p53 
HIF-la 
GLUT-I SKBR3 
p53 
HIF-Ia 
GLUT-I T47D 
p53 
HIF-Ia 
GLUT-I ZR75 
p53 
N 2 4 6 8 24 48 Hours Hypoxic 
Figure 3.5. HIF-la, GLUI-1 and p53 mRNA expression in MCF7, SKBR3, T47D and 
ZR75 breast carcinoma cells that had been exposed to normoxia (N) and to 2 to 48 hours 
hypoxia, analysed by RP A. Results show a varied response through both an increase and 
decrease in mRNA expression (Table 3.4). A IOO bp marker was run to ensure correct 
protected fragment size. 
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Table 3.4. The fold change in HIF-1 a, GLUT-I andp53 mRNA expression from normoxia in breast carcinoma cell lines exposed to hypoxia 
{51% 0 2) for up to 48 hours. 
Hypoxic MCF7 SKBRJ T47D ZR75 
Exposure 
{51% 02) HIF-1a GLUT-I p53 HlF-Ia GLUT-I p53 H1F-1a GLUT-I p53 HIF-1a GLUT-I p53 
2 hours 0.8 ± 0.1 0.3 0.9 2.2 ± 1.0 0.3 1.0 1.6 ± 0.8 0.5 0.7 1.4 0.6 0.6 
4 hours 0.8 ± 0.03 0.8 1.0 2.7 ± 0.7 0.2 0.6 1.3 ± 0.4 0.9 0.8 1.0 0.5 0.2 
6 hours 0.8 ± 0.6 1.3 0.1 1.1 ± 0.3 0.2 0.9 1.4 ± 0.4 2.2 0.2 0.3 0.3 0.3 
8 hours 0.6 ± 0.1 1.0 0.8 1.4 ± 0.1 0.4 1.2 1.0 ± 0.2 5.9 0.4 0.6 0.3 0.2 
24 hours 0.4 ± 0.2 1.3 0.0 0.8 ± 0.3 1.1 1.0 0.8 ± 0.3 8.8 0.6 1.0 0.9 0.2 
48 hours 1.0 0.9 0.6 0.4 0.2 1.0 1.2 0.6 0.7 1.8 0.8 0.9 
Results are expressed as mean values± standard error from at least 2 separate experiments of the fold change (increase or decrease) in rnRNA 
against the level obtained under normoxic (21% 02, 5% C02, 74% N2 at 37° C) conditions. Where no standard error is shown, only one experiment 
was performed. Results are displayed graphically in Figures 3.6, 3. 7 and 3.8. 
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HIF-1 
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Figure 3.6. The fold change in HIF-1 a mRNA expression from normoxia in breast 
carcinoma cell lines exposed to hypoxia (~1 %02) for up to 48 hours. Polynomial trend 
lines, with respective R2 values, are indicated for each cell line. A change of less than 2 
fold expression from normoxic levels was considered non-significant. The SKBR3 cell line 
expressed up to a 2.7 fold increase in HIF-1 a mRNA expression after 4 hours of hypoxic 
exposure which steadily decreased with prolonged exposure to hypoxia (Table 3.4). 
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Figure 3.7. The fold change in GLUI'-1 mRNA expression from normoxia in breast 
carcinoma cell lines exposed to hypoxia (~1 %02) for up to 48 hours. Polynomial trend 
lines, with respective R2 values, are indicated for each cell line. A change of less than 2 
fold expression from normoxic levels was considered non-significant. The T47D cell line 
expressed up to an 8.8 fold increase in GLUI'-1 mRNA expression after 24 hours of 
hypoxic exposure which dropped off at 48 hours of hypoxic exposure (Table 3.4). 
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Figure 3.8. The fold change in p53 m.RNA expression in breast carcinoma epithelial cell 
lines exposed to hypoxia ( <1 %02) for up to 48 hours. Polynomial trend lines, with 
respective R2 values, are indicated for each cell line. A change of less than 2 fold 
expression from normoxic levels was considered non-significant. Overall, the cell lines 
displayed decreased expression of p53 mRNA under prolonged hypoxia (Table 3.4). 
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3.3 Basal levels of HJF-1 a, GLUT-1 and p53 mRNA Expression In Breast 
Carcinoma Cell Lines Cultured Under Normoxia 
The mean expression of HIF-Ia, GLUT-I andp53 mRNA, analysed by RPA, for 
each cell line cultured for 5 days at normoxic culture conditions (21% 02, 5% C02, 74% 
N2 at 37° C) was used to determine the corresponding basal levels and ratios of mRNA 
expression (Table 3.5; Figure 3.9). Under normoxic conditions, basal expression of HIF-
I a, GLUT-I andp53 mRNA were detected at varying levels in all of the cell lines studied. 
The abundance of each mRNA varied between cell lines over a range of approximately 9 
fold. For HIF-I a mRNA expression, the cell lines conditioned to long-term high glucose 
displayed increased basal levels to those not conditioned to high glucose, ranging between 
1 and 2.3 fold difference. The basal level of HJF-Ia mRNA varied approximately 3 fold 
from the lowest expressing cell line SKBR3, to the highest expressing cell line ZR75. 
For GLUT-I, the basal level of mRNA varied approximately 5.7 fold from the 
lowest expressing cell line T47D, to the highest expressing cell line ZR75. Basal levels p53 
mRNA expression varied approximately 3.5 fold from the lowest expressing cell line 
ZR75, to the highest expressing cell line T47D. In the MCF7 and SKBR3 cell lines, basal 
expression of GLUT-I and p53 mRNA was approximately 3 to 4 fold higher than that of 
HIF-la. Interestingly, basal expression levels of p53 mRNA was 4 to 5 fold higher than 
both HIF-1 a and GLUT-I mRNA in the T47D cell line. 
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Table 3.5. Mean basal expression of HJF-la, GLUT-I andp53 mRNA at normoxia (21% 
0 2, 5% C02, 74% N 2 at 37° C) in all breast carcinoma cell lines. 
Mean Expression at Normoxia 
Cell Line (Arbitrary Units) Ratio 
IDF-la GLUT-1 p53 HIF-l:GLUT-1: p53 
n= 10 n= 2 n= 2 
MCF7 1.03 ± 0.30 3.46 ± 1.55 3.77 ± 0.9 1 : 3.35 : 3.52 
(0.19 - 3.49) (1.91- 5.01) (2.87- 4.67) 
n=6 n=2 n=1 
MCF7Hyper 1.04 ± 0.28 2.85 ± 0.96 3.56 1 : 2.74 : 3.42 
(0.34 - 2.29) (1.89- 3.80) 
Ratio 1: 1 1: 0.82 1: 0.94 
n= 9 n= 2 n= 1 
SKBRJ 0.86 ± 0.29 3.36 ± 0.98 2.65 1 : 3.95 : 3.08 
(0.09- 2.87) (2.38 - 4.34) 
n=5 n=2 n=1 
SKBR3Hyper 1.94 ± 0.56 3.35 ± 1.62 3.26 1 : 1.73 : 1.68 
(0.89- 3.56) (1.73 - 4.92) 
Ratio 1:2.25 1: 1 1: 1.23 
n=9 n= 3 n= 2 
T47D 1.06 ± 0.35 0.64 ± 0.17 5.57 ± 1.16 1 : 0.60 : 5.25 
(0.14- 3.14) (0.31-0.87) (4.41 - 6.73) 
n=5 n=2 n= l 
T47DHyper 1.37 ± 0.61 1.27 ± 0.22 5.15 1 : 0.93 : 3.76 
(0.43- 3.75) (1.05- 1.49) 
Ratio 1: 1.29 1: 1.98 1: 0.92 
n= 7 n= 3 n= 2 
ZR75 2.34 ± 0.99 3.62 ± 0.94 1.61 ± 1.41 1 : 1.55 : 0.69 
(0.12 - 5.99) (1.76- 4.82) (0.20- 3.02) 
n=2 n=2 
ZR75Hyper 2.77 ± 2.31 4.12 ± 1.44 NID 1 : 1.49 
(0.46 - 5.08) (2.68 - 5.56) 
Ratio 1:1.15 1: 1.14 -
The mean expression for each cell line is given in arbitrary units (± standard deviation) 
together with the range (in parentheses) and the number (n) of times the experiment was 
repeated, where applicable. The mean expression is relative to an equivalent area analysed 
for each sample (5.4 mm2) . N/D = not done. Results are expressed graphically in Figure 
3.9. 
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Figure 3.9. Mean basal expression of HIF-I a, GLUT-I and p53 mRNA cultured for 5 
days at normoxia (21% 0 2, 5% C02, 74% N2 at 37 °C) in all breast carcinoma cell lines. 
Results are expressed in arbitrary units ± standard deviation. The basal ratio of HIF-I a: 
GLUT-I: p53 mRNA expression for each cell line is listed in Table 3.5. 
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3.4 HIF-1 a, GLUT-I and p53 mRNA Expression In Breast Carcinoma 
Cell Lines Exposed To Short-Term Higb Glucose (3 day culture) 
The effect of short-term high glucose (3 day culture) on the induction of HIF-I a, 
GLUT-I andp53 mRNA in breast carcinoma established cell lines was analysed by RPA 
(Figure 3.10). The fold changes in mRNA expression from normal culture conditions for 
each gene in each of the breast carcinoma cell lines exposed to short-term high glucose (3 
day cultures supplemented with 20 mM D-glucose) are listed in Table 3.6. A change of 
less than 2 fold expression from normal culture conditions (increase or decrease) was 
considered as non-significant due to background noise or other inconsistencies. 
When the breast carcinoma cell lines were exposed to high glucose (supplemented 
with 20 mM D-glucose) for 3 days, a 2.1 fold (MCF7) and a 12.9 fold (ZR75) increase in 
the expression of HIF-Ia mRNA and a 1.9 fold decrease (T47D) in HIF-Ia mRNA 
expression was observed compared to those cells not subjected to high glucose (Table 3.6; 
Figure 3.11). Similar results were observed for GLUT-I andp53 mRNA expression in the 
same cell lines. A 1.1 fold (MCF7) and a 2.9 fold (ZR75) increase in the expression of 
GLUT-I mRNA and a 1.6 fold decrease (T47D) in GLUT-I mRNA expression was 
observed compared to cells not subjected to high glucose (Table 3.6; Figure 3.11). 
Similarly, a 1.3 fold (MCF7) and a 5.0 fold (ZR75) increase in the expression of p53 
mRNA and a 1.5 fold decrease (T47D) in p53 mRNA expression was observed compared 
to cells not subjected to high glucose (Table 3.6; Figure 3.11). 
The ZR75 cell line exhibited the greatest increase in mRNA expression for all three 
genes. In contrast to the effects of hypoxia seen on the T47D cell line (section 3.2; Figure 
3.6), short-term exposure to high glucose decreased the expression of HIF-1 a, GLUT-I 
and p53 mRNA expression in this cell line. 
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Table 3.6. The fold change in HIF-1 a, GLUT-1 and p5 3 mRNA expression from normal culture conditions in breast carcinoma cell lines 
cultured for 3 days in moderate and high glucose. 
Fold change in Fold change in Fold change in 
Glucose HIF-lamRNA GLUT-1 mRNA p53mRNA 
Concentration 
MCF7 T47D ZR7S MCF7 T47D ZR7S MCF7 T47D ZR7S 
Moderate 
(10 mM D-glucose) 2.1 ± 1.4 0.5 ± 0.1 5.0 ±0.2 0.9 1.2 2.4 1.2 1.0 3.4 
High 
(20 mM D-glucose) 2.1 ± 1.5 0.7±0.5 12.9 ± 4.9 1.1 0.6 2.9 1.3 0.7 5.0 
Results are expressed as mean values± standard error from at least 2 separate experiments of the fold change (increase or decrease) in mRNA 
exposed to high glucose against the level obtained under normal culture conditions. Where no standard error is shown, only one experiment was 
performed. Results are displayed graphically in Figure 3.11. 
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Figure 3.10. Expression of HIF-1 a, GLUT-1 and p53 mRNA in MCF7, T47D and ZR75 breast carcinoma cell lines exposed to high glucose. Cell 
lines were exposed to normal glucose, moderate and high glucose in cultures for 3 days. MCF7 and ZR75 cell lines displayed increases in mRNA 
expression for all 3 genes and T47D cells displayed a decrease in expression for all 3 genes (Table 3.6). Results are expressed as the value of the 
fold change in mRNA exposed to high glucose compared to the level obtained under normal glucose and are expressed graphically in Figure 3.11. 
N= normal, M= moderate, H= high. 
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Figure 3.11. The fold change in HIF-1 a, GLUT-I and p53 mRNA expression from normal 
culture conditions in breast carcinoma cell lines cultured for 3 days in moderate or high 
glucose (Table 3.6; Figure 3.10). 
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3.5 HIF-1 a, GLUT-I and p53 mRNA Expression In Breast Carcinoma 
Cell Lines Conditioned To Long-Term High Glucose and Exposed To 
Hypoxia 
The breast carcinoma cell lines were conditioned to long-term high glucose (20 
mM D-glucose >30 days culture), exposed to hypoxia(~ 1% 02) for up to 48 hours and 
analysed by RP A. The fold changes in mRNA expression from normoxia for each gene in 
each of the breast carcinoma cell lines exposed to hypoxia are listed in Table 3.7 (Figure 
3.12). A change of less than 2 fold expression from normoxic levels (increase or decrease) 
was considered as non-significant due to background noise or other inconsistencies. 
Minor non-significant responses were observed in the cell lines in HIF-I a, GLUT-
I and p53 mRNA expression. All lines showed an initial decrease in the expression of 
HIF-I a, GLUT-I and p53 mRNA (Table 3.7). Both the MCF7 Hyper and SKBR3 Hyper 
cell lines displayed decreased HIF-I a mRNA expression throughout the 48 hours of 
hypoxic exposure, whereas the T47D Hyper cell lines showed increased expression from 4 
to 24 hours of hypoxic exposure, dropping after 48 hours of hypoxic exposure (Figure 
3.13). With the exception of the T47D Hyper cell line, the remaining cell lines showed 
decreased expression of GLUT-I mRNA for up to 8 hours of hypoxic exposure (Table 3. 7; 
Figures 3.15). p53 mRNA expression increased in the MCF7 Hyper cell line from 6 hours 
of hypoxic exposure (1.1 fold) to 24 hours (1.3 fold), where it then decreased after 48 
hours of exposure (2.6 fold) (Figure 3.17). The remaining cell lines all expressed 
decreased levels of p53 mRNA expression at all time points. 
Direct comparison of the normal cell lines and those conditioned to long-term high 
glucose and exposed to hypoxia for HIF-I a, GLUT-I and p53 mRNA expression are 
displayed graphically in Figures 3.14, 3.16 and 3.18. With the exception of the T47D cell 
lines, the extreme combined stresses of hypoxia and high glucose decrease the expression 
of HIF-la and GLUT-/ mRNA. p53 was the only decreased mRNA expression seen in 
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Table 3. 7. The fold change in H/F-1 a., GLUT-I and p53 mRNA expression from normoxia in breast carcinoma cell lines exposed to long-term 
high glucose and exposed to hypoxia (~1% 02) for up to 48 hours. 
Hypoxic MCF7Hyper SKBRJHyper T47DHyper ZR75Hyper 
Exposure 
(<1% 02) HIF-1a GLUT-1 p53 HIF-1a GLUT-1 p53 HIF-1a GLUT-1 p53 HIF-1a GLUT-1 p53 
2 hours 0.8±0.3 0.7 1.0 0.8±0.2 0.5 0.9 0.8± 0.3 2.7 0.5 NID 0.6 NID 
4 hours 0.4 ± 0.1 0.3 0.6 0.4 ± 0.1 0.4 0.9 1.2 ± 0.5 0.1 0.6 NID 0.2 NID 
6 hours 0.9±0.2 1.0 1.1 0.4 ± 0.1 0.5 0.5 1.4 ± 0.6 0.2 0.7 NID 0.1 NID 
8 hours 0.5 ± 0.1 0.8 1.1 0.7±0.2 0.6 1.0 1.0 ± 0.1 0.3 0.8 NID 0.2 NID 
24 hours 0.5±0.1 1.9 1.3 0.2 ± 0.1 0.5 0.7 1.2 ± 0.6 2.9 0.6 NID 0.7 NID 
48 hours 0.5 ±0.04 0.8 0.4 0.5 ±0.4 0.6 0.8 0.8 0.3 0.7 NID 0.7 NID 
Results are expressed as mean values± standard error from at least 2 separate experiments of the fold change (increase or decrease) in mRNA 
against the level obtained under normoxic (21% 02, 5% C02, 74% N2 at 37° C) conditions. Where no standard error is shown, only one experiment 
was performed. Results are displayed graphically in Figures 3.13, 3.15 and 3.17. N/D = not done 
-245-
Chapter 3. Results 
HIF-Icx 
GLUT-I MCF7Hyper 
p53 
HIF-lcx 
GLUT-I SKBR3 Hyper 
p53 
.J"'-;~ 
I 
I 
HIF-Icx 
GLUT-I T47DHyper 
p53 
N 2 4 6 8 24 48 Hours Hypoxic 
Figure 3.12. HIF-1 a, GLUT-I and p53 mRNA expression in MCF7 Hyper, SKBR3 
Hyper and T47D Hyper breast carcinoma cells exposed to nonnoxia (N) and to 2 to 48 
hours hypoxia, analysed by RP A. Results show a varied response through both an increase 
and decrease in mRNA expression (Table 3. 7). A 100 bp marker was run to ensure correct 
protected fragment size. 
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Figure 3.13. The fold change in HIF-1 a mRNA expression from normoxia in breast 
carcinoma cell lines conditioned to long-term high glucose (20 mM D-glucose >30 days) 
and exposed to hypoxia (~1% 0 2) for up to 48 hours. Polynomial trend lines, with 
respective R2 values, are indicated for each cell line. A change of less than 2 fold 
expression from normoxic levels was considered non~significant (Table 3.7). 
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Figure 3.14. The fold change in HIF-1 a mRNA expression from normoxia in the MCF7, 
SKBR3 and T47D breast carcinoma cell line and in the same cell lines conditioned to 
long-term high glucose and exposed to hypoxia (~1% 0 2) for up to 48 hours. Polynomial 
trend lines, with respective R2 values, are indicated for each cell line. A change ofless than 
2 fold expression from normoxic levels was considered non-significant (Table 3.7). 
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Figure 3.15. The fold change in GLUT-I mRNA expression from normoxia in breast 
carcinoma cell lines conditioned to long-term high glucose (20 mM D-glucose >30 days) 
and exposed to hypoxia (~1% 0 2) for up to 48 hours. Polynomial trend lines, with 
respective R2 values, are indicated for each cell line. A change of less than 2 fold 
expression from normoxic levels was considered non-significant (Table 3. 7). 
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Figure 3.16. The fold change in GLUT-I mRNA expression from nonnoxia in MCF7, 
SKBR3, T47D and ZR75 breast carcinoma cell lines and in the same cell lines conditioned 
to long-term high glucose and exposed to hypoxia (51% 0 2) for up to 48 hours. 
Polynomial trend lines, with respective R 2 values, are indicated for each cell line. A change 
of less than 2 fold expression from nonnoxic levels was considered non-significant (Table 
3.7). 
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Figure 3.17. The fold change in p53 mRNA expression from nonnoxia in breast 
carcinoma cell lines conditioned to long-term high glucose (20 mM D-glucose >30 days) 
and exposed to hypoxia ( <1% 02) for up to 48 hours. Polynomial trend lines, with 
respective R 2 values, are indicated for each cell line. A change of less than 2 fold 
expression from normoxic levels was considered non-significant (Table 3.7). 
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Figure 3.18. The fold change inp53 m.RNA expression from normoxia in MCF7, SKBR3 
and T47D breast carcinoma cell line and in the same cell lines conditioned to long-term 
high glucose and exposed to hypoxia ( <1% 0 2) for up to 48 hours. Polynomial trend lines, 
with respective R2 values, are indicated for each cell line. A change of less than 2 fold 
expression from normoxic levels was considered non-significant (Table 3. 7). 
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3.6 HIF-1 a mRNA Expression In Breast Carcinoma Cell Lines Exposed 
To 24 Hours Hypoxia and Subsequently Normoxia 
The effect of hypoxia, and subsequent exposure to normoxia, on the induction of 
HIF-la, GLUT-I andp53 mRNA in breast carcinoma established cell lines was analysed 
by RPA (Figures 3.19 and 3.20). The fold changes in mRNA expression from nonnoxia 
for each gene in each of the breast carcinoma cell lines exposed to hypoxia for up to 48 
hours are listed in Table 3.8. A change ofless than 2 fold expression from normoxic levels 
(increase or decrease) was considered as non-significant due to background noise or other 
inconsistencies. 
When all of the cell lines, both the normal and those conditioned to long-term high 
glucose, were exposed to 24 hours hypoxia and subsequently to nonnoxia (21% (h. 5% 
C02, 74% N2 at 37° C) for up to 24 hours, varying responses were observed in HJF-la 
mRNA expression {Table 3.8; Figures 3.19 and 3.20). Both the MCF7 and MCF7 Hyper 
cell lines, as well as the SKBR3 Hyper cell line displayed increased HJF-1 a mRNA 
expression after one hour recovery in nonnoxia. In the majority of the cell lines, prolonged 
exposure to hypoxia and recovery in normoxia resulted in HJF-1 a mRNA levels remaining 
similar to or just below that of normal control levels. 
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Table 3.8. The fold change in HIF-1 a mRNA expression from normoxia in breast carcinoma cell lines exposed to hypoxia (~1% 02) for 24 hours 
and subsequently to normoxia for up to 24 hours. 
Normoxic MCF7 SKBR3 T47D ZR75 MCF7 SKBR3 T47D ZR75 
Exposure Hyper Hyper Hyper Hyper 
1 hours 7.94 0.81 1.26 0.10 3.31 2.38 0.97 0.16 
2 hours 1.72 0.82 3.15 0.26 0.55 0.41 0.48 0.35 
4 hours 1.23 0.79 1.17 0.19 0.51 0.53 0.15 0.51 
6 hours 4.65 0.63 2.49 0.15 2.22 0.51 0.44 0.09 
8 hours 0.66 0.81 0.83 0.28 1.29 0.27 0.36 0.43 
24 hours 3.09 0.99 4.89 0.44 3.1 0.31 1.58 0.77 
Results are expressed as the value of the fold change in mRNA against the level obtained under normoxic conditions. 
Results are expressed graphically in Figures 3.19 and 3.20. 
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Figure 3.19. The fold change in HIF-1 a mRNA expression in breast carcinoma cell lines 
and breast carcinoma cell lines conditioned to long-term high glucose, exposed to hypoxia 
( ~ 1% 0 2) for 24 hours and subsequently to normoxia for up to 24 hours. Results are 
expressed as the value of the fold change in mRNA against the level obtained under 
normoxic conditions (Table 3.8). 
- 255 -
Chapter 3. Results 
5 
c:;4 
0 
·;;; 
eP 
$2 
'"Cl 
0 
11-<1 
0 
5 
4 
d 
0 
·~3 
... 
$ 2 
'"Cl 
0 
11-< 1 
0 
NC 
BJF-1 
2 4 6 8 
Hours in Nonnoxia after 24 hours 
Hypoxic Exposure 
24 
-+-MCF7 -e-MCF7 Hyper 
NC 
BJF-1 
1 2 4 6 8 
Hours in Nonnoxia after 24 hours 
Hypoxic Exposure 
24 
-+-T47D -e-T47D Hyper 
5 
§4 
.... 
tll 
e3 
~ 
~2 
-o 
-&:1 
0 
5 
4 
6 
·~ 3 
ft 
~2 
'"Cl 
0 
11-< 
0 
BJF-1 
A 
/\ ... 
..., );, 
--
-- -
NC 2 4 6 8 24 
Hours in Normoxia after 24 hours 
Hypoxic Exposure 
-+- SKBR3 -e- SKBR3 Hyper 
HIF-1 
-
"'-
..... 
:;: -
....d 
..., 
NC 2 4 6 8 24 
Hours in Normoxia after 24 hours Hypoxic 
Exposure 
-+-ZR75 -e-ZR75 Hyper 
Figure 3.20. The fold change in H/F-1 a mRNA expression in MCF7, SKBR3, T47D and 
ZR75 breast carcinoma cell lines and in the same cell lines conditioned to long-term high 
glucose, exposed to hypoxia ( <1% 0 2) for 24 hours and subsequently to normoxia for up to 
24 hours. Results are expressed as the value of the fold change in mRNA against the level 
obtained under normoxic conditions (Table 3.8). 
-256 -
Chapter 3. Results 
3.7 HIF-la mRNA Expression In Breast Carcinoma Cell Lines Exposed 
To Hypoxia and Hypoglycaemia 
The combined stresses of hypoglycaemia and hypoxia on the expression of HIF-1 a 
mRNA was also analysed in the cell lines by RP A. As seen with the combined stress of 
hypoxia and high glucose, all cell lines with the exception of T47D, expressed decreased 
levels of HIF-lamRNA when exposed for 24 hours to hypoglycaemia and hypoxia (Table 
3.9). 
The T47D and T47D Hyper cell lines were subsequently exposed to 7 days culture 
in hypoglycaemia where again an increase in HIF-Ja mRNA was observed (Table 3.10). 
Exposure of these two cell lines, as well as the MCF7 and MCF7 Hyper cell lines, to 7 
days culture in media supplemented with 20 mM L-glucose resulted in an increased 
expression of HIF-Ja mRNA (Table 3.10). This preliminary result would indicate that 
increased expression may be due to differences in osmolarity, however the experiments 
should be repeated several times to confirm this. 
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Table 3.9. Levels of HIF-1 a mRNA in breast carcinoma cell lines exposed to both 
hypoglycaemia and hypoxia (:::;1% 0 2) for 24 hours. 
Fold change in 
Culture HJF-lamRNA 
Condition 
MCF7 SKBRJ T47D ZR75 
24 hour exposure to 
hypoglycaemia+ 0.58 0.53 1.14 0.71 
hypoxia (:::;1% 02) 
Results are expressed as the values of the fold change in mRNA against the level obtained 
under nonnoxic conditions. 
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Table 3.10. Levels of H/F-1 a mRNA in breast carcinoma cell lines exposed for 7 days 
to hypoglycaemia or 20 mM L-glucose. 
Fold change in 
Culture HIF-lamRNA 
Condition 
MCF7 MCF7Hyper T47D T47DHyper 
Hypoglycaemia NID NID 1.41 6.64 
20 mM L-glucose 4.77 2.85 5.61 6.61 
Results are expressed as the value of the fold change in mRNA against the level obtained 
at normal culture conditions. 
NID = not done. 
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3.8 Osmolarity and High Glucose Controls 
To control for osmolarity and high glucose, and to determine whether the increased 
or decreased expression of HIF-1 a and GLUT-I was specific for D-glucose each of the 
breast carcinoma cell lines were stimulated with either L-glucose, which competes with D-
glucose for the transporter, or mannitol, an osmolyte and analysed by RPA. In the first 
experiment, 20 mM mannitol was used as a supplement with the 20 mM D-glucose. A 
second, parallel culture consisted of20 mM L-glucose being used as a supplement with the 
20 mM D-glucose. Mannitol is known to activate p38 mitogen activated protein kinase 
(Igarashi et a/, 1999). 
When the tissue culture media for the cell lines was supplemented with either 20 
mM L-glucose or 20 mM mannitol, up to a 100 fold decrease was seen in the expression of 
HIF-1 a mRNA (Table 3.11). Additionally, in contrast to initial results where cultures 
supplemented with 20 mM D-glucose alone for 3 days displayed an increased expression 
of HIF-1 a, a decrease in HIF-1 a mRNA was observed. 
GLUT-I mRNA expression was also quantitated in the same cultures where GLUT-
] mRNA was induced by D-glucose, L-glucose and mannitol in the MCF7 and ZR75 cell 
lines and by mannitol and long-term exposure to D-glucose in the T47D cell line (Table 
3.11). These results would indicate that the expression of HIF-1 a and GLUT-1 mRNA in 
the breast carcinoma cell lines is not specific for D-glucose alone but possibly due to 
differences in osmolarity. Although cell lines supplemented with either 20 mM L-glucose 
or 20 mM mannitol show an increase in GLUT-I mRNA, this increase is not as great as 
that found in cell lines cultured in long-term high glucose (with the exception of the ZR75 
cell line). As only one experiment was performed for each cell line under each culture 
condition, several repeated experiments are required to confirm these observations. 
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Table 3.11. Fold change in HIF-1 a and GLUT-/ mRNA expression in breast carcinoma 
cell lines exposed to 20 mM D-glucose supplemented with either 20 mM 
L-glucose or 20 mM mannitol. 
Fold change in HIF-1 a mRNA Fold change in GLUT-I mRNA 
Culture Conditions 
MCF7 SKBRJ T47D ZR75 MCF7 T47D ZR75 
High Glucose 0.36 2.51 0.48 0.02 1.12 0.43 1.16 (20 mM D-glucose) 
L-glucose 
(20 mM D-glucose + 0.59 1.31 0.92 0.32 1.20 0.97 2.34 
20 mM L-glucose) 
Mannitol 
(20 mM D-glucose + 0.84 1.96 0.43 0.01 1.67 1.02 1.14 
20 mM mannitol) 
Long-term 
High glucose 0.71 2.63 1.21 0.12 1.69 1.22 1.8 (20 mM D-glucose 
<30 days exposure) 
Results are expressed as the fold change in mRNA against the level obtained at normal 
culture conditions. 
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3.9 Measurement of Lactic Acid 
Measurement of lactic acid was determined for each cell line exposed to hypoxia, 
high glucose as well as the osmolarity controls (Tables 3.12 and 3.13). Basal levels of 
lactic acid were found to be relatively high in the MCF7 and ZR75 cell lines, dropping 
approximately 3 fold in both cell lines after 2 hours exposure to hypoxia. Increased 
production was then observed with increased exposure time to hypoxia. surpassing 
normoxia levels after 24 to 48 hours of exposure (Table 3.12). In cell lines exposed to high 
glucose, L-glucose and mannitol, lactate levels remained similar in all cell lines in all 
conditions with decreased production of lactate when cultured in long-term high glucose. 
The T47D cell line displayed the highest basal level of lactic acid, two fold greater then the 
lowest basal level observed in the ZR75 cell line (Figures 3.21). 
-262-
Chapter 3. Results 
Table 3.12. Measured lactate concentrations (mmoi/L) in breast carcinoma cell line 
culture media exposed to hypoxia. 
Hypoxic Exposure MCF7 ZR75 
(>1% 02) OD Lactate Cone. OD Lactate Cone. 
(340 run) (mmoi!L) (340 run) (mmoi!L) 
Normoxia (21% 02) 0.85 8.66 0.81 8.30 
2 hours 0.26 2.60 0.30 3.08 
4 hours 0.30 3.04 0.35 3.52 
6 hours 0.31 3.12 0.43 4.38 
8 hours 0.37 3.81 0.43 4.41 
24 hours 0.69 6.99 0.83 8.45 
48 hours 1.13 11.50 1.12 11.45 
Lactate concentrations were calculations as described in Chapter 2, section 2.11.1.3. 
-263-
Table 3.13. Measured lactate concentrations (mmol/L) in breast carcinoma cell" line culture media exposed to high glucose and osmolarity 
controls. 
MCF7 SKBRJ T47D ZR75 
Culture Conditions OD Lactate Cone. OD Lactate Cone. OD Lactate Cone. OD Lactate Cone. 
(340nm) (mmoVL) (340nm) (mmoVL) (340nm) (mmoVL) (340nm) (mmoVL) 
Normal media (basal glucose) 0.93 9.51 1.07 10.88 1.74 17.71 0.84 8.55 
20 mM D-glucose 0.93 9.51 1.07 10.88 2.06 21.01 0.75 7.67 
20 mM D-glucose + 20 mM L-glucose 0.75 7.63 1.02 10.44 1.94 19.75 0.62 6.28 
20 mM D-glucose + 20 mM Mannitol 0.98 10.04 0.87 8.85 2.01 20.55 0.64 6.54 
Long-term high glucose 0.80 8.18 0.61 6.25 1.67 17.03 0.48 4.93 
(20 mM D-glucose > 30 days) 
Lactate concentrations were determined as described in Chapter 2, section 2.11.1.3. Results are expressed graphically in Figure 3.21. 
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Figure 3.21. Measured lactate concentrations (mmol/L) in breast carcinoma cell line 
culture media exposed to high glucose and osmolarity controls. The graph displays the 
results of all culture conditions per cell line and shows similar decreased production of 
lactate in all cell lines during culture in long-term high glucose (Table 3.13). 
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3.10 HIF-1 DNA Binding Activity In Breast Carcinoma Cell Lines 
Exposed To Hypoxia and High Glucose 
IDF-1 DNA-binding activity was induced in nuclear extracts made from all breast 
carcinoma epithelial cells exposed to hypoxia for up to 48 hours (Figure 3.22) as well as in 
extracts exposed to long-term high glucose and hypoxia (Table 3.14; Figure 3.22). DNA-
binding of IDF-1 functional complexes was also observed under normoxic conditions in 
the cell lines. 
The relative amounts or intensity of the bands seen varied in all extracts. Of the 
cell lines exposed to hypoxia, the MCF7 cell line displayed a decrease in binding activity. 
The SKBR3 cell line displayed an initial increase in DNA-binding activity but then 
decreased below normoxic control levels. This was also observed in the SKBR3 Hyper cell. 
line. Extracts from the T47D and ZR75 cell lines displayed increases in binding activity 
when exposed to prolonged hypoxia. Extracts from the ZR75 cell line exposed to hypoxia 
displayed the highest binding activity, where up to a 3 fold increase in activity was seen 
over the level observed in the other cell lines. DNA-binding activity in the cell lines 
conditioned to long-term high glucose and exposed to hypoxia was similar to those 
exposed to hypoxia alone (Table 3.14). 
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Table 3.14. Mean fold change in expression ofHIF-1 DNA binding activity in nuclear extracts isolated from breast carcinoma cell lines exposed 
to hypoxia and long-term high glucose (20 mM D-glucose> 30 days culture). 
Hypoxic Exposure MCF7 SKBR3 T47D ZR75 MCF7 SKBR3 T47D ZR75 
(<1% 02) Hyper Hyper Hyper Hyper 
2 hours 0.6±0.08 1.1 1.1 ± 0.02 4.5 ± 3.6 0.6 ± 0.13 1.3 1.5 ± 0.45 1.3 ±0.02 
4 hours N/D 1.3 1.4 ± 0.09 NID 0.4 ± 0.05 1.5 1.4 ± 0.05 NID 
6 hours 0.6 ± 0.12 1.1 1.1 ± 0.01 4.9±3.5 1.0±0.17 0.5 1.4 ± 0.41 1.2 ± O.ol 
8 hours 0.6 ±0.01 0.4 1.8 ± 0.05 4.5 ± 1.9 1.1 ±0.06 0.1 1.5 ±0.05 1.3 ±0.08 
24 hours 0.6±0.02 N/D 1.7 ± 0.04 4.4 ± 3.1 1.1 ± 0.05 NID NID 1.3 ± 0.02 
48hours 0.5 ± O.ol N/D 1.0 ± 0.12 N/D 1.0 ±0.04 N/D 1.2 ± 0.35 NID 
Hypoxia + excess 
unlabelled probe 
0.1±0.01 0.1 0.7±0.41 0.5 ± 0.08 0.2±0.08 0.1 0.3 ± 0.18 0.7±0.01 
Results are expressed as the mean value of the fold change in HIF-1 DNA-binding activity in nuclear extracts isolated from cultures exposed to 
hypoxia compared to the level obtained under normoxic culture conditions. Results represent the mean of 2 separate experiments and are 
expressed graphically in figure 3.22. Only one experiment was performed on the SKBR3 and SKBR3 Hyper cell lines. N/D = Not Done 
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Figure 3.22. The fold change in IDF-1 DNA-binding activity in breast carcinoma cell lines 
and in the same cell lines conditioned to long-term high glucose and exposed to hypoxia 
(~1% 0 2) for up to 48 hours. The cell lines displayed varied responses to hypoxia. The 
addition of excess unlabelled probe in competition assays displaced IDF-1 binding 
complexes (Figure 3.23). 
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3.11 HIF-1 Competition Assays 
In competition assays, HIF-1 bands induced by hypoxia were displaced by 
excessive unlabelled probe (up to 6 fold excess) in the extracts of all cell lines tested, 
suggesting that these bands are specific for the HIF-1 binding site (Figure 3.23). The same 
result was obtained with hypoxia and high glucose-treated extracts where again bands 
induced by these treatments were displaced with excess unlabelled probe (Figure 3.23). 
Several attempts were made to supershift the HIF-1 DNA complexes with the 
addition of a monoclonal HIF-1 antibody without success (Figure 3.24). Two separate 
monoclonal HIF-1 antibodies were used with 2 separate assay conditions: one involved an 
incubation of the reaction mixture on ice for 1 hour and the other an incubation of the 
reaction mixture at room temperature for 1 hour, after the addition of the antibody. 
Although these antibodies specific for HIF-1a could not supershift the complexes, the 
hypoxia/high glucose induced DNA-binding activity was due to HIF-1 as the binding 
complex was knocked out in the competition assays. 
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Figure 3.23. The effect of hypoxia and high glucose on HIF-1 DNA binding activity. 
Nuclear protein was extracted from the nuclei of MCF7 cells and MCF7 Hyper celJs 
(conditioned to long-tenn high glucose) subjected to normoxia (N), or to 2, 6, 8, 24, and 48 
hours hypoxia and analysed by EMSA. 15 J.tg of nuclear protein was analysed. HIF-1 
binding complex (HIF-1) bands are indicated. The addition of excess unlabelled probe in 
competition assays displaced HIF-1 binding complexes. 
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Figure 3.24. Supershifting of HIF-1 DNA complexes. Two separate monoclonal 
antibodies to HIF-1 (Ab1 and Ab2) were added to the EMSA reactions containing nuclear 
protein from ZR75 cells subjected to normoxia (N), or to 2 and 8 hours hypoxia in an 
attempt to supershift the HIF-1 DNA complexes without success. The complex was 
displaced with excess unlabelled probe (E). 15 J..lg of nuclear protein was analysed. HIF-1 
binding complex (HIF-1) bands are indicated. 
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3.12 Comparison of Methodologies for Harvesting Nuclear Protein 
Extracts 
Several different methodologies have been published describing appropriate 
techniques for harvesting nuclear protein extracts for investigation ofHIF-1 DNA-binding 
activity by EMSA. As HIF-1 has a very short half-life, it is important to ascertain that the 
correct methodology is used. Two of the most tried and popular methodologies have been 
used in this study. As both techniques are very different in their methodology and 
processing time, nuclear extracts prepared from each technique were compared for any 
notable differences in the detection ofHIF-1 DNA-binding activity. 
Figure 3.25 displays a graphical comparison of the 2 techniques in 4 cell lines. 
Both methods produced extracts from the cell lines which display HIF-1 DNA binding 
activity with minor differences in the levels. The most notable difference is in the ZR75 
cell line exposed to hypoxia which displays a 3 fold increase in the level of activity of one 
technique versus the other. Although the MCF7 cell line exposed to hypoxia shows a 
decreased level of binding activity after exposure to hypoxia in one extraction 
methodology, the second extraction methodology shows an equal level of binding activity 
with the normoxia control. Thus, no increase in binding activity occurred. As the second 
methodology was accessed only once due to time constraints, this is not an accurate 
comparison but nevertheless shows that both methodologies are adequate for harvesting 
nuclear protein extracts for the investigation of HIF-1 binding activity. 
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Figure 3.25. Comparison of methodologies for harvesting nuclear protein extracts. Two 
different methodologies for the harvesting of nuclear protein extracts for investigation of 
IDF-1 DNA-binding activity were accessed with slight differences observed in the level of 
binding activity. 
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3.13 HIF-la Protein Expression In Breast Carcinoma Cell Lines 
Exposed to Hypoxia 
Severn! different protocols were followed in attempts to obtain a signal from the 
HIF-1a antibody used in the Western blotting experiments analysing breast carcinoma cell 
lines exposed to hypoxia. 
Following electrophoresis and transfer to nitrocellulose paper, gels were stained 
with Coomassie blue to access the success of the transfer. Good sepamtion of the protein 
was obtained however on a few occasions the protein transfer was incomplete in the upper 
quadrant of the gel (Figure 3.26). Despite this, protein expression could be obtained using 
the GLUT -1 antibody but not with the HIF-1 a antibody. 
Although the suppliers' recommended protocol for use with the antibody was 
followed and adapted where necessary, in addition to trying various protocols from 
published papers, a signal could not be detected. Additional attempts to solve the detection 
problem included accessing whole cell protein extracts, cytoplasmic protein and nuclear 
protein extracts from the breast carcinoma cell lines that had been exposed to hypoxia. The 
amount of protein sepamted and blotted was also increased (up to 90 J.tg), in attempts to 
detect the correct size fragment (120 kDa for HIF-1a). A fragment approximately 66 kDa 
in size was detected on several occasions which was confirmed to be bovine serum 
albumin (BSA) by subsequent spiking experiments (Figure 3.27). 
Contact with the supplier revealed that there had been seveml complaints from 
customers about the particular batch of antibody that had been released. The company 
confirmed through in house testing that specificity problems were found with the batch of 
antibody used in the Western blotting experiments. A second different HIF-Ia antibody 
was received from the company and tested but a signal still could not be obtained. An 
eventual follow-up response from the technical assistance department at the company 
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(A) 12% polyacrylamide gel (B) GLUT -1 lmmunoblot 
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Figure 3.26. Separation of protein by SDS-polyacrylamide gel electrophoresis on a 12% 
polyacrylamide gel. In this example, 40 J.lg of total protein from MCF7, ZR75 and T47D 
breast carcinoma cell lines that had been exposed to hypoxia for 4 hours was separated and 
transferred onto a nitrocellulose membrane. The corresponding immunoblot demonstrates 
increased expression of GLUT -1 protein. One of the difficulties of the procedure was 
attaining complete transfer of the protein to the nitrocellulose membrane. The gel pictured 
in (A) had been transferred overnight at 3 mA, stained with Coomassie blue and lightly 
destained. The corresponding blot was then probed with a monoclonal anti-HIF-1 or a 
polyclonal anti-GLUT -1 antibody and detected by ECL chemiluminescence (B). 
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Figure 3.27. Western blot of breast carcinoma cell lines exposed to hypoxia 
demonstrating the detection of bovine serum albumin (BSA) by the IllF-1a. antibody in the 
nuclear extracts. Cells were incubated in complete media under hypoxic conditions for 6 
hours prior to nuclear extract preparation. Lane 1 and 2 contain 70 ~g and 50 ~g, 
respectively, of nuclear protein from T47D cells exposed to hypoxia for 4 hours, lane 3 
contains 50 ~g of nuclear protein from ZR75 cells exposed to hypoxia for 6 hours. Lanes 4 
and 5 are the same as lanes 2 and 3 but spiked with 50 ~g ofBSA, lane 6 contains 50 ~g of 
BSA alone. The H1F-1a. antibody detected BSA in the cell lines but not HlF-la.. M = 
marker, Phos b = Phosphorylase b 
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3.14 GLUT-I Protein Expression in Breast Carcinoma Cell Lines 
Exposed To Hypoxia and High Glucose 
GLUT -1 protein expression was also assessed in breast carcinoma cell lines 
exposed to hypoxia and long-term high glucose. A 55 kDa band was detected in all cell 
lines studied suggesting a moderate basal level in all cells at normoxia (Figure 3.28). 
GLUT -1 protein levels varied in response to hypoxia and long-term high glucose in the 
majority of cell lines. 
In the MCF7 cell line exposure to hypoxia increased GLUT-1 protein levels, 
however long-term exposure to high glucose (MCF7 Hyper cell line) and exposure to 
hypoxia was found to decrease the response {Table 3.15; Figure 3.29). No increase in the 
expression of GLUT-1 protein from normoxic levels was seen in the SKBR3 and ZR75 
cell lines after exposure to hypoxia. The T47D cell line showed an initial decrease in 
GLUT-1 protein after exposure to hypoxia which then increased to 1.5 fold above that seen 
at normoxia. All of the cell lines conditioned to long-term high glucose and exposed to 
hypoxia, with the exception of the T47D hyper cell line, showed decreased expression of 
GLUT -1 protein from that seen at normoxia. 
The level ofGLUT-1 protein detected by Western blotting is consistent with results 
obtained at the mRNA level with the SKBR3, SKBR3 Hyper, ZR75 and ZR75 Hyper cell 
lines all displaying decreased GLUT-I expression at both the mRNA and protein levels. 
GLUT-1 mRNA and protein levels are consistent in the MCF7 cell line at 24 hours 
exposure to hypoxia and in the MCF7 Hyper cell line at 4 hours exposure to hypoxia. 
Consistent expression in GLUT-1 at the mRNA and protein levels in seen in the T47D cell 
line at 4 hours of exposure to hypoxia. As only a few time points were sampled it is 
difficult to assess the behaviours of all the cell lines throughout the entire time period. 
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Figure 3.28. Western blot analysis ofGLUT-1 protein expression in breast carcinoma cell 
lines exposed to hypoxia and long-term high glucose. After exposure to normoxia and 
hypoxia(~ 1% 02) for up to 48 hours, cellular proteins (60 J..lg/lane) were separated by 12 
% SDS-Page, blotted on nitrocellulose and probed with a polyclonal anti-GLUT antibody. 
A 55 kDa band was observed and quantified (Table 3.15). N= Normoxia 
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Table 3.15. Expression of GLUT -1 protein in breast carcinoma cell lines exposed to 
hypoxia and long-term high glucose (20 mM D-glucose >30 days culture). 
Hypoxic Exposure 
Cell Line (~1% 02) 
2 hours 4 hours 24 hours 48 hours 
MCF7 2.29 NID 2.77 NID 
MCF7Hyper N/D 0.73 0.32 NID 
SKBR3 N/D 0.80 N/D NID 
SKBR3Hyper N/D 0.63 N/D NID 
T47D NID 0.45 N/D 1.54 
T47DHyper NID 1.51 N/D N/D 
ZR75 0.99 0.65 0.64 N/D 
ZR75 Hyper N/D 0.82 0.94 N/D 
Results are expressed as the fold change in GLUT-I protein expression in extracts isolated 
from cultures exposed to hypoxia (~1% 0 2) for up to 48 hours, compared to the level 
obtained under normoxia. Results are expressed graphically in figure 3.29. N/D =Not 
Done. 
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Figure 3.29. GLUT -1 protein expression in extracts isolated from all breast carcinoma 
cell lines exposed to hypoxia for up to 48 hours. The expression of GLUT -1 protein in the 
cell lines varied. The MCF7, T47D and T47D Hyper cell lines displayed increased GLUT-
1 protein expression after exposure to hypoxia whereas the remaining cell lines displayed 
decreased GLUT -1 protein expression after exposure to hypoxia. Results are expressed as 
the fold change in GLUT -1 protein expression in cell lines exposed to hypoxia compared 
to the level obtained under normoxia (Table 3.15). 
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3.15 Conclusion 
This is a preliminary report of HIF-I a and p53 mRNA expression in high glucose 
and of HIF-Ia, GLUT-I andp53 mRNA expression in the combined stresses of hypoxia 
and high glucose. Each cell line studied produced minor genetic expression responses to 
the stresses of hypoxia, high glucose or the combined stresses of both, displaying slight 
increased expression of both the hypoxia-regulated genes HIF-Ia and GLUT-I. It was 
found that short-term exposure (3 days) to high glucose increased the expression of HIF-
I a, GLUT-I and p53 mRNA in 2 of 3 breast cancer cell lines studied. However, the 
combined stresses of hypoxia and long-term exposure to high glucose decreased the 
expression of HIF-Ia, GLUT-I and p53 mRNA in the majority of breast cancer cell lines 
studied. 
Under normoxic conditions, H/F-I a, GLUT-I and p53 mRNA was detected at 
varying concentrations in all of the breast carcinoma cell lines studied. Basal levels of 
expression of each gene varied by up to 9 fold in all cell lines, with HIF-I a mRNA 
expression increasing up to 2.3 fold in the cell lines conditioned to long-term high glucose. 
Basal levels of HIF-I a mRNA expression have been shown to vary according to 
differences in culture conditions (Semenza, 1998). 
Exposure of the breast carcinoma cell lines to hypoxia demonstrated a small but 
non-significant increase in the expression of HIF-Ia mRNA, GLUT-I and p53 mRNA 
expression in the majority of cell lines. This slight increase may not be a consequence of 
low oxygen tension but may instead represent a general adaptation response to of the cells 
during cultivation. This hypoxic exposure resulted in an initial decrease in the level of 
lactate from normoxic levels that steadily increased over normoxic levels after 24 and 48 
hours of exposure. The initial decrease in lactate levels would indicate recovery from the 
hypoxic stress followed by an increase in the rate of glycolysis. 
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A decrease in the expression of HIF-la and GLUT-I mRNA was observed in the 
cell lines exposed to the combined stresses of high glucose and hypoxia. Experiments 
controlling for osmolarity determined that the limited responses were not specific for D-
glucose and were probably due to differences in osmolarity as no significant increase in 
mRNA expression was observed in the cell lines exposed to L-glucose and mannitol. 
However, as only one experiment was performed for each cell line under each culture 
condition, several repeats are required to confirm these observations. As oxygen 
deprivation and excess glucose represent an additional disturbant of glucose transporter 
expression in human breast carcinoma cells, it is possible that a redox effect may promote 
any observed induction of HIF-1 a and GLUT-I mRNA in these cell lines and not hypoxia 
or D-glucose alone. 
IDF-1 DNA binding activity was observed in breast carcinoma cells exposed to 
normoxia, hypoxia and long-term high glucose. IDF-1 binding to its cognate DNA 
sequence increased after only 2 hours exposure to hypoxia in the majority of breast 
carcinoma cell lines investigated. The observed IDF-1 binding was specific as it could be 
effectively inhibited with excess unlabelled probe in competition experiments. 
Methodological difficulties with Western blotting prevented the assessment ofiDF-
1a protein expression in the breast carcinoma cell lines exposed to hypoxia and long-term 
high glucose. However, Western blot analysis of GLUT-1 protein expression showed no 
increase in the majority of breast carcinoma cell lines exposed to hypoxia for up to 24 
hours, which was consistent with observed mRNA levels. Cell lines conditioned to long-
term high glucose and exposed to hypoxia displayed a decrease in GLUT -1 protein 
expression. The MCF7, T4ID and the T4ID Hyper cell lines were the only cell lines which 
expressed an increase in GLUT -1 protein expression from normoxic levels after exposure 
to hypoxia for up to 24 hours. 
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These experimental results confirm that hypoxic regulation of HIF-la, GLUT-1 
and p53 occurs post-transcriptionally and the variation in response demonstrates the 
difficulties in working with cell lines. 
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4.0 Expression ofHIF-la and GLUT-1 in PBMCs Isolated From Patients 
with TlDM and Exposed to High Glucose 
Many of the genes that are induced by hypoxia through HIF-la, such as VEGF and 
GLUT-I, are up-regulated in response to glucose in both experimental and clinical 
diabetes. Hence the stimulation of glucose transport in the adaptive response of cells and 
tissues to hypoxia is of particular importance (Zhang, 1999). Moreover, it is known that the 
cellular redox state determines HIF-la binding activity {Haddad and Land 2000; Huang et 
a/, 1996) and that hyperglycaemia-induced redox imbalance mimics the effects of hypoxia 
(Williamson et a/, 1993). 
Presently little is known about the hyperglycaemia-induced expression of HIF-la. 
in the PMBCs of patients with or without diabetic complications. The expression profiles 
of both the HIF-I a and GLUT-I genes under hyperglycaemic conditions may offer an 
explanation as to why certain individuals with diabetes develop complications whilst 
others do not. Further information about HIF-1 DNA binding activity and HIF-la. and 
GLUT -1 protein expression levels will also offer additional insight. 
One of the aims of this work was to study the expression of HIF-I a by RT-PCR 
and quantitate the expression of HJF-I a and GLUT-I mRNA in the PBMCs of patients 
with TIDM exposed to high glucose using the RPA. A probe for HIF-Ia was amplified 
via RT-PCR from cDNA synthesised from total RNA. which was isolated from the T47D 
breast carcinoma cell line exposed to hypoxia {:S:l% 0 2) for 24 hours. For both HIF-Iaand 
GLUT-I mRNA expression analysis, PBMCs from patients with TIDM and normal 
healthy controls were exposed to normal glucose (11 mM D-glucose basal level within the 
media), modemte glucose (supplemented with 10 mM D-glucose) or high glucose 
(supplemented with 20 mM D-glucose) in PHA stimulated cultures for 5 days. 
Another aim of this study was to investigate the HIF-1 DNA binding activity and 
HIF-1 and GLUT-I protein expression in cellular and nuclear extmcts isolated from 
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PBMCs of nonnal controls and patients with TlDM exposed to high glucose. The DNA-
binding activity of HIF-1 was analysed by electrophoretic mobility shift assays (EMSA), 
using a double stranded oligonucleotide probe containing the HIF-1 binding site from the 
EPO enhancer (Semenza & Wang, 1992) that binds both HIF-1 and constitutively 
expressed factors. Protein expression levels were detennined by Western blot analysis 
using a monoclonal antibody to HIF-1 a and a polyclonal antibody to GLUT -1. 
4.1 Clinical Characteristics 
The clinical chamcteristics of all subjects studied for H/F-1 a mRNA expression are 
listed in Table 4.1 and those studied for GLUT-1 mRNA expression are listed in Table 
4.2. Of the 38 patients analysed in the H1F-1 a study, 25 patients had diabetic nephropathy 
(DN), 27 had diabetic retinopathy and 11 had remained free of microvascular disease 
(absence of background retinopathy, microalbuminuria and overt neuropathy) after 20 
years duration of diabetes (without complications). Of the 39 patients analysed in the 
GLUT-1 study, 26 patients had diabetic nephropathy, 27 had diabetic retinopathy and 12 
had remained free of microvascular disease after 20 years dumtion of diabetes (without 
complications). No statistically significant differences were found between the HbA1c and 
Insulin values between the patient groups in either study group. 
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Table 4.1. Clinical characteristics of normal controls and patients with TIDM studied in 
the IDF-Ia RPA. 
Characteristics Normal Patients with TlDM 
Controls 
Without Complications With Complications All Patients 
Number of subjects 6 11 27 38 
Sex (m:f) 4:2 3:8 11:16 14:24 
Age (years) 35 ± 6.4 42.2 ± 15.1 42.5 ± 12.1 42.4 ± 12.8 
(Range) (27-44) (27-70) (17-69) (17-70) 
Age at onset (years) 
- 17.8 ± 12.9 14.4±10.1 15.4 ± 10.9 
(Range) (2-42) (1-38) (1-42) 
Duration (years) 
- 26.5 ± 11.7 28.2 ± 8.7 27.7 ± 9.6 
(Range) (11-51) (8-43) (8-51) 
HbA1c 
- 8.1 ± 0.8 8.7 ± 1.58 8.5 ± 1.4 
(Range) (7.2-9.8) (6.1-12.4) (6.1-12.4) 
Insulin (Units/kg) 
- 45.1 ± 28.9 41.9 ± 18.5 42.8 ± 21.7 
(Range) (16-118) (10-94) (10-118) 
Thirty-eight patients with TlDM were considered in this study. Twenty-five of these had 
diabetic nephropathy, 27 had diabetic retinopathy and 11 had remained free of 
microvascular disease (absence of background retinopathy, microalbuminuria and overt 
neuropathy) after 20 years duration of diabetes (without complications). Six normal 
healthy controls were also studied. The data are expressed as mean values (± standard 
deviation). Neither the HbAlc values (T-test = 1.61, p = 0.12) nor the Insulin values (T-
test = - 0.40, p = 0.69) were significantly different between the patient groups. 
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Table 4.2. Clinical characteristics ofnonnal controls and all patients with TIDM studied 
in the GLUT-1 RP A. 
Characteristics Nonnal Patients witb TlDM 
Controls Without Complications With Complications All Patients 
Number of subjects 7 12 27 39 
Sex(m:f) 4:3 2:10 10:17 12:27 
Age (years) 37.9 ±7.0 36.3 ± 12.6 37.3 ± 10.6 37.2 ± 11.1 
(Range) (31-49) (22-70) (13-56) (13-70) 
Age at onset (years) 
- 13.0±8.6 13.0 ± 8.6 13.0 ± 8.5 
(Range) (2-30) (1-28) (1-30) 
Duration (years) 
- 25.7± 11.7 25.3 ± 8.0 25.4 ± 9.1 
(Range) (11-51) (8-38) (8-51) 
HbA1c 
- 8.3 ± l.1 9.1 ± 1.5 8.8 ± 1.4 
(Range) (6.8-10.1) (6.4-12.4) (6.4-12.4) 
Insulin (Units/kg) 
- 53.6 ± 24.7 47.4 ±26.0 49.3 ±25.4 
(Range) (20-100) (10-128) (10-128) 
Thirty-nine patients with TIDM were considered in this study. Twenty-six of these had 
diabetic nephropathy, 27 had diabetic retinopathy and 12 had remained free of 
microvascular disease (absence of background retinopathy, microalbuminuria and overt 
neuropathy) after 20 years duration of diabetes (without complications). Seven nonnal 
healthy controls were also studied. The data are expressed as mean values (± standard 
deviation). Neither the HbA1c values (T-test = 1.89, p = 0.07) nor the Insulin values (T-
test=- 0.70, p = 0.49) were significantly different between the patient groups. 
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4.2 HIF-1 a and GLUT-1 mRNA Expression 
The effect of high glucose on inducing the expression of HIF-1a and mRNA in the 
PBMCs of patients with TlDM and normal controls was determined by RT-PCR and RP A. 
RT-PCR was performed using amplimers for an alternative splice variant to IDF-la 
(Gothie et a/, 2000). In figure 4.1, increased and decreased expression of HIF-1 a can be 
seen in the PBMCs isolated from patients with TlDM, cultured in normal glucose or high 
glucose, by the intensity of the amplified DNA which were confirmed by RPA analysis 
(Figure 4.2). 
The optimal experimental culture time for the induction of IDF-la mRNA 
expression was determined by comparing the expression of HIF-I a mRNA in the PBMCs 
of two patients with TlDM cultured in high glucose for 3, 4 or 5 days (Table 4.3). As 
minor variations were observed in the expression of HIF-la mRNA between the culture 
time periods, 5 days was chosen to obtain maximal quantities of mRNA. The same culture 
times were used for experiments investigating GLUT-1 mRNA expression. It was not 
possible to analyse the same patient population that was studied for HIF-1a mRNA 
expression due to limited amounts ofmRNA. Further, PBMCs from 13 patients were only 
exposed to normal and high glucose and not to moderate glucose due to low yields of 
PBMCs. 
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Figure 4.1. HIF-1 a mRNA expression in the PBMCs isolated from a normal healthy 
control and patients with T1DM exposed to normal glucose (N), high glucose (H), 
analysed by RT-PCR. Amplification products were 487 bp for HlF-1a amplified product 
containing exon 14 and 350 bp for HlF-1a. amplified product without exon 14 (M = 100 
base pair ladder). Increased and decreased expression of HlF-1a can be seen by the 
intensity of the amplified DNA which was confirmed by RP A analysis. Arrows (t .J..) 
indicate increased or decreased expression or(:::) near equivalent expression from normal 
glucose cultures. 
NC = Normal Control, DC = Diabetic Control, DN = Diabetic Nephropath 
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Table 4.3. H/F-1 a mRNA expression in the PBMCs isolated from patients with T lDM 
exposed to normal glucose and high glucose for 3, 4 and 5 days. 
High Glucose Fold change in 
(20 mM D-glucose) HIF-lamRNA 
3 days 1.39 ± 0.05 
4days 1.29 ± 0.06 
5 days 1.24 ± 0.10 
Results are expressed as the mean fold increase in mRNA expression above the level 
obtained under normal conditions(± standard deviation). 
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An illustration of the expression of H/F-la and GLUT-I mRNA in PBMCs 
isolated from patients with TlDM, as well as normal healthy controls, exposed to normal 
glucose, moderate glucose and high glucose and analysed by RPA is shown in figure 4.2 A 
and 4.2B. To control for mRNA quality and loading variations, the level of P-actin 
expression was determined in the mRNA from the PBMCs of patients with diabetic 
nephropathy stimulated with either normal glucose, moderate or high glucose by RPA. 
Expression levels of mRNA were measured as fold increase or decrease in expression 
(Figure 4.2C). Similar levels of expression between the samples ensure that variations in 
gene expression are true and not due to loading errors (Hodgkinson et a/, 2001). 
Additionally, an 18S rRNA internal control was run on 5 diabetic PBMCs exposed to 
normal glucose and high glucose, showing that expression was consistent and equal with a 
mean fold difference of 1.00 ± 0.08 from normal glucose. 
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Figure 4.2. A) lllustration of HIF-1 a and B) GLUT-I mRNA expression in PBMCs 
isolated from normal healthy controls and of patients with TlDM that had been exposed to 
normal glucose (N), moderate (M) and high glucose (H), analysed by RP A. C) Dlustration 
of ~actin mRNA expression in PBMCs isolated from a patient with complications 
exposed to normal glucose, moderate and high glucose. Similar levels of expression 
between the samples ensured mRNA quality, equal loading and true gene expression 
(published in Hodgkinson et al, 2001). A 100 bp MW marker was run to ensure correct 
protected fragment size. 
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The overall mean levels of HIF-la and GLUT-/ mRNA expression in the PBMCs 
isolated from normal controls, all patients with TlDM as well as their subgroups (patients 
with and without complications) and exposed to normal glucose, moderate and high 
glucose are listed in Table 4.4 and displayed graphically in figures 4.3 and 4.4. The 
results are expressed as the fold change in mRNA from the level obtained under normal 
culture conditions. Statistical analyses of the overall mean levels of expression are listed in 
Table 4.5. 
In the patients with complications, HIF-1 a mRNA expression did not change from 
normal glucose levels when exposed to moderate glucose, 1.1 ± 0.12 (± standard error), 
whilst in high glucose it increased slightly by 1.3 ± 0.33 fold. HIF-1 a mRNA expression 
in the normal controls did not change with increasing concentration of D-glucose, 1.1 ± 
0.08 in moderate glucose to 1.2 ± 0.20 in high glucose. Patients without complications 
demonstrated a similar fold increase in HIF-1 a mRNA expression in both moderate 
glucose, 2.0 ± 0.53, and high glucose 2.2 ± 0.56. 
GLUT-/ mRNA expression remained constant in the patient group with 
complications with increasing concentration of D-glucose, 1.5 ± 0.41 in moderate glucose 
and 1.4 ± 0.20 in high glucose. Patients without complications demonstrated a decrease in 
GLUT-/ mRNA expression from 2.22 ± 0.62 in moderate conditions to 1.82 ± 0.39 in high 
glucose, however this change was not significant (Table 4.4 and Figure 4.4). Moreover, 
GLUT-/ mRNA expression was 1.5 fold higher in patients without complications (p= 0.14) 
then that of patients with complications at moderate glucose and 1.3 fold higher (p= 0.07) 
at high glucose. Although the expression of GLUT-/ mRNA was notably lower in the 
normal controls at high glucose then in the patients with complications, this decrease was 
not significant (p = 0.80). However, a significant difference in GLUT-/ mRNA expression 
was found between normal controls and patients without complications (p=0.03). (Table 
4.5). 
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When all patients with TlDM were analysed together, there was no significant 
difference in HIF-Ja or GLUT-! mRNA expression at both concentrations ofD-glucose. 
The increases observed in HIF-1 a mRNA expression in all patients studied at both 
moderate glucose and high glucose were not significantly different from normal controls. 
Although GLUT-! mRNA expression decreased with D-glucose concentration in all 
patients analysed, the expression was still greater than that found in the normal controls 
exposed to high glucose. 
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Table 4.4. Overall mean fold change in HIF-1 a and GLUT-I mRNA expression from normal glucose in PBMCs, isolated from normal controls 
and patients with TIDM, exposed to moderate and high glucose for 5 days. 
Glucose Normal Controls Patients without complications Patients with complications All patients with TIDM 
Concentration HIF-1a GLUT-1 HIF-1a GLUT-1 pvalue HIF-1a GLUT-1 pvalue HIF-1a GLUT-1 pvalue 
(n=6) (n=7) (n=9) (n=29) (n=38) 
Moderate (n=6) (n=20) (n=26) 
(10 mM D-glucose) 1.1 ±0.08 N/D 2.2 ± 0.56 2.2 ± 0.62 p=0.65 1.1 ±0.12 1.5 ± 0.41 p = 0.59 1.3±0.18 1.7 ±0.34 p=0.44 
(Range) (0.9-1.4) (0.3-4.6) (0.9-4.5) (0.4-3.5) (0.2-8.8) (0.3-4.6) (0.2-8.8) 
High Glucose (n=10) (n=29) (n=39) 
(20 mM D-glucose) 1.2 ± 0.20 0.9±0.10 2.0 ± 0.53 1.8 ±0.39 1.3 ±0.33 1.4 ±0.20 1.4 ±0.28 1.4±0.19 p=0.42 
(Range) (0.7-2.1) (0.6-1.2) (0.3-4.2) (0.5-4.0) p= 0.71 (0.2-10.2) (0.3-6.1) p = 0.70 (0.2-10.2) (0.3-6.1) 
pvalue p=0.75 - p=0.77 p=0.90 - p= 0.65 p=0.81 
-
p=0.64 p= 0.55 
Results are expressed as mean values of the fold increase or decrease in mRNA against the level obtained at normal glucose (± standard error). 
Statistical analyses were performed using the Mann-Whitney U-test. No statistically significant differences were found within any of the patient 
groups. Overall mean HJF-I a and GLUT-I mRNA levels are expressed graphically in Figures 4.3 and 4.4, respectively. N/D= not done, n= 
number of subjects. 
-297-
-
Chapter 4. Results 
Table 4.5. StatisticaJ analysis of the overall mean levels of HIF-1 a and GLUT-I mRNA expression in PBMCs isolated from normal controls and 
patients with TIDM, exposed to moderate and high glucose. 
Statistical Comparison HIF-la GLUT-I 
Moderate High Glucose Moderate High Glucose 
Patients with complications 
vs. p=0.20 p= 0.47 p= 0.14 p=0.07 
Patients without complications 
Patients with complications 
VS. p=0.62 p=0.62 - p=0.80 
Normal controls 
Patients without complications 
vs. p= 0.51 p= 0.80 - p=0.03 * 
Normal controls 
All patients with TlDM 
vs. p=0.91 p=0.80 - p= 0.41 
Normal controls 
Statistical analyses were performed using the Mann-Whitney U test A p value of <0.05 was considered significant. HIF-1 a and GLUT-I mRNA 
expression levels are listed in Table 4.4 and expressed graphicaJly in Figures 4.4 and 4.5, respectively. * = statistically significant 
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Figure 4.3. The mean fold increase of HIF-1 a m.RNA in PBMCs isolated from normal 
controls and patients with TlDM, exposed to normal glucose, moderate and high glucose. 
No statistically significant difference was found between culture conditions and patient 
subgroups (Table 4.4). 
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Figure 4.4. The mean fold change in GLUT-I mRNA in PBMCs isolated from normal 
controls and patients with TlDM, exposed to normal glucose, moderate and high glucose. 
GLUT-I mRNA expression levels and patient numbers are listed in Table 4.4. A 
statistically significant difference was found between the patient group without 
complications and normal controls(* p=0.03, Mann-Whitney U test) (Table 4.5). 
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Analysis of the ratios of HIF-la and GLUT-I mRNA expression in each of the 
patients groups studied showed 2 distinct trends compared to normal controls (Figures 4.5 
and 4.6). Overall, patients with TIDM displayed an increase in H/F-1 a mRNA expression 
in both moderate and high glucose, similar but higher expression as that seen in the normal 
controls, yet not significant (Figure 4.5). The overall pattern of GLUT-I mRNA 
expression in the patient population was an increase at moderate glucose followed by a 
decrease in expression at high glucose. The normal controls showed a slight decrease in 
expression at high glucose (Figure 4.6). 
- 301 -
d 
0 
.... 
{/) 
{/) 
11) 
.... 
ft 
~ 
"'0 
-0 ~ 
Chapter 4. Results 
HIF-1 
3 ~--------------------------------------------------, 
2.5 +------------------------------------------r------~ 
2 
1.5 
1 
0.5 +-----------------
0 +-----------------.----------------,----------------4 
normal moderate 
D-glucose Concentration 
-+-Mean of all patients (n=38) 
--Mean of patients with increasing expression (n=18) 
Mean of patients with decreasing expression (n=14) 
high 
-M-Mean of patients with increasing and decreasing expression (n=6) 
- Mean of controls (n=6) 
Figure 4.5. H/F-1 a mRNA expression in PBMCs isolated from normal controls and 
patients with TlDM, exposed to normal glucose, moderate, and high glucose. The pattern 
of H/F-1 a mRNA expression is charted, expressed as fold change, illustrating both distinct 
and interesting trends between the control and patient groups, and between the two patient 
groups with increasing only and decreasing only trends. Results are expressed as the mean 
fold increase or decrease in mRNA expression from the level obtained under normal 
conditions. There is no significant difference between normal controls and all patients with 
TlDM studied. n = number of subjects. 
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Figure 4.6. GLUT-I mRNA expression in PBMCs of normal controls and patients with 
T1DM exposed to normal glucose, moderate, and high glucose. The pattern of GLUT-I 
mRNA expression is charted, expressed as fold change, illustrating both distinct and 
interesting trends between the control and patient groups, and between the two patient 
groups with increasing only and decreasing only trends. Results are expressed as the mean 
fold increase or decrease in mRNA expression from the level obtained under normal 
conditions. 
n = number of subjects 
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4.3 Basal Levels of mRNA Expression 
The basal level of HIF-I a mRNA was found to be lower in the patients compared 
to the normal controls in all culture conditions after 5 days (Figure 4.7). The former had 
approximately 1.4 fold lower HIF-1 a mRNA expression in normal, moderate or high 
glucose conditions when compared with normal controls. Although no statistically 
significant differences were observed between the control and patient groups, a near 
significant difference was observed between the control and patient groups exposed to 
moderate glucose levels (p=0.05; Mann-Whitney U test). 
The basal level of GLUT-I mRNA expression was significantly lower in the 
patients with TlDM compared to the normal controls (Figure 4.8). Normal controls had a 
1.81 fold higher GLUT-I mRNA expression in normal glucose (p={).020; Mann-Whitney 
U test) and a 1.63 fold higher expression in high glucose (p={).04; Mann-Whitney U test). 
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Figure 4.7. Basal H/F-1 a mRNA expression in the PBMCs isolated from healthy normal 
controls and patients with TlDM exposed to normal glucose, moderate and high glucose 
for 5 days. H/F-1 a mRNA expression in PBMCs of normal controls was found to be 1.4 
fold hlgher then those of patients with diabetes whlch is independent of glucose 
concentration. No statistically significant differences were found between the control and 
patient groups at all D-glucose concentrations (Mann-Whitney U-test). 
Normal glucose: p = 0.18, Moderate glucose: p = 0.05, High glucose: p = 0.11 
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Figure 4.8. Basal GLUI'-1 mRNA expression in PBMCs isolated from normal controls 
and patients with TIDM exposed to normal glucose and high glucose for 5 days. GLUI'-1 
mRNA expression in PBMCs of normal controls was found to be significantly higher than 
those of patients with diabetes at normal glucose and high glucose, 1.81 and 1.63 fold, 
respectively (Mann-Whitney U test). * = statistically significant 
Normal glucose (normal controls vs patients with TlDM): p = 0.02* 
High glucose (normal controls vs patients with TIDM): p =0.04* 
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4.4 Osmolarity and High Glucose Controls 
To control for osmolarity and high glucose, and to determine whether the increased 
or decreased expression of HIF-Ja and GLUT-I mRNA was specific forD-glucose the 
PBMCs from 2 patients with nephropathy were stimulated with either L-glucose, which 
competes with D-glucose for the transporter, or mannitol, an osmolyte. In the first, 20 mM 
mannitol was used as a supplement with the 20 mM D-glucose. A second, parallel culture 
consisted of20 mM L-glucose being used as a supplement with the 20 mM D-glucose. 
When the tissue culture media containing the PBMCs isolated from patients with 
TlDM was supplemented with either 20 mM L-glucose or 20 mM mannitol, a 1.3 fold 
increase was seen in the expression of HIF-1 a mRNA (Table 4.6). In cultures 
supplemented with 20 mM D-glucose alone, one patient displayed a 1.4 fold increase and 
the other a 1.2 fold decrease in HIF-1 a mRNA expression. The mean of the two values for 
each experimental culture demonstrated that the supplements had no effect on HIF-Ia 
mRNA expression. 
GLUT-I mRNA expression was also quantitated in the same cultures where GLUT-
I mRNA was induced by D-glucose, L-glucose and mannitol in one patient and by D-
glucose and mannitol in the other (Table 4.6). As with HIF-1 a mRNA expression, the 
supplements had no effect on GLUT-I mRNA expression. 
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Table 4.6. Fold change in the levels of H1F-1 a and GLUF-1 mRNA in the PBMCs of 
patients with complications exposed to high glucose and supplemented with 
either 20 mM 1...-glucose or 20 mM mannitol. 
Fold change in IDF-1 a mRNA Fold change in GLUT-I mRNA 
Culture 
conditions 
DN 1 DN2 Mean(±SE) DN 1 DN2 Mean (±SE) 
High Glucose 
(20 mM D-glucose) 1.36 0.81 1.1 ± 0.28 1.74 1.15 1.5 ± 0.30 
I.-glucose 
(20 mM D-glucose + 1.32 0.98 1.2 ± 0.17 0.7 1.14 0.9 ±0.22 
20 mM L-glucose) 
Mannitol 
(20 mM D-glucose + 1.19 1.22 1.2 ± 0.02 1.03 1.28 1.2 ± 0.13 
20 mM mannitol) 
Results are expressed as the fold change in rnRNA against the level obtained at normal 
glycaemia. SE = standard error 
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4.5 Measurement of Lactic Acid 
The concentration of lactate was determined in the supernatant of cultures of 
PBMCs isolated from 4 patients without diabetic complications, 2 patients with diabetic 
complications and from 2 normal controls exposed to normal glucose and high glucose 
(Tables 4. 7). Basal levels of lactate were near equivalent in both normal glucose and high 
glucose cultures in the normal control and in the patients with diabetic complications. In 
the patients without complications, 3 of the 4 patients displayed increased levels of lactate 
(up to 1.3 fold) in high glucose. Of the 6 cultures of PBMCs isolated from patients with 
TIDM, 4 displayed higher levels of lactate than the normal control. The mean 
concentration of lactate in the 6 cultures ofPBMCs isolated from patients with TlDM was 
1.3 fold higher than the normal control after exposure to both normal glucose and high 
glucose. None of these increases were statistically significant. 
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Table 4.7. Measured lactate concentrations (mmol/L) in the culture media ofPBMCs 
isolated from a normal control and from patients with T1DM exposed to 
high glucose. 
PBMCs Measurement Culture Conditions 
Cultured Normal glucose High glucose 
OD(340nm) 1.34 1.45 
DC Lactate Cone. 13.67 14.82 (mmol/L) 
OD(340 run) 1.33 1.27 
DC Lactate Cone. 
(mmol/L) 13.57 12.95 
OD (340 run) 1.38 1.44 
DC Lactate Cone. 
(mmol/L) 14.10 14.66 
OD(340 run) 0.78 1.00 
DC Lactate Cone. 
(mmol/L) 7.93 10.17 
OD (340 run) 0.99 0.97 
DN Lactate Cone. 
(mmol/L) 10.10 9.86 
OD (340 nm) 1.42 1.44 
DN Lactate Cone. 
(mmol/L) 14.48 14.66 
Mean (±SE) Lactate Cone. (mmol/L) 12.0 ± 0.96 12.5 ± 0.87 
OD (340 run) 1.01 1.01 
Normal Lactate Cone. 
(mmol/L) 10.35 10.35 
Lactate concentrations were determined as described in chapter 2 (section 2.11.1.3). 
DC = Diabetic Control, DN = Diabetic Nephropath. SE = standard error. 
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4.6 HIF-1 DNA Binding Activity 
HIF-1 DNA-binding activity was observed in nuclear extracts prepared from the 
PBMCs of normal controls and patients with TIDM exposed to high glucose (Figure 4.9). 
Decreased HIF-1 binding activity, from the level observed at normal culture conditions, 
was seen in both the normal control and in the patient extracts with near equivalent levels 
seen in both groups (Table 4.8; Figure 4.10). 
In competition assays, HIF-1 bands induced by exposure to high glucose were 
displaced by the addition of excess unlabelled probe (up to 6 fold excess) in the extracts 
from cultured PBMCs of normal controls and patients with TlDM under both normal 
glucose and high glucose, suggesting that these bands are specific for the HIF-1 binding 
site (Figure 4.9). Attempts to supershift the HIF-1 DNA complexes with the addition of a 
monoclonal antibody to HIF-1 proved unsuccessful, however the observed high glucose 
induced DNA-binding activity was due to HIF-1 as the binding complex was knocked out 
in the competition assays. 
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Table 4.8. Mean levels ofHIF-1 DNA binding activity in nuclear extracts from the 
PBMCs of normal controls and patients with T1DM exposed to high 
glucose. 
Experimental Normal Patients with Controls TlDM Condition (n=2) (n=3) 
High glucose 0.87 ± 0.07 0.89 ± 0.06 (20 mM D-glucose) 
High glucose + 0.58 ± 0.02 0.21 ± 0.04 
excess unlabelled probe 
P value T= 4.35, 
T = 9.26, 
p = 0.049 p = 0.03 
Results are expressed as the mean value (± standard error) of the fold change in HIF-1 
DNA-binding activity in nuclear extracts isolated from cultures exposed to high glucose 
compared to the level obtained under normal culture conditions. Results are expressed 
graphically in figure 4.10. 
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N H H+E N H H+E N H H+E N H H+E N H H+E 
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Free 
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Figure 4.9. EMSA of nuclear extracts prepared from the PBMCs of normal controls and 
patients with T1DM that had been exposed to normal glucose and high glucose. 15 J.lg of 
nuclear protein was analysed. IDF-1 binding complex (IDF-1) bands are indicated. The 
addition of excess unlabelled probe in competition assays displayed IDF-1 binding 
complexes. Results are displayed graphically in figure 4.10. N= Normal glucose, H = 
High glucose, H+E = High glucose + Excess unlabelled probe, DN= Diabetic Nephropath, 
NC = Normal Control. 
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HIF-1 Binding Activity 
Normal High 
D-glucose Concentration 
High + excess unlabelled 
probe 
•Normal controls (n=2) •Patients with T1DM (n=3) 
Figure 4.10. Graphical expression ofHIF-1 DNA binding activity in nuclear extracts from 
the PBMCs isolated from normal controls and patients with T1DM exposed to high 
glucose for 5 days. HIF-1 DNA-binding activity decreased after exposure to high glucose 
in both cultures with near equivalent activity. The addition of excess unlabelled probe 
displaced the binding activity. Results are expressed as the value of the fold change in IllF-
1 DNA-binding activity in nuclear extracts isolated from cultures exposed to high glucose 
compared to the level obtained under nonnal glucose. 
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4.7 HIF-la and GLUT-1 Protein Expression 
Methodological difficulties with Western blotting prevented the assessment ofHIF-
1a protein expression in the PBMCs of patients with TlDM and normal controls (see 
chapter 3, section 3.13 for initial experimental results). 
However, the effect of high glucose on inducing the expression ofGLUT-1 protein 
in the PBMCs of patients with TlDM and normal controls was determined by Western 
blotting (Table 4.9; Figures 4.11 and 4.12). Exposure to high glucose was found to 
increase GLUT-1 protein expression by up to 1.4 fold in protein extracts isolated from the 
PBMCs of 2 normal controls, and decrease GLUT-1 protein expression by half in protein 
extracts isolated from the PBMCs of a patient without complications and of a patient with 
complications. 
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Figure 4.11. Western blot analysis of GLUT-1 protein expression in the PBMCs isolated 
from normal controls and from patients with T1DM exposed to high glucose. PBMCs were 
exposed for 5 days to high glucose, cellular proteins (30 J.lg/lane) were separated by 12% 
SDS-Page, blotted on nitrocellulose paper and probed with a polyclonal anti-GLUT -1 
antibody. A 55 kDa band was observed and quantified (Table 4.9). N = Normal glucose, 
H= High glucose, DC = Diabetic Control, DN = Diabetic Nephropath, NC = Normal 
ControL 
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Table 4.9. Expression of GLUT-I protein in extracts isolated from the PBMCs of normal 
controls and patients with TIDM exposed to high glucose for 5 days. 
High glucose GLUT-I fold Mean (±SE) 
(20 mM D-glucose) protein expression 
Normal control I 1.43 
1.28 ± 0.15 
Normal control 2 1.13 
Diabetic Control 0.51 
0.49 ± 0.03 
Diabetic Nephropath 0.46 
Results are expressed as the fold change in GLUT-I protein expression in extracts isolated 
from cultures exposed to high glucose compared to the level obtained under normal 
glucose (± standard error). Results are expressed graphically in figure 4.12. 
Normal controls vs. patients with TIDM: T-test = 5.23, p = 0.03 
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GLUT-1 
Normal High 
D-glucose Concentration 
Normal Controls (n=2) •Patients with TlDM (n=2) 
Figure 4.12. GLUT -1 protein expression in extracts isolated from the PBMCs of normal 
controls and from patients with TlDM exposed to nonnal glucose and high glucose for 5 
days. The expression of GLUT -1 protein in the PBMCs of patients with TlDM exposed to 
high glucose decreased to half the level expressed under nonnal glucose whilst the GLUT-
1 protein expression in nonnal controls increased up to 1.4 fold when exposed to high 
glucose. Results are expressed as the mean fold change in GLUT-I protein expression in 
PBMCs exposed to high glucose compared to the level obtained under normal glucose. 
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4.8 Conclusion 
In this study, the expression of HIF-Ia and GLUT-I mRNA in the PBMCs of 
patients with TlDM increased upon exposure to D-glucose. Although results showed that 
the patients without complications displayed a greater fold increase in mRNA expression 
for both genes, above that of normal controls and of patients with complications, this 
increase was only significant in GLUT-I mRNA expression. The experiments controlling 
for osmolarity determined that this response was not specific for D-glucose and was 
probably due to differences in osmolarity as exposure of PBMCs to L-glucose and 
mannitol had no effect on mRNA expression. It is possible that the PBMCs from patients 
with TlDM may be preconditioned to hyperglycaemia and that the expression and function 
of glucose transporters differs between patients with and without complications. 
A slight but non-significant increase in basal lactate levels was observed in cultures 
of PBMCs from patients with TlDM than in cultures of PBMCs from normal healthy 
controls, indicating that increased glycolysis occurs in patients with TlDM. Exposure to 
hyperglycaemia does not seem to further up-regulate glycolysis in these patients nor in 
normal controls. A possible explanation for this may be that the glucose receptors are 
saturated due to the high concentration of D-glucose in the cultures, thereby producing a 
slower observed response. 
Although HIF-1 binding activity was observed in the PBMCs from normal healthy 
controls and from patients with TlDM, the binding activity decreased after exposure to 
high glucose. The observed HIF-1 binding was specific as it could be inhibited effectively 
with excess unlabelled probe in competition experiments. 
Methodological difficulties with Western blotting prevented the assessment ofHIF-
la protein expression, however Western blot analysis of protein extracts from the PBMCs 
of normal controls exposed to high glucose displayed an increase in GLUT-I protein 
expression whilst those from patients with TlDM exposed to high glucose showed a 
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dramatic decrease in GLUT-1 protein expression. This would imply that the induction of 
GLUT-I mRNA is not mediated at the transcriptional level in patients with TlDM. As 
these initial results were obtained from analysis of only 2 patients with TlDM, one with 
and one without complications, further experiments are required on a larger patient 
population to elucidate the response seen. 
This novel preliminary report suggests that HJF-1, in conjunction with GLUT-1, 
may be an important regulator of the cellular response to hyperglycaemia as abnormal 
expression of HIF-la and its target genes, through activation by hyperglycaemia, may 
contribute to diabetic complications. Further studies of subsequent gene and protein 
regulation by HIF-la are required as the molecular basis of the cellular response to 
hypoxia and hyperglycaemia has yet to be determined. 
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5.0 Expression ofHIF-1a and GLUT-1 in Tumours of Patients with 
Breast Cancer 
HIF-la and GLUT-1 mRNA expression was assessed in the total RNA extracted 
from 22 tumour samples from patients with breast cancer by RT-PCR and RPA. HIF-la. 
amplifications were performed using amplimers for a recently discovered alternative splice 
variant to HIF-la. (Gothie et a/, 2000). HIF-1 protein expression was assessed by 
immunocytochemistry, using a monoclonal antibody to the a. subunit (HIF-la.). 
5.1 Clinical Characteristics 
The clinical characteristics of the 22 patients from which these tumours were 
derived are listed and summarised in Tables 5.1 and 5.2. The mean age of diagnosis was 
66.7 ± 15.8 years (42-91 years). The majority of patients had advanced T stage (31.8% T2-
3), grade (95.5% G2.3) or positive node stage (56.4% N1•3). 
-322-
Chapter 5. Results 
Table 5.1. Clinical characteristics of patients with breast tumours. 
Characteristics Patients witb Breast Tumours 
Number of 22 
subjects 
Age at Diagnosis 
(years) 66.7± 15.8 
(Range) (42-91) 
Survival (years) 3.44 ± 1.4 
(Range) (1.2-8.0) 
Survival (weeks) 179.1±72.9 
(Range) (59.7-417.2) 
The data are expressed as mean values (± standard deviation). 
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Table 5.2. Frequencies of the clinicopathological characteristics of patients with breast 
tumours 
Variable Frequency 
(n} 
Patients 100 (22) 
Age (median) 
<66 45.5 (10) 
~66 54.5 (12) 
T stage 
1 68.2 (15) 
2 31.8 (7) 
3 0 (0) 
4 0 (0) 
N stage 
0 45.5 (10) 
1 36.4 (8) 
2 9.1 (2) 
3 9.1 (2) 
Grade 
1 4.5 (1) 
2 36.4 (8) 
3 59.1 (13) 
n = actual number of patients (in parenthesis). 
T = tumour stage, N = node stage 
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5.2 HIF-la and GLUT-1 mRNA Expression 
The expression of HIF-Ia mRNA was analysed by RT-PCR using amplimers for a 
recently discovered alternative splice variant to IDF-1a. (Gothie et a/, 2000) (Figure 5.1). 
Only 1 J,lg of total RNA was available for cDNA synthesise, due to a low yield of total 
RNA from limited tissue samples, thus the assay was not performed under optimal 
conditions. When HIF-1 a mRNA expression was detected, the intensity of the amplified 
band ranged from very faint to strong resulting in 13 of22 tumours being positive for HJF-
1 a mRNA expression 
HIF-Ia and GLUT-I mRNA expression was also analysed by RPA (Table 5.3, 
Figure 5.2). RT-PCR results were not entirely confirmed by this additional analysis, not 
due to the technique but rather due to a lack of cDNA available for analysis in the RT-PCR 
assay. As RP A is an extremely sensitive and quantitative technique, this method of 
analysis for mRNA expression is more likely to be accurate. Results are expressed as the 
fold increase in expression from the lowest expression level (Table 5.3). As no normal 
control tissue was available for analysis a visual cut off point of 0.40 for band intensity 
was taken as positive expression, thus values in bold indicate increased expression of the 
respective gene and are at least 2.5 fold higher then the lowest expression level. Both genes 
were moderately overexpressed in the breast tumours but the incidence and amplitude of 
overexpression varied. Of the 22 tumours analysed by RPA, 13 were considered positive 
for HIF-Ia mRNA expression and 15 were considered positive for GLUT-I mRNA 
expression. Although the majority of tumours showed overexpression of both or neither of 
the two genes, 11 of the 22 tumours expressed significantly higher levels of HIF-1 a of 
GLUT-I mRNA only. 
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Figure 5.1. HIF-1 a and /)-actin mRNA expression in tumours from patients with breast 
cancer. Amplification products were 487 bp for HIF-1et amplified product containing exon 
14, 350 bp for HIF-1et amplified product without exon 14 and 661 bp for ~-actin. (M = 100 
base pair ladder). Lanes 3, 4, 7, 8 and 9 were scored positive for HIF-1et (weak and strong 
expression). ~-actin expression demonstrates the quality of cDNA and equal sample 
loading. The band products were quantified and are listed in Table 5.3. 
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HIF-1 and GLUT 1 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 21 22 
Patients with Breast Cancer 
lllF-1 • GLUT 1 I 
Figure 5.2. The fold change in HIF-1 a and GLUT-I m.RNA expression in tumours from 
patients with breast cancer as determined from RP A analysis. Fold change represents the 
fold increase in expression from the lowest expression level in all patients, as no normal 
control tissue was available for analysis. Of the 22 tumours analysed, 13 were considered 
positive for HIF-1 a mRNA expression and 15 were considered positive for GLUI'-1 
mRNA expression using RP A analysis. Expression levels are listed in Table 5.3. 
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Table 5.3. HIF-1 a and GLUT-I mRNA expression and HIF-la. protein expression in 
tumours from patients with breast cancer. 
Patient Tumour HIF HIF Fold HIF GLUT-1 Fold 
# Stage mRNA mRNA Change Protein mRNA Change 
(RT-PCR) (RP A) (RP A) 
1 T1NOG1 0.44 0.11 1.00 ++ 1.72 10.75 
2 T2NOG3 1.58 0.12 1.09 
-
1.84 11.50 
3 T2N1G3 0.01 0.6 5.45 
-
0.88 5.50 
4 T2N2G3 0.16 0.64 5.82 
-
0.34 2.13 
5 T1NOG3 0.15 0.94 8.55 -(c) 0.39 2.44 
6 T1N1G3 0.71 2.05 18.64 
-
0.4 2.50 
7 T2NlG3 0.85 1.87 17.00 
-
1.64 10.25 
8 TlNlG2 0.56 0.41 3.73 
-
0.83 5.19 
9 T1NlG2 0.55 0.33 3.00 -(c) 1 6.25 
10 TlNOG2 0.42 0.23 2.09 -(c) 0.16 1.00 
11 T2N3G3 0.41 2.22 20.18 -(c) 4.41 27.56 
12 TlNOG2 0.38 0.38 3.45 
-
0.27 1.69 
13 T2NlG2 0.36 0.39 3.55 
-
0.54 3.38 
14 T2N3G3 1.01 6.36 57.82 -(c) 9.9 61.88 
15 TlNOG3 0 0.61 5.55 -(c) 0.5 3.13 
16 T1N1G3 0.06 0.42 3.82 -(c) 2.25 14.06 
17 T2NOG3 1.27 1.37 12.45 ++ 6.69 41.81 
18 T1NOG2 1.2 0.94 8.55 + 6.9 43.13 
19 TlNOG3 0.36 0.17 1.55 - (c) 0.33 2.06 
20 T1N1G2 0.36 
- - -(c) - -
21 TlN2G2 0.63 0.27 2.45 + 0.28 1.75 
22 T1NOG3 1.28 0.94 8.55 + 4.23 26.44 
RT-PCR and RPA expression levels are given as raw values minus background. Fold 
change represents the fold increase in expression from the lowest expression level (i.e. 0.11 
for HIF-1a. m.RNA, patient 1). For RT-PCR, values in bold indicate a visual band. As no 
normal control tissue was available for analysis a visual cut off point of0.40 for RPA band 
intensity was taken as positive expression, thus values in bold indicate increased 
expression of the respective gene. Speannan's correlation between HIF-la. and GLUT-1 
mRNA expression was significant for analyses by RT-PCR (p=0.02) and by RPA (p=0.03). 
For immunohistochemical analysis: 
(-) = negative nuclear staining/expression , (- (c)) = negative nuclear staining but strong 
cytoplasmic staining, ( +) = local/weak nuclear staining, ( ++) = strong nuclear staining 
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HIF-Ia and GLUT-I mRNA expression was analysed statistically 2 ways: as 
numerical values which included all expression values (one group), and as categorical 
values which were divided into 2 groups, tumours which overexpressed or did not 
overexpress either mRNA Analysis of all expression values in the tumours showed that 
there was a significant association between HIF-I a and GLUT- I mRNA expression 
(Spearman's non-parametric correlation p=0.03; Table 5.4). This association was lost 
when the mRNA expression was categorised (p=0.09). Additionally, a significant 
association was also found between HIF-I a mRNA expression and age (p=0.04), T stage 
(p=0.02), N stage (p=0.03) and grade (p=0.02). No associations were found with GLUT-I 
rnRNA expression in the tumours using this analysis. When expression levels were 
categorised, the association between HIF-Ia mRNA expression and T stage was lost 
(p=O.ll), however an association was found between GLUT-I mRNA expression and age 
(p=0.03) and N stage (p=0.03) (Table 5.4). No significant association was found between 
HIF-Iaor GLUT-I mRNA expression and HIF-Ia. protein expression. 
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Table 5.4. Association between disease variables and HIF-1 a and GLUT-I m.RNA 
expression and HIF-1 a. protein expression in the tumours of 22 patients 
with breast cancer. 
Analysed as Test variable with corresponding p value (p) 
numerical variables HIF-lamRNA GLUT-1 mRNA HIF-la. protein (All expression levels) 
expression expression expression 
HIF-lam.RNA - 0.478 , p=0.03* -0.018 , p = ns 
GLUT-I mRNA 0.478 , p=0.03* 
-
0.34\ p= ns 
HJF-1a. protein -0.018 , p = ns 0.348 , p = ns -
Survival (years) -0.238 , p = ns -0.018 , p = ns -0.048 , p = ns 
Age -0.458 , p=0.04* -0.348 , p = ns 0.038 , p = ns 
T stage 5.36c, p=0.02* 2.01c, p= ns -0.27c, p = ns 
N stage 6.75c, p=0.03* 2.30c, p = ns -0.27\ p = ns 
Grade 3.50c, p=0.02* 0.2lc, p = ns -0.19c, p = ns 
Analysed as 
categorical variables HIF~lamRNA GLUT-1 mRNA HIF-la. protein 
(Overexpressed vs. expression expression expression 
not overexpressed) 
HIF-lamRNA - 2.9ld, p = ns 0.002d, p = ns 
GLUT-I mRNA 2.9ld, p = ns 
-
0.08d, p = ns 
HlF -1 a. protein 0.002d, p = ns 0.08d, p = ns -
Survival (years) 47.5b, p = ns 29.0b, p = ns 0.20b, p = ns 
Age 23.5b, p = 0.04* 17.5b, p = 0.03* 0.001 b' p = ns 
T stage 2.52d, p= ns 1.05d, p = ns 1.92d, p = ns 
N stage 2.22d, p = ns 9.24d, p = 0.03* 0.2r, p = ns 
Grade 7.77d, p = 0.02* 1.12d, p = ns 0.60d, p = ns 
Non-parametric analysis was performed using 8Spearman's coefficient of correlation, 
"Mann-Whitney U, '1<ruskal-Wallis Hand dPearson Chi-square tests. ns = not significant 
* = statistically significant 
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5.3 HIF-la Protein Expression 
Immunohistochemical analysis ofHIF-1a. protein expression was performed using 
antibodies to HIF-1a. that had just become commercially available, which had not yet been 
validated for immunohistochemical analysis. An immense amount of time was spent 
optimising and validating this procedure of which the results of at least four separate and 
consistent analyses are described below. All slides were assessed by a neuropathologist 
(Dr. David Hilton). 
Tumour cell immunoreactivity was scored according to the nuclear staining. Both 
the extent of staining (relative number of HIF-1a. positive cells) and the intensity of the 
reaction were taken into account:(-)= negative nuclear staining/expression, -(c)= negative 
nuclear staining but strong cytoplasmic staining, ( +) = local/weak nuclear staining, ( ++) = 
strong nuclear staining. For purposes of statistical analysis, HIF-1a. observed 
immunoreactivity was classified as 3 grades of staining: 0 = negative nuclear staining, 1 = 
strong cytoplasmic staining, and 2 = positive nuclear staining. Immunohistochemical 
results for HIF-1a. protein expression in the tumours from patients with breast cancer are 
shown in Table 5.3. 
Of the 22 samples analysed, strong HIF-la. immunoreactivity was seen in 2/22 
tumours (Figure 5.3), 3/22 tumours displayed weak HIF-1a. immunoreactivity and 17 were 
negative for expression. Of the 16 scored negative for HIF-1a. expression, 9 specimens 
(40.9 %) displayed strong cytoplasmic staining. Cytoplasmic staining consisted primarily 
of a granular staining pattern distributed throughout the cell cytosol. Of the 5 samples 
which displayed HIF-Ia. immunoreactivity, 3 also overexpressed HIF-1 a and GLUT-/ 
mRNA. No significant association was found between HIF-la. protein expression and 
HIF-1 a or GLUT-I mRNA expression or with clinicopathological characteristics (Table 
5.4). 
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Figure 5.3. Immunohistochemical analysis ofHIF-la. protein expression in tumours from 
patients with breast cancer. Strong nuclear immunoreactivity is seen infiltrating the tumour 
margin (Xl50) (haematoxylin counterstain). 
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Table 5.5. Univariate and multivariate analysis of cumulative overall survival of22 
patients with breast cancer. 
Univariate Analysis Hazard Ratio 95%CI p value 
HIF-1a 0.02 1.52x10-6-304.9 ns (negative vs. positive mRNA) 
GLUT-1 1.27 0.12-13.99 (negative vs. positive mRNA) ns 
HIF-la 3.48 0.32-38.7 ns (negative vs. positive protein) 
Age (continuous) 0.97 0.90-1.05 ns 
T stage (T 1-z) 0.04 2.35x10-8-549.7 ns 
N stage (No-J) ns 
No vs. N1 61532 8.54xl0"185 -4.43xl0193 ns 
No vs. N2 310102 4.30x10-184 -2.23xl0194 ns 
No vs. N3 390704 5.42x1 0"184 -2.82x1 0194 ns 
Grade (Gt-J) ns 
G1 vs. G2 0.02 1.24x10-14- 3.13x1010 ns 
G1 vs. G3 0.02 9.03x10·7 -429.6 ns 
Multivariate Analysis Hazard Ratio 95%CI p value 
mF-1a 0.03 1.11x 10"254 -1. 07x 10251 ns (negative vs. positive mRNA) 
GLUT-1 608 1.03x10-168 -3.58x10178 (negative vs. positive mRNA) ns 
HIF-la 1.40 3.80x10-73 -5.17x1072 ns (negative vs. positive protein) 
Age (continuous) 0.979 0.88-1.08 ns 
T stage (T 1-2> 6.89x104 1.43x10-35 -3.32xl 028 ns 
N stage (Na-3) ns 
No vs. N1 1.98x104 5.83x10-102-6.72x1 093 ns 
No vs. N 2 0.74 0.04-12.59 ns 
No vs. N3 0.01 1.29x10"173 -4.72x10168 ns 
Grade (Gt-J) ns 
G1 vs. G2 2314 0-0 ns 
G1 vs. G3 0.02 8.86xl0-252-6.32x10247 ns 
Hazard ratios (HR), p values and 95 % confidence intervals (Cl) are indicated. Multivariate 
analysis was performed using a backward elimination procedure to remove variables with 
p ~ 0.10. The qualifying criteria for inclusion in the multivariate analysis were p<O.l, or 
hazard ratios <0.5 or >2 in the univariate analysis. ns = not significant 
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5.4 Survival 
Survival of the 22 patients with breast cancer from whom tumours were accessed 
was followed up, with overall survival being measured from the time of diagnosis to the 
date of death or until October 2001. Two groups of patients were formed with regard to 
HIF-Ia and GLUT-I mRNA expression: positive or negative expression for HIF-Ia and 
GLUT-I mRNA. Univariate analysis of overall survival was performed by Kaplan-Meier 
analysis (Kaplan and Meier, 1985). Although statistical power was limited because of the 
relatively low number of cases, the Cox proportional hazards model was used for 
multivariate analysis. For all tests, a p value of less than or equal to 0.05 was considered as 
significant. All p values are results of two-sided tests. 
All but 3 patients remained alive at the time of follow up and all patients had an 
overall survival time averaging 3.44 ± 1.4 years (179.1 ± 72.9 weeks) (Table 5.1). 
Univariate and multivariate analysis of the patient group showed that none of the disease 
variables were significantly associated with survival in the patient group (Table 5.5). This 
was expected due to the small test group and the restricted variety in tumour grading. 
Kaplan-Meier analysis revealed a significant influence of T stage (log-rank test, 
p=0.006; Figure 5.4) and N stage (log-rank test, p=0.009; Figure 5.5) on cumulative 
overall survival, where patients with a T stage of T1 surviving longer than patients with a 
T stage ofT2 and patients with aN stage ofNo or N1 surviving longer than patients with a 
N stage of N2 or N3. Tumour grade did not show an influence due to the small number of 
patients with a low G1 grade (n=l) (log-rank test, p=0.32; Figure 5.6). No significant 
influence from either HIF-Ia or GLUT-I positive or negative mRNA expression was 
found on the cumulative overall survival in the patient group (log-rank test, p=0.16 and 
0.85 respectively; Figures 5.7 and 5.8), or from HIF-la protein expression (log-rank test, 
p=0.47, Figure 5.9). 
-334-
Chapter 5. Results 
Overall Survival in Patients with Breast Cancer 
1.1 
t /'\ 
-- __._._ J. . V _, -· . 
ea 
> 
·-~ .9 
m 
-1! 
4) 
0 .8 
4) 
- ~ ~ 
.7 1 
u 
.6 
.5 
0 1 2 3 4 5 6 7 8 9 
Survival (years) 
T stage 
-- T2 Tl 
Figure 5.4. Cumulative overall survival of patients with breast cancer (n=22) differentiated 
by tumour stage (T stage) and analysed by Kaplan-Meier. Overall survival is defined from 
the day of diagnosis until day of death. Log rank test 7.57, p = 0.006*. 
* = statistically significant 
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Figure 5.5. Cumulative overall survival of patients with breast cancer (n=22) differentiated 
by node stage (N stage) and analysed by Kaplan-Meier. N stages were grouped in order to 
produce the survival plot as the majority of patients remained alive at the time of analysis. 
Overall survival is defined from the day of diagnosis until day of death. Log rank test 6.87, 
p = 0.009*. 
* = statistically significant 
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Figure 5.6. Cumulative overall survival of patients with breast cancer (n=22) differentiated 
by grade and analysed by Kaplan-Meier. Overall swvival is defined from the day of 
diagnosis until day of death. Log rank test 2.26, p = 0.32. 
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Figure 5.8. Cumulative overall survival of patients with breast cancer (n=22) with negative 
mRNA expression of GLUT-I , compared with patients with positive mRNA expression of 
GLUT-I, determined by RPA and analysed by Kaplan-Meier. Overall survival is defmed 
from the day of diagnosis until day of death. Log rank test 0.04, p = 0.85. 
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Figure 5.9. Cumulative overall survival of patients with breast cancer (n=22) with negative 
HIF-la. nuclear protein expression, compared with patients with either strong HIF-la 
cytoplasmic protein expression or positive HIF-la. nuclear protein expression, determined 
by immunohistochemistry and analysed by Kaplan-Meier. Overall survival is defined from 
the day of diagnosis until day of death. Log rank test 1.5, p = 0.47. 
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The Nottingham Prognostic Index (NPI) was also assessed in the patient group (see 
Chapter 2, section 2.12.6). Calculated NPI's in the 22 patients with breast cancer in this 
study showed that the majority of subjects were in the range of the moderate prognostic 
group (63.6 %) (Table 5.6). Interestingly, all 3 of the patients who succumbed to the 
disease were determined to be in the poor prognostic group and had an average survival 
time of 2.14 ± 0.90 years. A significant correlation was found between survival and NPI 
(Spearman's coefficient of correlation -0.466, p=0.03), with a hazard ratio of7.96, p = 0.03 
(1.24-50.92; 95% Cl), log rank 18.36, p=O.OOOI, and between HIF-la mRNA expression 
and NPI (Spearman's coefficient of correlation 0.477, p=0.03). 
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Table 5.6. Nottingham Prognostic Index (NPQ of the 22 patients with breast cancer. 
NPI Subjects Survival 
n(%) n(%) Years(± SD) 
Good Prognostic Group (GPG) (<3.4) 4 (18.2) 4 (100) 4.05 ± 1.91 
Moderate Prognostic Group (MPG) (3.41-5.4) 14 (63.6) 14 (100) 3.58 ± 1.30 
Poor Prognostic Group (PPG) (>5.41) 4 (18.2) 1 (25) 3.11 
Of the 3 patients with breast cancer assessed in this study that are deceased, all had an NPI 
greater than 5.41 and had an average survival time of2.14 ± 0.91 years. Survival time is 
measured from the time of diagnosis to the date of death or until October 2001 and is 
presented in years ± standard deviation. A correlation was observed between survival and 
NPI (Spearman's coefficient of correlation 0.466, p=0.03*; Kruskai-Wallis H test 5.89, 
p=0.05*). 
n = number of subjects. 
* = statistically significant 
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5.5 Conclusion 
This study investigated the expression of HIF -1 a in breast tumours as well as its 
predictive potential and found a significant association between HIF-1 a and GLUT-1 
mRNA expression in breast tumours (p=0.03). RPA analysis showed that 13 of22 tumours 
were positive for HIF-1 a mRNA expression which correlated significantly with patient 
and disease characteristics of age and grade, but not with T stage or N stage. Expression of 
GLUT-1 mRNA was found in 15 of 22 tumours and correlated significantly with patient 
age and N stage, but not with T stage or grade. Only 5 of 22 tumours displayed HIF-1a. 
immunoreactivity with 9 of 22 tumours displaying cytoplasmic staining. No association 
was found between HIF-1a. protein expression and HIF-la or GLUT-1 mRNA expression 
or with clinicopathological characteristics. Univariate and multivariate analysis did not 
find any association with disease variables and patient survival. However, Kaplan-Meier 
analysis revealed a significant influence ofT stage (log-rank test, p=0.006) and N stage 
(log-rank test, p=0.009) on cumulative overall survival. No significant influence from 
either HIF-1 a or GLUT-1 positive or negative mRNA expression or from HIF-1a. protein 
expression was found on the cumulative overall survival in the patient group. However, a 
significant association was found between survival time and NPI and between HIF-1 a 
mRNA expression and NPI in the patient group. 
This is a preliminary report of HIF-1a and GLUT-1 mRNA expression in breast 
tumours. The results may suggest that overexpression of both HIF-1 a and GLUT-1 mRNA 
increase with disease progression. The significance of these results may reflect the weak 
statistical power of the small patient group analysed (n=22). 
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6.0 Expression ofHIF-la, VEGF and p53 in Glial Cell Tumours 
Recent work has suggested a role for IDF-1a in glioblastomas, although little is 
known about the mechanisms controlling its expression (Zagzag et a/, 2000; Zhong et a/, 
1999). The expression of IDF-1, VEGF and p53 protein and mRNA was accessed in a 
range of astrocytic tumours, including glioblastomas. IDF-1 protein expression in 
glioblastoma multiforme tissue was assessed in forty-one specimens by 
immunocytochemistry, using a monoclonal antibody to the a subunit (IDF-1a). VEGF and 
p53 protein expression was assessed in the same specimens using separate polyclonal 
antibodies to VEGF and p53. H/F-1 a and VEGF mRNA expression was assessed in the 
total RNA extracted from 34 tumour samples and 2 normal brain samples by reverse 
transcriptase PCR (RT-PCR) and the ribonuclease protection assay (RPA), including an 
18S rRNA control. 
H/F-1 a and VEGF mRNA expression were originally assessed by Northern 
blotting however, due to the limited specimen size and the high quantity of mRNA 
required to attain a signal, the above mentioned techniques were used. DIG-IT labelled 
DNA probes to IDF-1a were used in the initial assessment of mRNA expression in the 
tissue sections. Two separate probes, one of 135 bp and another of 283 bp, were prepared 
via RT-PCR. As the results were unsatisfactory, in that a signal could not be detected, the 
approach was changed to immunohistochemistry when the first commercially available 
antibody to IDF-1a became available. 
The aim of this study was to investigate the levels and expression of IDF-la, 
VEGF and p53 with respect to different grades of tumour. Results are expressed as the 
ratio of intensity of the expression of the gene of interest compared to the housekeeping 
gene f3-actin. Statistical significance was assessed on the data groups using analysis of 
variance (ANOVA) followed by F-test and the student's t-test for comparison of means 
with values ofp< 0.05 considered as significant. 
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6.1 Clinical Characteristics 
The clinical characteristics of the patients from which these tumours were derived 
are listed in Table 6.1. There were 19 male patients and 15 female patients included in the 
study of which the overall mean age of diagnosis was 55± 15.3 years (25-80 years). 
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Table 6.1. Clinical characteristics of normal controls and patients with glial cell tumours. 
Characteristics Normal Diffuse Anaplastic Glioblastomas All Patients 
Controls Astrocytomas Astrocytomas 
Number of 2 3 4 27 34 
subjects 
Sex (m:t) 2:0 0:3 1:3 18:9 19:15 
Age at Diagnosis 
(years) 74.5 ± 19.1 30.7 ± 5.13 43.5 ± 11.3 59.4 ± 13.1 55.0 ± 15.3 
(Range) (61-88) (25-35) (32-59) (35-80) (25-80) 
Survival (years) 4.46 ± 0.23 2.36 ±0.71 0.58 ± 0.51 1.13 ± 1.4 
(Range) - (4.01-4.73) (1.08-4.05) (0.01-2.11) (0.01-4.73) 
Survival 232.0 ± 11.72 122.9 ± 37.0 30.1 ± 26.3 58.8 ± 70.5 
(weeks) 
- (208.74-245.97) (56.14-210.67) (0.74-109.47) (0.74-245.97) 
(Range) 
Forty-one samples of formalin fixed and paraffin embedded sections of tumours samples 
were studied Tissue from 34 of these tumour samples was snap-frozen in liquid nitrogen 
prior to RNA extraction. Tumours were classified according to current World Health 
Organisation guidelines (Kleihues et a/, 2000). Of the 41 samples, 27 were glioblastomas, 
4 were anaplastic astrocytomas, 5 were diffuse astrocytomas (only 3 with frozen tissue), 
and 5 pilocytic astrocytomas (none with frozen tissue). Two frozen samples of normal 
brain tissue obtained at autopsy were also used as controls. The data is expressed as mean 
values(± standard deviation). 
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6.2 HIF-la and VEGF m.RNA Expression 
The expression of HIF-Ia and VEGF mRNA was analysed by RT-PCR using 
specific amplimers for each (Figure 6.1), as well as by RPA. There were marked 
differences in the level of expression of H/F-1 a mRNA in the tumour samples from the 
different study groups (Figures 6.3A and 6.3B). There was a highly significant increase in 
the mean ratios ofiDF-1a to (}-actin expression in the glioblastomas when compared to the 
low grade diffuse astrocytomas (mean value 0.45 vs 0.25 respectively, p=0.005) as well as 
the anaplastic astrocytomas (mean value 0.45 vs 0.3 respectively, p=0.04). The differences 
in the IDF-1a/P-actin ratio in the low-grade diffuse astrocytomas, the anaplastic 
astrocytomas as well as the glioblastomas were significantly different from the normal 
brain (mean values 0.25, 0.3, 0.45 and 0.1 respectively, p<0.05). 
IDF-1a amplifications were verified by performing an additional RT-PCR assay 
using amplimers for an alternative splice variant to IDF-la (Gothie et a/, 2000) (Figure 
6.2). 
Results obtained from RT-PCR were confmned by performing RPA on 8 
glioblastoma samples where there was significant tissue for the assay (IO!J.g of total RNA 
was required per sample for the assay). A glioblastoma sample negative for HIF-1 a 
expression was verified as having no HIF-Ia expression by RPA and was used as a 
control. The remaining 7 samples analysed confirmed upregulation of HIF-1 a mRNA 
expression varying from 8.5 to 23 fold (mean 16.3 fold), Table 6.2. Expression of 18S 
rRNA on the 8 samples showed that expression was consistent and equal. RP A analysis for 
VEGF mRNA expression was not consistent. Synthesis of a RP A probe for VEGF mRNA 
expression proved difficult and the assay could not be optimised due to an insufficient 
amount of sample material. 
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Figure 6.1. HIF-1 a, VEGF and {Jactin mRNA expression in glial cell tumours analysed 
by RT-PCR and RP A. (A) Amplification products were 520 bp for lllF-1a and 441 bp for 
VEGF and 661 bp for P-actin. (M= 100 base pair ladder). Lanes 1,2,3,5,8,9,10 and 11 
were scored positive for HIF-1 a. All of the lanes with the exception oflanes 7 and 11 were 
scored positive for VEGF. VEGF expression varied from 1 to 100 fold (mean 25 fold). P-
actin expression demonstrates the quality of cDNA and equal sample loading. (B) IDF-1a 
RT-PCR results were confirmed by performing RPA on 8 glioblastoma samples which 
confirmed up-regulation of HIF-1 a mRNA varying from 8.5 to 23 fold (mean 16.3 fold) 
against a negative control sample (C), (lane 1) (Table 6.2). AA = anal plastic astrocytoma, 
LGA = low-grade astrocytoma, GBM = glioblastoma 
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Table 6.2. RP A analysis of H/F-1 a mRNA expression in 8 glioblastoma tissue samples 
Sample Mean Volume Standard Adjusted Volume Fold Increase 
(OD) (0Dxmm2) Deviation (0Dxmm2) In Expression 
1 0.04 8.52 0.02 0.26 
-
2 0.60 12.14 0.15 3.89 14.96 
3 0.92 14.23 0.14 5.89 22.65 
4 0.41 10.93 0.12 2.68 10.31 
5 0.34 10.48 0.13 2.23 8.58 
6 0.83 13.62 0.12 5.37 20.65 
7 0.71 12.89 0.14 4.63 17.81 
8 0.77 13.27 0.19 5.02 19.31 
Signal band intensities were quantitated by densitometric scanning of the autoradiographs 
using a Fluor-STM imager and Multi-Analyst® image analysis software (Bio-Rad 
Laboratories, Hemel Hempstead, UK). Background intensity was subtracted from band 
intensity values. Sufficient tissue was only available from the above samples for analysis in 
this assay {lOJ.lg of total RNA required per sample). Results are expressed as fold increase 
from the negative control level (sample 1) which was confirmed as having no HIF-Ia 
mRNA expression. A constant band area size of 6.5 mm2 was used in the expression 
analysis of each sample. Results confirm up-regulation of H/F-1 a mRNA varying from 8.5 
to 23 fold (mean 16.3 fold). A control probe of 18S rRNA was hybridised to samples to 
control for the quality of mRNA and ensure equal sample loading (mean adjusted volume 
17.42 ± 0.05 SE). 
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Figure 6.2. HIF-1 a splice variant mRNA expression in glial cell twnours analysed by 
RT-PCR. Amplification products were 487 bp for the HIF-1n amplified product containing 
exon 14, 350 bp for the HIF-1n amplified product without exon 14. (M= 100 base pair 
ladder). Results coincide with and verify the original RT-PCR assay. In this example, 
showing a selection of samples from each of the tumour categories as well as nonnal 
controls, lanes 1, 4, 5, 8, 9 and 10 were scored positive for HIF-1 a, and lanes 2 and 3 
(normal controls), 6 and 7 were scored negative for HIF-1 a. 
N = normal control 
AA = anaplastic astrocytoma 
LGA = low-grade astrocytoma 
GBM = glioblastoma multiforme 
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Figure 6.3 (A). H1F-1 a mRNA expression in individual tumour samples from patients 
with glioblastoma, lower grade tumours and normal brain, analysed by RT-PCR Results 
are represented as the percentage change in abundance of H1F-1 a with respect to ~actin 
and show the range of distribution between samples. n = number of subjects 
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Figure 6.3 (B). Mean HIF-1 a mRNA expression in tumour samples from patients with 
glioblastoma, lower grade tumours and normal brain, analysed by RT-PCR. A highly 
significant increase in the mean ratios of HIF-1 atoP-actin expression was observed in the 
glioblastomas (GBM) when compared to the low-grade diffuse astrocytomas (LGA) as 
well as the anaplastic astrocytomas (AA) (p<O.Ol). Additionally a significant difference 
was also observed between the normal brain and the two lesser glioblastoma classes 
(p<0.05 by students t-test). Mean of at least 4 independent experiments. ± standard errors 
(SE) are shown. n = number of subjects 
GBM vs. LGA (mean value 0.45 vs. 0.25 respectively, p = 0.005)* 
GBM vs. AA (mean value 0.45 vs. 0.3 respectively, p = 0.04)* 
GBM vs. normal brain (mean value 0.45 vs. 0.1 respectively, p = 0.00003)* 
Normal brain vs. LGA (mean value 0.1 vs. 025 respectively, p = 0.03)* 
Normal brain vs. AA (mean value 0.1 vs. 0.3 respectively, p = 0.01)* 
Between group and within group variance of all 4 means (F-test = 1.46, p = ns) 
* = statistically significant, ns = not significant 
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In contrast to the results for HIF- I a, there were no significant differences in the 
level of expression of VEGF with respect to grade or type of tumour or with nonnal brain 
tissue. The mean ratio of VEGF to fJ-actin levels was 0.18 for nonnal brain, 0.18 for low 
grade diffuse astrocytomas, 0.24 for. anaplastic astrocytomas and 0.19 for glioblastoma 
(Figure 6.4). A significant difference was found in the medians of HIF-la and VEGF 
mRNA expression in the glioblastoma tumours samples (p=0.0003) but not in the other 
tumours types (Table 6.3). 
No correlations were found between the expression of HIF-la and VEGF mRNA 
in the glioblastoma tumour samples (correlation coefficient = 0.18, p=0.36) (Figure 6.5), 
nor in the other tumour types (p=0.30 for low grade diffuse astrocytomas, p=0.40 for 
anaplastic astrocytomas). The mean ratio of HJF-1 a to VEGF levels was 0.26 for nonnal 
brain, 3.81 for low-grade diffuse astrocytomas, 4.66 for anaplastic astrocytomas and 8.01 
for glioblastomas. Statistically significant differences were found in the HIF-1a/VEGF 
ratio in the anaplastic astrocytomas and the glioblastomas from the nonnal brain (p=0.03 
and p=0.000002, respectively), but not in the low-grade diffuse astrocytomas ( p=0.17). 
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Figure 6.4. Mean VEGF mRNA express10n in tumour samples from patients with 
glioblastoma, lower grade tumours and normal brain, analysed by RT-PCR. Results are 
represented as change in abundance of VEGF with respect to fJ-actin. The mean ratio of 
VEGF to fJ-actin levels was 0.18 for normal brain, 0.18 for low-grade diffuse 
astrocytomas, 0.24 for anaplastic astrocytomas and 0.19 for glioblastoma. Mean of at least 
4 independent experiments. ± SE is shown. n= number of subjects. ns = not significant 
GBM vs. LGA (mean value 0.19 vs. 0.18 respectively, p = ns) 
GBM vs. AA (mean value 0.19 vs. 0.24 respectively, p = ns) 
GBM vs. normal brain (mean value 0.19 vs. 0.18 respectively, p = ns) 
Normal brain vs. LGA (mean value 0.18 vs. 0.18 respectively, p = ns) 
Normal brain vs. AA (mean value 0.18 vs. 0.24 respectively, p = ns) 
Between group and within group variance of all 4 means (F-test = 0.71, p = ns) 
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Figure 6.5. Mean H1F-1 a and VEGF m.RNA expression in tumour samples from patients 
with glioblastoma, lower grade tumours and normal brain, analysed by RT-PCR. Results 
are expressed as the percentage change in abundance of H1F-1 a with respect to VEGF. A 
significant increase in the mean ratios of H/F-1 a to VEGF was observed in the normal 
brain when compared to the anaplastic astrocytomas (p<0.05 by students t-test). A marked 
trend and correlation between the expression of HIF-1 a and VEGF m.RNA in the GBM 
tumour samples was observed. Mean of at least 4 independent experiments. ± SE is shown. 
n = number of subjects. * = statistically significant, ns = not significant 
GBM vs. LGA (mean value 8.01 vs. 3.81 respectively, p = ns) 
GBM vs. AA (mean value 8.01 vs. 4.66 respectively, p = ns) 
GBM vs. normal brain (mean value 8.01 vs. 0.26 respectively, p = 0.000002)* 
Normal brain vs. LGA (mean value 0.26 vs. 3.81 respectively, p = ns) 
Normal brain vs. AA (mean value 0.26 vs. 4.66 respectively, p = 0.03)* 
Between group and within group variance of all4 means (F-test = 1.56, p = ns) 
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Table 6.3. Statistical analysis of the mean ratios of HIF-1 a to VEGF mRNA expression 
between glioblastoma tumour types and coefficients of correlation. 
Tumour HIF-la VEGFmRNA p value Correlation p value Type mRNA expression coefficient 
expression (mean value) 
(mean value) 
GBM 0.45 0.19 0.0003* 0.182 0.36 
LGA 0.30 0.27 0.08 0.500 0.67 
AA 0.25 0.48 0.27 -0.800 0.20 
Normal brain 0.10 0.18 0.10 -1.0 1.00 
Mann-Whitney U non-parametric test was employed for comparison of medians and 
Spearman's coefficient of correlation was employed for correlation analysis. 
* = statistically significant 
GBM = Glioblastoma multiforme 
LGA = Low-grade astrocytoma 
AA = Anaplastic astrocytoma 
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6.3 HIF-la Protein Expression 
Immunohistochemical analysis of HIF-la protein expression was performed using 
antibodies to HIF-1 a that had just become commercially available, which had not yet been 
validated for immunohistochemical analysis. An immense amount of time was spent 
optimising this procedure of which the results of at least four separate and consistent 
analyses are described below. All slides were assessed by a neuropathologist (Dr. David 
Hilton, Derriford Hospital, Plymouth, UK). 
Tumour cell immunoreactivity was scored according to the nuclear staining. Both 
the extent of staining (relative number of HIF-la positive cells) and the intensity of the 
reaction were taken into account, classified as 4 grades of staining: 0 = not detected, I = 
weak staining, 2 =moderate staining, and 3 =strong staining. Staining scores for HIF-la, 
VEGF and p53 expression are shown in Table 6.4. 
In most of the samples scattered weakly immunoreactive tumour cell nuclei were 
seen. However, widespread HIF-la immunoreactivity was seen in tumour cell nuclei in 
21/27 glioblastomas, 3/4 anaplastic astrocytomas, 2/10 low grade astrocytomas and in none 
of the 2 samples of normal brain. In glioblastomas HIF-la immunoreactivity was 
particularly strong in tumour cells around areas of necrosis (Figure 6.6A), which was 
predominantly present in palisading tumour cell nuclei (Figure 6.68). In some cases, HIF-
la immunoreactivity was seen in the larger more atypical nuclei (Figure 6.6C). Where 
tumour cells were seen infiltrating brain, immunoreactivity was much more prominent in 
neoplastic than reactive cells. 
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Table 6.4. Immunohistochemical analysis ofHIF-1a., VEGF and p53 expression in 
glial cell tumours. 
Tumour HIF-1 VEGF 
Type Score Score 
PA 1 1 
PA 1 1 
PA 1 1 
PA 1 1 
PA 1 1 
LGA 1 1 
LGA 1 1 
LGA 2 2 
LGA 2 1 
LGA 1 1 
AA 0 1 
AA 2 1 
AA 2 2 
AA 2 1 
GBM 2 2 
GBM 1 3 
GBM 1 N/D 
GBM 1 3 
GBM 1 2 
GBM 1 3 
GBM 1 2 
GBM 3 2 
GBM NID 2 
GBM 3 N/D 
GBM 2 2 
GBM 2 2 
GBM 1 2 
GBM NID 3 
GBM 1 2 
GBM 1 3 
GBM 2 1 
GBM 2 3 
GBM 2 3 
GBM 3 2 
GBM 3 3 
GBM 2 1 
GBM 3 0 
GBM 1 3 
GBM 2 2 
GBM 1 3 
GBM 1 1 
P A = pilocytic astrocytoma 
LGA = low-grade diffuse astrocytoma 
p53 pS3 Microvascular 
Score (%) Proliferation 
N/D N/D 0 
N/D N/D 0 
N/D N/D 0 
N/D N/D 0 
NID N/D 0 
N/D NID 0 
N/D N/D 0 
NID N/D 0 
N/D NID 0 
2 30 0 
3 80 0 
3 60 0 
1 15 0 
0 5 0 
3 70 1 
N/D N/D 1 
3 60 1 
2 30 1 
1 10 1 
1 15 1 
2 50 1 
2 20 1 
I 10 I 
3 80 1 
3 80 1 
I 10 1 
3 80 1 
1 20 1 
3 80 1 
3 80 1 
2 30 1 
2 50 1 
2 50 I 
3 80 1 
1 20 I 
I 20 1 
2 30 1 
I 20 1 
3 80 1 
I IO 1 
0 5 I 
AA = anaplastic astrocytoma 
GBM = glioblastoma 
Necrosis 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 
1 
1 
1 
1 
1 
I 
1 
1 
1 
1 
I 
I 
1 
1 
1 
1 
I 
1 
1 
I 
I 
I 
1 
1 
I 
1 
NID = not done 
IllF-la. and VEGF tumour cell immunoreactivity was scored according to the nuclear staining: 
0 = not detected, 1 = weak staining, 2 = moderate staining, and 3 = strong staining. 
p53 tumour cell immunoreactivity was scored for nuclear expression on a four-point scale: 
0 = < 10% of cell nuclei with positive staining, 1 = 10-20% of cell nuclei stained, 2 = 20-50% 
of cell nuclei with positive staining, and 3 = > 50-100 % of cell nuclei with positive staining. 
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A) 
B) 
C) 
Figure 6.6. Immunohistochemical analysis ofiDF-la expression in glioblastoma. A) Low 
power view (X50) of IDF-la immunoreactivity in a glioblastoma showing widespread 
nuclear immunoreactivity, which at high magnification (B), is particularly prominent in 
tumour cells surrounding foci of necrosis (XI 50) (haematoxylin counterstain). C) Strong 
IDF-la immunoreactivity is observed in glioblastoma cells, particularly those with large 
atypical nuclei (X200) (haematoxylin counterstain). 
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6.4 VEGF Protein Expression 
Tumour cell immunoreactivity for VEGF expression was scored as described for 
HIF-la above. VEGF expression was consistently found in all but one specimen evaluated 
(Table 6.4; Figure 6.7A and 6.7B). Approximately 59% of all specimens and 84% of 
glioblastomas displayed greater than 20% of tumour cell nuclei positive. No correlation 
was found between VEGF, HIF-la or p53 immunoreactivity (Pearson's Chi-squared test, 
p=0.90 for HIF-la vs. p53, p=0.90 for VEGF vs. p53, and p= 0.69 for HIF-la and 
VEGF). 
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A) 
B) 
Figure 6.7. Immunohistochemical analysis ofVEGF expression in glioblastomas. (A) Low 
power view (X50) of VEGF immunoreactivity showing strong cytoplasmic staining 
(brown) in tumour cells adjacent to necrosis (left of photo). (B) High-power view showing 
brown granular cytoplasmic staining (Xl50) (haematoxylin counterstain). 
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6.5 p53 Protein Expression and Correlation with HIF-la 
Tumour cell immunoreactivity for p53 expression was scored for nuclear 
expression on a four-point scale from 0 to 3. A score of 0 indicated < 10% of cell nuclei 
with positive staining, 1 indicated 10-20% of cell nuclei stained, 2 indicated 20-50% of cell 
nuclei with positive staining, and 3 indicated > 50-100 % of cell nuclei with positive 
staining. 
Of all tumours studied, 0-80% of tumour cell nuclei showed p53 immunoreactivity, 
with 63% of all glioblastomas having greater than 20% of tumour cell nuclei positive 
(Figure 6.8A and 6.8B). A correlation between p53 immunoreactivity and either HIF-la 
or VEGF mRNA expression could not be demonstrated. 
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Figure 6.8. Immunohistochemical analysis of p53 expression in glioblastomas. A) A low-
grade astrocytoma shows strong nuclear p53 immunoreactivity in a proportion of tumour 
cells (X300). B) A glioblastoma shows strong nuclear p53 immunoreactivity in the 
majority of tumour cells (X300) (haematoxylin counterstain). 
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6.6 Survival 
Survival of the 34 patients with glioblastoma was followed up, with overall 
survival being measured from the time of diagnosis to the date of death. The patients were 
analysed as a whole group (n=36) to include all tumour types and also as patients who had 
glioblastoma tumours (n=27). Univariate analysis of overall survival was performed by 
Kaplan-Meier analysis (Kaplan and Meier, 1985). Although statistical power was limited 
because of the relatively low number of cases, the Cox proportional hazards model was 
used for both univariate and multivariate analysis. HIF-la, VEGF and p53 expression, sex 
and age at surgery (continuous) were entered into Cox regression. For all tests, a p value of 
less than or equal to 0.05 was considered as significant. A11 p values are results of two-
sided tests. 
Patients diagnosed with a diffuse astrocytoma all remained alive at the time of 
follow up and had the greatest survival time averaging 4.46 ± 0.23 years. These patients 
also had the youngest age of diagnosis at 30.7 ± 5.13 years. Patients diagnosed with an 
anaplastic astrocytoma averaged the second longest survival time of 2.36 ± 0.71 years, 
presenting with an average age of 43.5 ± 11.3 years at the time of diagnosis. As expected, 
patients diagnosed with glioblastoma, the most severe tumour type, had the shortest 
survival time of0.58 ± 0.51 years (30.1 ± 26.3 weeks) and presented with the greatest age 
at diagnosis, 59.4 ± 13.1 years (Table 6.1). The median age for all patients was 55 years 
and the median survival following initial surgery was 1.13 ± 1.36 years (58.8 ± 70.5 
weeks). 
Univariate analysis on the glioblastoma patient group showed that sex, HIF-la, 
VEGF or p53 expression were not associated with survival, however age was associated 
(p=O.Ol; Table 6.5). In multivariate analysis, age remained an independent prognostic 
factor on overall survival (p=0.006; Table 6.5). Univariate analysis on all patients to 
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include all tumour types showed a weak association of VEGF protein expression with 
overall survival (p=0.06; Table 6.6), which was significant with weak versus strong 
protein expression. Age and sex were also significantly associated with survival in the total 
patient group (p=O.OOOl and p=0.009, respectively). 
Multivariate analysis on all patients showed that VEGF protein expression was 
eliminated from the model, however HIF-1 a protein expression became a prognostic factor 
with overall significance of p=0.008, and low and moderate versus strong protein 
expression having p=0.002 and p=0.0006, respectively. Age and sex remained in the model 
and were significant prognostic factors with p=O.OOOl and p=0.002, respectively (Table 
6.6). A correlation was found between age of diagnosis and survival in both the 
glioblastoma patient group and in all patients analysed (Spearman's coefficient of 
correlation p=0.02 and p=O.OOOl, respectively). 
When multivariate analysis was limited to protein expression, a statistically 
significant interaction was found between HIF-la and VEGF protein expression in all 
patients with brain tumours and overall survival (p=0.03 and p=O.Ol, respectively; Table 
6.7) indicating that both HIF-la and VEGF protein expression are significant predictors of 
outcome as protein expression is associated with shorter survival (VEGF log-rank test 
8.45, p=0.04; Figure 6.16). When p53 protein expression was included in the analysis, the 
overall significance in HIF-la and VEGF protein expression and overall survival was lost, 
however the significance with low to strong expression remained (p=O.Ol for low and 
p=0.03 for high HIF-la expression; p=0.03 for low and p=0.04 for high VEGF expression) 
(Table 6. 7). 
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Table 6.5. Univariate and multivariate analysis of cumulative overall survival of27 
patients with glioblastoma. 
Univariate Analysis Hazard Ratio 95%CI pvalue 
HIF-la Expression ns 
1 vs 3 1.14 0.45-2.91 ns 
2 vs. 3 1.73 0.57-5.25 ns 
VEGF Expression ns 
0 vs. 3 0.98 012-7.86 ns 
1 vs. 3 0.72 0.19-2.65 ns 
2 vs. 3 0.78 0.32-1.89 ns 
p53 Expression ns 
Ovs. 3 0.39 0.05-3.12 ns 
1 vs. 3 0.77 0.30-1.96 ns 
2 vs. 3 0.71 0.25-2.02 ns 
Age 1.05 1.01-1.10 0.01* (continuous) 
Sex 1.19 0.52-2.76 (male vs. female) ns 
Multivariate Analysis Hazard Ratio 95%CI p value 
Age 1.06 1.02-1.11 0.006* (continuous) 
Hazard ratios (HR), p values and 95% confidence intervals (Cl) are indicated. The HR for 
age as a continuous variable indicates the increase in hazard per year on a per year basis. 
Multivariate analysis was performed using a backward elimination procedure to remove 
variables with p ;;:: 0.1 0. The qualifYing criteria for inclusion in the multivariate analysis 
were p<0.1, or hazard ratios <0.5 or >2 in the univariate analysis. 
* = statistically significant, ns = not significant 
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Table 6.6. Univariate and multivariate analysis of cumulative overall survival of all 36 
patients with glial cell tumours. 
Univariate Analysis Hazard Ratio 95%CI pvalue 
BIF-la. Expression ns 
Ovs. 3 0.32 0.04-2.87 ns 
1 vs. 3 0.37 0.12-1.12 0.08 
2 vs. 3 0.41 0.14-1.26 ns 
VEGF Expression 0.06 
Ovs. 3 0.97 0.12-7.70 ns 
1 vs. 3 0.21 0.07-0.64 0.007* 
2vs. 3 0.59 0.25-1.40 ns 
p53 Expression ns 
Ovs. 3 0.47 0.10-2.16 ns 
1 vs. 3 0.84 0.35-2.04 ns 
2 vs. 3 1.26 0.47-3.36 ns 
Age 1.07 1.03-1.10 0.0001* (continuous) 
Sex 2.82 1.29-6.15 0.009* (male vs. female) 
Multivariate Analysis Hazard Ratio 95%CI p value 
BIF-la. Expression 0.008* 
Ovs. 3 0.39 0.04-4.16 ns 
1 vs 3 0.08 0.01-0.40 0.002* 
2 vs. 3 0.05 0.01-0.27 0.0006* 
Age 1.09 1.05-1.14 0.0001* (continuous) 
Sex 6.21 1.91-20.16 0.002* (male vs. female) 
Hazard ratios (HR), p values and 95 % confidence intervals (Cl) are indicated. The HR for 
age as a continuous variable indicates the increase in hazard per year on a per year basis. 
Multivariate analysis was performed using a backward elimination procedure to remove 
variables with p ~ 0.10. The qualifying criteria for inclusion in the multivariate analysis 
were p<0.1, or hazard ratios <0.5 or >2 in the univariate analysis. 
* = statistically significant, ns = not significant 
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Table 6. 7. Multivariate analysis of cumulative overall survival of all 36 patients with glial 
cell tumours based on HIF-1a, VEGF and p53 immunohistochemical status. 
All Patients Hazard Ratio 95%CI pvalue (n=36) 
HJF-la Expression 0.03* 
Ovs. 3 0.31 0.02-4.69 ns 
1 VS. 3 0.09 0.02-0.46 0.004* 
2 vs. 3 0.18 0.04-0.83 0.03* 
VEGF Expression 0.01* 
Ovs. 3 0.11 0.01-1.38 0.08 
1 vs. 3 0.11 0.03-0.47 0.003* 
2 VS. 3 0.30 0.11-0.85 0.02* 
HJF-la Expression 0.08 
Ovs. 3 0.22 0.02-3.34 ns 
1 VS. 3 0.12 0.02-0.60 0.01* 
2 VS. 3 0.17 0.04-0.81 0.03* 
VEGF Expression 0.09 
0 VS. 3 0.12 0.01-1.54 ns 
1 vs. 3 0.25 0.15-0.92 0.04* 
2 VS. 3 0.34 0.12-0.98 0.04* 
p53 Expression ns 
0 vs. 3 0.94 0.13-6.83 ns 
1 vs. 3 0.68 0.19-3.50 ns 
2 vs. 3 0.92 0.26-3.33 ns 
Tumours were scored for HIF-1a, VEGF and p53 expression by immunohistochemistry 
(Table 6.4). A Cox multivariate analysis was performed to test for associations of 
immunohistochemical status with survival. Hazard ratios (HR), 95% confidence intervals 
(Cl) and p values are indicated. 
* = statistically significant, ns = not significant 
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Kaplan-Meier analysis revealed no significant influence of sex (log-rank test, 
p=0.67; Figure 6.9), HIF-la (p=0.61; Figure 6.10), VEGF (p=0.94; Figure 6.11) or p53 
(p=O. 77; Figure 6.12) protein expression on cumulative ovemll survival in the 
glioblastoma patients. However tumour type had a significant influence on ovemll survival 
where analysis by Cox regression resulted in a hazard mtio of 9.16, p = 0.001 (2.35-35.8; 
95% Cl) (Figure 6.13). Kaplan-Meier analysis of all patients to include all tumour types 
did reveal a significant association of sex (p=0.007; Figure 6.14) and VEGF protein 
expression (p=0.04; Figure 6.16) on cumulative overall survival but not with HIF-Ia 
(p=0.30; Figure 6.15) or p53 protein expression (p=0.63; Figure 6.17). 
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Overall Survival of Patients with Glioblastoma 
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Figure 6.9. Cumulative overall survival of patients with glioblastoma (n=27) differentiated 
by sex and analysed by Kaplan-Meier. Overall survival is defined from the day of surgery 
until day of death. Log rank test 0.18, p = ns. 
ns = not significant 
-371-
";} 
> 
1.2 
1.0 
·~ .8 
tZl 
~ 
~ 6 0 . 
~ 
·-~ .4 
§ 
u 
.2 
0 
Chapter 6. Results 
Overall Survival in Patients with Glioblastoma 
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Figure 6.10. Cumulative overall survival of patients with glioblastoma (n=27) 
differentiated by HIF-1 a. protein expression and analysed by Kaplan-Meier. Overall 
survival is defined from the day of surgery until day of death. Log rank test 1.00, p = ns. 
ns = not significant 
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Overall Survival in Patients with Glioblastoma 
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Figure 6.11. Cumulative overall survival of patients with glioblastoma (n=27) 
differentiated by VEGF protein expression and analysed by Kaplan-Meier. Overall 
survival is defined from the day of surgery until day of death. Log rank test 0.43, p = ns. 
ns = not significant 
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Overall Survival in Patients with Glioblastoma 
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Figure 6.12. Cumulative overall survival of patients with glioblastoma (n=27) 
differentiated by p53 protein expression and analysed by Kaplan-Meier. Overall survival is 
defined from the day of surgery until day of death. Log rank test 1.12, p = ns. 
ns = not significant 
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Overall Survival of All Patients 
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Figure 6.13. Cumulative overall survival of all patients with glial cell tumours analysed by 
Kaplan-Meier. Overall survival is defined from the day of surgery until day of death. Log 
rank 17.9, p=O.OOOI *. Cox regression, hazard ratio=9.16, p = 0.001 * (2.35-35.8~ 95% Cl). 
* = statistically significant 
LGA = Low-grade astrocytoma 
AA = Anaplastic astrocytoma 
GBM = Glioblastoma multiforme 
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Overall Survival in All Patients 
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Figure 6.14. Cumulative overall survival of all patients with glial cell tumours (n=36) 
differentiated by sex and analysed by Kaplan-Meier. Overall survival is defined from the 
day of surgery until day of death. Log rank test 7.41 , p = 0.007*. 
* = statistically significant 
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Figure 6.15. Cumulative overall survival of all patients with glial cell tumours (n=36) 
differentiated by HIF-la. protein expression and analysed by Kaplan-Meier. Overall 
survival is defmed from the day of surgery until day of death. Log rank test 3.67, p = ns. 
ns = not significant 
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Figure 6.16. Cumulative overall survival of all patients with glial cell tumours (n=36) 
differentiated by VEGF protein expression and analysed by Kaplan-Meier. Overall 
survival is defined from the day of surgery until day of death. Log rank test 8.45, p = 
0.04*. 
* = statistically significant 
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Figure 6.17. Cumulative overall survival of all patients with glial cell tumours (n=36) 
differentiated by p53 protein expression and analysed by Kaplan-Meier. Overall survival is 
defined from the day of surgery until day of death. Log rank test 1. 72, p = os. 
ns = not significant 
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6. 7 Conclusion 
Strong nuclear expression of HIF-la protein was seen in the majority of 
glioblastomas and anaplastic astrocytomas, particularly surrounding areas of necrosis in 
glioblastomas. In the majority of these tumours up-regulation of HIF-la mRNA was also 
demonstrated, with a significant increase in glioblastoma multiforme compared to low 
grade forms of brain tumour as well as in all the tumour types versus normal brain. 
Additionally, a significant difference between the levels of HIF-la and VEGF mRNA 
expression in anaplastic astrocytomas and glioblastoma multiforme was observed 
compared to normal brain. However, no correlation was found between the presence of 
HIF-la or VEGF protein and immunohistochemical expression ofp53 protein. Moreover, 
no significant associations were found between HIF-la, VEGF or p53 protein expression 
with patient characteristics. 
Both univariate and multivariate analysis showed that age had a significant 
influence on overall survival in addition to both lllF-la and VEGF levels of protein 
expression. Kaplan-Meier analysis of all 36 patients revealed a significant association of 
sex and VEGF protein expression on cumulative overall survival in all patients but not 
with lllF-la or p53 protein expression. 
These fmdings are in keeping with an important role for lllF-la in the 
vascularisation of glioblastomas and suggest that up-regulation is at least partly at a 
transcriptional level. Moreover, that lllF-la and VEGF protein expression may be 
important prognostic factors in glioblastoma. 
-380-
lPolymoFpbisms, in tbe.p53: JF!amily 
~ofT:umour S11~ppr~ssor Genes and 
iSus.ceptibility !tO Breast c~~ncet 
-381-
Chapter 7. Results 
7.0 Polymorphisms in the p53 Family of Tumour Suppressor Genes and 
Susceptibility to Breast Cancer 
p73 is a new member of the growing family of p53 tumour suppressor genes, all of 
which share high homology (Kaghad et a/, 1997). Recent studies have suggested that the 
genes coding for p53 and p73 contain polymorphisms that may increase susceptibility to 
certain cancers (Storey et a/, 1998). One of these studies has shown that individuals 
homozygous for p53 Arg are 7 times more likely to develop HPV-associated cancer 
(Storey et a/, 1998). To elucidate the roles of both p53 and p73 in the susceptibility to 
carcinoma of the breast, polymorphisms of both p53 and p73 genes in 97 women with 
breast cancer and two normal healthy control populations (one of pure Cornish Celtic 
origin) were investigated. Polymorphisms of the p53 and p73 genes were determined by 
nested PCR followed by RFLP (Figure 7.1). 
7.1 Clinical Characteristics 
The clinical characteristics of the 97 patients with breast cancer are listed and 
summarised in Tables 7.1 and 7.4. The mean age of diagnosis was 52 ± 12.3 years (27-80 
years). Interestingly, the cancer was diagnosed in near equivalent percentage of either the 
right (49.5 %) or left (47.4 %) breast. with 3.1 % diagnosed with bilateral disease. The 
majority of patients had advanced T stage (48.5 % T24), grade (90.7% G2.3) or positive 
node stage (46.4 % NI-3), and were non-smokers (82.5 %). For treatment, 63.9 % had 
received chemothempy and 84.5% had received mdiotherapy. 
The mean age of the Celtic control population was 55 ± 15.8 years (7-89 years). 
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Figure 7.1. Analysis of p73 allelic expression and p53 Pro/Arg polyrnorphisms in the 
lymphocytes of patients with breast cancer. A) p73 allelic expression was analysed in 97 
patients with breast cancer using a C/T polymorphism found in exon 2. p73 products of 
482 bp were amplified using nested PCR (PCR-RL). Biallelic expression was identified 
after RFLP using Styl restriction enzyme digestion. Restriction sizes for the GC allele are 
482 bp and 284 bp, and for the AT allele 376 bp plus 106 bp and 234 bp plus 50 bp. 
Incomplete digestion is observed in some of the lanes. B) Sequence specific amplimers 
were used to amplify and detect p53 Pro/Arg polyrnorphisms in the lyrnphocytes of 
patients with breast cancer, producing a fragment size of 177 bp for the p53 Pro allele and 
141 bp for the p53 Arg allele. The presence of both fragments indicates the p53 Pro/Arg 
allele genotype. All products were analysed on a 1.5 % agarose gel and visualised with 
ethidium bromide. (M= 100 bp ladder). 
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Table 7.1. Clinical characteristics of patients with breast cancer. 
Characteristics Patients with Breast 
Cancer 
Nwnberof 97 
subjects 
Breast Affected 
Right 48 
Left 46 
Bilateral 3 
Age at Diagnosis 
(years) 52.0 ± 12.3 
(Range) (27- 80) 
Survival (years) 5.42 ± 3.91 
(Range) (0.70 - 24.2) 
Results are presented as mean values(± standard deviation). 
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7.2 Genotyping of The p73 Dinucleotide Polymorphism 
p73 genotypes were verified by automated sequencing of two of the obtained PCR 
products, a p73 GC/ AT heterozygous genotype and a p73 GC/GC homozygous genotype 
(Figure 7.2). Although sequencing confirmed the p73 genotypes, some incomplete 
digestion of the PCR products was observed and further controls should have been used. 
Out of the 98 patients with breast cancer, 36 (37.1%} had the p73 GC/AT 
heterozygous genotype compared to 35.2% (50 of 142) of the 142 normal controls (Table 
7.2). As the p73 AT/AT homozygous genotype was not found in any of the patients with 
breast cancer nor the normal controls and was found in only 4 individuals in the Cornish 
control population, it would seem that the homozygous AT/AT genotype is very rare (1.25 
%). A statistically significant difference was found between the p73 AT/AT genotype and 
the p73 GC/GC and p73 GC/AT genotypes in the 2 control populations (p=0.02, pc=0.04), 
between the patients with breast cancer and the Celtic population (p=0.03, pc=0.05) and 
between all 3 populations (p=0.006, pc=0.012) (Table 7.3). The over-representation of the 
p73 GC/GC homozygous genotype does not appear to be linked to the population of 
patients with breast cancer, as similar results were obtained in the two control populations. 
The frequency of the p73 genotypes was categorised with disease variables in the 
patients with breast cancer and a significant association was found between age at 
diagnosis and p73 genotype (x2= 4.75, p=0.03; Table 7.4). Nearly three times as many 
patients diagnosed after 52 years of age (median age) had the p73 GC/GC genotype 
(73.5%, 36 of 49) rather than the GC/AT polymorphism (26.5%, 13 of 49}, (Table 7.5). 
Patients diagnosed before 52 years of age had a similar frequency of p73 genotypes. This 
same trend was not observed in the Cornish Celtic population (Table 7.6). Allele 
frequencies for the p73 genotypes for each population are given in Table 7.7. 
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Figure 7.2. Automated sequencing of p73 amplified and genotyped DNA from the 
lymphocytes of two patients with breast cancer. The sequences are of two individual p73 
nested PCR products (forward sequence and reverse complimented sequence), one 
genotyped as a p73 GC/AT heterozygote (top sequence labelled B25), the other genotyped 
as a p73 GC/GC homozygote (third sequence labelled B26). The arrow points to the 
polymorphic substitution R (A) to Y (T) at nucleotide position 91 and 101 in exon 2 (red 
font). Only part of the sequence is shown. 
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Table 7.2. Frequency ofp73 genotype in patients with breast cancer and control 
populations. 
Population p73GC/AT p73GC/GC p73AT/AT 
Breast Cancer Patients (n=97) 37.1 (36) 62.9 (61) 0.0 (0) 
Celtic population (n=85) 35.3 (30) 60 (51) 4.7 (4) 
Cord blood (n=142) 35.2 (50) 64.8 (92) 0.0 (0) 
n= number of samples 
Figures in parentheses represent actual numbers. 
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Table 7.3. Statistical analysis of patient and control populations for each p73 genotype. 
Populations 
x2 (p value) 
p73GC/AT p73GC/GC p73AT/AT 
Breast vs Cord vs Celtic 0.10 (0.95) 0.52 (0.77) 11.4 (0.003)• 
(pc=0.006)* 
Breast vs Cord 0.09 (0.76) 0.09 (0.76) 0 (0.00) 
Breast vs Celtic 0.06 (0.80) 0.16 (0.69) 4.67 (0.03)* 
(pc=0.05)* 
Celtic vs Cord 0 (0.99) 0.52 (0.47) 6.80 (0.02)* 
(pc=0.04)* 
pc= corrected p value 
• = statistically significant 
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Table 7.4. Frequency of disease variables and association with p73 genotype in patients 
with breast cancer. 
Variable Number of p73 Genotype Association 
patients GC/AT GC/GC (test value) 
Patients 97 (lOO) 36(37.1) 61 (62.9) r!= 2.678 , p= ns 
Age (median) 
<52 48 (49.5) 23 (47.9) 25 (52.1) ·l= 4.75b 
~52 49 (50.5) 13 (26.5) 36 (73.5) p=0.03* 
Tstage 
I 50 (51.5) I9 (38.0) 31 (62.0) 
2 34 (35.1) 12 (35.3) 22 (64.7) x2= 1.57b 
3 I1 (11.3) 5 (45.5) 6 (54.5) p=ns 
4 2 (2.1) 0 (0) 2 (100) 
N stage 
0 52 (53.6) 22 (42.3) 30 (57.7) 
I 26 (26.8) 8 (30.8) 18 (69.2) ·/= 1.44b 
2 10 (10.3) 5 (50.0) 5 (50.0) p=ns 
3 9 (9.3) I (11.1) 8 (88.9) 
Grade 
1 9 (9.3) 3 (33.3) 6 (66.7) ·l=0.72b 
2 30 (30.9) 13 (43.3) 17 (56.7) p=ns 
3 58 (59.8) 20 (34.5) 38 (65.5) 
Smoking habits 
Smoker 80 (82.5) 3(17.6) 14 (82.4) ·l= 3.358 
Non-smoker 17 (17.5) 33(41.3) 47 (58.8) p=ns 
Chemotherapy 
Yes 62 (63.9) 23 (37.1) 39 (62.9) ·l= o.oo• 
No 35 (36.1) 13 (37.1) 22 (62.9) p=ns 
Radiotherapy 
Yes I 82 (84.5) 30 (36.6) I 52 (63.4) x2= o.o6" 
No 15 (15.5) 6 (40.0) 9 (60.0) p=ns 
Figures in parentheses represent percentages. Non-parametric analysis was performed 
using 8Pearson Chi-square and "KruSkai-Wallis H tests. *=statistically significant 
T stage = tumour stage, N stage = node stage, p = p value, ns = not significant 
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Table 7.5. Frequency of p73 genotype with respect to age of diagnosis in patients with 
breast cancer. 
Age(n=97) p73GC/AT p73GC/GC 
20-30 0.0 (0) 2.1 (2) 
31-40 8.2 (8) 8.2 (8) 
41-51 15.5 (15) 15.5 (15) 
52-60 6.2 (6) 21.6 (21) 
61-70 4.1 (4) 9.3 (9) 
71-80 3.1 (3) 6.2 (6) 
p73 GC/AT vs GC/GC genotype in patients diagnosed over 52 years of age (median, 
n=49) results in a ·l = 4.75, p=0.03* (corrected ·J! = 3.88, p=0.05)* 
n= number of subjects 
Figures in parentheses represent actual numbers. 
* = statistically significant 
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Table 7.6. Frequency of the p73 genotype in the Celtic population. 
Age(n=77) p73 GC/AT p7JGC/GC p7JAT/AT 
<20 1.3 (1) 0.0 (0) 0.0 (0) 
20-30 0.0 (0) 3.9 (3) 0.0 (0) 
31-40 7.8 (6) 7.8 (6) 1.3 (1) 
41-51 2.6 (2) 9.1 (7) 0.0 (0) 
52-60 15.6 (12) 10.4 (8) 0.0 (0) 
61-70 3.9 (3) 18.2 (14) 0.0 (0) 
71-80 5.2 (4) 10.4 (8) 2.6 (2) 
No significant differences were found between any of the groups. 
p73 GC/AT vs GC/GC genotype in Celtic population over 52 years of age (n=51) 
results in a ·l = 0.05, p=ns 
n= number of subjects 
ns= not significant 
Figures in parentheses represent actual numbers. 
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Table 7.7. Allele frequencies of the p73 genotype in patients with breast cancer and control populations. 
p73 Genotype 
Population GC/AT GC/GC AT/AT Allele Frequency 'X.l 
Observed Expected Observed Expected Observed Expected GC AT (p<0.05) 
Breast (n=97) 37.1 (36) 30.8 (29.9) 62.9 (61) 65.6 (63.6) 0.0 (0) 3.6 (3.5) 0.81 0.19 4.85 
Celtic (n=85) 35.3 (30) 34.4 (29.2) 60.0 (51) 60.8 (51.7) 4.7 (4) 4.8(4.1) 0.78 0.22 0.02 
Cord controls (n=l42) 35.2 (50) 29.5 (41.9) 64.8 (92) 67.3 (95.5) 0.0 (0) 3.2 (4.6) 0.82 0.18 6.30* 
Figures in parentheses represent actual numbers. 
n = number of subjects, p = p value 
* = statistically significant Cl distribution table, 2 degrees of freedom; Murdoch and Bames, 1981) 
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7.3 Genotyping of The p53 Codon 72 Polymorphism 
The frequency of p53 Pro or Arg polymorphism was determined in all populations 
(Table 7.8). Of the 97 patients with breast cancer studied, 42.3% (41 of97) had the p53 
Pro/Arg heterozygous isoform, 56.7% (55 of 97) had the p53 Arg/Arg homozygous 
isoform and 1% (1 of97) had the p53 Pro/Pro homozygous isoform. 
The Cornish Celtic population was also examined for the frequency of the p53 
isoform. In this group 32.9% (28 of85) had the p53 Pro/Arg isoform, 63.5% (54 of85) had 
the p53 Arg/Arg and 3.53% (3 of 85) had the p53 Pro/Pro isoform. As with the p73 AT/AT 
genotype, the p53 Pro isoform is very rare having occurred in only 1 individual in the 
patients with breast cancer and in 3 individuals in the Celtic control population (1.25 %). A 
statistically significant difference was found in the frequency of p53 isoforrns between the 
control populations (p=0.03), which lost significance when corrected for variables (p=0.06, 
Table 7.9). 
The frequency of the p53 isoforms was categorised with disease variables in the 
patients with breast cancer and no significant correlations were found between clinical 
features and genotype (Table 7.10). Comparison of the age of diagnosis versus the p53 
isoform in patients with breast cancer did not result in a trend being observed for either the 
patients with breast cancer nor the Celtic population (Tables 7.11 and 7.12). Allele 
frequencies for the p53 Pro and p53 Arg isoforms for each population are given in Table 
7.13. 
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Table 7.8. Frequency of the p53 isoform in patients with breast cancer and control 
populations. 
Population pSJPro p53Arg p53Pro/Arg 
Breast Cancer Patients (n=97) 1.0 (1) 56.7 (55) 42.3 (41) 
Celtic population (n=85) 3.5 (3) 63.5 (54) 32.9 (28) 
Cord blood (n=136) 0.0 (0) 64.7 (88) 35.3 (48) 
n= number of subjects 
Figures in parentheses represent actual numbers. 
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Table 7.9. Statistical analysis of patient and control populations for each p53 isoform. 
Populations x
2 (p value) 
p53 Pro p53Arg p53 Pro/Arg 
Breast vs Cord vs Celtic 5.30 (0.07) 1.66 (0.44) 1.92 (0.38) 
Breast vs Cord 1.41 (0.24) 1.53 (0.22) 1.17 (0.28) 
Breast vs Celtic 1.32 (0.25) 0.88 (0.35) 1.67 (0.20) 
Celtic vs Cord 4.87 (0.03)* 0.03 (0.86) 0.13 (0.72) 
(pc=0.06) 
Figures in parentheses represent the respective p value 
pc = corrected p value 
* = statistically significant 
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Table 7.10. Frequency of disease variables and association with p53 isofonns in patients 
with breast cancer. 
Variable Number of p531soform Association 
patients Pro Arg Pro/Arg (test value) 
Patients 97 {lOO) 1 (1.0) 55 (56.7) 41 (42.3) x2=2.67", p= ns 
Age (median) 
<52 48 (49.5) 1 (2.1) 28 (58.3) 19 (39.6) x2= I.23" 
~52 49 (50.5) 0 (0) 27 (55.1) 22 (44.9) p=ns 
Tstage 
1 50 (51.5) 0 (0) 28 (56.0) 22 (44.0) 
2 34 (35.I) I (2.9) 17 (50.0) 16(47.1) x2= 2.54b 
3 11 (11.3) 0 (0) 8 (72.7) 3 (27.3) p=ns 
4 2 (2.1) 0 (0) 2 (IOO) 0 (0) 
N stage 
0 52 (53.6) 0 (0) 26 (50.0) 26 (50.0) 
I 26 (26.8) I(3.8) I7 (65.4) 8 (30.8) x2= 3.I2b 
2 IO (I0.3) 0 (0) 6 (60.0) 4 (40.0) p=ns 
3 9 (9.3) 0 (0) 6 (66.7) 3 (33.3) 
Grade 
I 9 (9.3) 0 (0) 4 (44.4) 5 (55.6) x2= 0.92b 
2 30 (30.9) 0 (0) I7 (56.7) 13 (43.3) p=ns 
3 58 (59.8) I (1.7) 34 (58.6) 23 (39.7) 
Smoking habits 
Smoker 80 (82.5) 0 (0) IO (58.8) 7 (41.2) x2=0.24a 
Non-smoker 17 (17.5) I (1.2) 45 (56.3) 34 (42.5) p=ns 
Chemotherapy 
Yes 62 (63.9) I (1.6) 37 (59.7) 24 (38.7) x2= l.35a 
No 35(36.I) 0 (0) 18 (51.4) I7 (48.6) p=ns 
Radiotherapy 
Yes 82 (84.5) I (1.2) 46 (56.1) 35 (42.7) x2 = 0.24" 
No I5 (I5.5) 0 (0) 9 (60.0) 6 (40.0) p=ns 
Figures in parentheses represent percentages. Non-parametric analysis was performed 
using a "Pearson Chi-square and ~skal-Wallis H and tests. 
T stage =tumour stage, N stage = node stage, p = p value, ns = not significant 
-396-
Chapter 7. Results 
Table 7.11. Frequency ofp53 isofonn with respect to age at diagnosis in patients with 
breast cancer. 
Age(n=97) p53 Pro/Arg p53 Arg p53 Pro 
20-30 0.0 (0) 1.0 (I) 1.0 (1) 
31-40 8.2 (8) 8.2 (8) 0.0 (0) 
41-51 11.3 (11) 19.6 (19) 0.0 (0) 
52-60 14.4 (14) 13.4 (13) 0.0 (0) 
61-70 5.2 (5) 8.2 (8) 0.0 (0) 
71-80 3.1 (3) 6.2 (6) 0.0 (0) 
p53 Pro/ Arg vs p53 Arg vs p53 Pro isofonns in patients diagnosed over 52 years of age 
(n=49) results in a ·J! = 1.2, p = ns 
n= number of subjects 
ns = not significant 
Figures in parentheses represent actual numbers. 
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Table 7.12. Frequency of the p53 isoforms in the Celtic population. 
Age(N=77) p53 Pro/Arg p53Arg p53Pro 
<20 0.0 (0) 0.0 (0) 1.3 (1) 
20-30 3.9 (3) 0.0 (0) 0.0 (0) 
31-40 1.3 (1) 14.3 (11) 1.3 (I) 
41-51 2.6 (2) 9.1 (7) 0.0 (0) 
52-60 14.3 (11) 10.4 (8) 1.3 (1) 
61-70 6.5 (5) 5.6 (12) 0.0 (0) 
71-80 6.5 (5) 11.7(9) 0.0 (0) 
p53 Pro/Arg vs p53 Arg isoforms in the Celtic population over 52 years of age (n=51) 
results in a ·l = 2.0, p = ns 
n= number of subjects 
ns = not significant 
Figures in parentheses represent actual numbers. 
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Table 7.13. Allele frequencies of the p53 isoforms in patients with breast cancer and control populations. 
p53 Isoform 
Population Pro/Arg Arg Pro Allele Frequency 
·l 
Observed Expected Observed Expected Observed Expected Pro Arg (p<0.05) 
Breast (n=97) 42.3 (41) 34.3 (33.3) 56.7 (55) 60.8 (59) 1.0 (I) 4.9 (4.7) 0.22 0.78 4.96 
Celtic (n=85) 32.9 (28) 32.0 (27.2) 63.5 (54) 64.0 (54.4) 3.5 (3) 4.0 (3.4) 0.20 0.80 0.07 
Cord controls (n=I36) 35.3 (48) 29.7 (40.4) 64.7 (88) 67.1 (91.4) 0.0 (0) 3.2 (4.4) 0.18 0.82 5.96 
Figures in parentheses represent actual numbers. 
n = number of subjects, p = p value 
C'l distribution table, 2 degrees of freedom; Murdoch and Bames, 1981) 
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7.4 p73 Genotype and p53 Isoform 
A comparison of p73 genotypes with p53 isoforms in patients with breast cancer 
showed that 47.5% (29 of61) ofthose with the p73 GC genotype also had the p53 Pro/Arg 
isoform whilst 50.8% (31 of61) had the p53 Arg isoform (Table 7.14). In contrast, 33.3% 
(12 of36) ofthose individuals with the p73 GC/AT genotype had the p53 Pro/Arg isoform 
and 66.6% (24 of 36) had the p53 Arg/Arg isoform. This trend is not significant but 
indicates that an association may exist between the p73 GC genotype and the p53 Pro/Arg 
isoform in patients with carcinoma of the breast. No correlation was found between the 
disease variables with either p73 genotype or p53 isoform in the patient group. 
The opposite trend was found in both the cord blood and Celtic controls. In the cord 
bloods, 35.5% (22 of62) ofthose individuals with the p73 GC/GC genotype bad the p53 
Pro/Arg isoform and 64.5% (40 of 62) had the p53 Arg/Arg isoform. In the Celtic 
population, 30.6% (15 of 49) of those with the p73 GC/GC genotype had the p53 Pro/Arg 
isoform whilst 67.3% (33 of 49) had the p53 Arg/Arg isoform. When the frequency of both 
the p73 genotypes and the p53 isoforms was compared between all three populations no 
significant correlation was found. 
Analysis of the frequency of the p73 and p53 alleles showed that the p53 Pro/Pro 
isoform was more frequently found with the p73 GC allele than with the p73 AT allele. 
This occurs in all three populations (Table 7.15) and suggests that the p53 and p73 genes, 
despite being on separate chromosomes, appear to have a synergistic effect and certain 
combinations are inherited together more frequently then expected. The odds ratio and 
relative risk for the development of breast cancer is shown in Table 7 .16. 
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Table 7.14. Frequency ofp73 genotype versus p53 Pro/Arg genotype in patients with 
breast cancer and control populations. 
p53 Isoform 
Population p73 Genotype 
Pro/Arg Arg Pro 
GC/AT(36) 33.3 (12) 66.6 (24) 0.0 (0) 
Breast ( n=97) GC/GC(61) 47.5 (29) 50.8(31) 1.2 (1) 
AT/AT (0) 0.0 (0) 0.0 (0) 0.0 (0) 
GC/AT(31) 41.9 (13) 51.6(16) 6.5 (2) 
Celtic (n=84) GC/GC(49) 30.6 (15) 67.3 (33) 2.1 (1) 
AT/AT (4) 0.0 (0) 100 (4) 0.0 (0) 
GC/AT(31) 45.2 (14) 54.8 (17) 0.0 (0) 
Cord controls (n=93) GC/GC(62) 35.5 (22) 64.5 (40) 0.0 (0) 
AT/AT (0) 0.0 (0) 0.0 (0) 0.0 (0) 
No statistically significant differences were obtained between the breast population and 
cord controls or between the Celtic population and cord controls. 
n= number of subjects 
Figures in parentheses represent actual numbers. 
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Table 7.15. Observed and expected frequencies ofp73 and p53 allele combinations in 
observed patient and control populations. 
Allele Combination Observed Expected x2 
(p<O.Ol) 
p73GC-p53Pro 72 63.2 1.2 
p73GC-p53Arg 331 339.6 0.2 
p73A T -p53Pro 2 10.6 6.97* 
p73AT -p53Arg 65 56.7 1.2 
* = statistically significant 
(x2 distribution table; 1 degree of freedom; Murdoch and Barnes, 1981) 
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Table 7.16. Odds ratios (relative risk) for patients with breast cancer and control 
populations for each p73 and p53 genotype. 
Populations 
p73 Genotype pS3 Genotype 
GC/AT GC/GC AT/AT Pro/Arg Arg 
Breast vs Cord l.ll 0.90 0.00 0.00 0.70 
Breast vs Celtic l.ll 1.10 0.00 0.28 0.73 
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7.5 Survival 
Survival of the 97 patients with breast cancer was followed up, with survival time 
being measured from the time of diagnosis to the date of death or until October 200 I. 
Two groups of patients were formed with regard to p73 genotypes: GC/AT and 
GC/GC. Univariate analysis of overall survival was performed by Kaplan-Meier analysis 
(Kaplan and Meier, I985) and Cox regression. The Cox proportional hazards model was 
used for multivariate analysis, where a backward elimination procedure was included to 
remove variables with p 2: 0.10. The qualifying criteria for inclusion in the multivariate 
analysis were p<O.I, or hazard ratios <0.5 or >2 in the univariate analysis. For all tests, a p 
value of less than or equal to 0.05 was considered as significant. All p values are results of 
two-sided tests. 
At the time of follow up, the mean survival of the 97 patients was 5.42 ± 3.91 years 
(0.70-24.2 years) {Table 7.1). Univariate analysis of the patient group showed that T stage 
(p=0.02), grade (p=0.04) and treatment with chemotherapy (p=O.OI) were significantly 
associated with survival (Table 7.17). Neither age, N stage, smoking habits, treatment with 
radiotherapy, p73 or p53 genotypes showed an association with survival (Figures 7.3 and 
7.4). Multivariate analysis of the patient group showed that only treatment with 
chemotherapy became an independent prognostic factor (p=0.05) (Table 7.18; Figure 7.8). 
T stage, stages I versus 2, were also an independent prognostic factor in multivariate 
analysis (p=O.OI). In contrast there was no influence of patient age, tumour N stage, grade, 
smoking habits nor treatment with radiotherapy on overall survival in multivariate analysis 
as they were eliminated from the model. 
Although no correlation was found between p73 genotypes and p53 isoforms, a 
strong correlation was found between T stage and N stage (p=0.03) as well as between T 
stage and treatment with chemotherapy (p=0.04) (Table 7.18). Additionally, treatment 
with chemotherapy also correlated with age of diagnosis (p=O.OOOI), N stage (p= O.OOI) 
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and grade (p=O.OOI). A correlation was also found between survival and N stage (p=0.03) 
and between N stage and grade (p=0.008). 
Kaplan-Meier analysis revealed a significant influence of T stage (Log rank 12, 
p=0.007; Cox regression, hazard ratio =2.1, p=0.006; Figure 7.5) and grade (Log rank 
7.64, p=0.02; hazard ratio =0.024, p=0.009; Figure 7.7) on cumulative overall survival. 
Treatment with chemotherapy also had a significant influence on overall survival 
(p=0.009; Figure 7.8) but not treatment with radiotherapy (p=0.37; Figure 7.9). No 
significant influence from either N stage (p=O.I2; Figure 7.6) or smoking habits (p=O.l4; 
Figure 7.10) was found on the cumulative overall survival in the patient group. 
The Nottingham Prognostic Index (NPI) was also assessed in the patient group (see 
Chapter x, section x). Calculated NPis in the 97 patients with breast cancer in this study 
showed that the majority of subjects were in the range of the moderate prognostic group 
(55.2 %) (Table 7.20). There is a significant correlation between survival time and NPI 
(Spearman's coefficient of correlation --0.29, p=0.005), with a hazard ratio of 2.86, p = 
0.005 (1.38-5.91; 95% en. log rank 10.48, p=0.005. 
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Table 7.17. Univariate analysis of cumulative overall survival of97 patients with breast 
cancer. 
Variable Hazard Ratio 95%CI pvalue 
p73 Genotype 
(GC/AT vs GC/GC) 1.36 0.60-3.18 ns 
p53 Genotype ns 
(Pro vs Pro/ Arg) 2.02 X 10"5 0.00 ns 
(Arg VS Pro/Arg) 1.43 0.60-3.38 ns 
Age (continuous) 0.99 0.96-1.03 ns 
T stage (T 1-4) 0.02* 
r. vs. r2 4.61 1.63-13.0 0.004* 
r. vs. r3 4.00 0.94-16.98 0.06 
r. vs. r4 10.43 1.16-93.41 0.04* 
N stage (No..J) ns 
No vs. N1 2.72 0.86-8.55 ns 
No vs. N2 3.36 0.83-13.56 ns 
No vs. N3 2.09 0.45-9.69 ns 
Grade (GI..J) 0.04* 
a. vs. G2 0.21 0.03-1.63 ns 
G. VS. G3 0.25 0.07-0.85 0.03* 
Smoking (no vs. yes) 0.22 0.03-1.65 ns 
Chemotherapy (no vs. yes) 4.66 1.38-15.75 0.01* 
Radiotherapy (no vs yes) 1.80 0.42-7.74 ns 
Hazard ratios (HR), p values and 95 % confidence intervals (Cl) are indicated. The HR for 
age as a continuous variable indicates the increase in hazard per year on a per year basis. 
* = statistically significant, ns = not significant 
-406-
Chapter 7. Results 
Table 7 .18. Multivariate analysis of cumulative overall survival of 97 patients with 
breast cancer. 
Variable Hazard Ratio 95%CI p value 
T stage (T I-4) 0.07 
T1 vs. T2 4.11 1.36-12.46 0.01* 
T1 vs. T3 3.81 0.83-17.42 ns 
T1 vs. T4 8.28 0.88-78.10 0.07 
Grade (GI-J) 0.09 
G1 vs. G2 0.31 0.03-3.67 ns 
G1 vs. G3 1.30 0.14-11.84 ns 
Smoking (no vs. yes) 5.89 0.77-44.85 ns 
Chemotherapy (no vs. yes) 3.60 0.99-13.03 0.05* 
Hazard ratios (HR), p values and 95 % confidence intervals (Cl) are indicated. 
Multivariate analysis was performed using a backward elimination procedure to remove 
variables with p ~ 0.1 0. The qualifying criteria for inclusion in the multivariate analysis 
were p<O.l, or hazard ratios <0.5 or >2 in the univariate analysis. 
* = statistically significant, ns = not significant 
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Table 7.19. Correlation between survival variables and clinical characteristics in 97 
patients with breast cancer. 
Variables Correlation 
(test value, p value) 
Age of diagnosis vs. Chemotherapy 430", p=0.0001 * 
Chemotherapy vs. T stage 8.26c, p=0.04* 
Chemotherapy vs. N stage 17.10c, p=0.001* 
Chemotherapy vs. Grade 13.06c, p=0.001 * 
T stage vs. N stage J8.41c, p=0.03* 
T stage vs. Grade 0.26c, p=O.OJ * 
Grade vs. N stage 17.51 c, p=0.008* 
Survival vs. N stage 8.91 c, p=0.03* 
Non-parametric analysis was performed using "Mann-Whitney U, "Kruskal-Wallis Hand 
"Pearson Chi-square tests. 
* = statistically significant 
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Figure 7.3. Cumulative overall survival of patients with breast cancer (n=97) with the p73 
GC/AT genotype compared with patients with the p73 GC/GC, analysed by Kaplan-Meier. 
Overall survival is defined from the day of diagnosis until day of death. Log rank 0.55, 
p=0.46, Cox regression, hazard ratio = 1.35, p= 0.50 (0.57-3 .21~ 95% CI). 
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Figure 7.4. Cumulative overall survival of patients with breast cancer (n=97) with p53 Pro, 
p53 Arg and p53 Pro/ Arg genotypes, analysed by Kaplan-Meier. Overall survival is 
defined from the day of diagnosis until day of death. Log rank 0.81 , p=0.67. Cox 
regression, hazard ratio = 1.22, p=0.66 (0. 53-2.96~ 95% Cl). 
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Figure 7.5. Cumulative overall survival of patients with breast cancer (n=97) differentiated 
by T stage and analysed by Kaplan-Meier. Overall survival is defined from the day of 
diagnosis until day of death. Log rank 12, p=0.007*. Cox regression, hazard ratio = 2.1 0, 
p= 0.004* (1.27-3.48~ 95% Cl). 
* = statistically significant 
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Figure 7.6. Cumulative overall survival of patients with breast cancer (n=97) who 
differentiated by N stage and analysed by Kaplan-Meier. Overall survival is defined from 
the day of diagnosis until day of death. Log rank 4.52, p=0.21. Cox regression, hazard ratio 
= 1.4, p= 0.12 (0.92-2.12; 95% Cl). 
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Figure 7.7. Cumulative overall survival of patients with breast cancer (n=97) differentiated 
by grade and analysed by Kaplan-Meier. Overall survival is defined from the day of 
diagnosis until day of death. Log rank 7.64, p=0.02*. Cox regression, hazard ratio"" 2.80, 
P"" o.o2• (1.14-6.85; 95% en. 
* = statistically significant 
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Figure 7.8. Cumulative overall survival of patients with breast cancer (n=97) who have 
had treatment with chemotherapy, compared with patients who have not had treatment 
with chemotherapy, analysed by Kaplan-Meier. Overall survival is defined from the day of 
diagnosis until day of death. Log rank 7.39, p=().007*. Cox regression, hazard ratio = 0.14, 
p= 0.009* (0.03-0.62; 95% Cl). 
* = statistically significant 
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Figure 7.9 Cumulative overall survival of patients with breast cancer (n=97) who have had 
treatment with radiotherapy, compared with patients who have not had treatment with 
radiotherapy, analysed by Kaplan-Meier. Overall survival is defined from the day of 
diagnosis until day of death. Log rank 0.64, p=0.42. Cox regression, hazard ratio = 0.51, 
p= 0.37 (0. 12-2 .21~ 95% Cl). 
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Figure 7.10. Cumulative overall survival of patients with breast cancer (n=97) who smoke 
compared with patients who do not smoke, analysed by Kaplan-Meier. Overall survival is 
defmed from the day of diagnosis until day of death. Log rank 3.28, p=0.07. Cox 
regression, hazard ratio = 0.22, p= 0.14 (0.29-1.65; 95% Cl). 
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Table 7.20. Nottingham Prognostic Index (NPD for 97 patients with breast cancer 
accessed in this study. 
NPI Subjects Survival 
n(%) n (%) Years(± SD) 
Good Prognostic Group (GPG) (<3.4) 17 (17.5) 14 (87.5) 7.10 ± 5.89 
Moderate Prognostic Group (MPG) (3 .41-5.4) 53 (54.6) 43 (81.1) 5.38 ± 3.47 
Poor Prognostic Group (PPG) (>5. 41) 27 (27.8) 18 (66.7) 4.84 ± 1.61 
Survival time is measured from the time of diagnosis to the date of death or until October 
2001 and is presented in years± standard deviation. There is a correlation between survival 
time and NPI (Spearman's coefficient of correlation -0.285, p=0.005*; Kruskal Wallis H 
test 8.02, p=0.018*). Cox regression, hazard ratio =2.86, p = 0.005* (1.38-5.91; 95% en. 
Log rank 10.48, p=0.005* 
n = number of subjects 
* = statistically significant 
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7.6 Conclusion 
This is a novel study of both p53 isofonns and p73 genotypes in individuals with 
breast cancer. Both the p73 AT/AT genotype and the p53 Pro isoform were found to be 
rare in all populations studied. A significant association was found with the p73 GC/GC 
genotype and patients with breast cancer diagnosed over 52 years of age (median). No 
association was found with the p53 codon 72 Pro/ Arg polymorphism and breast cancer. 
The results suggest that polymorphisms of either p53 or p73 genes are not risk factors in 
the development of carcinoma of the breast. Both the p73 genotypes and p53 isoforms had 
no significant influence on overall survival in the patient group however, T stage, grade 
and treatment with chemothempy were all found to have a significant influence on overall 
survival in the patient group. A significant correlation was also found between survival 
time and NPI in the patient group. 
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8.0 Discussion 
Cells respond to stress by regulating the expression of adaptive and/or pathological 
genes depending on the actual magnitude and duration of the stimulus or condition. This 
stress may be hypoxic, high glucose or oxidative, and include pH and temperature changes. 
The adaptive response to these stimuli is mediated in part by the transcription factor HIF-
1a by signalling through heterodimeric PAS family member interactions, resulting in the 
increased expression of glucose transporters, and glycolytic enzymes. Ultimately 
angiogenesis is enhanced and erythropoiesis increased (Guillemin and .Krasnow, 1997). 
Under conditions of sustained metabolic stress, HIF-la stabilisation increases cellular p53 
levels thereby up-regulating the transactivation of pathological genes and ultimately 
resulting in cell death (Halter man et a/, 1999). However, p53 also decreases the stability 
of IDF-1a by inhibiting the hypoxia-induced expression of IDF-1a and assisting its 
ubiquitination and subsequent degradation (Ravi et a/, 2000). 
It is known that hypoxia is prevalent in solid tumours and it is the adaptation to 
hypoxic conditions that is the critical step in the survival and progression of tumours and 
disease. One major point of consideration is the definition and severity of hypoxia. Much 
debate has arisen over optimal hypoxia conditions as opposed to anoxia. IDF-la has been 
shown to be optimally induced at 0.5% 0 2 (Wenger and Gassmann, 1997), however 
several studies have reported that oxygen concentrations found to induce the expression of 
p53 were indeed anoxic (0.02%) (Graeber et a/, 1996; An et a/, 1998), suggesting that 
anoxic mechanisms are involved in oxygen-dependent p53 regulation. A recent report 
found that the sensitivity of pathways to hypoxia varies in cell lines where both HIF-la 
and HIF-2a were found to be detectable at a range of 0.1% to 3% 0 2 suggesting that some 
tumours in vivo may be more able to respond to small changes in the microenvironment 
with less severe hypoxia (Blancher et a/, 2000). All hypoxic experiments in this work were 
performed at :s; 1% oxygen, as verified by a Fyrite® gas analyser. 
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8.1 HIF-la, GLUT-1 and p53 Expression In Breast Carcinoma Cell 
Lines 
Although cell lines derived from human tumours have been extensively used as 
experimental models of neoplastic disease, clear difficulties exist. Established cell lines 
differ from both normal and cancerous tissue, however they provide a convenient and 
unlimited source of human tissue. A recent study has shown that breast carcinoma cell 
lines are broadly representative of fresh tumours (Davidson et a/, 2000). The majority of 
experimental work was performed on established cell lines. Cell lines were chosen to 
represent a spectrum of breast cancer types as well as reflect the heterogeneity of human 
breast cancer progression pathways. 
Initial studies investigating the mRNA expression of HIF-la, VEGF, p53 and~ 
actin in four individual breast carcinoma cell lines exposed to hypoxia were performed 
using Northern blot analysis and showed that upregulation occurred after exposure of cells 
to CoCh and hypoxia. As it was found that large quantities of mRNA were required for 
genetic expression, the newer and more sensitive RPA was utilised for determining and 
quantitating m.RNA expression. 
Under normoxic conditions, HIF-la, GLUT-I and p53 mRNA was detected at 
varying concentrations in all of the breast carcinoma cell lines studied. After prolonged 
exposure to hypoxia, the majority of cell lines studied exhibited little or no change in the 
expression of HIF-la m.RNA. Initial studies found that the gene for HJF-la was 
transcriptionally induced under hypoxia (Wang et a/, 1996) however, further studies have 
shown that HIF-1 a mRNA is expressed constitutively in a large number of human tissue 
and cell lines and that these steady-state expression levels are not further up-regulated by 
hypoxia (Huang et a/, 1996; Kallio et a/, 1997; Wenger et a/, 1997). Conversely, studies 
have reported that the H/F-1 a mRNA level increases in hypoxia in the human Hep3B cell 
line, in bovine pulmonary artery endothelial cells and in rat brain and kidney (Ladoux and 
-421-
Chapter 8. Discussion 
Frelin, 1997; Wiener et a/, 1996; Palmer et a/, 1998; Wenger et a/, 1997). Thus, it may be 
that the presence of a transcriptional up-regulation mechanism for HIF-1a is species and/or 
cell-type specific. Although little or no change in HIF-1 a mRNA expression was observed 
in the majority of cell lines exposed to hypoxia, this may not be a consequence of low 
oxygen tension but may instead represent a general adaptation response of the cells during 
cultivation. 
At the time of this study, conflicting reports remained as to the transcriptional 
induction ofHIF-la which warranted further investigation considering that very little work 
had been performed with breast tissue or breast carcinoma cell lines. Little is known about 
the hyperglycaemia-induced expression of HIF-la in breast carcinoma cell lines and it is 
possible that the expression profiles of HIF-1 a and GLUT-1 genes under hypoxic and high 
glucose conditions may offer further insight as to how cancer cells behave under 
conditions of extreme stress. 
The transcription of the GLUT-/ gene is enhanced in response to hypoxia, or cobalt 
chloride, to inhibition of oxidation phosphorylation by azide, to an ionophore-induced 
increase in the concentration of cytosolic calcium, and after transformation (Zhang et a/, 
1999; Wertheimer et a/, 1991). The studies presented here on breast carcinoma cell lines 
determined that HIF-1 a, GLUT-1 and p53 mRNA expression increased in response to high 
glucose but decreased in response to the combined stresses of hypoxia and high glucose 
(D-glucose) from normoxic levels. Additionally, the combination stress of oxygen and 
glucose deprivation resulted in the decreased expression of HIF-1 a mRNA from normoxic 
levels in 3 of the 4 cell lines investigated. Controls for osmolarity determined that this 
response was not specific for either hypoxia or high glucose and was probably due to 
differences in osmolarity as increases in H/F-1 a and GLUT-1 mRNA expression were 
observed after exposure to either L-glucose or mannitol. This would imply that a redox 
effect promotes the induction of HJF-Ja and GLUT-1 mRNA in these cell lines and not 
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hypoxia or D-glucose alone. This fmding is confirmed by a recent study which 
demonstrated that hyperosmolarity increases GLUT-I mRNA content in a non-transformed 
rat liver cell line, the response was mediated by both enhanced transcription and 
stabilisation of GLUT-I mRNA as was associated with increases in GLUT-1 content and 
glucose transport activity (Hwang and Ismail-Beigi, 2001). As this study also found that 
increased expression of aldose reductase is associated with significant increases in the 
cellular content of sorbitol, it would be interesting to study the effect of hypoxia, high 
glucose and hyperosmolarity on both aldose reductase mRNA expression and glucose 
transport via measurement of the cellular content of sorbitol in the breast carcinoma cell 
lines. Obtaining a description of mRNA profiles for genes encoding for enzymes for the 
entire metabolic pathway may provide a useful insight into the induction and regulation of 
these genes under conditions of extreme stress. Additionally, it is possible that other 
osmolytes such as dextrose, NaCl and urea may produce similar results and should 
therefore also be investigated. 
It is possible that an increase or decrease in mRNA expression may be mediated by 
an increase or decrease in the stability of the mRNA Therefore, both the stability and the 
transcriptional rate of HIF-1 a and GLUT-I should be determined by nuclear runoff 
transcription assays to establish whether hypoxia and high glucose affect the transcript 
levels in both genes through enhanced or decreased mRNA A wide disparity in GLUT-I 
half-lives has been observed in different cell types indicating celV tissue specific regulation 
of GLUT-I mRNA stability (Stein et a/, 1995; Jain et a/, 1997; Behrooz and Ismaii-Beigi, 
1997; Vinals et a/, 1997). This factor may account for the varied responses observed in this 
study. 
An additional factor may have been the high basal levels of D-glucose in the 
culture media. The DMEM culture media contained a basal D-glucose level of 25 mM, 
slightly above the moderate glucose conditions of 21 mM in the RPMI culture media. The 
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result of adding additional D-glucose to the DMEM culture media to create moderate and 
high glucose conditions may have instead slowed any observed effect on mRNA 
expression due to saturation of glucose receptors. 
When DNA binding was investigated in the breast carcinoma cell lines, EMSA 
revealed a very efficient DNA-binding of functional lllF-1 complexes under normoxic 
conditions as well as induced binding activity under hypoxic and hyperglycaemic 
conditions. A recent study has also reported lllF-1 binding under normoxia in the MX-1 
human breast cancer cell line (Marxsen et a/, 2001). Competition experiments determined 
that the observed lllF-1 binding was specific as it could be effectively inhibited with 
excess unlabelled probe. The MCF7 breast cell line was the only cell line in which extracts 
displayed a decrease in binding activity from normoxic control levels. The largest 
induction in binding activity was observed in extracts from the ZR75 breast cell line 
exposed to hypoxia which exhibited a 3 fold greater binding activity than that observed in 
the other breast cell lines. These variations in binding activity may be attributed to 
different states of phosphorylation. DNA binding of lllF-1 is regulated by protein 
phosphorylation (Wang et a/, 1995) and the status of phosphorylation can affect the 
mobility of the target protein in polyacrylamide gels. It is also possible that different 
coactivators may be involved in lllF-1 activation by hypoxia when compared with that 
activated by high glucose. 
To better understand how extreme stress affected these cells, lllF-la and GLUT-1 
protein expression was investigated. Unfortunately, attempts at determining lllF-la 
protein expression through Western blotting were unsuccessful. Spiking experiments 
determined that the only signal detected was that ofBSA. 
GLUT -1 protein expression was also investigated in the breast carcinoma cell lines 
exposed to hypoxia and long-term high glucose where no increase in protein expression 
was observed in the majority of cell lines exposed to hypoxia for up to 24 hours, results 
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which are consistent with observed mRNA expression levels. However, the combined 
exposure to both stresses resulted in decreased protein expression from that observed at 
normoxic levels. A recent study involving Western analysis of MCF7 breast cell protein 
exposed to hypoxia for up to 4 hours did not show any increase in the levels of HIF-1a., 
HIF-ljl, p53, GLUT-1 or GLUT 3 (Burgman et a/, 2001) suggesting that there may be a 
defect in the hypoxia-sensing signal transduction pathway in these cells. Conversely, this 
present study found increased expression of GLUT -1 protein in the MCF7 cell line after 2 
and 24 hours exposure to hypoxia, indicating that longer exposure to hypoxia may be 
required to invoke a response in this particular cell line. However, GLUT-I protein 
expression was not induced in the SKBR3 and ZR75 breast carcinoma cell lines after 
exposure to hypoxia. It has been reported that only GLUT -1 and GLUT 3 are expressed in 
MCF7 breast cells (Aioj et a/, 1999) thus, it is possible that differences in GLUT species 
expressed in the various cell lines can account for the different expression patterns 
observed in each cell line under the various treatments. Moreover, consistent findings at 
the mRNA and protein levels in the majority of breast cell lines that exposure to hypoxia 
and long-term high glucose resulted in decreased GLUT-I mRNA or protein expression, 
indicate that conditions of extreme stress overload and curtail the response pathway. 
Oxygen deprivation and excess glucose represent an additional disturbant of glucose 
transporter expression in human breast carcinoma cells. 
It is possible that breast epithelial carcinoma cells have a decreased capacity to 
store glycogen and therefore do not have a reservoir of metabolisable substrates available 
under conditions of extreme stress. Exposure of breast carcinoma cell lines to hypoxia 
resulted in an initial decrease in the level of lactate from normoxic levels that steadily 
increased over normoxic levels after 24 and 48 hours of exposure. The initial decrease in 
lactate levels would indicate recovery from the hypoxic stress followed by an increase in 
the rate of glycolysis. Concurrent measurement of the A TP levels during hypoxic exposure 
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would verity upregulation of glycolysis in these cells. It is known that part of the 
adaptation to hypoxia involves upregulation of genes that encode the enzymes required for 
anaerobic glycolysis, thus allowing cells to switch to this form of metabolism from 
oxidative phosphorylation. The slow recovery time observed by the decreased levels of 
lactate produced under prolonged exposure to hypoxia may indicate that the cells have not 
switched to anaerobic glycolysis. Therefore oxidative phosphorylation has not been 
inhibited and GLUT-1 mRNA expression is not induced Studies have shown that GLUT-1 
mRNA induction by hypoxia requires the inhibition of oxidative phosphorylation (Behrooz 
and Ismaii-Beigi, 1997). It is however, difficult to understand the complex metabolic 
processes that occur at the cellular level. 
It is interesting to note that the magnitude of change in GLUT -1 protein expression 
impeded by hypoxia or by the combined stresses of hypoxia and excess glucose, was 
slightly less than the observed decrease in GLUT-1 mRNA expression levels. If these 
discrepancies occur in vivo than cell damage may be due in part to the inability of breast 
cancer cells to translate GLUT-1 messages sufficiently during conditions oflimited oxygen 
availability with over availability of glucose. 
Each cell line studied produced varied genetic expression responses to the stresses 
of hypoxia, high glucose or the combined stresses of both, displaying limited increased 
expression of both the hypoxia-regulated genes HJF-la and GLUT-1. Although these 
experimental results confirm that hypoxic regulation of HIF-la, GLUT-1 and p53 occurs 
post-transcriptionally, this variation in response demonstrates the difficulties in working 
with cell lines. Although culture and experimental cell conditions were standardised by 
determining cell densities to ensure that experimental work was performed in an optimal 
exponential growth phase, cells may have exceeded their exponential phase through the 
duration of some experiments. Mild hypoxia may occur from cell-to-cell contact (Jones et 
a/, 2001) and cell confluence can produce stresses, such as low glucose and acidosis, 
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resulting in nutritional deprivation and possible hypoxia-triggered apoptosis (Schmaltz et 
al, 1998). The toxicity of hypoxia is therefore proportional to cell density and may 
contribute to the regulation ofboth HIF-la. and GLUT-I. 
In conclusion, experimental results produced from this study suggest that when 
breast carcinoma cells are subjected to extreme stress, such as the combined stresses of 
hypoxia and high glucose, the hypoxia response pathway is impeded. It is probable that 
hypoxia, high glucose, hypoglycaemia and hyperosmolarity do not share a common 
transcriptional stress response pathway. Various studies on the response of the GLUT-I 
gene to cellular stress have found that different regions of the GLUT-I promoter have been 
identified which mediate responses to stresses such as hypoxia, azide, transformation and 
hyperosmolarity (Behrooz and lsmail-Beigi, 1997; Ebert et a/, 1995; Hwang and Ismail-
Beigi, 2001). Moreover, a recent study has shown that the basal levels of HIF-2a are 
highly related to the inducible level of the HIF protein in breast carcinoma cell lines 
(Blancher et a/, 2000). Thus, it would be of interest to elucidate the regulation and role of 
HIF-2 a mRNA expression in these cell lines. 
8.2 HIF-la and GLUT-1 Expression In PBMCs of Patients with TlDM 
Excessive flux through the polyollsorbitol pathway caused by hyperglycaemia is 
likely to lead to a number of metabolic and vascular defects that ultimately give rise to 
tissue hypoxia and ischaemia. Currently, little is known about the hyperglycaemia-induced 
expression of HIF-la. and GLUT-I in the PBMCs of patients with or without diabetic 
complications. 
In this study, the basal levels of HIF-la. and GLUT-I mRNA expression in the 
PBMCs of normal healthy controls was found to be significantly higher then in those of 
patients with TIDM. It is known that basal levels of HJF-1 a mRNA expression varies 
according to differences in culture conditions (Semenza, 1998). As HIF-1 a and GLUT-I 
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rnRNA were present in high levels in the non-hypoxic PBMCs of normal controls, 
induction of expression of either gene under high glucose was not significant, however 
significant differences were found between the control and patient groups at both moderate 
and high glucose levels. The PBMCs from patients with TlDM may be preconditioned to 
high glucose and oxidative stress and therefore may behave in a different way to cells 
subjected to short term exposure to high glucose. 
Two distinct trends were observed in the expression of both HIF-1 a and GLUT-I 
rnRNA in the PBMCs of patients with TlDM. Considering the response found in the breast 
carcinoma cell lines, where short-term exposure to high glucose increased HIF-1 a and 
GLUT-I mRNA expression, it was unexpected to fmd a large group of patients with a 
marked decrease in HIF-1 a and GLUT-I mRNA expression in high glucose. As seen in the 
breast carcinoma cell lines, controls for osmolarity determined that this response was not 
specific for D-glucose and was probably due to differences in osmolarity. Increases in 
HIF-1 a and GLUT-I mRNA expression were observed after the PBMCs from two patients 
with diabetic complications were stimulated with mannitol and both an increase and 
decrease in both HIF-la and GLUT-I mRNA was observed after stimulation with L-
glucose. 
Although the average expression of both HIF-1 a and GLUT-I mRNA in the 
PBMCs of all patients investigated increased in high glucose, there may be a number of 
factors as to why an increase in HIF-1 a and GLUT-I mRNA expression was not observed 
in all patients with TlDM. It is possible that the expression and function of glucose 
transporters differs between patients with and without complications. Patients without 
complications displayed a 1.5 and 2.0 fold increase in HIF-1 a mRNA expression, and a 
1.3 and 1.5 fold increase in GLUT-I mRNA expression in moderate glucose and high 
glucose, respectively, over patients with complications. Additionally, the increase or 
decrease in HIF-Ia and GLUT-I mRNA expression may be mediated by transcription of 
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the genes as well as by stabilisation of the mRNAs. Moreover, the stimulation of HIF-Ia, 
and hence GLUT-I, mRNA by high glucose may be due to increased conversion of an 
inactive to active form of the protein due to changes in the redox state of the cells. It may 
be that patients with TlDM have more active protein in their cells. 
Another possible factor may be that patients with TlDM may have an aldose 
reductase protective polymorphism. Studies have suggested that genetic variation in the 
aldose reductase gene may contribute to the genetic susceptibility to diabetic nephropathy 
(Shah et a/, 1998; Moczulski et a/, 2000). Polymorphisms in the aldose reductase gene 
may be markers of different levels of expression of the gene, of altered tissue expression or 
the ability to respond to stimuli. It would be interesting to obtain the mRNA profiles for 
genes coding for the aldose reductase genotypes, as well as sorbital dehydrogenase, to 
determine if the response to uptake and disposal of D-glucose is different between the 
groups of patients with and without complications and normal controls, as was found in a 
recent study (Hodgkinson et a/, 200 I). 
Investigation of HIF-Ia DNA binding activity in the nuclear extracts from the 
PBMCs of patients with TlDM and normal controls revealed efficient DNA-binding of 
functional HIF-I complexes under normoxic conditions. Binding activity was slightly 
decreased after exposure to high glucose in all extracts. Preliminary investigation of 
GLUT-I protein expression in the PBMCs of normal controls exposed to high glucose 
displayed an increase in GLUT-I protein expression whilst those from patients with 
TlDM, one patient with complications and one without, exposed to high glucose showed a 
dramatic decrease in GLUT-I protein expression. This would imply that the induction of 
GLUT-I mRNA is not mediated at the transcriptional level in the PBMCs of patients with 
TlDM. As a similar finding was observed in breast carcinoma cell lines exposed to long-
term high glucose and hypoxia, it is possible that the regulation of GLUT-I expression and 
function may be mediated at multiple levels. Further protein studies are required to 
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elucidate the response seen and this hypothesis. 
It is known that vascular changes induced by increased glucose or sorbitol levels 
are prevented by raising tissue pyruvate levels, which drives the oxidation of NADH to 
NAD+ coupled to the reduction of pyruvate to lactate by lactate dehydrogenase (Brownlee, 
2001). This same redox imbalance also develops in hypoxic and ischaemic tissues due to 
impaired oxidation of NADH to NAD+ by the mitochondrial electron transport chain. 
Measurement of lactate levels in the culture medium of PBMCs of four patients without 
diabetic complications and of two patients with diabetic complications exposed to high 
glucose, showed only minor increases over normal culture levels. Exposure to high glucose 
does not seem to significantly up-regulate glycolysis in these patients nor in normal 
controls. Pyruvate has been shown to attenuate vascular dysfunction induced by hypoxia 
and ischemia, by acute high glucose in nondiabetic rats and by diabetes (Bunger et a/, 
1989; Cavallini et a/, 1990). 
This is a novel preliminary report of HIF-1 a and GLUT-/ mRNA expression in 
high glucose which suggests that HIF-la may be an important regulator of the cellular 
response to high glucose. It is possible that abnormal expression of HIF-la and its target 
genes, through activation by high glucose, may contribute to diabetic complications. As the 
molecular basis of the cellular response to hypoxia and high glucose has yet to be 
determined, further studies of subsequent gene and protein regulation by HIF-la are 
required. 
8.3 HIF-la and GLUT-1 Expression In Breast Tumours 
Oxygen and glucose are important for tumour growth as they fuel tumour cell 
survival and proliferation. It has long been known that tumours display numerous 
metabolic changes compared with normal cells, such as increased glycolytic metabolism 
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even under aerobic metabolism (Warburg, 1930). This increased glycolysis is managed by 
the increased uptake of glucose by GLUT-1, the first in the family of glucose transporters 
to be cloned (Mueckler et a/, 1985). The mechanism by which hypoxia increases GLUT-I 
mRNA expression is fairly well understood, believed to be through anaerobic glycolysis 
and inhibition of oxidative phosphorylation (Behrooz and lsmail-Beigi, 1997). 
At the time of this study there were no reports of HIF-I a or GLUT-I mRNA or 
lllF-1a protein expression in breast tumours. Increases in GLUT-I mRNA expression have 
however been described in tumours of the oesophagus, colon, pancreas (Yamamoto et a/, 
1990), lung (Ogawa et a/, 1997) and brain (Boado et a/, 1994; Tsukamoto et a/, 1996). 
Normal control tissue for this study could not be obtained and limited tissue was available 
for analysis as the collaborating pathologist left at the beginning of the study and was not 
replaced for some time. This made the interpretation of HIF-Ia and GLUT-I mRNA 
expression and lllF-1a protein expression in these breast tumours difficult. 
In this preliminary study, HIF-I a and GLUT-I mRNA were overexpressed in 59% 
and 68% of the breast tumours assessed, respectively, however the amplitude of 
overexpression varied. A significant correlation was found between the expression of both 
genes (p=0.03) which was lost when the expression was compared categorically. 
Significant correlations were also found between HIF-I a mRNA expression with patient 
age at diagnosis and tumour Grade, and between GLUT-I mRNA expression with patient 
age at diagnosis and tumour N stage. Over-expression of lllF-1 a and GLUT -1 mRNA may 
promote an increase in tumour size by supporting glycolysis thereby enhancing tumour cell 
viability and providing energy for cell division and tumour growth. 
Until recently, the significance oflllF-1a expression in human tumours remained 
largely unexplored, as monoclonal antibodies available for immunohistochemistry have 
only recently been developed. Indeed, immunohistochemical analysis performed in this 
study used monoclonal antibodies to lllF-la which had just become commercially 
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available and had not yet been used widely for immunohistochemical analysis. Several 
studies have only just emerged accessing the expression ofHIF-Ia in a variety of tumours 
types, including breast (Bimer et al, 200I; Aebersold et al, 200 I; Qin et a/, 200 I; Bimer et 
al, 2001b). A recent report found that HIF-Ia protein was undetectable in normal breast 
tissue and benign breast lesions but was expressed in in situ and invasive breast cancers, 
with increased levels as dedifferentiation progressed (Bos et al, 2001). The report also 
found HIF-Ia positivity in normal tissue adjacent to tumour, thus emphasising the 
importance of obtaining control tissue from healthy control subjects. 
In this study, immunohistochemical analysis revealed that only 23 % of breast 
tumours displayed nuclear HIF-1a immunoreactivity. It is possible that there was less 
oxygen consumption and less metabolically driven hypoxia and therefore, less induction 
of HIF-Ia in the tumours. Although a high percentage of HIF-Ia immunoreactivity was 
found in the cytoplasm ( 4I% ), as a granular staining pattern distributed throughout the 
cytosol, the significance of this is not certain and is difficult to explain. While nuclear illF 
is the active form, HIF-1a is synthesised as well as degraded in the cytoplasm (Wang et a/, 
1995; Jiang et a/, 1996). Cytoplasmic staining has also been reported in a number of recent 
studies (Zhong et al, 1999; Aebersold et a/, 2001; Giatromanolaki et al, 2001) with 
possible explanations of diffusion of the HIF-1a protein from within the nucleus, or 
sequestration of an inactive pool (Karth et a/, 2000). As a sensitive biotin based method 
with amplification was used in this study, higher levels of background staining were 
observed. Given that biotin is in mitochondria, it is possible that the tumour cells analysed 
in this study may have contained large amounts of mitochondria which would also account 
for this observation, although staining was not seen with omission of the primary antibody. 
It has also been suggested that strong cytoplasmic HIF expression better reflects the illF 
up-regulated pathway in paraffm-embedded material (Giatromanolaki et al, 2001). 
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Although GLUT-I protein expression was not investigated in this study, 
immunostaining for GLUT-I has been described as a sensitive and specific means of 
detecting breast carcinoma in effusions (Burstein et a/, I998), although a more recent 
report has found that GLUT-I expression is of limited value (Zimmerman et a/, 200I). 
GLUT-I has been investigated immunohistochemically in a variety of malignant and 
normal tissues, including tumours of the breast (Brown and Wahl, I993; Younes et a/, 
I995), thyroid (Haber et a/, 1997), head and neck (Mellanen et a/, I994), bladder (Chang 
et a/, 2000), lung (Brown et a/, I999), renal cell carcinoma (Nagase et a/, I995) and more 
recently in gastric carcinoma (Kawamura et a/, 2001), ovarian carcinoma (Cantuaria et a/, 
200I), and carcinoma of the cervix (Airiey et a/, 200I). In all cases, expression of GLUT-I 
increased relative to corresponding normal tissue. Where the prognostic value of GLUT -1 
expression had been assessed, results suggest that overexpression is associated with tumour 
aggressiveness and poor survival (Kawamura et a/, 200I; Cantuaria et a/, 2001). An 
additional study has found that GLUT-I expression correlates with tumour hypoxia (Airley 
et a/, 2001). 
In this study, breast tumours were observed in which only one of the two genes, 
HIF-1 a or GLUT-I mRNA was overexpressed or where GLUT-/ mRNA was 
overexpressed but HIF-la protein was not, suggesting that possible additional regulatory 
mechanisms exist. It is known that hypoxia regulates GLUT-I mRNA expression 
(Mueckler, 1994), mediated by HIF-1 which binds to a cis-acting binding sites located 
within the 5' flanking region of the GLUT-I gene (Ebert et a/, 1995). Thus where the 
expression of GLUT-I mRNA is increased, an increase in HIF-la protein is also expected, 
however this did not always occur in this study. A recent report supports the findings in 
this study where although a progressive increase in GLUT-I mRNA expression with 
increasing abundance ofHIF-la protein was observed in clear cell renal carcinoma, single 
tumours were observed in which GLUT-I was not overexpressed (Wiesener et a/, 2001). 
-433-
Chapter 8. Discussion 
Analysis of p53 expression in the breast tumours would provide additional information as 
accumulation is a result of its stabilisation by HIF-1a (An et a/, 1998) and wild-type p53 
promotes degradation of HIF-1a protein (Ravi et a/, 2000). Additionally, the breast 
tumours analysed in this study were classified as either T1 (<2 cm) or Tz (2-5 cm) tumour 
stage, the earlier stages. It is widely accepted that the development of hypoxia is caused by 
the rapid growth rate of the tumour that is not accompanied by an adequate 
neovascularisation (Dang et a/, 1999). As the intra-cellular 0 2 levels were not known, it is 
possible that these tumours were well vascularised and hence well oxygenated. 
Experiments have shown that an oxygen concentration of Sl.5% up-regulates cellular 
glucose uptake independent of glucose deprivation (Clavo et a/, 1995), thus any Oz level 
above this would not up-regulate HIF-1a protein or GLUT-1 gene expression. However, 
previous studies have shown that tumour oxygenation is independent of tumour 
characteristics, such as tumour size and grading (Hockel et a/, 1996; Brizel et a/, 1996), 
thus tumour oxygenation is not a predictable factor and must be assessed in each tumour 
individually. 
Overall cumulative survival was assessed in this small series of patients with breast 
tumours with no significant influence found from either HIF-1 a or GLUT-1 positive or 
negative mRNA expression. However, tumour T stage and N stage were found to be 
significantly associated with survival in this study group. Tumour grade was not expected 
to influence survival in this study group as only one G1 grade tumour was available for 
analysis. Although statistical power was also limited due to the low number of cases 
analysed (n=22) with a relatively short follow-up, a significant correlation was found 
between survival time and the NPI. It is interesting to note that all 3 of the patients who 
succumbed to the disease were categorised in the poor prognosis group, implying that the 
NPI is a good prognostic indicator for patients with breast cancer. 
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8.4 HIF-la., VEGF and p53 Expression In Glioblastoma 
Glioblastoma multiforme is one of the most frequent forms of brain tumour and 
accounts for approximately 12-15% of all intra-cranial neoplasms (Zulch, 1986). It is 
characterised by high proliferation rates, necrosis and prominent angiogenesis. HIF-1a 
plays a critical role in the regulation of many genes which have important roles in 
neovascularisation and tumour metabolism, such as VEGF and p53. VEGF has been shown 
to be upregulated by hypoxia in glioma cells, where it is found in both low and high-grade 
gliomas and in brain metastasis from different primary tumours (Machein and Plate, 2000). 
Until recently, no data existed on the expression of HIF-1a in human brain 
tumours. At the time of this study there were no reports of HIF-la mRNA or protein 
expression in glioblastoma. Recent data have suggested a role for HIF-1a expression in 
glioblastoma, although little is known about the mechanism controlling its expression 
(Zagzag et a/, 2000; Zhong et a/, 1999). 
In this preliminary study, 77 % of high-grade astrocytic astrocytic tumours were 
found to over-express HIF-1a protein and 84 % VEGF protein. As noted in previous 
studies (Zagzag et a/, 2000; Zhong et a/, 1999), HIF-1a protein expression was 
particularly strong surrounding areas of necrosis in glioblastomas, which is in keeping with 
a direct role for HIF-1 in the regulation of VEGF (Plate et a/, 1992), with prominent 
nuclear expression being consistent with HIF-Ia acting as a transcription factor. Hypoxia 
is known to stabilise HIF-1a protein (Huang et a/, 1996) and may explain expression 
adjacent to necrosis, but HIF-1a was present more diffusely in high grade astrocytic 
tumours, and was stronger in infiltrating tumour cells then reactive glia suggesting that 
expression is aberrantly controlled. 
There were clear differences in the level of expression of HIF-1a between the 
glioblastoma samples compared to lower grade tumours and normal brain. All 
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glioblastoma samples displayed similar degrees of necrosis and vascular proliferation. In 
many of the tumours over-expressing IDF-1a, increased expression of H/F-1 a mRNA was 
also found, suggesting that control is at least partly at the transcriptional level. However, in 
several tumours over-expressing IDF-1a protein, no increase in HIF-Ia mRNA was 
detected Although this finding could be due to sampling error, as relatively small samples 
were available for mRNA analysis, it is also possible that post-transcriptional mechanisms 
may play a role. Three possible mechanisms are reduced HIF-I a degradation due to loss of 
p53, PTEN and/or VHL function. PTEN is a tumour suppressor gene originally isolated 
from a homozygous deletion on chromosome l0q23 in glioblastoma (Li et al, 1998; Steck 
et a/, 1997). Recently it has been shown that wild-type PTEN mediates the degradation of 
HIF-la and therefore the frequent loss ofPTEN in glioblastoma (Wang et a/, 1997), which 
may facilitate aberrant expression ofiDF-la (Zundel et a/, 2000). Wild-type p53 promotes 
degradation ofHIF-1a protein (Ravi et a/, 2000) and it might be expected that inactivation 
of p53 may lead to increased HIF-la expression As most solid tumours contain hypoxic 
regions, a mutated p53 gene may confer a survival advantage to tumour cells under very 
low oxygen conditions (Graeber et a/, 1996). 
Although all of the glioblastoma samples displayed some degree of 
immunohistochemical p53 expression in some tumour cells, over-expression of the protein 
only occurred in 64% of samples. Mutations in p53 are usually missense, which prolong 
the half-life of the protein and render it immunodetectable (Simmons et a/, 2001). No 
correlation was found between p53 over-expression with either IDF-la protein or mRNA 
expression, a finding supported by a recent report where p53 over-expression was found in 
only 2 of 51 specimens of oligodendrogliomas (Birner et a/, 2001). However, this does not 
preclude an association between IDF-la and p53 in glioblastoma as p53 protein over-
expression in gliomas is not always due to a gene mutation and the relationship between 
HIF-la and p53 is complex with wild-type p53 being stabilised by HIF-la (An et a/, 
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1998). The results in this study concur with a previous study that found no evidence for 
increased expression of the VEGF gene in glioma cells that contain a mutated form of p53 
(Plate et a/, 1994). It is also known that levels ofp53 in cultured neurons increases with the 
duration of hypoxia, thus changes in the duration of hypoxia can alter cellular levels of p53 
(Banasiak et a/, 1998). Western blot analysis ofp53 protein expression and screening p53 
gene abnormalities in these tumours may help in further clarifying this association. 
Another possible mechanism is that loss of VHL function may lead to HIF-1cx 
accumulation. The VHL gene product (pVHL) is required for regulation of the HIF-1 
transcriptional control system (Maxwell et a/, 1999) and the VHL gene may be mutated in 
glial neoplasms (Kanno et a/, 1997). VHL forms a complex with elongins Band C, Cul2 
and the Ring-H2 finger protein Rbx1 (VCBCR complex) by binding to the oxygen 
dependent destruction domain of HIF-1cx subunits through the j3-domain of pVHL 
(Lonergan et a/, 1998; Kamura et a/, 2000; Ohh et a/, 2000). pVHL then acts as the 
recognition component of the E3 ubiquitin ligase complex mediating HIF-1 ex destruction 
(Cockman et al, 2000; Iwai et al, 1999; Tanimoto et a/, 2000). Under hypoxia, VHL-
mediated degradation of HIF-1cx does not occur leading to accumulation of HIF-1cx. 
Additionally, non-functional VHL also results in the accumulation ofHIF-1cx in normoxic 
conditions (Maxwell et a/, 1999). 
The increased expression of both HIF-1 a and VEGF support recent in-vitro studies 
showing that transcription of the VEGF gene is regulated by HIF-1 in cells grown under 
hypoxic conditions (Forsythe et a/, 1996). The amplimers did not differentiate between the 
known VEGF isoforms, however previous studies have shown that in glioblastoma the 
121, 165 and 189 isoforms are all present with the 165 isoform being most abundant 
(Berkman et a/, 1993). Although previous studies found over-expression of VEGF in 
glioblastoma, this feature was not demonstrated in this study. This may be due to technical 
difficulties occurred within the assay. It is clearly difficult to compare the data obtained in 
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this study with those obtained in other studies using disparate techniques. Further, in this 
study it was not possible to compare VEGF mRNA with the protein or, rate of transcription 
of this gene in the tumour. 
However, there was a marked correlation between HIF-1 a and VEGF expression in 
the glioblastoma samples, which is probably a reflection of the small sample size used in 
this study. Factors such as the quality and the quantity of the tumour tissue collected may 
explain this lack of correlation as it was not possible to control for sample size, location, 
nor the cross-sectional heterogeneity of the tumour samples at the time of collection. 
Additionally, the expeditious expression of 1 to 2 hours for HIF-Ja mRNA (Wang et a/, 
1995) makes its labile compared to VEGF. 
Glioblastomas are the most common type of primary brain tumour, and despite 
treatment has a median survival of only 9-12 months (Walker et a/, 1980). In contrast to 
most lower grade astrocytic tumours, glioblastomas show prominent new blood vessel 
formation, which is an important independent indicator of poor prognosis (Daumas-Duport 
et a/, 1988). To investigate whether HIF-1a, VEGF and p53 protein expression could be 
used as a prognostic factor in the pathogenesis of glioblastoma, overall cumulative survival 
was assessed in all patients with brain tumours as well as in patients with glioblastomas. 
To date, the most consistent predictor of survival in malignant gliomas is patient age at 
diagnosis. Multiple studies have shown that younger patients with these tumours live 
longer following initial diagnosis, even after adjustments for histological grade, size of 
tumour, extent of resection and treatment following biopsy/resection (Salmon et a/, 1994, 
Kim et a/, 1991, Rasheed et a/, 1994; Sneed et a/, 1995). Results from this study support 
these previous findings where age at diagnosis was found to be an independent prognostic 
factor on overall survival. 
When survival analysis was limited to protein expression, both HIF-1a and VEGF 
protein expression were found to be significantly associated with overall survival in all 
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patients with brain tumours but not in patients with glioblastoma. A recent study found that 
the relative intensity of HIF-1a protein expression is of independent prognostic 
significance in oligodendrogliomas, as well as extent of resection in univariate and 
histologic grading in multivariate analysis (Bimer et a/, 2001). Univariate analysis of a11 
patients with brain tumours and of patients with glioblastoma in this study did not find that 
IDF-1a protein expression is an independent prognostic factor in overall survival. As the 
number of patients with various tumour types analysed were relatively small, it would be 
interesting to see if these frndings were consistent in a larger patient population. 
The recent discovery of two new members of the HIF family, HIF-2a (Ema et a/, 
1997; Flamme et a/, 1997; Tian et a/, 1997) and HIF-3a (Gu et a/, 1998), demonstrates the 
complexity involved in the regulation of angiogenesis. These new family members may 
a1so play a role in mediating the response of the cell to hypoxia. Recent studies have 
shown that IDF-2a is an important co-factor in the regulation of VEGF in bladder cancer 
(Jones et a/, 2001) as well as being an independent prognostic indicator in non-small cell 
lung cancer (Giatromanolaki et a/, 2001). Further studies are now required using a larger 
sample population to include Western blot analysis of HIF-la protein, in order to 
determine the precise role of HIF-1 in the response to hypoxia and angiogenesis in these 
tumours. This study has demonstrated a marked increase in the level of expression of the 
transcription factor HIF-la in glioblastoma multiforme when compared to lower grade 
tumours or normal brain tissue, suggesting that it has an important role in this disease. 
8.5 p53 and p73 Expression In Patients with Breast Cancer 
p73, like p53, is ubiquitously expressed in peripheral blood cells and has been 
reported to be monoallelically expressed and possibly imprinted (Kaghad et a/, 1997). 
Although polymorphisms of the p73 gene have been studied in a number of tumours 
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including bladder, colorectal, oesophageal, liver, lung, neural, prostate, and renal cell 
carcinoma (Yokomiza et a/, 1999; Sunahara et a/, 1998; Nimura et a/, 1998; Mihara et a/, 
1999; Nomoto et a/, 1998; Kovalev et a/, 1998; Takahashi et a/, 1998; Mai et a/, 1998), at 
the time of this study there were no reports of p73 expression in breast cancer. These 
reports have found several p73 polymorphisms and showed that p73 somatic mutations are 
very rare in solid tumours (Han et a/, 1999). Recently however, p73 expression has been 
reported in several breast cell lines and tumours (Zaika et al, 1999; Shishikura et a/, 1999; 
Ahomadegbe et al, 2000). 
In this study, where p73 genotypes were ascertained in patients with breast cancer 
and normal control populations; similar genotype frequencies were observed in all three 
populations. The frequency of the p73 AT/AT homozygous genotype was found to be very 
rare in all 3 populations studied, with a statistically significant difference found between 
the expression of the p73 AT/AT genotype and the remaining genotypes in all 3 
populations studied. The over-representation of the p73 GC/GC genotype was not linked to 
the population of patients with breast cancer as similar results were obtained in the 2 
control populations. This finding was confirmed in a recent report where only 18% of the 
sample population were found to have the p73 GC/AT heterozygous genotype with the AT 
allele being preferentially silent in 10 of 12 breast tumours (Ahomadegbe et a/, 2000). 
Another study in primary gliomas found the p73 AT/AT genotype to be rare, being 
expressed in only 1 of 27 tumours (4%) (Watanabe et a/, 2002). Although the initial 
analysis on lymphocytes from five healthy individuals and a neuroblastoma cell line 
described only monoallelic expression of the p73 gene, subsequent analysis on normal lung 
(Nomoto et a/, 1998), thyroid, lymphocytes, neuroblastoma (Kovalev et a/, 1998), kidney 
(Mai et a/, 1998) and melanoma (Tsao et a/, 1999) demonstrated biallelic expression in the 
majority of the cases studied. Consistent with these data, results from this study also 
indicate biallelic expression, which were confirmed in another report assessing breast 
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cancer tissue where p73 was found to be biallelically expressed in 57% of tumours (Zaika 
et a/, 1999). It can be concluded that monoallelic expression of p73 is highly uncommon 
and varies from tissue to tissue and person to person. 
As carcinoma of the breast affects predominately older women, the frequency of 
the p73 genotypes was compared with the age at diagnosis. A significant association was 
found with the frequency of the p73 GC/GC genotype and patients with breast cancer 
diagnosed over 52 years of age (median). This association was not observed in the age 
matched Celtic control population. These results suggest that there may be an association 
between the p73 GC/GC polymorphism and carcinoma of the breast. 
A single point substitution at nucleotide position 216 leads to a change at residue 
72 of the p53 polypeptide chain. A recent report suggests that the p53 polymorphism is 
associated with increased risk of developing HPV-associated cancers (Storey et a/, 1998). 
However, further reports contradict this finding and have found that these p53 
polymorphisms are not risk factors in the development of these cancers (Hayes et al, 1998; 
Rosenthal et a/, 1998; Helland et a/, 1998; Josefsson et al, 1998; Hildesheim et al, 1998). 
In this study two separate populations were screened, patients with breast cancer and a 
Cornish Celtic population, for p53 polymorphisms and no significant differences between 
the populations were found. The frequency of the p53 polymorphisms in the patients with 
breast cancer (57% p53 Arr§Arg, 42% p53 Pro/Arg, 1% p53 Pro/Pro) were similar to those 
found in another study where 109 patients with breast cancer were used as a control 
population for patients with cervical cancer (58% p53 Arr§Arg, 37% p53 Pro/Arg, 5% p53 
Pro/Pro) (Helland et al, 1998). 
Large differences exist in the frequency of the p53 Pro and p53 Arg alleles between 
different populations (Beckman et a/, 1994; To-Figueras et a/, 1996) thus, screening an 
additional control population of known Celtic origin has eliminated the possibility of 
variation in p53 isoform expression due to mixed ethnic origin. Consequently the results 
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obtained support recent reports that the p53 polymorphism may not be a risk factor in the 
development of certain cancers. As with the p73 AT/AT genotype, the p53 Pro isoform 
was found to be rare in all 3 populations studied. 
At the present time the function of p73 is not known, however it is thought to be 
similar to p53 as both inhibit cell growth, possibly through different induction pathways, 
induce apoptosis and strongly interact with each other. A recent report suggests a 
functional interaction between p53 and p73 in a breast carcinoma cell line leads to 
enhanced induction of apoptosis (Zhu et a/, 2001 ). Comparison of the frequencies of the 
p73 genotypes versus p53 Pro/Arg isoforms in all three populations showed no statistically 
significant correlation between either the breast patient popuJation or the Celtic popuJation 
with the control cord bloods. However, a synergistic effect was observed betweenp73 and 
p53 in all three popuJations. Despite being located on separate chromosomes, certain p73 
and p53 alleles were found together more frequently than expected. It is possible that 
particuJar combinations of p73 and p53 alleles have an enhanced function for maintenance 
of genome integrity compared to other combinations of alleles. This may have an 
important role in embryonic development where genome integrity is of critical importance 
for the survival of the zygote. It has already been proposed that p73, an ancestral p53, may 
play a role in development through induction of differentiation of certain tissues (Kaghad 
et a/, 1997), a significant instance where loss of p53 has no phenotypical consequence. 
To investigate whether p73 genotyping and p53 isoforms could be used as 
prognostic factors in the pathogenesis of breast cancer, cumulative overall survival was 
assessed and correlated with both p73 genotypes and p53 isoforms and clinical 
characteristics in the 97 patients with breast cancer. Correlation studies between both 
genotypes and disease variables in breast carcinoma did not demonstrate any significant 
associations, however tumour T stage, G stage and patient treatment with chemotherapy 
were found to be significantly associated with survival in this study group. To date, only 
-442-
Chapter 8. Discussion 
one study has been reported which suggests that allelic loss of heterozygosity (LOH) in the 
p73 region could be pathologically related to breast cancer and possibly to poor tumour 
prognosis (Dominguez et a/, 2000). Previous studies have not found any correlations 
between breast tumours with LOH in the p73 region or with p73 allelic expression and 
certain pathological parameters associated with poor prognosis (Shishikura et a/, 1999; 
Ahomadegbe et al, 2000). Allelic loss in several chromosomal regions in breast cancer has 
been used as a prognostic factor (Harada et a/, 1994). Allelic loss in the p73 region could 
indicate gene inactivation ifmonoallelic expression and LOH occurred at the same allele. 
There has been extensive research into identifying clinically useful prognostic 
factors in the pathogenesis of primary breast cancer. The Nottingham prognostic index 
(NPI) is considered a reliable standard for prognosis in breast cancer patients as it is based 
on the morphopathologic features of lymph node stage (N stage), tumour size (T stage) and 
histologic grading of malignancy (Grade) (Haybittle et al, 1982). The NPI has been 
validated in several studies and has proven to maintain over time a valuable discriminating 
power in differentiating patients in low, intermediate and high risk subsets (Galea et a/, 
1992; Balslev et a/, 1994). The NPI was assessed in this study group with a significant 
correlation found between survival time and NPI. When both p73 genotypes and p53 
isoforms were correlated with the NPI no association was found, thus p73 genotypes and 
p53 isoforms do not contribute prognostically to the NPI. 
It is believed that wild-type p73 functions similarly to p53, as a guardian when 
overexpressed and as a cell cycle regulator as a tumour suppressor gene. It is possible that 
wild type p73, not mutant p73, is overexpressed in cancers and it has been proposed that 
p73 may also function as an oncogene in the upregulation of cell growth (Nomoto et a/, 
1998) and silences p53 function by binding to its functional binding site (Vikhanskaya et 
a/, 2000). To date, overexpression of p73 has been found in tumours of the breast, lung, 
neuroblastoma, oesophagus, stomach, colon, bladder, ovary, ependymoma, hepatocellular 
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carcinoma and myeloid leukaemia (Zaika et a/, 1999; Nomoto et al, 1998; Kovalev et a/, 
1998; Mai et a/, 1998; Cai et a/, 2000; Kang et a/, 2000; Sunahara et a/, 1998; Imyanitov et 
a/, 1999; Peters et a/, 1999; Yokomizo et a/, 1999; Loiseau et a/, 1999; Herath et a/, 2000). 
In contrast, analysis of normal human tissue determined that p73 is expressed at very low 
levels (Kovalev et a/, 1998; Ikawa et a/, 1999; Zaika et a/, 1999). Overexpression of wild-
type p73 mRNA is to date the most relevant alteration involving p73 in breast cancer. 
However, a recent contradictory report has found that LOH, allele silencing and decreased 
expression of the p73 gene may play a role in breast cancer (Ahomadegbe et a/, 2000). 
This contradiction in results may be explained by the methods of quantitation used and the 
multiple origin of the normal tissue analysed, which may show a different pattern ofp73 
expression than breast epithelium. It has also been reported that oncogenes can signal p73 
in vivo, where overexpression of cellular and viral oncogenes up-regulate endogenous p73 
proteins and activate their transactivation function (Zaika et a/, 200 l ). 
As the p53 family of tumour suppressor genes grows (Osada et a/, 1998; Trinket 
a/, 1998; Yang et a/, 1998), the necessity for genotype screening increases. This is the fust 
report ofbothp73 genotypes and p53 isoforms in individuals. At the time ofthis study this 
was the first report of p73 in breast cancer, however a further study has recently been 
reported with fmdings that p73 somatic mutations were very rare in breast cancer (Han et 
a/, 1999). It is becoming clearer that p73 is not a tumour suppressor gene in a classic 
Knudson two-hit manner as p73 is infrequently mutated in many human cancers, unlike 
p53. In extensive searches very few mutations have been found in a variety of primary 
cancers analysed (lchiyama et a/, 1999; Han et a/, 1999). 
Overall the results in this study indicate that no association exists between p73 
genotypes and p53 isoforms in patients with breast cancer and are therefore, not risk 
factors in the development of carcinoma of the breast in the British Caucasoid population. 
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8.6 Conclusions 
The principle findings of this work are as follows; 
+ HIF-la, GLUT-I andp53 mRNA expression increased in response to high glucose 
but decreased in response to the combined stresses of hypoxia and high glucose from 
normoxic levels in breast carcinoma cell lines. HIF-la mRNA levels were observed in 
breast carcinoma cell lines under normoxic conditions which displayed both increased and 
decreased expression in response to exposure to hypoxia and/or high glucose as well as to 
controls for osmolarity. These combined results confirm that hypoxic regulation of HIF-
la, p53 and possibly GLUT-1 occurs post-transcriptionally. HIF-la, in conjunction with 
GLUT-I and p53 may be an important regulator of the cellular response to osmotic stress 
and high glucose. 
~ Up-regulation of H/F-1 a and GLUT-I mRNA was observed in the PBMCs from 
patients with TlDM exposed to high glucose. The GLUT-I mRNA up-regulation observed 
in patients without complications was significantly different from that seen in normal 
controls, where up to a 2.1 fold increase in mRNA expression was seen over that expressed 
in patients with complications. This would indicate that the expression and function of 
glucose transporters may differ in these patients, potentially leading to fewer 
complications. 
+ A significant correlation was found between the expression of H/F-1 a and GLUT-I 
mRNA in patients with breast tumours. Additional significance was found between HIF-
1 a mRNA expression and age of diagnosis and grade, and between GLU/'-1 mRNA 
expression and age of diagnosis and N stage, in the patient group. These results suggest 
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that both HIF-la and GLUT-I mRNA expression increases with disease progression and 
may contribute to tumour aggressiveness. 
~ Up-regulation of H/F-1 a mRNA was observed in glioblastomas with significant 
differences found between normal tissue and low-grade diffuse (LGA), anaplastic 
astrocytomas (AA), and glioblastomas (GBM) and between GBM and WA and AA, 
indicating that up-regulation ofHIF-la is partly at the transcriptional level. No correlation 
was found between HIF-la and p53 protein expression in these tumours however, age at 
diagnosis and HIF-la protein expression, as well as HIF-la and VEGF protein expression, 
were significant prognostic factors in cumulative overall survival. Although a small 
number of samples was studied, a significant association was also found between sex and 
VEGF protein expression on cumulative overall survival. 
~ Polymorphisms of either p53 or p73 genes are not risk factors in the development 
of carcinoma of the breast. However, subtle interactions may occur between these genes 
and these may be involved in the pathogenesis of the disease. A significant association was 
found with the frequency of the p73 GC/GC genotype and patients with breast cancer 
diagnosed over 52 years of age (median). Both p73 genotype and p53 isoforms have no 
significant influence on overall survival in patients with breast cancer. 
It has been seven years since the purification ofHIF-1 protein (Wang and Semenza, 
1995) and cloning ofHIF-la cDNA sequences (Wang et a/, 1995). Throughout this time, 
rapid progress has been made in elucidating the role that this transcription factor plays in 
normal development and physiology as well as in cancer biology. The accelerated rate of 
discovery and expanding knowledge about HIF-la certainly limits the work that one 
researcher can perform in a restricted time and environment. However, the limited studies 
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presented here represent interesting, informative and novel observations into how HIF-la 
and other oxygen related genes behave in different disease and disease models in man. It is 
hoped that this work will offer new insights and pose new questions as to how these 
diseases may be linked through a common factor, HIF-1. 
8.7 Future Work 
8.7.1 HIF-la 
Most studies have focused on HIF-1 a as a regulatory component of HIF-1. Future 
studies should investigate the roles of HIF-2a and HIF-3a in disease. HIF-2a is a 
structurally related alternative dimerisation partner ofHIF-113 which can also transactivate 
reporter genes via HIF DNA recognition sites (Wenger and Gassmann, 1997). In vitro it is 
regulated in an oxygen-dependent fashion very similar to that for HIF-1 a (Wiesener et a/, 
1998) where studies have shown that VHL deficiency also stabilises HIF-2a (Maxwell et 
a/, 1999). Moreover, a recent study has shown that the basal levels of HIF-2a are highly 
related to the inducible level of the HIF protein in breast carcinoma cell lines (Biancher et 
a/, 2000) and HIF-2a expression has been seen in solid tumours (Talks et a/, 2000). 
Additionally, overexpression of HIF-2a mRNA has been reported in hemangioblastomas 
(Flamme et a/, 1998). It would therefore be interesting to address in future studies the 
extent to which HIF-2 and HIF-3 are induced in breast and bmin tumours, and how it may 
contribute to and amplify the induction ofHIF-responsive genes. 
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8.7.2 VEGF 
VEGF is constitutively expressed by many tumour cells, transformed cell lines and 
by some normal cells, however VEGF expression is substantially up-regulated by hypoxia, 
cytokines, hormones, and certain oncogenes including activated forms of Ras and Src (Rak: 
et a/, 1995; Pal et a/, 2001; Mukhopadhyay et a/, 1995). Although it has been 
demonstrated that breast cancer cells express both VEGF and VEGF receptors (Yoshiji et 
a/, 1996; Speirs and Atkin, 1999; Blancher et a/, 2000; Price et a/, 2001), little is known 
about the regulation of VEGF expression in breast cancer cells. A recent study 
demonstrated that p53 plays an important role in regulating breast tumour angiogenesis 
through inhibition of VEGF transcriptional activation, under both normoxic and hypoxic 
conditions, by inhibiting the binding of Sp 1 to the promoter region of the VEGF gene (Pal 
et a/, 2001). Additionally, VEGF was recently shown to require extracellular matrix 
(ECM) binding components, such as fibronectin, heparin and heparin sulfate proteoglycans 
to induce a mitogenic response and cell migration in breast carcinoma cells (Miralem et a/, 
200 I). Thus, VEGF obviously plays an important role in the pathogenesis of breast cancer 
and warrants further investigation 
8.7.3 GLUT-1 
As an increase in glucose transport is observed in malignancies and increased 
uptake of glucose has potential value as a prognostic indicator (Minn et a/, 1997) it would 
be interesting to determine glucose transporter activity (measurement of 2 DG 
accumulation) in the breast carcinoma cell lines exposed to hypoxia as well as in breast 
and brain tumours and correlate the results with survival. Experiments have shown that an 
oxygen concentration of !>1.5% up-regulates cellular glucose uptake independent of 
glucose deprivation (Ciavo et a/, 1995). 
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8.7.4 Other HIF-1 Induced Genes 
Most tumour cells retain the ability to undergo apoptosis in response to hypoxic 
stress (Shimizu et a/, 1996), resulting in cells that are more resistant to treatment and 
which may contribute to a reoccurrence of the tumour (Schmaltz et a/, 1998). HIF-1 
inducible genes are well documented however, genes other than anaerobic metabolism 
associated genes may also play a role in tumour growth and survival as well as in 
resistance to apoptosis. It is probable that these genes may function as anti-apoptotic 
factors when induced by hypoxia and glucose deprivation. Thus, it would be interesting to 
screen for genes induced by hypoxia and hypoglycaemia in breast carcinoma cell lines 
using gene expression arrays (DNA microarray system). 
A recent report detected the up-regulation of BNIP3 (Bcl2/adenovirus Em 19 kD-
interacting protein 3) by hypoxia in the breast carcinoma cell line T47D using gene 
expression arrays (Sowter et a/, 2001). BNIP3 is a pro-apoptotic mitochondrial protein that 
was isolated through its interaction with E1B 19K and Bcl-2 (Boyd et a/, 1994). Other 
genes found to be regulated by HIF-1 include the transferring receptor (Tacchini et a/, 
1999) and ceruloplasmin (Mukhopodhyay et a/, 2000) genes. Conversely, screening for 
genes induced by hypoxia and other extreme stresses, such as high glucose, in breast 
carcinoma cell lines would be equally worthwhile. 
8.7.5 p73 
It has been widely reported that p73 is highly expressed in cancer but not in normal 
cells or benign tumours with contradictory reports. This paradox requires further 
investigation. particularly as the conflicting reports have been reported in breast cancer. 
One of the effects of p73 up-regulation is to steer cells into apoptosis (Jost et a/, 1997; Zhu 
et a/, 1998) and to block cells in the Go/G1 phase of the cell cycle (DeLaurenzi et a/, 2000). 
Mutant p53 is known to physically interact with p73 to inhibit the induction of apoptosis 
by p73 (DiComo et a/, 1999). It is possible that enhanced p73 expression could act as a 
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feedback mechanism to compensate for the loss of p73 function. The exact function of p73 
protein is not completely known and its expression in various cancers has not been 
extensively analysed (Peters et a/, 1999; Tannapfel et a/, 1999; Zwahlen et a/, 2000). Little 
is known about the upstream signals that induce a p73 response, in contrast to p53 protein 
which is stabilised and activated in response to a variety of cellular stresses. p73 protein 
may have additional important functions in normal cells and cancer cells which have not 
been elucidated. Thus it is important to analyse and quantitate the expression of p73 in a 
large sample of breast tumours with their corresponding normal tissue, as well as 
determine protein expression to establish whether p73 protein plays an important in the 
pathogenesis of breast cancer. p53 phenotyping would also be required to assess wild-type 
or mutant status. Difficulties in detecting p73 protein expression have been reported in 
both breast tissue and breast carcinoma cell lines (Zaika et a/, 1999; Zhu et a/, 2001) using 
commercially available monoclonal antibodies, thus a more sensitive radioactive RT-PCR 
method (Marin et al, 1998; Sunahara et a/, 1998) and better quality antibodies would be 
required. 
8.7.6 Apoptosis 
Angiogenesis and apoptosis have been shown to play a role in the development of 
solid tumours. As both HIF-1a and the apoptotic index represent individual markers of 
these complex processes, it would be interesting to determine the apoptotic rate in both 
breast and brain tumour samples using an indirect TUNEL (terminal deoxynucleotidyl 
transferase-mediated nick end-labelling) assay and compare it with HIF-1a expression to 
identify a possible survival advantage. Bcl-2 expression should also be determined as 
hypoxia inhibits Bcl-2, an anti-apoptotic factor, via HIF-1 (Carmeliet et al, 1998). A 
previous study found that HIF-la was strongly positively associated with the apoptotic 
rate in breast cancer (Mommers et a/, 1999). It is known that the apoptotic rate increases 
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during breast carcinogenesis (Carmeliet et a/, 1998) and is high in highly prolifemtive and 
poorly differentiated cancers (De Jong et a/, 2000). 
-451-
Chapter 9. Appendix 
Chapter 9~ 
Appendn 
-452-
Chapter 9. Appendix 
9.0 p53 Allelic Response To Hypoxia 
It is known that increased IDF-la expression is associated with multiple genetic 
alterations, such as loss of function mutations in the p53 twnour suppressor gene. IDF-la 
binds directly to and stabilises p53 (An et a/, 1998). Additionally, p53 interacts with IDF-
la in vivo and inhibits expression of IDF-la, thereby inducing its degradation through 
ubiquitination. Thus, it is possible that p53 mutants may correlate with the ability of a cell 
to respond to hypoxia through differential binding to IDF-la. Moreover, it is also possible 
that IDF-1 a contains polymorphisms in its binding region and may preferentially recognise 
either of the two forms ofp53. 
9.1 Transfection of Saos-2 cells with p53 Pro/Arg plasmids 
To test these hypotheses, p53 null Saos-2 cells were transfected with plasmids 
expressing either p53 Pro or p53 Arg to study their ability to induce IDF-la mRNA 
expression, and other oxygen regulated genes, under hypoxia (Dr. A. Storey, Imperial 
Cancer Research Fund, London, (Storey et a/, 1998). 
Saos-2 cells harbour a homozygous deletion of the p53 gene locus and do not 
produce a p53 protein (Diller et a/, 1990). Plasmids containing p53Pro and p53 Arg 
cDNAs were cloned, isolated (Figure 9.1) and transfected by calcium phosphate 
precipitation into Saos-2 cells. Transfection efficiencies were monitored by co-transfecting 
a /acZ-expressing plasmid on parallel plates and staining for LacZ expression. 
Although transfections of both plasmids were successful, the cells failed to 
proliferate. Limited growth resulted in an insufficient quantity of cells following selection 
to further proceed. Selection conditions were optimised. Transfections were performed 
successfully on 4 separate occasions, verified by staining for P-galactosidase, each time 
resulting in a lack of cell proliferation. To alleviate the possibility of failure of the 
methodology, consultations were sought with Dr. Storey in London who also could not 
-453-
' iChapter\9. AP,pen4i"· 
detenniliejtlti!pio~ienL time constraints fo'r'the rrese~~lt,dt:W~. rre_sUltc;:cl,iQr a dec;;ision .i9 
abandonithis'F·oJtheiJlr~j~tTand.contiilue With anoth.er'afea of research: 
- 454.'" 
23.1Kb-
7.4 Kb-
6.6 Kb-
4.4 Kb-
2.3 Kb-
2.0Kb-
MW 
Chapter 9. Appendix 
1 2 3 4 
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-Insert DNA 
p53 Pro p53 Arg 
Figure 9.1 . lllustration of p53 Pro and p53 Arg isolated plasmid DNA and subsequent 
double digestions using Hindiii and EcoRI restriction enzymes. Lane 2 contains p53 Pro 
plasmid DNA and lane 4 contains p53 Arg plasmid DNA, producing a DNA insert of 
approximately 2 Kb. (MW= 23 Kb ladder). 
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Expression of hypoxia-inducible factor 1a in tumours of patients with glioblastoma 
Angiogenesis is a prominent feature of glioblastomas 
but the mechanisms involved in the control of this 
process are poorly understood. We have investigated 
the potential role of a recently described transcrip-
tion factor. hypoxia-inducible factor 1 (HIP-1 ). which 
initiates the transcription of a number of hypoxia-
inducible genes. including those encoding vascular 
endothelial growth factor and its receptors. HIF-1 pro-
tein expression was assessed by immunocytochemistry. 
using a monoclonal antibody to the et subunit (HIF-1 et). 
HIP- 1 mRNA expression was assessed by reverse 
transcriptase-polymerase chain reaction (RT-PCR) and 
the ribonuclease protection assay (RPA). Strong nuclear 
expression of HIF-la protein was seen in the majority 
of glioblastomas and anaplastic astrocytomas. particu-
larly surrounding areas of necrosis in glioblastomas. In 
the majority of these tumours upregulation of HIP-l et 
mRNA was also demonstrated. with a significant 
increase in glioblastomas compared to lower grade 
tumours. No correlation was found between the pre-
sence of HIP-l ex protein and immunohistochemical 
expression of p') 3 protein. These findings are in keeping 
with an important role of HIF- la in the vascularization 
of glioblastomas and suggest that upregulation is at 
least partly at a transcriptional level. 
Keywords: hypoxia-inducible factor l. pS 3. angiogenesis. glioblastoma 
Introduction 
Glioblastomas are the most common type of primary 
brain tumour and. despite treatment. have a median 
survival of only 9-12 months [34]. In contrast to most 
lower grade astrocytic tumours. glioblastomas show 
prominent new blood vessel formation. which is an 
important independent indicator of poor prognosis (4]. 
Angiogenesis is also associated with more aggressive 
. tumour growth in several other human malignancies 
[10]. Experimental evidence and early reports of 
human trials suggest that inhibition of angiogenesis in 
Correspondence: Dr A. G. Demaine. Department of Molecular Medicine. 
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UK. E-mail: ademaine@plymouth.ac.uk 
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glioblastomas may reduce tumour growth. A better 
understanding of the underlying mechanisms is clearly 
important to the development of new antiangiogenic 
treatment strategies (30.32). 
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric 
nuclear transcription factor that plays a critical role in 
the cellular response to low oxygen tension [35.37). It 
is composed of HIP- l et and HIF-1~ subunits which are 
both members of the basic helix- loop-helix (bHLH) PAS 
family of transcription factors [3 7). Activation of HIF-la 
in cells exposed to hypoxia is media ted by stabilization 
of the HIF-l et protein and possibly increased expression 
of the gene (15). HIF-lcx is thought to play an import-
ant role in the pathogenesis of a number of condi-
tions. including myocardial infarction. cerebrovascular 
r: 2002 Blackwell Science Ltd 
disease. hypoxic lung disease and tumour vascularization 
[9 .22.38]. Under hypoxic conditions. HfF-lex binds to 
the hypoxia responsive elements (HREs) that are loca ted 
in either the 5' or the 3' flanking region of the gene. 
Approximately 30 genes have been shown to be 
activated by HIF-l. including vascular endothelial 
growth factor (VEGF). erythropoietin. insulin-like growth 
factor 2. glycolytic enzymes and glucose transporter 1 
[5.7.9.27.28]. 
Recent work has suggested a role for HIF-lex in 
glioblastomas. although little is known about the mech-
anisms controlling its expression [39.40]. We have 
assessed the expression of HIF-1 protein and mRNA. 
and p53 protein. in a range of astrocytic tumours. 
including glioblastomas. The aim of this study was to 
investigate the levels and expression of these factors with 
respect to different grades of tumour. 
Materials and methods 
Tumour material 
Forty-one samples of formalin-fixed and paraffin-
embedded sections of tumour samples were studied. 
Tissue from 34 of these tumour samples was snap-frozen 
and stored in liquid nitrogen prior to RNA extraction. 
Tumours were classified according to current World 
Health Organization guidelines [19]. Twenty-seven 
glioblastomas. four anaplastic astrocytomas. five diffuse 
astrocytomas (only three with frozen tissue) and 
five pilocytic astrocytomas (none with frozen tissue) 
were identified. Two frozen samples of normal brain 
tissue obtained at post-mortem were a lso used for 
the study. 
RNA isolation and reverse transcriptase-
polymerase chain reaction (RT-PCR) 
Total cellular RNA was isolated from the frozen tissue 
using RNA Stat-60™ (Biogenesis, Poole, UK) according 
to the manufacturer's instructions. The concentration 
of the RNA was determined by optical density. 
Five llg of this RNA was used to generate first-strand 
cDNA using the Superscript™ preamplification system 
(Life Technologies. Paisley, UK) according to the manu-
facturer's instructions. One-twentieth of the cDNA 
was amplified in a polymerase chain reaction using 
amplimers specific for HIF-l ex. 
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Amplimer sequences for HIP-lex were designed from 
a known sequence (accession no. U2243l [35]) as 
follows: 5' CACITCCACATAATGTGAGTICGG (sense) 
and 5' GGTICACAAATCAGCACCAAGCAGG (antisense) 
using an initial denaturation step of 94 oc for 3 m in 
followed by 30 cycles of 94°C for 1 min. 55°C for 2 min 
and 72°C for 3 min. HIP-lex amplifications were verified 
by performing an additional assay using amplimers 
for a recently discovered alternative splice variant to 
HIP-l ex [11]. 
The efficiency of amplifications was determined using 
13-actin amplimers as an internal standard to control 
for the quality of the cON A in each sample. The reaction 
was performed in duplicate. first in the same sample 
reaction tube and then in separate reaction tubes. All 
amplification products were analysed by gel electro-
phoresis on a single 1.5% agarose gel and fragments 
were visualized using ethidium bromide. The intensity of 
the 13-actin and HIF-lex amplified products was quantified 
using a gel documentation and analysis system (Bio-Rad. 
Hertfordshire. UK). Background intensity was subtracted 
from band intensity values. This was repeated several 
times with consistent findings. and the ratios of HIP-lex 
to ~-actin are presented as a percentage expression 
where ratio values represent the mean of four separate 
experiments. 
Ribonuclease protection assay (RPA) 
A probe for the quantification of HIP mRNA was 
synthesized as follows: 4 llg of total RNA from the 
renal cell carcinoma cell line ACHN that had been 
exposed to hypoxia for 24 h was used as a template for 
cDNA using a Superscript™ preamplification system 
(Life Technologies) according to the manufacturer's 
instructions. An aliquot of the cDNA was then used 
to amplify the HIP sequence with the following 
cycle conditions: denaturation 4 min at 94 oc followed 
by 30 cycles of94°C for 30 s. 55°C for 1.5 min and noc 
for 2 min. The length of the HIP probe was 280 bp 
(accession number U2243l). The antisense RNA probes 
were synthesized using a T7 in vitro synthesis kit 
(MaxiScript™, Ambion. Austin, UK) in the presence of 
[ 32P] uridine triphosphate (30 TBq/mmol) (Amersham. 
Little Chalfont. UK). 
The RP A was performed using an RP A n TM kit 
(Ambion. Austin, USA) according to the manufacturer's 
instructions. Briefly . 10 llg of RNA was hybridized with 
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500 pg of radioactively labelled HIF-1 probe in 80% 
formamide. 100 mM sodium citrate (pH 6.4). 300 mM 
sodium acetate (pH 6.4) and 1 mM ethylenediamine-
tetraacetic acid (EDTA) at -!2QC overnight. Samples were 
then digested with RNase A/RNase T1 for 30 min at 
3 7°C and then inactivated and the RNA precipitated. 
The protected fragments were separated on an 
8 M urea/5% polyacrylamide denaturing gel and 
subsequently exposed to Kodak X-OMATTM LS film. A 
control probe of 18S rRNA was run on samples to con-
trol for the quality of mRNA and equal sample loading. 
Signals were quantified from the gel using direct 
radioactivity measurement with a Fluor-STM imager 
and Multi-Analyst'' image analysis software (Bio-Rad). 
Results are expressed as the percentage expression of the 
mRNA against negative control levels. 
p53 immunocytochemistry 
Primary antibodies to p53 were used (polyclonal CMl. 
Novacastra. Newcastle upon Tyne, UK). Sections 
(5 jlm) of paraffin-embedded tissue were collected onto 
3-aminopropyltriethoxysilane-coated glass slides. The 
dewaxed sections were given microwave pretreatment 
for 12 min in sodium citrate. pH 6.0. then blocked with 
3% hydrogen peroxide followed by normal goat serum. 
prior to overnight incubation with the primary anti-
body at a dilution of 1 : 64 000. Detection was with 
biotinylated goat antimouse/rabbit immunoglobulin and 
streptavidin- biotin horseradish peroxidase amplification 
(DAKO. Cambridgeshire. UK). Colour was developed with 
diaminobenzidine. 
M 2 3 4 5 
~' ' 
HIF -1 a immunocytochemistry 
Immunocytochemistry for HIP-I ex was performed as 
above using a monoclonal antibody to HlF-lcx (clone 
OZ12. Neomarkers. Fremont. USA) at 1: 1000 dilution 
and detection with the catalysed signal amplification 
system (DAKO). 
Statistical analysis 
Results are expressed as the ratio of intensity of the 
expression of the gene of interest compared to the 
housekeeping gene ~actin . Statistical significance was 
assessed on the data groups using analysis of variance 
(ANOVA) followed by F-test and the students t-test 
for comparison of means. with values of P < 0.05 
considered as significant. 
Results 
HIF-ln mRl~A expression 
The expression of HIF-lcx mRNA was analysed by 
RT-PCR using specific amplimers for each (Figure 1) 
and by RP A. There were marked differences in the level 
of expression of HIP-la mRNA in the tumour samples 
from the different study groups (Figure 2a). There 
was a highly significant increase in the mean ratios of 
HIP-la to ~actin expression in the glioblastomas when 
compared to the low-grade diffuse astrocytomas (mean 
value 0 .45 vs. 0.3. respectively. P= O.OOS) as well as 
the anaplastic astrocytomas (mean value 0.45 vs. 0.25. 
respectively. P<O.OS) (Figure 2b). There was a marked 
6 7 8 9 10 11 
IDF-1a ~ • . 1ft> tilt~ ... • .. <4 
. - . 
520 bp 
P-Actin 661 bp 
Figure 1. HJF-la and !}-actin mRNA expression in glioblastoma. Amplification products were 520 base pairs (bp) for HIP-la and 661 bp for 
!}-actin (M= 100 bp ladder). Lanes 1. 2, 3. 5, 8. 9. 10 and 11 were scored positive for HIP-la. HIF-la mRNA expression was conHrmed with 
RPA where expression varied from 8.5- to 23-fold (mean 16.4-fold). ~Actin expression demonstrates tbe quality of cON A and equal sample 
loading. 
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Figure 2. {a) Hypoxia-inducible factor 1 (HlF- la) mRNA expres-
sion in individual tumour samples from patients with glioblastoma. 
lower grade tumours and normal brain. Results are represented 
as the percentage change in abundance of H!F-Ja with respect 
to ~actin and show the range of distribution between samples. 
(b) A highly significant Increase in the mean ratios of HIF- la to 
!}-actin mRNA expression was observed in the glioblastomas when 
compared to the low-grade diiTuse astrocytomas and to the 
anaplastic astrocytomas (P<O.Ol). Additionally. a significant 
difference was a lso observed between the normal brain and the two 
lesser glioblastoma classes (P < O.OS by students Hest). Means of 
at least four independent experiments. ±standard errors (se) a re 
shown. 
increase in the mean ratio ofHIF- l ex to j3-actio expression 
In the glioblastomas when compared to the normal brain 
(0.43 vs. 0 .1). The differences in the HIF-lcxlj3-actin 
ratio in the low-grade diffuse astrocytomas as well as 
the anaplastic astrocytomas were significantly different 
from the normal brain (0.3. 0 .25 and 0.1. respectively, 
P < 0.05). 
Results obtained from RT-PCR were confirmed by 
performing RPA on eight glioblastoma samples where 
there was sufficient tissue for the assay. A glioblastoma 
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sample negative for HIF-lex mRNA expression was 
verified as having no HIF· l ex expression by RPA and 
was used as a control. The seven remaining samples 
analysed confirmed upregulation of HIF-lex mRNA 
expression varying from 8.5- to 23-fold (mean 
16.4-fold) (data not shown). 
HIF-la protein expression 
In most of the samples scattered weakly immunoreactive 
tumour cell nuclei were seen. However. widespread 
HIF-lex immunoreactivity was seen in tumour cell nuclei 
in 21/2 7 glioblastomas. 3/4 an aplastic astrocytomas. 
211 0 low-grade astrocytomas and in none of the two 
samples of normal brain. In glioblastomas HIP immuno-
reactivity was particularly strong in arens surrounding 
necrosis (Figure 3a). which was predominantly present in 
palisading tumour cell nuclei (Figure 3b). In some cases, 
HIF immunoreactivity was seen in the larger. 
more atypical, nuclei (Figure 4). Where tumour cells 
were seen infiltrating brain. immunoreactivity was much 
more prominent in neoplastic than in reactive cells. 
p53 protein expression and correlation 
with HIF-la 
Between 0% and 80% of tumour cell nuclei showed p53 
immunoreactivity. with 65% of glioblnstomas having 
greater than 20% of tumour cell nuclei positive 
(Figure 5). A correlation between p53 immunoreactivity 
and either HIF-lex or mRNA expression could not be 
demonstrated. 
Discussion 
In this study, 77% of high-grade astrocytic tumours 
were found to overexpress HIF-lex protein. As noted 
in previous reports [39.40). HIF-lex protein expression 
was particularly strong surrounding areas of necrosis in 
glioblastomas, which is in keeping with a direct role for 
HIF-1 in the regulation of VEGF [25). Hypoxia is known 
to stabilize HIP-lex protein (1 5) and might explain 
expression adjacent to necrosis. but HIP-lex was present 
more diffusely in high-grade astrocytic tumours and was 
stronger in infiltrating tumour cells than reactive glia. 
suggesting that expression is aberrantly controlled. 
In many of the tumours overexpressing HIF-la. 
increased expression of HIF-lex mRNA was a lso found. 
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Figure 3. Immunohistochemical analysis of HIP-la expression in 
glioblastoma. {a) Low-power view (original magnitication X 50) or 
HIF-l a immunoreactivity in a glioblastoma showing widespread 
nuclear immunoreactivity. whkh at higher magnitication t b) is 
particularly prominent in tumour cells surrounding foci or necrosis 
(xl50). 
suggesting that control is at lenst partly at the tran-
scriptional level. However. in several tumours over-
expressing HIP-l ex protein we could not detect an 
increase in HIP-lex mRNA. Although Jhis finding could 
be due to sampling error (relatively small samples were 
available for mRNA analysis). it is also possible that 
posttranscriptional mechanisms might play a role. Three 
possible mechanisms are reduced HIP-I ex degradation 
due to loss of p53. PTEN nnd/or VHL function. PTEN 
is a tumour suppressor gene originally isolated from 
a homozygous deletion on chromosome 10q23 in 
glioblastoma [20.29]. Recently it has been shown that 
wild-type PTEN mediates the degradation of HIP-lex 
and therefore the frequent loss of PTEN in glioblastomas 
Figure 4. Strong HJF-1 'Z immunoreilctivity in glioblastoma tumour 
ce lls. particularly those with large atypinil nudei ( x 200). 
Figure 5. t\ glioblastoma shows strong nuclear p5 3 immuno-
reactivity in the majority or tumour cells ( x 300). 
[36]. which might facilitate aberrant expression of 
HIP-lex [42]. 
Wild-type p53 promotes degradation of HIP-lex protein 
[26] and it might be expected that inactivation of p53 
would lead to increased HIP-h expression. We did 
not find a correlation between p53 overexpression with 
either HIP-lex protein or mRNA expression. However. this 
does not preclude an association between HIF-la and 
p53 in glioblastomas. as p53 protein overexpression in 
gliomas is not always due to a gene mutation and the 
relationship between HIF-la and pS 3 is complex with 
wild-type p53 being stabilized by HIP-lex [1. 12 . 13]. It is 
also known that levels of p53 in cultured neurones 
increases with the duration of hypoxia. thus changes in 
[· 2002 Blad,-well Science Ltd. Nwropatl•ology nnd ,-\pplird Neurobiology. 28. 21(}-21 7 
the duration of hypoxia can alter cellular levels of p53 
[2]. Western blot analysis of p53 protein expression and 
screening p5 3 gene abnormalities in these tumours 
might help to further clarify this association. 
Another possible mechanism is that loss of VHL 
function might lead to HIF-la accumulation. The VHL 
gene product (pVHL) is required for regulation of the 
HrF-1 transcriptional control system [23] and the VHL 
gene might be mutated in glial neoplasms [18]. VHL 
forms a complex with elongins B and C. Cui 2 and the 
Ring-H2 finger protein Rbxl (VCBCR complex) by 
binding to the oxygen-dependent destruction domain 
of HIF-la subunits through the ~-domain of pVHL 
(1 7,2 1.24]. pVHL then acts as the recognition compo-
nent of the E3 ubiquitin ligase complex mediating 
HfF-la destruction [3 .16.31]. Under hypoxia. VHL-
mediated degradation of HIF-la does not occur. leading 
to accumulation of HIF-la. Additionally. nonfunctional 
VHL also res ults in the accumulation of HlF-la in 
normoxic conditions [23]. 
T he recent discovery of two new members of the HrF 
family. HlF-2a [6.8.33] and HIF-3a (14]. demonstrates 
the complexity involved in the regulation of angio-
genesis. These new family members might also play a 
role in mediating the response of the cell to hypoxia. 
Further studies are now required using a larger sample 
population to include Western blot analysis of HIP-la 
protein to determine the precise role of HrF-1 in the 
response to hypoxia and angiogenesis in these tumours. 
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Aldose reductase expression is induced by hyperglycemia in 
diabetic nephropathy 
AND REA D . HooGKINSON, KAREN L. SeNDERGAARD, BrNGMEI Y ANG, DEBBIE F. Caoss, 
BEVERLEY A. MILLWARD, and ANDREW G. DEMAINE 
Department of Molecular Medicine, University of Plymouth, Plymouth, England, United Kingdom 
Aldose reductase expression is induced by hyperglycemia in 
diabetic nephropathy. 
Background. Despite good metabolic control, many patients 
with type I diabetes still develop nephropathy, implicating a 
role for ge netic factors. Recent studies examining the regula-
tory region of the aldose reductase (ALR2) gene, the rate-
limiting enzyme of the polyol pathway, support its role as a 
candidate gene fo r nephropathy. Here we report the quanti.ta-
tion of ALR2, together with sorbitol dehydrogenase mRNA · 
in the peripheral blood mononuclear cells (PBMCs) of type 1 
diabetic patients with (N = 29) and without nephropathy (N = 
11) fo llowing stimulation with high levels of o-glucose. 
Methods. PBMCs from patients and normal controls were 
cultured for five days with phytohemagglutinin in either normo-
glycemia {11 mmoi/L o-gl ucose) or supplemented with 10 mmoi/L 
o -glucose (moderate hyperglyemia) or 20 mmoi!L o-glucose (hy-
perglycemia). The RNA was extracted and analyzed by ribonu-
clease protection assay. 
Resr1lts. ALR2 mRNA levels were significantly elevated with 
increasing o-glucose concentration (normal to hyperglycemic) 
in those patients with nephropathy (P < 0.0001). In marked 
contrast, in those without nephropathy and in the normal healthy 
controls, there was no change in mRNA expression. Further-
more, those patients with nephropathy and the Z-2/X. suscepti-
bility genotype had the greatest increase in ALR2 mRNA 
compared with those with low-risk genotypes (P < 0.007). 
Conclusion. These results show that patients with nephropa-
thy exhibit marked disturbances in the expression of the en-
zyme components of the polyol pathway. Ultimately this leads 
to tissue damage and ischemia. 
There is increasing evidence to suggest that genetic 
factors are involved in the pathogenesis of diabetic ne-
phropathy in patients with type 1 diabetes [1-3]. The 
incidence peaks between 15 and 20 years duration of 
diabetes and subsequently declines rapidly [4, 5]. This is 
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supported by the familial clustering of nephropathy in 
those patients with type 1 or type 2 diabetes [6, 7]. 
Recent studies have suggested that genetic variation in 
the aldose reductase (ALR2) gene may contribute to the 
genetic susceptibility to diabetic nephropathy [8-12]. Al-
dose reductase is the first and rate-limiting enzyme of the 
polyol pathway and converts glucose to sorbitol in a 
nicotinamide adenine dinucleotide phosphate (NADPH)-
dependent reaction. Sorbitol is metabolized to fructose 
by sorbitol dehydrogenase (SORD) using NAD as a co-
factor [13-16]. Excessive flux through the polyol pathway 
caused by hyperglycemia is likely to lead to a number of 
metabolic and vascular defects that ultimately may give 
rise to tissue hypoxia and ischemia. Patients with diabetic 
microvascular complications have been shown to have 
raised enzymatic activity of aldose reductase as well as 
an increased amount of the protein compared with those 
with no microvascular complication [17, 18]. Patients 
with type 1 diabetes and nephropathy also have been 
shown to have increased levels of ALR2 mRNA [19]. 
This increase in mRNA appears to be linked to a genetic 
variation in the promoter region of the ALR2 gene [11]. 
Two polymorphic regions in the promoter region of 
ALR2 have been identified and shown to be associated 
with susceptibility to nephropathy in Caucasoid patients 
who have type 1 diabetes. A CA dinucleotide repeat 
region designated 5' ALR2 is located at approximately 
2.1 kb upstream of the initiation site in close proximity 
to the osmotic response elements [20]. A second poly-
morphism, the C( - l06)T site, occurs in the basal promoter 
region [21]. The Z-2 5' ALR2 allele, where Z is the most 
common allele and consists of 24 CA repea~. has been 
shown to occur with increased frequency in patients with 
type 1 diabetes and nephropathy. Patients with either 
type 1 or type 2 diabetes and retinopathy from a number 
of e thnic groups, including Caucasoid, Japanese, and 
Chinese origin, have also been found to have an increased 
frequency of the Z-2 allele (8-12, 20, 21]. 
The level of mRNA expression of ALR2 has been 
shown to be increased in the peripheral blood mononu-
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Table L Clinical characterization of patient subgroups and normal controls 
No. of subjects 
Age years (range) 
Age at onset of diabetes years (range) 
Duration of diabetes (range) 
Hemoglobin A1, (range) 
Insulin dosage units 
Sex male:female 
Diabetic nephropaths 
29 
43 :!: 11.3 (24-69) 
12.6:!: 9.0 (1-36) 
30.6:!: 7.9 (15-43) 
9.2:!: 1.6 (6.1-12.2) 
38.2 :!: 10.4 (24-70) 
12:17 
Diabetic controls 
(uncomplicated) 
11 
46.5:!: 13.4 (27-70) 
19.6:!: 11.1 ( 4-42) 
31 :!: 10.5 (22-51) 
8.5:!: 1.5 (7.2-11.2) 
61.1:!: 31.7 (20-118) 
4:7 
Normal controls 
10 
35.4:!: 8.4 (24-49) 
7:3 
Data are expressed as mean values :!: standard deviation together with the range (in parentheses). All patients bad type I diabetes mellitus as defined by the 
National Diabetes Data Group. The hemoglobin A1, values were not significantly different between the patient groups. 
clear cells (PBMCs) of Caucasoid patients with type 1 
diabetes and nephropathy who have the Z-2 allele [11 ]. 
The Z-4 allele of Japanese patients with type 2 diabetes 
and retinopathy has been shown to confer increased gene 
expression in reporter assays using human retinal pig-
ment epithelial cells exposed to hyperglycemia [22]. How-
ever, at the present time, nothing is known about hyper-
glycemia-induced expression of the ALR2 and SORD 
genes in the PBMCs of patients with or without nephrop-
athy. The expression profile of ALR2 and SORD genes 
under hyperglycemic conditions may explain why certain 
individuals with diabetes develop complications while 
others do not. 
Here we provide compelling evidence to show that 
the expression profile of the ALR2 and SORD genes 
differs substantially between those patients with nephrop-
athy compared with those who remain free of microvas-
cular complications after 20 years of diabetes. 
METIIODS 
Study subjects 
Forty patients were recruited from the Diabetic Out-
Patient Clinic (Dr. Millward, Derriford Hospital, Ply-
mouth, UK). Local ethical committee approval was ob-
tained. The patients were classified according to their 
microvascular complications, as previously described 
(8-10]. 
Uncomplicated patients (N = 11). These patients had 
type 1 diabetes for at least 20 years but remained free 
of retinopathy (fewer than 5 dots or blots per fundus), 
proteinuria (negative on urine Albustix on at least three 
consecutive occasions over the previous 12 months), and 
overt neuropathy. Overt neuropathy was defined if there 
was any clinical evidence of peripheral or autonomic 
neuropathy. 
Nephropachs (N = 29). These patients had type 1 dia-
betes for more than 10 years and had proteinuria (urine 
Albustix positive on at least three consecutive occasions 
over 12 months or three successive total urinary protein 
excretion rates of greater than 0.5 g/24 h) in the absence 
of hematuria or infection on midstream urine samples. 
Diabetic nephropathy was always associated with reti-
nopathy. Retinopathy was defined as more than five dots 
or blots per eye; hard or soft exudates, new vessels, 
or fluorescein angiographic evidence of maculopathy or 
previous laser treatment for preproliferative or prolifera-
tive retinopathy; and maculopathy or vitreous hemor-
rhage. Fundoscopy was performed by both a diabetolo-
gist and ophthalmologist (the clinical characteristics of 
the subjects are shown in Table 1). 
Normal healthy controls (N = 10). Peripheral blood 
samples were obtained from 10 healthy volunteers with 
no family history of type 1 or type 2 diabetes. 
Isolation and culturing of peripheral blood 
mononuclear cells from whole blood 
Twenty milliliters of peripheral blood were collected 
into 5% ethylenediaminetetraacetic acid (EDTA) Vacu-
tainers (Becton Dickinson, Oxford, UK). The blood was 
diluted 1:1 in phosphate-buffered saline (PBS), and the 
PBMCs were harvested following standard density gradi-
ent centrifugation. The PBMCs ~ere washed four times 
and resuspended at a concentration of 0.5 X 106/mL in 
RPMI 1640 (11 mmol!L o-glucose) supplemented with 
penicillin/streptomycin (GIBCO GRL, Paisley, Scotland, 
UK), 10% fetal calf serum (GIBCO) and L-glutamine 
(Sigma Chemicals, Poole, Dorset, UK) and separated 
into three flasks. The first of these was cultured for five 
days with phytohemagglutinin (11 mmol!L o-glucose 
concentration within the media normoglycemia), and the 
second was supplemented with 10 mmol!L o-glucose 
(moderate hyperglycemia) and the third with 20 mmoUL 
D-glucose (hyperglycemia) before culture. Additional 
experiments using cultures of PBMCs were established 
to control for osmosity and hyperglycemia. In the first, 
20 mmoUL mannitol were used as a supplement with the 
20 mmoVL D-glucose. A second, parallel culture con-
sisted of 20 mmol!L L-glucose being used as the supple-
ment with the 20 mmol!L o-glucose. 
Extraction of RNA 
At the end of the incubation period, the cells were 
pelleted by centrifugation. The supernatant was removed, 
and the cells were resuspended and lyzed in RNA Stat 
60"' (Biogenesis, Poole, UK). The solution was then 
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transferred to an RNase-free Eppendorf; 200 J..LL of chlo-
roform were adde.d (Sigma Chemicals), vortexed, and 
centrifuged at 13,000 x g for 15 minutes at 4°C. The 
upper aqueous phase was transferred to a clean Eppen-
dorf, mixed with 500 J..LL of isopropanol and centrifuged. 
The supematant was discarded, and the pellet was 
washed in 75% ethanol and resuspended in 50 J..LL diethyl 
pyrocarbonate (DEPC)-treated water by vortexing. The 
approximate amount of total RN A extracted was deter-
mined using a Cecil 5500 spectrophotometer scanning 
240 to 280 nm (Cecil Instruments Ltd., Nottingham, UK). 
Preparation, amplification, and radiolabeling and 
purification of antisense RNA probes 
High-molecular-weight DNA was prepared from 10 mL 
of peripheral blood using Nucleon extraction kits (Scat-
Jab, Paisley, Scotland, UK). An aliquot of this DNA was 
amplified using the polymerase chain reaction (PCR). 
Exons of ALR2 and SORD were amplified using three 
separate primers for each gene. The first round amplifi-
cation reaction was performed in 30 j.LL volumes con-
taining the amplimers for ALR2: sense, 5' -CTG TAG 
CfC CCA CAA CGA TIA CCC-3'; antisense, 5'-CAA 
GCA GTC AAA ACT CAA CCG TIA G-3'; and for 
SORD: sense, 5' -CAA AGC CAT CCT GGG CTG 
CAT GTG GG-3'; antisense, 5'-CTT TCC TGG CGA 
CCT GAG GGC-3' ; 10 mmol!L dNTPs (Pharmacia Bio-
ech, UK), 10 X buffer solution, 10 mmol!L MgC12, 1 U 
Taq polymerase (HT Biotech, Mayfield, UK). The sam-
les were subjected to an initial cycle of denaturation 
or two minutes at 96°C. This was followed by 30 cycles 
f amplification that consisted of denaturation for 30 
econds at 94°C, annealing for 1 minute at 50°C, and 
xtension for 1 minute at 72°C in a PTC-200 Thermal 
ycler (MJ Research, Essex, UK). A second round of 
mplification was then employed using the antisense am-
timer with an RNA polymerase T7 adapter and stuffer 
ucleotides, ALR2: Antisense + T7 - 5'-TAA TAC 
AC TCA CTA TAG GGA GG CAA GCA GTC 
ACT CAA CCG TIA G-3'; SORD: Antisense + 
- 5'-TAA TAC GAC TCA CTA TAG GGA GG 
TCC TGG CGA CCT GAG GGC-3'; 10 mmol!L 
NTPs, 10 X buffer solution, 10 mmol!L MgCh, 1 U Taq 
olyrnerase. The samples were then subjected to DNA 
mplification as described previously in this article. One 
icrogram of the product was used to generate the radio-
ctive RNA probes by incorporating a 32J> UTP (Amer-
am Pharrnacia Biotech, Amersham, Bucks, UK) using 
e MAXlscript System (Ambion, Abingdon, UK). 
An equal volume of gel loading buffer (Ambion) was 
ded to the reaction and heated to 85 to 95°C for 3 to 
minutes and then loaded onto a 5% acrylamide/8 mol!L 
ea gel and run at approiima~ely 100 to 200 V for 40 
· utes to 1 hour. The gel was wrapped in SaranWrap 
d exposed to Kodak X-Omat film (Scientific Imaging 
Systems, Cambridge, UK) for 10 to 30 seconds. The 
probe was excised, immersed in 350 J..LL of elution b_uffer 
(Ambion), and then incubated overnight at 3rC to ob-
tain 95% recovery. 
Hybridization of ribonuclease protection assay probe 
to RNA sample 
The RNA sample and the ribonuclease protection assay 
(RPA) antisense probe were mixed together and precipi-
tated with ethanol and ammonium acetate. The RNA mix 
was pelleted by centrifugation, dissolved in 20 J..LL of 
hybridization buffer (Ambion), and then centrifuged to 
collect at the bottom of the tube. The sample was then 
briefly incubated at 92°C, vortexed, centrifuged, and then 
incubated overnight at 42°C. For the Rnase digestion, 
200 J..LL of diluted RNase mix (Ambion) was then added, 
and the mixture was incubated for 30 minutes at 37°C, 
after which 300 J..LL of RNase inactivation/precipitation 
solution (Arnbion) was added, vortexed, and centri-
fuged. The reaction was then transferred to -20°C for 
at least 15 minutes. The protected fragments were sepa-
rated and detected by centrifugation of the sample for 
15 minutes at 4°C, and the pellet was resuspended in gel 
loading buffer. The sample was then heated for three to 
four minutes at 94°C and loaded onto a 5% acrylamide 
gel, and electrophorosed for approximately 40 minutes 
to 1 hour at 200 V, transferred to filter paper (Whatman, 
Maidstone, UK), and exposed to Kodak X-Omat film 
at -80°C overnight. The bands were analyzed using a 
phospho-imager (Biorad, Hertfordshire, UK). An inter-
nal controll3-actin was set up to ascertain any variations 
in the amount of RNA used in the RP A. pTRI-actin, a 
DNA template, was provided in the RPA kit (Ambion) 
and used for the transcription of an antisense 13-actin 
RNA probe. 
Statistical analysis 
Results are expressed as means ± SE. Statistical sig-
nificance was assessed by Student t tests after analysis of 
variance (ANOVA) or Mann-Whitney U test. A P value 
of < 0.05 was considered to be significant. 
RESULTS 
Forty patients with type 1 diabetes were recruited for 
the study. Twenty-nine of these had diabetic nephropa-
thy (nephropaths), and 11 had remained free of micro-
vascular disease (absence of background retinopathy, 
microalbuminuria, and overt neuropathy) after 20 years 
duration of diabetes (uncomplicated). Ten normal healthy 
controls were also studied. The clinical characteristics of 
the subjects are shown in Table 1. Figure lA shows the 
expression of the housekeeping gene 13-actin mRNA in 
a patient with diabetic nephropathy. The level of 13-actin 
expression was similar between the samples of PBMCs 
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Fig. 1. (A) An example of mRNA from pe-
ripheral blood mononuclear cells (PBMCs) of 
a patient with diabetic nephropathy that had 
been exposed to normal. modente, and severe 
hyperglycemia and hybridized to 13-actin in a 
ribonuclease protection assay. The fold differ-
ences in fl-actin mRNA between the normal, 
moderate, and severe samples were 1.2 and 
1.0, respectively. (B) The same mRNA sam-
ples from the patient with nephropathy as de-
picted in (A) as well as those from an uncom-
plicated patient. In contrast to the !3-actin 
results shown in (A), there was a 2.0- and 
7.6-fold increase in the expression of aldose 
reductase (ALR2) m RNA in PBMCs exposed 
to moderate and severe hyperglycemia in the 
patient with diabetic nephropathy. There was 
no change in the ALR2 mRNA expression 
with hyperglycemia in the uncomplicated pa-
tient. 
Diabetic 
nephropathy 
Uncomplicated 
patient 
o-glucose concentration 
stimulated with different concentrations of o-glucose 
(fold increase in the samples supplemented with o-glu-
cose.was up to 1.2 compared with normal samples). This 
demonstrates that equal amounts of study RNA (10 1-Lg) 
were loaded and that variations in ALR2 and SORD 
mRNA expression were real and not caused by loading 
errors. Figure lB shows the expression of ALR2 mRNA 
in PBMCs in the same patient with diabetic nephropathy 
as well as an uncomplicated subject stimulated with dif-
ferent concentrations of o-glucose. The fold increases of 
ALR2 mRNA in the diabetic nephropath were 2.0 and 
7.6 for the PBMCs exposed to moderate or hyperglyce-
mia, respectively. 
The mean levels of ALR2 as well as SORD mRNA 
in PBMC exposed to normal, moderate (supplemented 
with 10 mmoVL o-glucose), or severe hyperglycemia (sup-
plemented with 20 mmoVL o-glucose) in the nephro-
paths, uncomplicated, and the normal controls are shown 
in Table 2 and Figures 2 and 3. The results are expressed 
as fold increase in mRNA above the level obtained under 
normal conditions. In the nephropaths, the mean fold 
increase of ALR2 mRNA in moderate hyperglycemia 
was 1.8 :t 0.2-fold, while in severe hyperglycemia there 
was a 3.8 :t 0.8-fold increase (P < 0.0001). In marked 
contrast, in the uncomplicated group of patients as well 
as the normal controls, there was no elevation of ALR2 
m RNA expression with increasing o-glucose. concentra-
tion. Indeed, in both these groups, there was a slight 
decrease (0.9 :t 0.02 and 0.94 :t 0.1 for moderate hyper-
glycemia, respectively, and 0.8 :t 0.05 and 0.8 .:t 0.1 for 
severe hyperglycemia, respectively; Table 2). The differ-
ences in response of ALR2 between the nephropaths and 
Hodgkinson et a/: Aldose reductase and diaberic nephropathy 215 
Table 2. Overall mean levels of ALR2 and SORD mRNA in moderate and hyperglycemic conditions in the study groups 
Glucose concentration 
Moderate 
Hyperglycemic 
Diabetic nephropaths 
N = 29 
ALR2 
1.8:!:0.2' 
3.8:!: 0.8b 
SORD 
1.4 :!: OJ< 
2.2 :!:O.Jd 
The results a re expressed as mean values :t standard error. 
• vs. uncomplicated. P = 0.00002. and vs. normal controls. P = 0.0004 
•vs. uncomplicated. P = 0.0001. and vs. normal controls, P = 0.001 
'vs. uncomplicated. P = 0.01. and vs. normal controls, P = 0.001 
• vs. uncomplicated, P = 0.006. and vs. normal controls. P = 0.005 
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4.0 
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Q) 3.0 t 
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C\J 
Diabetic controls 
N = ll 
ALR2 
0.9:!:0.02 
0.8 :!: 0.05 
/ 
SORD 
0.9 :!:0.05 
0.9:!:0.05 
/ 
/ 
Normal controls 
N=IO 
ALR2 
0.94:!: 0.1 
0.8:!:0.1 
/ 
SORD 
0.94 :!:0.07 
0.84 :!:0.07 
2.0 a: 
...J 
<{ 1.5 -----r 
1.0 
------- • -y
0.5 
0 
Normal Moderate Severe 
Glucose level 
Fig. 2. Mean fold increase of ALR2 mRNA in PBMCs from nepbropaths (+)and uncomplicated (0) and nonnal (6 ) controls cultured under 
normal and hyperglycemic conditions. Glucose concentration vs. ALR2 m RNA, P < 0.00001. Moderate conditions: nephropaths vs. uncomplicated, 
P = 0.00002, nephropaths vs. normal controls, P = 0.004. Severe conditions: nephropaths vs. uncomplicated, P = 0.0001, nephropaths vs. normal 
controls, P = 0.001. 
uncomplicated as well as the normal controls was highly 
significant (moderate conditions, P = 0.00002 nephro-
paths vs. uncomplicated nephropaths, and P = 0.004 vs. 
normal control; severe conditions, P = 0.0001 nephro-
paths vs. uncomplicated; Table 2). Figure 2 shows an 
example of the increase in ALR2 mRNA of PBMCs stimu-
lated with o-glucose from a nephropath in contrast to 
the lack of a response ofPBMCs from an uncomplicated 
patient who was treated in the same way. To determine 
whether the increased expression of ALR2 in the nephro-
paths was specific for o-glucose the PBMCs from two 
patients with nephropathy were stimulated with either 
L-glucose, which competes with o-glucose for the trans-
porter, or mannitol, an osmolyte that at high concentra-
tions can activate p38 mitogen-activated protein kinase 
[23]. When the tissue culture media for the PBMCs was 
also supplemented with either 20 mmoVL L-glucose or 
20 mmol/L mannitol, there was a reduction in the expres-
sion of ALR2 (Fig. 4). In contrast, with o-glucose alone 
(supplemented with 20 mmolJL o-glucose), there was an 
expected increase in ALR2 mRNA (Fig. 4). 
When the SORD mRNA was measured in the same 
samples again, the nephropaths had a significant increase 
in mRNA expression with increasing concentrations of 
o-glucose (P < 0.01, 1.4 ::!: 0.1 and 2.2 ::!: 0.3 for moderate 
and severe hyperglycemia, respectively; Table 2 and Fig. 
3). There was a slight decrease in SORD mRNA expres-
sion in the uncomplicated and normal controls with in-
creasing concentration of o-glucose (Table 2 and Fig. 3). 
In the nephropaths, there was a significant correlation 
between the increase in ALR2 mRNA expression under 
severe hyperglycemic conditions and the Z-2/X (where 
X is not Z+2) 5' ALR2 susceptibility genotype {Table 3). 
In those patients with this genotype, there was an 8.4 ::!: 
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Fig. 3. Mean fold illaease or SORD mRNA ill PBMCs l'rom nepbropaths (+) and uncomplicated <•> aDd normal (.4) controls cultured under 
n0111U1111Dd byperglycemic conditions. Glucose concentrations vs. SORD mRNA, P = 0.01. Moderate conditions: nephropaths vs. uncomplicated, 
P = 0.01 ; nephropaths vs. normal controls, P = 0.03. Severe conditions: nephropaths vs. uncomplicated, P = 0.006; nephropaths vs. normal controls, 
p = 0.005. 
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mRNA is induced by o-glucose, but not by 
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3.5 increase of ALR2 mRNA in contrast to those with 
the Z+21Y (where Y is not Z-2) genotype, who only 
had a 2.9 ± 0.2 increase in ALR2 mRNA (P < 0.04). 
Surprisingly, those nephropaths with the Z-2JZ+2 geno-
type had the lowest increase in ALR2 m.RNA {1.3 ± 
03). Indeed, when the increase in the_ Z-2/X genotype 
group is compared with the Z+2JY and the Z-2JZ+2 ·as 
a whole, this difference was significant (P < 0.007). Also, 
it is clear from the SORD m.RNA results with respect 
to the 5' ALR2 genotype that those nephropaths with 
the highest ALR2 expression and the Z-2/X genotype 
did not necessarily h_ave the most SORD mRNA. In 
the uncomplicated group, there was no correlation with 
5' ALR2 genotype, as they did not increase their expres-
sion of ALR2 with hyperglycemia (data not shown). Four 
of the 11 uncomplicated patients had the Z-2/X geno-
type. Six had the Z+2JY genotype, and the last subject 
had the XIY genotype. 
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Table 3. Aldose reductase and SORD mRNA levels with respect 
to 5' ALR2 genotype in patients with diabetic nephropathy 
ALR2 SORD ARUJSORD ratio 
Z-2/X (N = 10) 8.4:!: 3.5 ... 2.14 :!: 0.8 4.4 :!: 1.5 
Z+VY (N = 6) 2.9:!: 0.2 2.9 :!: 1.0 1.9 :!: 0.2 
Z -VZ+2 (N = 4) 1.3:!: 0.3 1.65:!: 0.1 0.6:!:0.07 
X!Y (N = 9) 4.3:!: 1.0 1.6:!: 0.3 3.8 + 1.2 
The results are expressed as mean fold increases of tbe PBMC exposed to 
severe hyperglycemic compared with those cultured under normal conditions ± 
standard error. 
X = any allele other than Z +2; Y = any allele other than Z -2. 
'vs. ALR2 Z+2/Y, P = 0.04 
•vs. ALR2 Z + 2/Y plus Z-21Z+2. P = 0.007 
DISCUSSION 
This study shows, to our knowledge for the first time, 
~h~t the expression of both the ALR2 and SORD genes 
lS mduced by o-glucose in PBMCs in those patients with 
nephropathy. This response was specific for o-glucose 
and was not due to differences in osmolarity, as demon-
strated by the lack of response to L-glucose and mannitol. 
However, the major finding from this study is the quite 
striking and unexpected lack of a response of the ALR2 
gene to o-glucose in the PBMCs of the uncomplicated 
patients (no microvascular complications after 20 years 
duration of type 1 diabetes) as well as the normal controls. 
The reasons for this disparity are unclear at the present 
time, but obviotiSiy have major implications for under-
standing and possibly predicting diabe tic nephropathy 
and other microvascular complications of diabetes. It is 
possible that these differences can be accounted for by 
the expression and function of glucose transporters be-
tween those with and without nephropathy. We and others 
have recently shown that polymorphisms in GLUT!, the 
major facilitative glucose transporter in insulin-non-
responsible tissues, such as the retinal epithelial cells and 
glomeruli, is associated with susceptibility to diabetic 
nephropathy in patients with type 1 and type 2 diabetes 
[24, 25]. This association is related to the 5' ALR geno-
type. Therefore, the availability of glucose as a substrate 
may be an important factor, although this may not neces-
sarily be related to glycernic control. Indeed, the nephro-
paths and uncomplicated group had similar HbAtc re-
sults. It is possible that the uncomplicated group and 
normal controls did respond to o-glucose, but this was 
before the five-day end point by which time the response 
may have been down-regulated. Natural cellular inhibi-
tors of the polyol pathway have not been found and it 
is assumed that the flux through the pathway is' simply 
regulated by the concentration of the substrate and eo-
factors. It remains unclear why high concentrations of 
o -glucose should fail to stimulate the expression of the 
ALR2 gene in these groups of subjects. However, it has 
been recent!~ shown that human retinal epithelial cells 
that have a high level of expression of ALR2 are down-
regulated by a post-transcription mechanism, the taurine 
cotransporter, when the cells are exposed to high glucose 
[26]. This effect can be reversed by the addition of aldose 
reductase inhibitors. The increase in SORD mRNA 
~o~nd in the PBMCs of the patients with nephropathy 
JS m contrast to the response seen in rat inner medullary 
collecting duct cells exposed to high osmolarity [27). In 
this model tiSing a reverse transcription-PeR strategy, a 
fourfold increase in the level of aldose reductase m RNA 
is found within 24 hours of exposure to high osmolarity, 
but no difference in the expression of SORD is seen. It 
is also possible that the response to o-glucose in the 
nephropaths is due to the underlying renal dysfunction 
in these patients. This response may also occur in patients 
with nondiabetic renal disease. 
While nephropaths showed an increase in expression of 
the ALR2 gene with increasing concentration of o-glucose, 
the degree of the response varied. This correlated with the 
5' A_LR2 genotype with those possessing the Zr-VX type 
havmg the greatest response. An examination of both 
the ALR2 and SORD mRNA expression suggests that 
there may be at least two profiles of flux through the 
polyol pathway under hyperglycemic conditions. Those 
nephropaths with the Zr-2/X. genotype had the greatest 
increase in ALR2 mRNA, but only a modest increase 
in SORD mRNA. Consequently, it is possible that in 
these individuals there is an accumulation of sorbitol in 
the cell. In contrast, those nephropaths with the Z+2/Y 
as we ll as the Z-2/Z+2 genotype had a similar increase 
of both ALR2 and SORD mRNA. Sorbitol would not 
be expected to accumulate in these cells. Instead, the 
exaggerated flux through the entire polyol pathway 
would be important, and this would give rise to increased 
levels of fructose and perhaps depletion of the cofactors 
NADPH and NAD+. It is also apparent that the presence 
of the Z+2 allele is dominant over the Zr-2 allele. This 
is somewhat surprising and may be related to the affinity 
of the transcription factors for the regulatory response 
elements, which is perhaps modified by the presence of 
additional CA dinucleotide repeats. It has already been 
shown that the Z-4 allele can modify the efficiency of 
transcription in luciferase gene reporter assays [22]. 
In conclusion, this is the first description of mRNA 
profiles for genes coding for enzymes of an entire meta-
bolic pathway. We have found striking differences in the 
expression profile of ALR2 of patients with nephropathy 
compared with those without and the normal controls. 
The response to uptake and disposal of o-glucose may 
be quite different between these groups of patients and 
provides a novel insight into the role of the polyol path-
way in the pathogenesis of diabetic nephropathy. 
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The Origin of the Universe 
A. MARS, B. JUPITER and C. PLUTO 
(Department of Asteroids, University of Time and Space, Out-there, Milky Way) 
The origins of the universe has long been in doubt but recent experi-
ments have indicated that a computing error may have been the cause ... 
! Expression of the gene for hypoxia inducible factor-1 and the 
l molecular basis for oxidative stress and hypoxia in diabetes 
: K.L. SONDERGAARD, A. HODGKINSON and AG 
' DEMAINE Molecular Medicine Research Group, Postgraduate 
: Medical School, University ofPiymouth, UK. 
' ' ' : } J • ~ • ' ' I. ' 1 , • . , : • , ; l l • 
: Hypoxia inducible factdr-l ·(IDF-l) Ys a tra'ii"scription factor that 
: is intricately involved in the cellular response to hypoxia. 
; Hyperglycaemia is associated with a cascade of metabolic 
: abnormalities including oxidative stress and hypoxia. Hypoxia 
! stimulates the expression of fllF-1 mRNA which in turn binds 
: and activates a number of genes including vascular endothelial 
I i growth factor and glucose transporter 1. The aim of this study 
: was to quantitate fllF-1 mRNA levels in cell lines exposed either 
! to normal, moderate (14mM glucose) or hyperglycaemia (28mM 
: glucose) for a minimum period of 14 days. The cell lines were 
; also exposed to hypoxia for up to 24 hours. Lymphocytes from 3 
: patients with type 1 diabetes were also exposed to 
hyperglycaemia for 5 days. RNA was prepared from the cells 
and a ribonuclease protection assay (RP A) was used to quantitate 
the expression of HIF-1 using radioactively labelled riboprobes 
together with a Phosphor-Imager system. Exposure of 2 of the 
cell lines (MCF7 and ZR 75) to hyperglycaemia caused up to 16 
fold increase in expression ofHIF-1 (3 and 16 fold respectively) 
compared to baseline. Exposure of the cell lines to hypoxia for 
up to 24 hours gave a similar increase in HIF-1 mRNA 
expression. HIF-1 mRNA was increased in the RNA of 
lymphocytes from patients by up to 19 fold compared to 
baseline. ln conclusion, this is the first report of HIF-1 m RN A 
expression in hyperglycaemia and has important impl ications for 
understanding the molecular basis of diabetic complications. 
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Because angiopoietin-1 (Ang- 1) promotes endothelial 
cell survival in vitro, we wanted to test if angiopoietin-
2 (Ang-2), a naturally occurring antagonist of Ang- 1, 
could be linked to this process. Fluorescent-labeled 
glioma 261 cells were implanted in the brains of 28 
mice. Seven animals were sacrificed each week, over 
four weeks. We investigated the expression of Ang-2 by 
in silll hybridization and compared it to the distribution 
of apoptotic cells identified by TUNEL method and 
transmission electron microscopy (TEM). Ang-2 was 
detected as early as one week after implantation, in vas-
cular cells surrounded by tumor cells. At this time, no 
apoptosis was seen by TUNEL or TEM. TEM showed 
tumor cells adjacent to the vascular cells "lifting up" the 
normal astrocytic feet processes away from the endothe-
lial cells and disrupting normal pericytic cuffing. By 
two weeks, the number of perivascular glioma cells had 
increased. No increase in the number of blood vessels 
was detected at this time. Vascular cells remained posi-
tive for Ang-2 and rare cells were TUNEL positive. 
TEM showed closely packed proliferating perivascular 
tumor cells. At three weeks, there was vascular involu-
tion with scant zones of tumor necrosis. Ang-2 was 
again detected in vascular cells but now numerous vas-
cular cells were TUNEL positive and apoptotic by TEM. 
At week four, there were extensive areas of tumor 
necrosis with adjacent angiogenesis. Ang-2 was detect-
ed in cells of newly formed vessels at the edge of the 
tumors. Both at 3 and 4 weeks most of the TUNEL-pos-
itive tumor cells displayed morphological features con-
sistent with necrotic cell death by TEM. Only rare tumor 
cells appeared truly apoptotic. In contrast, the TUNEL-
positive endothelial cells and pericytes were round and 
shrunken, with condensed nuclear chromatin by TEM 
suggesting apoptotic cell death. Thus, Ang-2 is detected 
prior to the onset of apoptosis in vascular cells and could 
be linked to vascular involution which leads to tumor 
necrosis and angiogenesis. 
C46.07 Hypoxia Inducible Factor-1a Expression In 
Glioblastomas 
Hilton, 0'; Sondergaard, K'; Penney, M'; Demaine, A' 
'Deniford Hospital, UK; 'Plymouth University, UK 
lntro<:iJu:tion: Angiogenesis is crucial to the develop-
ment of most malignant tumours, and is a particularly 
prominent feature of glioblastomas. The mechanisms 
underlying microvascular proliferation in glioblastomas 
is not fully understood, although over-expression of vas-
cular endothelial growth factor (VEGF) occurs. Hypox-
ia inducible factor- la (HIF- la) is a transcription factor 
736 
that is widely expressed in tissues under hypoxic condi-
tions and controls several hypoxia-inducible genes, 
including VEGF. Recent studies have demonstrated 
increased expression of HIF-la in a number of tumours, 
although little is known about its expression in glioblas-
tomas. We have investigated the expression of HIF-la 
mRNA and protein in glioblastomas, lower grade 
tumours and normal brain. 
Methods: Immunocytochemistry was used to demon-
strate HIF-la protein in paraffin-embedded tissue sec-
tions using a commercially available monoclonal anti-
body, after microwave antigen retrieval. In cases where 
frozen tissue was available, RT-PCR was carried out 
using primers to HIF- la and b-actin mRNA. Scanning 
densitometry was used to semiquantitate reaction prod-
ucts. 
Results: Strong nuclear HIF-la immunoreactivity 
was seen in 10/10 glioblastomas. 416 anaplastic astrocy-
tomas and 2/10 low grade astrocytomas, but was not 
seen in normal brain. In positive cases immunoreactivi-
ty was present in the majority of tumour cell nuclei, 
however, in glioblastomas immunoreactivity was partic-
ularly strong in tumour cells surrounding foci of necro-
sis. Analyses of the RT-PCR products revealed upregu-
lation of HIF-la mRNA, compared to b-actin mRNA, in 
some of the glioblastomas. 
Conclusions: HIF-la protein over-expression is a 
consistent finding in glioblastomas, and is particularly 
prominent in tumour cells swrounding areas of necrosis. 
In some of the glioblastomas upregulation of IDF- la 
mRNA was also found. These findings are in keeping 
with a role for HIF- la in VEGF expression and angio-
genesis in glioblastomas. 
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Hypoxia inducible factor-! alpha (HlF-1 a) is a transcription factor that · 
stabilises wild-type p53 and is widely expressed in tissues under hypoxic · · 
conditions. HIF-la transcriptionally activates vascular endothelial growth . 
factor (VEGF) and is thought to play a critical role ifl the expression of genes 
involved in angiogenesis. Although VEGF is known to be upregulated in many 
tumours including glioblastoma multifonnes (GB M), at the present time little is 
known about the mode of expression of HIF-1 a . The aim ·of this study was to 
investigate the expression of HIF-la, as well as VEGF and p53, in 25 GBM 
samples using RT-PCR and immlinocytochemistry. Out of the 25 tumour 
samples, 20 (80%) expressed HIF-la, 21 of the 25 (84%) expressed VEGF and 
16 of the 25 (64%) tumour samples displayed over-expression of p53 (>20% 
labelling). Of the 20· HIF-la positive samples, 13 (65%)_ displayed over-
expression ofp53, with 3 of the 5 (60%) HlF-la negative tumours displaying 
. over-expression of p53. Only I of the 5 (20%) HIF- 1 a negative tumours was 
also VEGF negative. VEGF expression varied from I to lOO fold (mean 25 
fold) in all of the GBM tumour samples. All GBM tumour samples displayed 
similar degrees of necrosis and vascular proliferation. This study did not fmd a 
correlation between HIF-la expression, VEGF expression, over-expression of 
p53, tumour vascularity or necrosis. 
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p73, a novel homologue of the p53 tumour suppressor gene family, has recently · 
been identified and mapped to chromosome lp36, a region frequently deleted . 
in several cancers. p73 has been demonstrated to be monoallelically expressed. 
An allelic polymorphism exists within its 5' untranslated region consisting of a · 
double nucleotide substitution (G~A) and (C~ T) at position 4 and 14 of ex on 
2. We investigated the frequency of this genotype in the DNA extracted from 
peripheral blood samples of 75 patients with breast cancer and 100 sequential 
cord blood samples using PCR-RL. ·out of the 75 patients, 28 (37 .. 3%) were 
heterozygous for the err polymorphislJ.l and out of 100 controls, 33 (33%) also 
had the err polymorphism. T.he frequency of the err polymorphism was 
compared with tumour grade, size and node involvement and no significant 
correlation was found _be.tween clinical features and genotype. However, a non-
significant trend was observed with the age of diagnosis.- Twice as many 
patients diagnosed after 40 years of age had the GC monoallelic genotype 
"(65.6%, 40 of 61) rather than the err polyniorphism (34.4%, 21 of 61). 
Patients diagnosed before 40 years of age had a similar frequency of p73 
genotypes. As half o( all breast tumours harbour alterations in the p53 tumour 
suppressor gene, we also . investigated the frequency of p53Pro/Arg 
polymorphisms in all of the samples. Interestingly, 53.2% (25 of 47) of the G/C 
p73 genotype was p53Pro/Arg heterozygous and 44.7% (21 of 47i was p53Arg 
homozygous. In contrast, 39.3% (ll of 28) of the err p73 genotype was 
p53 Pro/ Arg heterozygous and 60% ( 17 of 28) was p53Arg homozygous. It has 
recently been shown that individuals homozygous for p53Arg are 7 times more 
likely to develop human papllloma~irus (HPV) associated cancer. An 
association may exist between p73 and p53Pro/Arg genotype in patients with 
breast cancer. 
